Novel proteins and nucleic acids encoding same

Abstract

Disclosed herein are novel human nucleic acid sequences which encode polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further disclosed therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Description

BACKGROUND OF THE INVENTION

[0002] The invention relates generally to polynucleotides and polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for producing these nucleic acids and polypeptides.

SUMMARY OF THE INVENTION

[0003] The invention is based in part upon the discovery of novel nucleic acid sequences encoding novel polypeptides. The disclosed FCTR1, FCTR2, FCTR3, FCTR4, FCTR5, FCTR6 and FCTR7 nucleic acids and polypeptides encoded therefrom, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as “FCTRX” nucleic acid or polypeptide sequences.

[0004] In one aspect, the invention provides an isolated FCTRX nucleic acid molecule encoding a FCTRX polypeptide that includes a nucleic acid sequence that has identity to the nucleic acids disclosed in SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24. In some embodiments, the FCTRX nucleic acid molecule will hybridize under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a FCTRX nucleic acid sequence. The invention also includes an isolated nucleic acid that encodes a FCTRX polypeptide, or a fragment, homolog, analog or derivative thereof. For example, the nucleic acid can encode a polypeptide at least 80% identical to a polypeptide comprising the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25. The nucleic acid can be, for example, a genomic DNA fragment or a cDNA molecule that includes the nucleic acid sequence of any of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24.

[0005] Also included in the invention is an oligonucleotide, e.g., an oligonucleotide which includes at least 6 contiguous nucleotides of a FCTRX nucleic acid (e.g., SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24) or a complement of said oligonucleotide.

[0006] Also included in the invention are substantially purified FCTRX polypeptides (SEQ ID NO: 2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25). In certain embodiments, the FCTRX polypeptides include an amino acid sequence that is substantially identical to the amino acid sequence of a human FCTRX polypeptide.

[0007] The invention also features antibodies that immunoselectively-binds to FCTRX polypeptides, or fragments, homologs, analogs or derivatives thereof.

[0008] In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, e.g., a FCTRX nucleic acid, a FCTRX polypeptide, or an antibody specific for a FCTRX polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this pharmaceutical composition.

[0009] In a further aspect, the invention includes a method of producing a polypeptide by culturing a cell that includes a FCTRX nucleic acid, under conditions allowing for expression of the FCTRX polypeptide encoded by the DNA. If desired, the FCTRX polypeptide can then be recovered.

[0010] In another aspect, the invention includes a method of detecting the presence of a FCTRX polypeptide in a sample. In the method, a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound. The complex is detected, if present, thereby identifying the FCTRX polypeptide within the sample.

[0011] The invention also includes methods to identify specific cell or tissue types based on their expression of a FCTRX.

[0012] Also included in the invention is a method of detecting the presence of a FCTRX nucleic acid molecule in a sample by contacting the sample with a FCTRX nucleic acid probe or primer, and detecting whether the nucleic acid probe or primer bound to a FCTRX nucleic acid molecule in the sample.

[0013] In a further aspect, the invention provides a method for modulating the activity of a FCTRX polypeptide by contacting a cell sample that includes the FCTRX polypeptide with a compound that binds to the FCTRX polypeptide in an amount sufficient to modulate the activity of said polypeptide. The compound can be, e.g., a small molecule, such as a nucleic acid, peptide, polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.

[0014] Also within the scope of the invention is the use of a Therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Colorectal cancer, adenomatous polyposis coli, myelogenous leukemia, congenital ceonatal alloimmune thrombocytopenia, multiple human solid malignancies, malignant ovarian tumours particularly at the interface between epithelia and stroma, malignant brain tumors, mammary tumors, human gliomas, astrocytomas, mixed glioma/astrocytomas, renal cells carcinoma, breast adenocarcinoma, ovarian cancer, melanomas, renal cell carcinoma, clear cell and granular cell carcinomas, autocrine/paracrine stimulation of tumor cell proliferation, autocrine/paracrine stimulation of tumor cell survival and tumor cell resistance to cytotoxic therapy, paranechmal and basement membrane invasion and motility of tumor cells thereby contributing to metastasis, tumor-mediated immunosuppression of T-cell mediated immune effector cells and pathways resulting in tumor escape from immune surveilance, neurological disorders, neurodegenerative disorders, nerve trauma, familial myelodysplastic syndrome, Charcot-Marie-Tooth neuropathy, demyelinating Gardner syndrome, familial myelodysplastic syndrome; mental health conditions, immunological disorders, allergy and infection, asthma, bronchial asthma, Avellino type eosinophilia, lung diseases, reproductive disorders, male infertility, female reproductive system disorders, male and female reproductive diseases, hemangioma, deafness, glycoprotein Ia deficiency, desmoid disease, turcot syndrome, liver cirrhosis, hepatitis C, gastric disorders, pancreatic diseases like diabetes, Schistosoma mansoni infection, Spinocerebellar ataxia, Plasmodium falciparum parasitemia, Corneal dystrophy—Groenouw type I, Corneal dystrophy—lattice type I, and Reis-Bucklers corneal dystrophy. The Therapeutic can be, e.g., a FCTRX nucleic acid, a FCTRX polypeptide, or a FCTRX-specific antibody, or biologically-active derivatives or fragments thereof.

[0015] The invention further includes a method for screening for a modulator of disorders or syndromes including, e.g., Also within the scope of the invention is the use of a Therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Colorectal cancer, adenomatous polyposis coli, myelogenous leukemia, congenital ceonatal alloimmune thrombocytopenia, multiple human solid malignancies, malignant ovarian tumours particularly at the interface between epithelia and stroma, malignant brain tumors, mammary tumors, human gliomas, astrocytomas, mixed glioma/astrocytomas, renal cells carcinoma, breast adenocarcinoma, ovarian cancer, melanomas, renal cell carcinoma, clear cell and granular cell carcinomas, autocrine/paracrine stimulation of tumor cell proliferation, autocrine/paracrine stimulation of tumor cell survival and tumor cell resistance to cytotoxic therapy, paranechmal and basement membrane invasion and motility of tumor cells thereby contributing to metastasis, tumor-mediated immunosuppression of T-cell mediated immune effector cells and pathways resulting in tumor escape from immune surveilance, neurological disorders, neurodegenerative disorders, nerve trauma, familial myelodysplastic syndrome, Charcot-Marie-Tooth neuropathy, demyelinating Gardner syndrome, familial myelodysplastic syndrome; mental health conditions, immunological disorders, allergy and infection, asthma, bronchial asthma, Avellino type eosinophilia, lung diseases, reproductive disorders, male infertility, female reproductive system disorders, male and female reproductive diseases, hemangioma, deafness, glycoprotein Ia deficiency, desmoid disease, turcot syndrome, liver cirrhosis, hepatitis C, gastric disorders, pancreatic diseases like diabetes, Schistosoma mansoni infection, Spinocerebellar ataxia, Plasmodium falciparum parasitemia, Corneal dystrophy—Groenouw type I, Corneal dystrophy—lattice type I, and Reis-Bucklers corneal dystrophy. The method includes contacting a test compound with a FCTRX polypeptide and determining if the test compound binds to said FCTRX polypeptide. Binding of the test compound to the FCTRX polypeptide indicates the test compound is a modulator of activity, or of latency or predisposition to the aforementioned disorders or syndromes.

[0016] Also within the scope of the invention is a method for screening for a modulator of activity, or of latency or predisposition to an disorders or syndromes including, e.g., Also within the scope of the invention is the use of a Therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Colorectal cancer, adenomatous polyposis coli, myelogenous leukemia, congenital ceonatal alloimmune thrombocytopenia, multiple human solid malignancies, malignant ovarian tumours particularly at the interface between epithelia and stroma, malignant brain tumors, mammary tumors, human gliomas, astrocytomas, mixed glioma/astrocytomas, renal cells carcinoma, breast adenocarcinoma, ovarian cancer, melanomas, renal cell carcinoma, clear cell and granular cell carcinomas, autocrine/paracrine stimulation of tumor cell proliferation, autocrine/paracrine stimulation of tumor cell survival and tumor cell resistance to cytotoxic therapy, paranechmal and basement membrane invasion and motility of tumor cells thereby contributing to metastasis, tumor-mediated immunosuppression of T-cell mediated immune effector cells and pathways resulting in tumor escape from immune surveilance, neurological disorders, neurodegenerative disorders, nerve trauma, familial myelodysplastic syndrome, Charcot-Marie-Tooth neuropathy, demyelinating Gardner syndrome, familial myelodysplastic syndrome; mental health conditions, immunological disorders, allergy and infection, asthma, bronchial asthma, Avellino type eosinophilia, lung diseases, reproductive disorders, male infertility, female reproductive system disorders, male and female reproductive diseases, hemangioma, deafness, glycoprotein Ia deficiency, desmoid disease, turcot syndrome, liver cirrhosis, hepatitis C, gastric disorders, pancreatic diseases like diabetes, Schistosoma mansoni infection, Spinocerebellar ataxia, Plasmodium falciparum parasitemia, Corneal dystrophy—Groenouw type I, Corneal dystrophy—lattice type I, and Reis-Bucklers corneal dystrophy by administering a test compound to a test animal at increased risk for the aforementioned disorders or syndromes. The test animal expresses a recombinant polypeptide encoded by a FCTRX nucleic acid. Expression or activity of FCTRX polypeptide is then measured in the test animal, as is expression or activity of the protein in a control animal which recombinantly-expresses FCTRX polypeptide and is not at increased risk for the disorder or syndrome. Next, the expression of FCTRX polypeptide in both the test animal and the control animal is compared. A change in the activity of FCTRX polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of the disorder or syndrome.

[0017] In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a FCTRX polypeptide, a FCTRX nucleic acid, or both, in a subject (e.g., a human subject). The method includes measuring the amount of the FCTRX polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the FCTRX polypeptide present in a control sample. An alteration in the level of the FCTRX polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the subject. Preferably, the predisposition includes, e.g., Also within the scope of the invention is the use of a Therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Colorectal cancer, adenomatous polyposis coli, myelogenous leukemia, congenital ceonatal alloimmune thrombocytopenia, multiple human solid malignancies, malignant ovarian tumours particularly at the interface between epithelia and stroma, malignant brain tumors, mammary tumors, human gliomas, astrocytomas, mixed glioma/astrocytomas, renal cells carcinoma, breast adenocarcinoma, ovarian cancer, melanomas, renal cell carcinoma, clear cell and granular cell carcinomas, autocrine/paracrine stimulation of tumor cell proliferation, autocrine/paracrine stimulation of tumor cell survival and tumor cell resistance to cytotoxic therapy, paranechmal and basement membrane invasion and motility of tumor cells thereby contributing to metastasis, tumor-mediated immunosuppression of T-cell mediated immune effector cells and pathways resulting in tumor escape from immune surveilance, neurological disorders, neurodegenerative disorders, nerve trauma, familial myelodysplastic syndrome, Charcot-Marie-Tooth neuropathy, demyelinating Gardner syndrome, familial myelodysplastic syndrome; mental health conditions, immunological disorders, allergy and infection, asthma, bronchial asthma, Avellino type eosinophilia, lung diseases, reproductive disorders, male infertility, female reproductive system disorders, male and female reproductive diseases, hemangioma, deafness, glycoprotein Ia deficiency, desmoid disease, turcot syndrome, liver cirrhosis, hepatitis C, gastric disorders, pancreatic diseases like diabetes, Schistosoma mansoni infection, Spinocerebellar ataxia, Plasmodium falciparum parasitemia, Corneal dystrophy—Groenouw type I, Corneal dystrophy—lattice type I, and Reis-Bucklers corneal dystrophy. Also, the expression levels of the new polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.

[0018] In a further aspect, the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject a FCTRX polypeptide, a FCTRX nucleic acid, or a FCTRX-specific antibody to a subject (e.g., a human subject), in an amount sufficient to alleviate or prevent the pathological condition. In preferred embodiments, the disorder, includes, e.g., Also within the scope of the invention is the use of a Therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Colorectal cancer, adenomatous polyposis coli, myelogenous leukemia, congenital ceonatal alloimmune thrombocytopenia, multiple human solid malignancies, malignant ovarian tumours particularly at the interface between epithelia and stroma, malignant brain tumors, mammary tumors, human gliomas, astrocytomas, mixed glioma/astrocytomas, renal cells carcinoma, breast adenocarcinoma, ovarian cancer, melanomas, renal cell carcinoma, clear cell and granular cell carcinomas, autocrine/paracrine stimulation of tumor cell proliferation, autocrine/paracrine stimulation of tumor cell survival and tumor cell resistance to cytotoxic therapy, paranechmal and basement membrane invasion and motility of tumor cells thereby contributing to metastasis, tumor-mediated immunosuppression of T-cell mediated immune effector cells and pathways resulting in tumor escape from immune surveilance, neurological disorders, neurodegenerative disorders, nerve trauma, familial myelodysplastic syndrome, Charcot-Marie-Tooth neuropathy, demyelinating Gardner syndrome, familial myelodysplastic syndrome; mental health conditions, immunological disorders, allergy and infection, asthma, bronchial asthma, Avellino type eosinophilia, lung diseases, reproductive disorders, male infertility, female reproductive system disorders, male and female reproductive diseases, hemangioma, deafness, glycoprotein Ia deficiency, desmoid disease, turcot syndrome, liver cirrhosis, hepatitis C, gastric disorders, pancreatic diseases like diabetes, Schistosoma mansoni infection, Spinocerebellar ataxia, Plasmodium falciparum parasitemia, Corneal dystrophy—Groenouw type I, Corneal dystrophy—lattice type I, and Reis-Bucklers corneal dystrophy.

[0019] In yet another aspect, the invention can be used in a method to identity the cellular receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules.

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0021] Other features and advantages of the invention will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION

[0022] The invention is based, in part, upon the discovery of novel nucleic acid sequences that encode novel polypeptides. The novel nucleic acids and their encoded polypeptides are referred to individually as FCTR1, FCTR2, FCTR3, FCTR4, FCTR5, FCTR6, and FCTR7. The nucleic acids, and their encoded polypeptides, are collectively designated herein as “FCTRX”.

[0023] The novel FCTRX nucleic acids of the invention include the nucleic acids whose sequences are provided in Tables 1A, 2A, 3A, 3C, 3E, 3F, 3G, 3H, 4A, 5A, 5C, 5E, 6A, 6C, and 7A inclusive (“Tables 1A-7A”), or a fragment, derivative, analog or homolog thereof. The novel FCTRX proteins of the invention include the protein fragments whose sequences are provided in Tables 1B, 2B, 3B, 3I, 4B, 5B, 5D, 6B, 6D, and 7B inclusive (“Tables 1B -7B”). The individual FCTRX nucleic acids and proteins are described below. Within the scope of this invention is a method of using these nucleic acids and peptides in the treatment or prevention of a disorder related to cell signaling or metabolic pathway modulation.

[0024] FCTR1

[0025] Novel FCTR1 is a growth factor (“FCTR”) protein related to follistatin-like gene, and mac25. FCTR1 (also referred to by proprietary accession number 58092213.0.36) is a full-length clone of 771 nucleotides, including the entire coding sequence of a 105 amino acid protein from nucleotides 438 to 753. The clone was originally obtained from thyroid gland, kidney, fetal kidney, and spleen tissues.

[0026] The nucleotide sequence of FCTR1 as presently determined is reported in Table 1A. The start and stop codons are bolded and the 5′ and 3′ untranslated regions are underlined.

TABLE 1A
FCTR1 nucleotide sequence (SEQ ID NO:1).
GGTCCTCACCCCCTTCCTCTCTCCCAGCCTCGGTGTCTGGTTACGGCTCCTCTGCTCGCATTGTGACTTTGGGCCAGGCTGGG
GGAAATGACCCGGGAGGGTCCCATGCGGCTACATAAAATTGGCAGCCTTAGAACTAGTGGGAAGGCGGGTGCGCGAAGTCGAG
GGGCGGAGAGAGGGGGCCGGAGGAGCTGCTTTCTGAATCCAAGTTCGTGGGCTCTCTCAGAAGTCCTCAGGACGGAGCAGAGG
TGGCCGGCGGGCCCGGCTGACTGCGCCTCTGCTTTCTTTCCATAACCTTTTCTTTCGGACTCGAATCACAGCTGCTGCGAAGG
GTCTAGTTCCGGACACTAGGGCCCCAGATCGTGTCACATCCATATGACACTTGGAATGTGACAGGGCAGGATGTGATCTTTGG
CTGTGAAGTGTTTGCCTACCCCATGGCCTCCATCGAGTGGAGGAAGGATGGCTTGGACATCCAGCTGCCAGGGGATGACCCCC
ACATCTCTGTGCAGTTTAGGGGTGGACCCCAGAGGTTTGAGGTGACTGCTGGCTGCAGATCCAGGCTGTGCGTCCCAGTGAT
GAGGGCACTTACCGCTGCCTTGCCCGCAATGCCCTGGGTCAAGTGGAGGCCCCTGCTAGCTTGACAGTGCTCACACCTGACCA
GCTGAACTCTACAGGCATCCCCCAGCTGCGATCACTAAACCTGGTTCCTGAGGAGGAGGCTGAGAGTGAAGAGAATGACGATT
ACTACTAGGTCCAGAGCTCTGGCC

[0027] The predicted amino acid sequence of FCTR1 protein corresponding to the foregoing nucleotide sequence is reported in Table 1B. FCTR1 was searched against other databases using SignalPep and PSort search protocols. The protein is most likely located in the cytoplasm (certainty=0.6500) and seems to have no N-terminal signal sequence. The predicted molecular weight of FCTR1 protein is 11711.8 daltons.

TABLE 1B
Encoded FCTR1 protein sequence (SEQ ID NO:2).
MASIEWRKDGLDIQLPGDDPHISVQFRGGPQRFEVTGWLQIQAVRPSDEGTYRCLARNALGQVEAPASLTVLTPDQLNSTGIP
QLRSLNLVPEEEAESEENDDYY

[0028] FCTR1 was initially identified with a TblastN analysis of a proprietary sequence file for a follistatin-like probe or homolog which was run against the Genomic Daily Files made available by GenBank. A proprietary software program (GenScan™) was used to further predict the nucleic acid sequence and the selection of exons. The resulting sequences were further modified by means of similarities using BLAST searches. The sequences were then manually corrected for apparent inconsistencies, thereby obtaining the sequences encoding the full-length protein.

[0029] In an analysis of sequence databases, it was found, for example, that the FCTR1 nucleic acid sequence has 31/71 bases (43%) identical and 46/71 bases positively alike to a Mus Musculus IGFBP-like protein (TREMBL Accession Number:BAA21725) shown in Table 1C. In all BLAST alignments herein, the “E-value” or “Expect” value is a numeric indication of the probability that the aligned sequences could have achieved their similarity to the BLAST query sequence by chance alone, within the database that was searched. For example, as shown in Table 1C, the probability that the subject (“Sbjct”) retrieved from the FCTR1 BLAST analysis, in this case the Mus Musculus IGFBP-like protein, matched the Query FCTR1 sequence purely by chance is 1.2×10−11.

TABLE 1C
BLASTP of FCTR1 against Mus Musculus
IGFBP-like protein (SEQ ID NO:38)
PTNR:REMTREMBL-ACC:BAA21725 IGFEP-LIKE PROTEIN - MUS MUSCULUS
(MOUSE), 270 AA.
LENGTH = 270
SCORE = 161 (56.7 BITS), EXPECT = 1.2E-11, P = 1.2E-11
IDENTITIES = 31/71 (43%), POSITIVES = 46/71 (64%)
QUERY:	9	DGLDIQLPGDDPHISVQFRGGPQRFEVTGWLQIQAVRPSDEGTYRCLARNALGQVEAPAS	68
		+||+ +||||  +|+|| ||||   | | |+ |  +|  ||| 51 | | ||+|+ ++  +
SBJCT:	191	EGLE-ELPGDHVNIAVQVRGGPSDHETTSWILINPLRKEDEGVYHCHAANAIGEAQSHGT	249
QUERY:	69	LTVLTPDQLNS 79
		+|||  ++  |
SBJCT:	250	VTVLDLNRYKS 260
The amino acid sequence of FCTR1 also had 26/58 bases (44%) identical, and 38/58 bases (65%) positive for Mus Musculus Follistatin-like Protein shown in Table 1D.

[0030]

TABLE 1D
BLASTP of FCTR1 against Mus Musculus Follistatin-like
Protein (SEQ ID NO:39)
PTNR:SPTREMBL-ACC:Q61582. FOLLISTATIN-LIKE 2 (FOLLISTATIN-LIKE PROTEIN) -
MUS MUSCULUS (MOUSE), 238 Ak.
LENGTH = 238
SCORE = 149 (52.5 BITS), EXPECT = 1.5E-10, P = 1.5E-10
IDENTITIES = 26/58 (44%), POSITIVES = 38/58 (65%)
QUERY:	15	LPGDDPHISVQFRGGPQRFEVTGWLQIQAVRPSDEGTYRCLARNALGQVEAPASLTVL 72
		||||  ++++| ||||++ |||||+ +  +   | | | | | |+ ||  | | +||+
SBJCT:	165	LPGDRENLAIQTRGGPEKHEVTGWVLVSPLSKEDAGEYECHASNSQGQASAAAKITVV	222

[0031] The amino acid sequence of FCTR1 also had 26/58 bases (44%) identical, and 38/58 bases (65%) positive for Homo sapiens MAC25 protein shown in Table 1E.

TABLE 1E
BLASTP of FCTR1 against Homo sapiens MAC25 protein
PTNR:SPTREMBL-ACC:Q07822 MAC25 PROTEIN - HOMO SAPIENS (HUMAN), 277 AA.
LENGTH = 277
SCORE = 149 (52.5 BITS), EXPECT = 3.2E−10, P = 3.2E−10
IDENTITIES = 26/58 (44%), POSITIVES = 38/58 (65%)
QUERY:	15	LPGDDPHISVQFRGGPQRFEVTGWLQIQAVRPSDEGTYRCLARNALGQVEAPASLTVL	72	(SEQ ID NO:40)
		||||  ++++| ||||++ |||||+ +  +   | | | | | |+ ||  | | +||+
SBJCT:	209	LPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSKEDAGEYECHASNSQGQASASAKITVV	266

[0032] The amino acid sequence of FCTR1 also had 26/58 bases (44%) identical, and 38/58 bases (65%) positive for Mus musculus MAC25 protein shown in Table 1F.

TABLE 1F
BLASTP of FCTR1 against Mus musculus MAC25 protein
PTNR:SPTREMBL-ACC:088812 MAC25 - MUS MUSCULUS (MOUSE), 281 AA
LENGTH = 281
SCORE = 149 (52.5 BITS), EXPECT = 3.4E−10, P = 3.4E−10
IDENTITIES = 26/58 (44%), POSITIVES = 38/58 (65%)
QUERY:	15	LPGDDPHISVQFRGGPQRFEVTGWLQIQAVRPSDEGTYRCLARNALGQVEAPASLTVL	72	(SEQ ID NO:41)
		||||  ++++| ||||++ |||||+ +  +   | | | | | |+ ||  | | +||+
SBJCT:	208	LPGDRENLAIQTRGGPEKHEVTGWVLVSPLSKEDAGEYECHASNSQGQASAAAKITVV	265

[0033] The amino acid sequence of FCTR1 also had 26/58 bases (44%) identical, and 38/58 bases (65%) positive for Homo sapiens Prostacyclin-stimulating factor shown in Table 1G.

TABLE 1G
BLASTP of FCTR1 against Homo sapiens Prostacyclin-stimulating factor
PTNR:SPTREMBL-ACC:Q16270 PROSTACYCLIN-STIMULATING FACTOR - HOMO SAPIENS (HUMAN), 282 AA
LENGTH = 282
SCORE = 149 (52.5 BITS), EXPECT = 3.4E−10, P = 3.4E−10
IDENTITIES = 26/58 (44%), POSITIVES = 38/58 (65%)
QUERY:	15	LPGDDPHISVQFRGGPQRFEVTGWLQIQAVRPSDEGTYRCLARNALGQVEAPASLTVL	72	(SEQ ID NO:42)
		||||  ++++| ||||++ |||||+ +  +   | | | | | |+ ||  | | +||+
SBJCT:	209	LPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSKEDAGEYECHASNSQGQASASAKITVV	266

[0034] The amino acid sequence of FCTR1 also had 18/44 bases (40%) identical, and 25/44 bases (56%) positive for rat Colorectal cancer suppressor shown in Table 1H.

TABLE 1H
BLASTP of FCTR1 against rat Colorectal cancer suppressor
PTNR:PIR-ID:B40098 COLORECTAL CANCER SUPPRESSOR DCC - RAT (FRAGMENTS)
LENGTH = 144
SCORE = 78 (27.5 BITS), EXPECT = 1.1E−05, SUM P(2) = 1.1E−05
IDENTITIES = 18/44 (40%), POSITIVES = 25/44 (56%)
QUERY:	33	FEVTGW--LQIQAVRPSDEGTYRCLARNALGQVEAPASLTVLTP	74	(SEQ ID NO:43)
		|++ |   |+|  |  |||| |+|+| |  |  ++ | | |  |
SBJCT:	101	FQIVGGSNLRILGVVKSDEGFYQCVAENEAGNAQSSAQLIVPKP	144
SCORE = 37 (13.0 BITS), EXPECT = 1.1E−05, SUM P(2) = 1.1E−05
IDENTITIES = 8/19 (42%), POSITIVES = 12/19 (63%)
QUERY:	1	MASIEWRKDGLDIQL-PGD	18
		| +| |+|+  |+   |||
SBJCT:	30	MPTIHWQKNQQDLTPNPGD	48

[0035] The amino acid sequence of FCTR1 also had 32/83 bases (38%) identical, and 45/83 bases (54%) positive to bases 55-137, and 24/68 bases (35%) identical, and 37/68 bases (54%) positive to bases 166-225 of Homo sapiens PTPsigma-(Brain) Precursor shown in Table 1I.

TABLE 1I
BLASTP of FCTR1 against Homo sapiens PTPsigma-(Brain) Precursor
PTNR:TREMBLNEW-ACC:AAD09360 PTPSIGMA-(BRAIN) PRECURSOR - HOMO SAPIENS (HUMAN), 1502 AA.
LENGTH = 1502
SCORE = 109 (38.4 BITS), EXPECT = 0.00010, P = 0.00010
IDENTITIES = 32/83 (38%), POSITIVES = 45/83 (54%)
QUERY:	14	QLPGDD-PHISVQFRG---GPQRFEVTGW-------LQIQAVR-PSDEGTYRCLARNALG	61	(SEQ ID NO:44)
		|  ||  | ++   +|     ||||   +       | || +| | ||  | |+|+|++|
SBJCT:	55	QATGDPKPRVTWNKKGKKVNSQRFETIEFDESAGAVLRIQPLRTPRDENVYECVAQNSVG	114
QUERY:	62	QVEAPASLTVLTPDQLNSTGIPQL	85
		++   | ||||  ||| | | | +
SBJCT:	115	EITVHAKLTVLREDQLPS-GFPNI	137
SCORE = 77 (27.1 BITS), EXPECT = 0.25, P = 0.22
IDENTITIES = 24/68 (35%), POSITIVES = 37/68 (54%)
QUERY:	4	IEWRKDGLDIQLPGDDPHISVQFRGGPQRFEVTGWLQIQAVRPSDEGTYRCLARNALG-Q	62
		| | || | +     ||  |    |  ++   +| |||++   +|+| | |+| |+ | +
SBJCT:	166	ITWFKDFLPV-----DPSAS---NGRIKQLR-SGALQIESSEETDQGKYECVATNSAGVR	216
QUERY:	63	VEAPASLTV	71
		+||+| |
SBJCT:	217	YSSPANLYV	225

[0036] The amino acid sequence of FCTR1 also had 32/83 bases (38%) identical, and 45/83 bases (54%) positive for amino acids 55-137 and 26/69 bases (37%) identical, and 38/69 (54%) positive for amino acids 166-234 of Homo sapiens Protein-Tyrosine Phosphatase Sigma shown in Table 1J.

TABLE 1J
BLASTP of FCTR1 against Homo sapiens PTPsigma-(Brain) Precursor
PTNR:SPTREMBL-ACC:Q13332 PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, S PRECURSOR
(EC 3.1.3.48) (PROTEIN-TYROSINE PHOSPHATASE SIGMA) (R-PTP-SIGMA) (PTPRS) - HOMO
SAPIENS (HUMAN), 1948 AA.
LENGTH = 1948
SCORE = 109 (38.4 BITS), EXPECT = 0.00013, P = 0.00013
IDENTITIES = 32/83 (38%), POSITIVES = 45/83 (54%)
QUERY:	14	QLPGDD-PHISVQFRG---GPQRFEVTGW-------LQIQAVR-PSDEGTYRCLARNALG	61	(SEQ ID NO:45)
		|  ||  | ++   +|     ||||   +       |+|| +| | ||  | |+|+|++|
SBJCT:	55	QATGDPKPRVTWNKKGKKVNSQRFETIEFDESAGAVLRIQPLRTPRDENVYECVAQNSVG	114
QUERY:	62	QVEAPASLTVLTPDQLNSTGIPQL 85
		++   | ||||  ||| | | | +
SBJCT:	115	EITVHAKLTVLREDQLPS-GFPNI 137
SCORE = 88 (31.0 BITS), EXPECT = 0.023, P = 0.022
IDENTITIES = 26/69 (37%), POSITIVES = 38/69 (55%)
QUERY:	4	IEWRKDGLDIQLPGDDPHISVQFRGGPQRFEVT---GWLQIQAVRPSDEGTYRCLARNAL	60
		| | || | +     +  |  | |   + || |   | |||++   +|+| | |+| |+
SBJCT:	166	ITWFKDFLPVDPSASNGRIK-QLRS--ETFESTPIRGALQIESSEETDQGKYECVATNSA	222
QUERY:	61	G-QVEAPASLTV 71
		| +  +||+|+|
SBJCT:	223	GVRYSSPANLYV 234

[0037] A ClustalW analysis comparing the protein of the invention with related protein sequences is given in Table 1K, with FCTR1 shown on line 2. In the ClustalW alignment of the FCTR1 protein, as well as all other ClustalW analyses herein, the black outlined amino acid residues indicate regions of conserved sequence (i.e., regions that may be required to preserve structural or functional properties), whereas non-highlighted amino acid residues are less conserved and can potentially be mutated to a much broader extent without altering protein structure or function.

[0038] IGFBP is expressed in neurostem cell and developing central nervous system. MAC-25, a follistatin like protein is a growth suppressor of osteosarcoma cells, and meningiomas. DCC is expressed in most normal tissues especially in colonic mucosa, but is deleted in colorectal cancers.

[0039] Since FCTR1 has similarity to these proteins (shown in BlastP, Tables 1C-1J, and in clustalW, Table 1K) it is likely that it has similar function. Therefore FCTR1 could function as on or more of the following: a tumor suppressor geneor regulator of neurological system development.

[0040] Based on the protein similarity and tissue expression, FCTR1 may be useful in the following diseases and uses:

[0041] (i) Tissue regeneration in vitro and in vivo

[0042] (ii) Neurological disorders, neurodegenerative disorders, nerve trauma

[0043] (iii) Reproductive health

[0044] (iv) Immunological disorders, allergy and infection

[0045] (v) In cancer as a diagnostic and prognostic marker, as well as a protein therapeutic

[0046] FCTR2

[0047] FCTR2 (alternatively referred to herein as AC012614—1.0.123), is a growth factor bearing sequence similarity to human KIAA1061 protein and to genes involved in neuronal development and reproductive physiology (e.g., cell adhesion molecules, follistatin, roundabout and frazzled). FCTR2 is a full-length clone of 5502 nucleotides, including the entire coding sequence of a 815 amino acid protein. This sequence is expressed in glioma, osteoblast, other cancer cells, lung carcinoma, small intestine (This sequence maps to Unigene Hs. 123420 which is expressed in brain, breast, kidney, pancreas, pooled tissue).

[0048] A FCTR2 ORF begins with an ATG initiation codon at nucleotides 420422 and ends with a TGA codon at nucleotides 2865-2867. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 2A, and the start and stop codons are in bold letters.

TABLE 2A
FCTR2 Nucleotide Sequence.
CAATTTCACACAGGAAACAGCTATGCCATGATTACGCAAGTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTG (SEQ ID NO:3)
TGCTGGAATTCGGCTTACTCACTATAGGGCTCGAGCGGCTGCCCGGGCAGGTCATTAATTCCATTTCTTTTTAGAGTATC
ACAGCTTTCTCCTTCACTGACCACCCTTTGCTTCCTGTCAGAAAGCCCTGGACAGAACTCTCTGTGGGATTCTGCCCATG
TTTCTGAGATATCGCCTCAATTGTCCTGGCTGGGCTGTCGGGTCTGCCCGTTTTACAGATGGGCAAACTGGAGTGGGAAG
TATCCGGGTGGCTTCCTCAGGCCTGCAGCTGGTGGAGCAGCTACTGAAACAATCAGGAGCCCAGAAGCTTTGAAGTCACA
AGAAGAGAAGACTCCCAGAATGCAGTGTGATGTTGGTGATGGACGCCTGTTTCGCCTTTCACTTAAACGTGCCCTTTCCA
GCTGCCCTGACCTCTTTGGGCTTTCCAGCCGCAACGAGCTGCTGGCCTCCTGCGGGAAGAAGTTCTGCAGCCGAGGGAGC
CGGTGCGTGCTCAGCAGGAAGACAGGGGAGCCCGAATGCCAGTGCCTGGAGGCATGCAGGCCCAGCTACGTGCCTGTGTG
CGGCTCTGATGGGAGGTTTTATGAAAACCACTGTAAGCTCCACCGTGCTGCTTGCCTCCTGGGAAAGAGGATCACCGTCA
TCCACAGCAAGGACTGTTTCCTCAAAGGTGACACGTGCACCATGGCCGGCTACGCCCGCTTGAAGAATGTCCTTCTGGCA
CTCCAGACCCGTCTGCAGCCACTCCAAGAAGGAGACAGCAGACAAGACCCTGCCTCCCAGAAGCGCCTCCTGGTGCAATC
TCTGTTCAGGGACTTAGATGCAGATGGCAATGGCCACCTCAGCAGCTCCGAACTGGCTCAGCATGTGCTGAAGAAGCAGG
ACCTGGATGAAGACTTACTTGGTTGCTCACCAGGTGACCTCCTCCGATTTGACGATTACAACAGTGACAGCTCCCTGACC
CTCCGCGAGTTCTACATGGCCTTCCAAGTGGTTCAGCTCAGCCTCGCCCCCGAGGACAGGGTCAGTGTGACCACAGTGAC
CGTGGGGCTGAGCACAGTGCTGACCTGCGCCGTCCATGGAGACCTGAGGCCACCAATCATCTGGAAGCGCAACGGGCTCA
CCCTGAACTTCCTGGACTTGGAAGACATCAATGACTTTGGAGAGGATGATTCCCTGTACATCACCAAGGTGACCACCATC
CACATGGGCAATTACACCTGCCATGCTTCCGGCCACGAGCAGCTGTTCCAGACCCACGTCCTGCAGGTGAATGTGCCGCC
AGTCATCCGTGTCTATCCAGAGAGCCAGGCACAGGAGCCTGGAGTGGCAGCCAGCCTAAGATGCCATGCTGAGGGCATTC
CCATGCCCAGAATCACTTGGCTGAAAAACGGCGTGGATGTCTCAACTCAGATGTCCAAACAGCTCTCCCTTTTAGCCAAT
GGGAGCGAACTCCACATCAGCAGTGTTCGGTATGAAGACACAGGGGCATACACCTGCATTGCCAAAAATGAAGTGGGTGT
GGATGAAGATATCTCCTCGCTCTTCATTGAAGACTCAGCTAGAAAGACCCTTGCAAACATCCTGTGGCGAGAGGAAGGCC
TCAGCGTGGGAAACATGTTCTATGTCTTCTCCGACGACGGTATCATCGTCATCCATCCTGTGGACTGTGAGATCCAGAGG
CACCTCAAACCCACGGAAAAGATTTTCATCAGCTATGAAGAAATCTGTCCTCAAAGAGAAAAAAATGCAACCCAGCCCTG
CCAGTGGGTATCTGCAGTCAATGTCCGGAACCGGTACATCTATGTGGCCCAGCCAGCACTGAGCAGAGTCCTTGTGGTCG
ACATCCAAGCCCAGAAAGTCCTACAGTCCATAGGTGTGGACCCTCTGCCGGCTAAGCTGTCCTATGACAAGTCACATGAC
CAAGTGTGGGTCCTGAGCTGGGGGGACGTGCACAAGTCCCGACCAAGTCTCCAGGTGATCACAGAAGCCAGCACCGGCAA
GAGCCAGCACCTCATCCGCACACCCTTTGCAGGAGTGGATGATTTCTTCATTCCCCCAACAAACCTCATCATCAACCACA
TCAGGTTTGGCTTCATCTTCAACAAGTCTGATCCTGCAGTCCACAAGGTGGACCTGGAAACAATGATGCCCCTCAAGACC
ATCGGCCTGCACCACCATGGCTGCGTGCCCCAGGCCATGGCACACACCCACCTGGGCGGCTACTTCTTCATCCAGTGCCG
ACAGGACAGCCCCGCCTCTGCTGCCCGACAGCTGCTCGTTGACAGTGTCACAGACTCTGTGCTTGGCCCCAATGGTGATG
TAACAGGCACCCCACACACATCCCCCGACGGGCGCTTCATAGTCAGTGCTGCAGCTGACAGCCCCTGGCTGCACGTGCAG
GAGATCACAGTGCGGGGCGAGATCCAGACCCTGTATGACCTGCAAATAAACTCGGGCATCTCAGACTTGGCCTTCCAGCG
CTCCTTCACTGAAAGCAATCAATACAACATCTACGCGGCTCTGCACACGGAGCCGGACCTGCTGTTCCTGGAGCTGTCCA
CGGGGAAGGTGGGCATGCTGAAGAACTTAAAGGAGCCACCCGCAGGGCCAGCTCAGCCCTGGGGGGGTACCCACAGAATC
ATGAGGGACAGTGGGCTGTTTGGACAGTACCTCCTCACACCAGCCCGAGAGTCACTGTTCCTCATCAATGGGAGACAAAA
CACGCTGCGGTGTGAGGTGTCAGGTATAAAGGGGGGGACCACAGTGGTGTGGGTGGGTGAGGTATGAAGGGCCCAGAGCA
GAGCCCTGGGCCAAGGAACACCCCCTAGTCCTGACACTGCAGCCTCAAGCAGGTACGCTGTACATTTTTACAGACAAAAG
CAAAAACCTGTACTCGCTTTGTGGTTCAACACTGGTCTCCTTGCAAGTTTCCTAGTATAAGGTATGCGCTGCTACCAAGA
TTGGGGTTTTTTCGTTAGGAAGTATGATTTATGCCTTGAGCTACGATGAGAACATATGCTGCTGTGTAAAGGGATCATTT
CTGTGCCAAGCTGCACACCGAGTGACCTGGGGACATCATGGAACCAAGGGATCCTGCTCTCCAAGCAGACACCTCTGTCA
GTTGCCTTCACATAGTCATTGTCCCTTACTGCCAGACCCAGCCAGACTTTGCCCTGACGGAGTGGCCCGGAAGCAGAGGC
CGACCAGGAGCAGGGGCCTCCCTCCCGAACTGAAAGCCCATCCGTCCTCGCGTGGGACCGCATCTTCTCCCTCGCAGCTG
CTTCTTGCTTTTCTTTCCATTTGACTTGCTGTAAGCCTGAGGGAGAGCCAACAAGACTTACTGCATCTTGGGGGATGGGG
AAATCACTCACTTTATTTTGGAAATTTTTGATTAAAAAAAAATTTTATAATCTCAAATGCTAGTAAGCAGAAAGATGCTC
TCCGAGGTCCAACTATATCCTTCCCTGCCTTAGGCCGAGTCTCGGGGGTGGTCACAACCCCACATCCCACAGCCAGAAAG
AACAATGGTCATCTGAGAATACTGGCCCTGTCGACTATTGCCACCCTGCTTCTCCAAGAGCAGACCAGGCCACCTCATCC
GTAAGGACTCGGTTCTGTGTTGGGACCCCAAAAAACCAGAACAAGTTCTGTGTGCCTCCTTTCAGCACAGAAGGGAGACA
TCTCATTAGTCAGGTCTGGTACCCCAGATTCAGGGCAGACTGGGCTTGCCTGGCAAGGTATGGGTGGCCTCCAGGCTCAA
TGCAGAAACCCCAAGGACACGAGTGGGGCCAGGTGAGTTCCTGAAGCTATACCTTTTCAAAACAGATTTTGTTTTCCTAC
CTGTGGCCCATCCACTCCTCTCTGGTACCCCATCCCCGCATCAGCACTGCAGAGAGAACACATTTCGGCGAGGGTTTTCT
TACCCACATTCCCCAATCAATACACACACACTGCAGAACCCAGAACAGAAGGCCACAGGCTGGCACTACTGCATTCTCCT
TATGTGTCTCAGGCTGTGGTGACTCTCACATGGGCATCGAAGAAGTACAACCCACATAGCCCTCTGGAGACCGCCTAGAT
CAGAGACTCAGCAAAAACAGGCTCGCCTTCCCTCTCCCACATATGAGTGGAACTTACATGTGTCCTGGTTTGAATGATCA
TTTTGCAAGCCACACGGGTTGGGAGAGGTGGTCTCACCACAGACGTCTTTGCTAATTTGGCCACCTTCACCTACTGACAT
GACCAGGATTTTCCTTTGCCATTAAGGAATGAACTCTTTCAAGGAGAGGAAACCCTAGACTCTGTGTCACTCTCAACACA
CACAGCTCCTTTCACTCCTGCCTGACTGCCAAGCCACCTGCATCCCCCGCCCCAGATCTCATGAGATCAATCACTTGTAT
GTCTCACGCAACTTGGTCCACCAAACGCCTGTCCCCTGTAACTCCTAGGGGTGCGCCTAGACAGGTACGTCTGTTTTTTA
TTTTAAAAGATATGCTATGTAGATATAAGTTGAGGAAGCTCACCTCAAAAGCCTAGAATGCAGTTTCACAGTAGCTGGGA
TGCATGGATGACCCATCTCACCCCTTTTTTTTTCCTGCCTCAATATCTTGATATGTTATGTTTACTCCCAATCTCCCATT
TTTACCACTAAAATTCTCCAACTTTCATAAACTTTTTTTTGGAAAAATTTCCATTGTATCAGCCCCTGACAGAAAAAGGA
TCTCTGAGCCTAAAGGAGGAAAAGTCCCACCAACTACCAGACCAGAACACGAGCCCCTCTGGGCAGCAGGATTCCTAAGT
CAAAGACCAGTTTGACCCAAACTGGCCTTTTAAAATAATCAGGAGTGACAGAGTCAACTTCTGCAGCACCTGCTTCTCCC
CCACTGTCCCTTCCATCTTGGAATGTGTCTAAAAAAGCATAGCTGCCCTTTGCTGTCCTCAGAGTGCATTTCCTGGAGAC
GGCAGGCTTAGGTCTCACTGACAGCATGCCAGACACAACTGAATCGAAGCAGGCCTGAAGCCTAGGTCAGGGTTTCAGGA
GTCCAGCCCCAGGAGGCAAAGTCACCAATGCAGGGAGGTAAATGCCTTTTGGCAGGAAAACCAATAGAGTTGGTTGGGTG
GGGAGTCAGGGGTGGGAGGAGAAGGAGGAAGAGGAGGAAGGCCAGACTGGCCTGCCCTTTCTCCCATACTTCACCCCAGC
AGAGGTTCATGGGACACAGTTGGAAAGCCACTGGGAGGAAATGCCTCACTACAGGGGGGCCTCCTGTAGCAAGCCCAGCC
GGTAATCCTCCTAATGAACCCACAAGGTCAATTCACAACTGATATCTTAGCTATTAAAGAAGTACTGACTTTACCAAAAG
AATCATCAAGAAAGCTATTTATATAAACCCCCTCAGTCATTTTGAAATAAAATTAATTTTAC

[0049] The predicted amino acid sequence of FCTR2 protein corresponding to the foregoing nucleotide sequence is reported in Table 2B. FCTR2 was searched against other databases using SignalPep and PSort search protocols. The protein is most likely located in the mitochondrial matrix space (certainty=0.4718) and seems to have no N-terminal signal sequence. The predicted molecular weight is 90346.9 Daltons.

TABLE 2B
FCTR2 Protein Sequence.
MQCDVGDGRLFRLSLKRALSSCPDLFGLSSRNELLASCGKKFCSRGSRCVLSRKTGEPECQCLEACRPSYVPVCGSDGRFYEN (SEQ ID NO:4)
HCKLHRAACLLGKRITVIHSKDCFLKGDTCTMAGYARLKNVLLALQTRLQPLQEGDSRQDPASQKRLLVESLFRDLDADGNGH
LSSSELAQHVLKKQDLDEDLLGCSPGDLLRFDDYNSDSSLTLREFYMAFQVVQLSLAPEDRVSVTTVTVGLSTVLTCAVHGDL
RPPIIWKRNGLTLNFLDLEDINDFGEDDSLYITKVTTIHMGNYTCHASGHEQLFQTHVLQVNVPPVIRVYPESQAQEPGVAAS
LRCHAEGIPMPRITWLKNGVDVSTQMSKQLSLLANGSELHISSVRYEDTGAYTCIAKNEVGVDEDISSLFIEDSARKTLANIL
WREEGLSVGNMFYVFSDDGIIVIHPVDCEIQRHLKPTEKIFMSYEEICPQREKNATQPCQWVSAVNVRNRYIYVAQPALSRVL
VVDIQAQKVLQSIGVDPLPAKLSYDKSHDQVWVLSWGDVHKSRPSLQVITEASTGQSQHLIRTPFAGVDDFFIPPTNLIINHI
RFGFIFNKSDPAVHKVDLETMMPLKTIGLHHHGCVPQAMAHTHLGGYFFIQCRQDSPASAARQLLVDSVTDSVLGPNGDVTGT
PHTSPDGRFIVSAAADSPWLHVQEITVRGEIQTLYDLQINSGISDLAFQRSFTESNQYNIYAALHTEPDLLFLELSTGKVGML
KNLKEPPAGPAQPWGGTHRIMRDSGLFGQYLLTPARESLFLINGRQNTLRCEVSGIKGGTTVVWVGEV

[0050] In a BLASTN search it was also found that nucleotides 784-5502 of FCTR2 nucleic acid had 4672 of 4719 bases (99%) identical to Homo sapiens mRNA for KIAA1061 protein, partial cds (GenBank Acc:AB028984) (Table 2C).

TABLE 2C
BLASTN of FCTR2 against Homo sapiens mRNA for KIAA1061 protein
>GI|5689458|DBJ|AB028984.1/AB028984 HOMO SAPIENS MRNA FOR KIAA1061 PROTEIN, PARTIAL CDS
LENGTH = 4719
SCORE = 9075 BITS (4578), EXPECT = 0.0
IDENTITIES = 4672/4719 (99%)
STRAND = PLUS/PLUS
QUERY:	784	AGAATGTCCTTCTGGCACTCCAGACCCGTCTGCAGCCACTCCAAGAAGGAGACAGCAGAC	843	(SEQ ID NO:46)
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1	AGAATGTCCTTCTGGCACTCCAGACCCGTCTGCAGCCACTCCAAGAAGGAGACAGCAGAC	60
QUERY:	844	AAGACCCTGCCTCCCAGAAGCGCCTCCTGGTGGAATCTCTGTTCAGGGACTTAGATGCAG	903
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	61	AAGACCCTGCCTCCCAGAAGCGCCTCCTGGTGGAATCTCTGTTCAGGGACTTAGATGCAG	120
QUERY:	904	ATGGCAATGGCCACCTCAGCAGCTCCGAACTGGCTCAGCATGTGCTGAAGAAGCAGGACC	963
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	121	ATGGCAATGGCCACCTCAGCAGCTCCGAACTGGCTCAGCATGTGCTGAAGAAGCAGGACC	180
QUERY:	964	TGGATGAAGACTTACTTGGTTGCTCACCAGGTGACCTCCTCCGATTTGACGATTACACAA	1023
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	181	TGGATGAAGACTTACTTGGTTGCTCACCAGGTGACCTCCTCCGATTTGACGATTACAACA	240
QUERY:	1024	GTGACAGCTCCCTGACCCTCCGCGAGTTCTACATGGCCTTCCAAGTGGTTCAGCTCAGCC	1083
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	241	GTGACAGCTCCCTGACCCTCCGCGAGTTCTACATGGCCTTCCAAGTGGTTCAGCTCAGCC	300
QUERY:	1084	TCGCCCCCGAGGACAGGGTCAGTGTGACCACAGTGACCGTGGGGCTGAGCACAGTGCTGA	1143
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	301	TCGCCCCCGAGGACAGGGTCAGTGTGACCACAGTGACCGTGGGGCTGAGCACAGTGCTGA	360
QUERY:	1144	CCTGCGCCGTCCATGGAGACCTGAGGCCACCAATCATCTGGAAGCGCAACGGGCTCACCC	1203
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	361	CCTGCGCCGTCCATGGAGACCTGAGGCCACCAATCATCTGGAAGCGCAACGGGCTCACCC	420
QUERY:	1204	TGAACTTCCTGGACTTGGAAGACATCAATGACTTTGGAGAGGATGATTCCCTGTACATCA	1263
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	421	TGAACTTCCTGGACTTGGAAGACATCAATGACTTTGGAGAGGATGATTCCCTGTACATCA	480
QUERY:	1264	CCAAGGTGACCACCATCCACATGGGCAATTACACCTGCCATGCTTCCGGCCACGAGCAGC	1323
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	481	CCAAGGTGACCACCATCCACATGGGCAATTACACCTGCCATGCTTCCGGCCACGAGCAGC	540
QUERY:	1324	TGTTCCAGACCCACGTCCTGCAGGTGAATGTGCCGCCAGTCATCCGTGTCTATCCAGAGA	1383
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	541	TGTTCCAGACCCACGTCCTGCAGGTGAATGTGCCGCCAGTCATCCGTGTCTATCCAGAGA	600
QUERY:	1384	GCCAGGCACAGGAGCCTGGAGTGGCAGCCAGCCTAAGATGCCATGCTGAGGGCATTCCCA	1443
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	601	GCCAGGCACAGGAGCCTGGAGTGGCAGCCAGCCTAAGATGCCATGCTGAGGGCATTCCCA	660
QUERY:	1444	TGCCCAGAATCACTTGGCTGAAAAACGGCGTGGATGTCTCAACTCAGATGTCCAAACAGC	1503
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	661	TGCCCAGAATCACTTGGCTGAAAAACGGCGTGGATGTCTCAACTCAGATGTCCAAACAGC	720
QUERY:	1504	TCTCCCTTTTAGCCAATGGGAGCGAACTCCACATCAGCAGTGTTCGGTATGAAGACACAG	1563
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	721	TCTCCCTTTTAGCCAATGGGAGCGAACTCCACATCAGCAGTGTTCGGTATGAAGACACAG	780
QUERY:	1564	GGGCATACACCTGCATTGCCAAAAATGAAGTGGGTGTGGATGAAGATATCTCCTCGCTCT	1623
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	781	GGGCATACACCTGCATTGCCAAAAATGAAGTGGGTGTGGATGAAGATATCTCCTCGCTCT	840
QUERY:	1624	TCATTGAAGACTCAGCTAGAAAGACCCTTGCAAACATCCTGTGGCGAGAGGAAGGCCTCA	1683
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	841	TCATTGAAGACTCAGCTAGAAAGACCCTTGCAAACATCCTGTGGCGAGAGGAAGGCCTCA	900
QUERY:	1684	GCGTGGGAAACATGTTCTATGTCTTCTCCGACGACGGTATCATCGTCATCCATCCTGTGG	1743
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	901	GCGTGGGAAACATGTTCTATGTCTTCTCCGACGACGGTATCATCGTCATCCATCCTGTGG	960
QUERY:	1744	ACTGTGAGATCCAGAGGCACCTCAAACCCACGGAAAAGATTTTCATGAGCTATGAAGAAA	1803
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	961	ACTGTGAGATCCAGAGGCACCTCAAACCCACGGAAAAGATTTTCATGAGCTATGAAGAAA	1020
QUERY:	1804	TCTGTCCTCAAAGAGNNNNNNNTGCAACCCAGCCCTGCCAGTGGGTATCTGCAGTCAATG	1863
		||||||||||||||        ||||||||||||||||||||||||||||||||||||||
SBJCT:	1021	TCTGTCCTCAAAGAGAAAAAAATGCAACCCAGCCCTGCCAGTGGGTATCTGCAGTCAATG	1080
QUERY:	1864	TCCGGAACCGGTACATCTATGTGGCCCAGCCAGCACTGAGCAGAGTCCTTGTGGTCGACA	1923
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1081	TCCGGAACCGGTACATCTATGTGGCCCAGCCAGCACTGAGCAGAGTCCTTGTGGTCGACA	1140
QUERY:	1924	TCCAAGCCCAGAAAGTCCTACAGTCCATAGGTGTGGACCCTCTGCCGGCTAAGCTGTCCT	1983
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1141	TCCAAGCCCAGAAAGTCCTACAGTCCATAGGTGTGGACCCTCTGCCGGCTAAGCTGTCCT	1200
QUERY:	1984	ATGACAAGTCACATGACCAAGTGTGGGTCCTGAGCTGGGGGGACGTGCACAAGTCCCGAC	2043
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1201	ATGACAAGTCACATGACCAAGTGTGGGTCCTGAGCTGGGGGGACGTGCACAAGTCCCGAC	1260
QUERY:	2044	CAAGTCTCCAGGTGATCACAGAAGCCAGCACCGGCCAGAGCCAGCACCTCATCCGCACAC	2103
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1261	CAAGTCTCCAGGTGATCACAGAAGCCAGCACCGGCCAGAGCCAGCACCTCATCCGCACAC	1320
QUERY:	2104	CCTTTGCAGGAGTGGATGATTTCTTCATTCCCCCAACAAACCTCATCATCAACCACATCA	2163
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1321	CCTTTGCAGGAGTGGATGATTTCTTCATTCCCCCAACAAACCTCATCATCAACCACATCA	1380
QUERY:	2164	GGTTTGGCTTCATCTTCAACAAGTCTGATCCTGCAGTCCACAAGGTGGACCTGGAAACAA	2223
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1381	GGTTTGGCTTCATCTTCAACAAGTCTGATCCTGCAGTCCACAAGGTGGACCTGGAAACAA	1440
QUERY:	2224	TGATGCCCCTCAAGACCATCGGCCTGCACCACCATGGCTGCGTGCCCCAGGCCATGGCAC	2283
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1441	TGATGCCCCTCAAGACCATCGGCCTGCACCACCATGGCTGCGTGCCCCAGGCCATGGCAC	1500
QUERY:	2284	ACACCCACCTGGGCGGCTACTTCTTCATCCAGTGCCGACAGGACAGCCCCGCCTCTGCTG	2343
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1501	ACACCCACCTGGGCGGCTACTTCTTCATCCAGTGCCGACAGGACAGCCCCGCCTCTGCTG	1560
QUERY:	2344	CCCGACAGCTGCTCGTTGACAGTGTCACAGACTCTGTGCTTGGCCCCAATGGTGATGTAA	2403
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1561	CCCGACAGCTGCTCGTTGACAGTGTCACAGACTCTGTGCTTGGCCCCAATGGTGATGTAA	1620
QUERY:	2404	CAGGCACCCCACACACATCCCCCGACGGGCGCTTCATAGTCAGTGCTGCAGCTGACAGCC	2463
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1621	CAGGCACCCCACACACATCCCCCGACGGGCGCTTCATAGTCAGTGCTGCAGCTGACAGCC	1680
QUERY:	2464	CCTGGCTGCACGTGCAGGAGATCACAGTGCGGGGCGAGATCCAGACCCTGTATGACCTGC	2523
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1681	CCTGGCTGCACGTGCAGGAGATCACAGTGCGGGGCGAGATCCAGACCCTGTATGACCTGC	1740
QUERY:	2524	AAATAAACTCGGGCATCTCAGACTTGGCCTTCCAGCGCTCCTTCACTGAAAGCAATCAAT	2583
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1741	AAATAAACTCGGGCATCTCAGACTTGGCCTTCCAGCGCTCCTTCACTGAAAGCAATCAAT	1800
QUERY:	2584	ACAACATCTACGCGGCTCTGCACACGGAGCCGGACCTGCTGTTCCTGGAGCTGTCCACGG	2643
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1801	ACAACATCTACGCGGCTCTGCACACGGAGCCGGACCTGCTGTTCCTGGAGCTGTCCACGG	1860
QUERY:	2644	GGAAGGTGGGCATGCTGAAGAACTTAAAGGAGCCACCCGCAGGGCCAGCTCAGCCCTNNN	2703
		|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1861	GGAAGGTGGGCATGCTGAAGAACTTAAAGGAGCCACCCGCAGGGCCAGCTCAGCCCTGGG	1920
QUERY:	2704	NNNNTACCCACAGAATCATGAGGGACAGTGGGCTGTTTGGACAGTACCTCCTCACACCAG	2763
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1921	GGGGTACCCACAGAATCATGAGGGACAGTGGGCTGTTTGGACAGTACCTCCTCACACCAG	1980
QUERY:	2764	CCCGAGAGTCACTGTTCCTCATCAATGGGAGACAAAACACGCTCCGGTGTGAGGTGTCAG	2823
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1981	CCCGAGAGTCACTGTTCCTCATCAATGGGAGACAAAACACGCTGCGGTGTGAGGTGTCAG	2040
QUERY:	2824	GTATAAANNNNNNNACCACAGTGGTGTGGGTGGGTGAGGTATGAAGGGCCCAGAGCAGAG	2883
		|||||||       ||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2041	GTATAAAGGGGGGGACCACAGTGGTGTGGGTGGGTGAGGTATGAAGGGCCCAGAGCAGAG	2100
QUERY:	2884	CCCTGGGCCAAGGAACACCCCCTAGTCCTGACACTGCAGCCTCAAGCAGGTACGCTGTAC	2943
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2101	CCCTGGGCCAAGGAACACCCCCTAGTCCTGACACTGCAGCCTCAAGCAGGTACGCTGTAC	2160
QUERY:	2944	ATTTTTACAGACAAAAGCAAAAACCTGTACTCGCTTTGTGGTTCAACACTGGTCTCCTTG	3003
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2161	ATTTTTACAGACAAAAGCAAAAACCTGTACTCGCTTTGTGGTTCAACACTGGTCTCCTTG	2220
QUERY:	3004	CAAGTTTCCTAGTATAAGGTATGCGCTGCTACCAAGATTGGGGTTTTTTCGTTAGGAAGT	3063
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2221	CAAGTTTCCTAGTATAAGGTATGCGCTGCTACCAAGATTGGGGTTTTTTCGTTAGGAAGT	2280
QUERY:	3064	ATGATTTATGCCTTGAGCTACGATGAGAACATATGCTGCTGTGTAAAGGGATCATTTCTG	3123
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2281	ATGATTTATGCCTTGAGCTACGATGAGAACATATGCTGCTGTGTAAAGGGATCATTTCTG	2340
QUERY:	3124	TGCCAAGCTGCACACCGAGTGACCTGGGGACATCATGGAACCAAGGGATCCTGCTCTCCA	3183
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2341	TGCCAAGCTGCACACCGAGTGACCTGGGGACATCATGGAACCAAGGGATCCTGCTCTCCA	2400
QUERY:	3184	AGCAGACACCTCTGTCAGTTGCCTTCACATAGTCATTGTCCCTTACTGCCAGACCCAGCC	3243
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2401	AGCAGACACCTCTGTCAGTTGCCTTCACATAGTCATTGTCCCTTACTGCCAGACCCAGCC	2460
QUERY:	3244	AGACTTTGCCCTGACGGAGTGGCCCGGAAGCAGAGGCCGACCAGGAGCAGGGGCCTCCCT	3303
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2461	AGACTTTGCCCTGACGGAGTGGCCCGGAAGCAGAGGCCGACCAGGAGCAGGGGCCTCCCT	2520
QUERY:	3304	CCCGAACTGAAAGCCCATCCGTCCTCGCGTGGGACCGCATCTTCTCCCTCGCAGCTGCTT	3363
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2521	CCCGAACTGAAAGCCCATCCGTCCTCGCGTGGGACCGCATCTTCTCCCTCGCAGCTGCTT	2580
QUERY:	3364	CTTGCTTTTCTTTCCATTTGACTTGCTGTAAGCCTGAGGGAGAGCCAACAAGACTTACTG	3423
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2581	CTTGCTTTTCTTTCCATTTGACTTGCTGTAAGCCTGAGGGAGAGCCAACAAGACTTACTG	2640
QUERY:	3424	CATCTTGGGGGATGGGGAAATCACTCACTTTATTTTGGAAATTTTTGATTNNNNNNNNNT	3483
		||||||||||||||||||||||||||||||||||||||||||||||||||         |
SBJCT:	2641	CATCTTGGGGGATGGGGAAATCACTCACTTTATTTTGGAAATTTTTGATTAAAAAAAAAT	2700
QUERY:	3484	TTTATAATCTCAAATGCTAGTAAGCAGAAAGATGCTCTCCGAGGTCCAACTATATCCTTC	3543
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2701	TTTATAATCTCAAATGCTAGTAAGCAGAAAGATGCTCTCCGAGGTCCAACTATATCCTTC	2760
QUERY:	3544	CCTGCCTTAGGCCGAGTCTCGGGGGTGGTCACAACCCCACATCCCACAGCCAGAAAGAAC	3603
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2761	CCTGCCTTAGGCCGAGTCTCGGGGGTGGTCACAACCCCACATCCCACAGCCAGAAAGAAC	2820
QUERY:	3604	AATGGTCATCTGAGAATACTGGCCCTGTCGACTATTGCCACCCTGCTTCTCCAAGAGCAG	3663
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2821	AATGGTCATCTGAGAATACTGGCCCTGTCGACTATTGCCACCCTGCTTCTCCAAGAGCAG	2880
QUERY:	3664	ACCAGGCCACCTCATCCGTAAGGACTCGGTTCTGTGTTGGGACCCCAAAAAACCAGAACA	3723
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2881	ACCAGGCCACCTCATCCGTAAGGACTCGGTTCTGTGTTGGGACCCCAAAAAACCAGAACA	2940
QUERY:	3724	AGTTCTGTGTGCCTCCTTTCAGCACAGAAGGGAGACATCTCATTAGTCAGGTCTGGTACC	3783
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2941	AGTTCTGTGTGCCTCCTTTCAGCACAGAAGGGAGACATCTCATTAGTCAGGTCTGGTACC	3000
QUERY:	3784	CCAGATTCAGGGCAGACTGGGCTTGCCTGGCAAGGTATGGGTGGCCTCCAGGCTCAATGC	3843
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3001	CCAGATTCAGGGCAGACTGGGCTTGCCTGGCAAGGTATGGGTGGCCTCCAGGCTCAATGC	3060
QUERY:	3844	AGAAACCCCAAGGACACGAGTGGGGCCAGGTGAGTTCCTGAAGCTATACCTTTTCAAAAC	3903
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3061	AGAAACCCCAAGGACACGAGTGGGGCCAGGTGAGTTCCTGAAGCTATACCTTTTCAAAAC	3120
QUERY:	3904	AGATTTTGTTTTCCTACCTGTGGCCCATCCACTCCTCTCTGGTACCCCATCCCCGCATCA	3963
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3121	AGATTTTGTTTTCCTACCTGTGGCCCATCCACTCCTCTCTGGTACCCCATCCCCGCATCA	3180
QUERY:	3964	GCACTGCAGAGAGAACACATTTCGGCGAGGGTTTTCTTACCCACATTCCCCAATCAATAC	4023
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3181	GCACTGCAGAGAGAACACATTTCGGCGAGGGTTTTCTTACCCACATTCCCCAATCAATAC	3240
QUERY:	4024	ACACACACTGCAGAACCCAGAACAGAAGGCCACAGGCTGGCACTACTGCATTCTCCTTAT	4083
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3241	ACACACACTGCAGAACCCAGAACAGAAGGCCACAGGCTGGCACTACTGCATTCTCCTTAT	3300
QUERY:	4084	GTGTCTCAGGCTGTGGTGACTCTCACATGGGCATCGAAGAAGTACAACCCACATAGCCCT	4143
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3301	GTGTCTCAGGCTGTGGTGACTCTCACATGGGCATCGAAGAAGTACAACCCACATAGCCCT	3360
QUERY:	4144	CTGGAGACCGCCTAGATCAGAGACTCAGCAAAAACAGGCTCGCCTTCCCTCTCCCACATA	4203
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3361	CTGGAGACCGCCTAGATCAGAGACTCAGCAAAAACAGGCTCGCCTTCCCTCTCCCACATA	3420
QUERY:	4204	TGAGTGGAACTTACATGTGTCCTGGTTTGAATGATCATTTTGCAAGCCACACGGGTTGGG	4263
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3421	TGAGTGGAACTTACATGTGTCCTGGTTTGAATGATCATTTTGCAAGCCACACGGGTTGGG	3480
QUERY:	4264	AGAGGTGGTCTCACCACAGACGTCTTTGCTAATTTGGCCACCTTCACCTACTGACATGAC	4323
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3481	AGAGGTGGTCTCACCACAGACGTCTTTGCTAATTTGGCCACCTTCACCTACTGACATGAC	3540
QUERY:	4324	CAGGATTTTCCTTTGCCATTAAGGAATGAACTCTTTCAAGGAGAGGAAACCCTAGACTCT	4383
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3541	CAGGATTTTCCTTTGCCATTAAGGAATGAACTCTTTCAAGGAGAGGAAACCCTAGACTCT	3600
QUERY:	4384	GTGTCACTCTCAACACACACAGCTCCTTTCACTCCTGCCTGACTGCCAAGCCACCTGCAT	4443
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3601	GTGTCACTCTCAACACACACAGCTCCTTTCACTCCTGCCTGACTGCCAAGCCACCTGCAT	3660
QUERY:	4444	CCCCCGCCCCAGATCTCATGAGATCAATCACTTGTATGTCTCACGCAACTTGGTCCACCA	4503
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3661	CCCCCGCCCCAGATCTCATGAGATCAATCACTTGTATGTCTCACGCAACTTGGTCCACCA	3720
QUERY:	4504	AACGCCTGTCCCCTGTAACTCCTAGGGGTGCGCCTAGACAGGTACGTCTGTTTTTTATTT	4563
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3721	AACGCCTGTCCCCTGTAACTCCTAGGGGTGCGCCTAGACAGGTACGTCTGTTTTTTATTT	3780
QUERY:	4564	TAAAAGATATGCTATGTAGATATAAGTTGAGGAAGCTCACCTCAAAAGCCTAGAATGCAG	4623
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3781	TAAAAGATATQCTATGTAGATATAAGTTGAGGAAGCTCACCTCAAAAGCCTAGAATGCAG	3840
QUERY:	4624	TTTCACAGTAGCTGGGATGCATGGATGACCCATCTCACCCCNNNNNNNNNCCTGCCTCAA	4683
		|||||||||||||||||||||||||||||||||||||||||         ||||||||||
SBJCT:	3841	TTTCACAGTAGCTGGGATGCATGGATGACCCATCTCACCCCTTTTTTTTTCCTGCCTCAA	3900
QUERY:	4684	TATCTTGATATGTTATGTTTACTCCCAATCTCCCATTTTTACCACTAAAATTCTCCAACT	4743
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3901	TATCTTGATATGTTATGTTTACTCCCAATCTCCCATTTTTACCACTAAAATTCTCCAACT	3960
QUERY:	4744	TTCATAAACNNNNNNNNGGAAAAATTTCCATTGTATCAGCCCCTGACAGAAAAAGGATCT	4803
		|||||||||        |||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3961	TTCATAAACTTTTTTTTGGAAAAATTTCCATTGTATCAGCCCCTGACAGAAAAAGCATCT	4020
QUERY:	4804	CTGAGCCTAAAGGAGGAAAAGTCCCACCAACTACCAGACCAGAACACGAGCCCCTCTGGG	4863
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4021	CTGAGCCTAAAGGAGGAAAAGTCCCACCAACTACCAGACCAGAACACGAGCCCCTCTGGG	4080
QUERY:	4864	CAGCAGGATTCCTAAGTCAAAGACCAGTTTGACCCAAACTGGCCTTTTAAAATAATCAGG	4923
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4081	CAGCAGGATTCCTAAGTCAAAGACCAGTTTGACCCAAACTGGCCTTTTAAAATAATCAGG	4140
QUERY:	4924	AGTGACAGAGTCAACTTCTGCAGCACCTGCTTCTCCCCCACTGTCCCTTCCATCTTGGAA	4983
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4141	AGTGACAGAGTCAACTTCTGCAaCACCTGCTTCTCCCCCACTGTCCCTTCCATCTTGGAA	4200
QUERY:	4984	TGTGTCTAAAAAAGCATAGCTGCCCTTTGCTGTCCTCAGAGTGCATTTCCTGGAGACGGC	5043
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4201	TGTGTCTAAAAAAGCATAGCTGCCCTTTGCTGTCCTCAGAGTGCATTTCCTGGAGACGGC	4260
QUERY:	5044	AGGCTTAGGTCTCACTGACAGCATGCCAGACACAACTGAATCGAAGCAGGCCTGAAGCCT	5103
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4261	AGGCTTAGGTCTCACTGACAGCATGCCAGACACAACTGAATCGAAGCAGGCCTGAAGCCT	4320
QUERY:	5104	AGGTCAGGGTTTCAGGAGTCCAGCCCCAGGAGGCAAAGTCACCAATGCAGGGACGTAAAT	5163
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4321	AGGTCAGGGTTTCAGGAGTCCAGCCCCAGGAGGCAAAGTCACCAATGCAGGGAGGTAAAT	4380
QUERY:	5164	GCCTTTTGGCAGGAAAACCAATAGAGTTGGTTGGGTGGGGAGTCAGGGGTGGGAGGAGAA	5223
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4381	GCCTTTTGGCAGGAAAACCAATAGAGTTGGTTGGGTGGGGAGTCAGGGGTGGGAGGAGAA	4440
QUERY:	5224	GGAGGAAGAGGAGGAAGGCCAGACTGGCCTGCCCTTTCTCCCATACTTCACCCCAGCAGA	5283
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4441	GGAGGAAGAGGAGGAAGGCCAGACTGGCCTGCCCTTTCTCCCATACTTCACCCCAGCAGA	4500
QUERY:	5284	GGTTCATGGGACACAGTTGGAAAGCCACTGGGAGGAAATGCCTCACTACAGGGGGGCCTC	5343
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4501	GGTTCATGGGACACAGTTGGAAAGCCACTGGGAGGAAATGCCTCACTACAGGGGGGCCTC	4560
QUERY:	5344	CTGTAGCAAGCCCAGCCGGTAATCCTCCTAATGAACCCACAAGGTCAATTCACAACTGAT	5403
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4561	CTGTAGCAAGCCCAGCCGGTAATCCTCCTAATGAACCCACAAGGTCAATTCACAACTGAT	4620
QUERY:	5404	ATCTTAGCTATTAAAGAAGTACTGACTTTACCAAAAGAATCATCAAGAAAGCTATTTATA	5463
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4621	ATCTTAGCTATTAAAGAAGTACTGACTTTACCAAAAGAATCATCAAGAAAGCTATTTATA	4680
QUERY:	5464	TAAACCCCCTCAGTCATTTTGAAATAAAATTAATTTTAC 5502
		|||||||||||||||||||||||||||||||||||||||
SBJCT:	4681	TAAACCCCCTCAGTCATTTTGAAATAAAATTAATTTTAC 4719

[0051] The FCTR2 amino acid sequence has 473 of 810 amino acid residues (58%) identical to, and 616 of 810 residues (76%) positive with, the 850 amino acid residue proteins from Homo sapiens KIAA1263 Protein fragment (ptnr: TREMBLNEW-ACC:BAA86577) (SEQ ID NO:47) (Table 2D).

TABLE 2D
BLASTP of FCTR2 against Homo sapiens KIAA1263 Protein fragment (SEQ ID NO:47)
ptnr: TREMBLNEW-ACC:BAA86577 KIAA1263 PROTEIN - Homo sapiens (Human), 850 aa
(fragment)
Length = 850
Score = 2573 (905.7 bits), Expect = 2.0e-267, P = 2.0e-267
Identities = 473/810 (58%), Positives = 616/810 (76%)
QUERY:	10	LFRLSLKRALSSCPDLFGLSSRNELLASCGKKFCSRGSRCVLSRKTGEPECQCLEACRPS	69
		| ||  |        + |   ++    ||  |+|  |  || ||+||+ || |++ |+
SBJCT:	40	LMRLRHKEKNQESSRVKGFMIQDGPFGSCENKYCGLGRHCVTSRETGQAECACMDLCKRH	99
QUERY:	70	YVPVCGSDGRFYENHCKLHRAACLLGKRITVIHSKDCFLKGDTCTMAGYARLKNVLLALQ	129
		| ||||||| ||||||++||||||  ++||++|++||| ||| |    |+++||+|| ||
SBJCT:	100	YKPVCGSDGEFYENHCEVHRAACLKKQKITIVHNEDCFFKGDKCKTTEYSKMKNMLLDLQ	159
QUERY:	130	TRLQPLQEGDSRQ-DPASQKRLLVESLFRDLDADGNGHLSSSELAQHVLKKQDLDEDLLG	188
		+   +|| ++   |  |+|+|||+ +|+  ||| || +  +|| | |+|+++| +||
SBJCT:	160	NQKYIMQENENPNGDDISRKKLLVDQMFKYFDADSNGLVDINELTQ-VIKQEELGKDLPD	218
QUERY:	189	CSPGDLLRFDDYNSDSSLTLREFYMAFQVVQLSLAPEDRVSVTTVTVGLSTVLTCAVHGD	248
		|+   ||++||+|+|  | | ||| ||||+||||  + + | |  ||| | || ||+ |
SBJCT:	219	CTLYVLLKYDDFNADKHLALEEFYRAFQVIQLSLPEDQKLSITAATVGQSAVLSCAIQGT	278
QUERY:	249	LRPPIIWKRNGLTLNFLDLEDINDFGEDDSLYITKVTTIHMGNYTCHASGHEQLFQTHVL	308
		|||||||||| + || ||||||||||+| ||||||||| |+|||||+| |+||++|||+
SBJCT:	279	LRPPIIWKRNNIILNNLDLEDINDFGDDGSLYITKVTTTHVGNYTCYADGYEQVYQTHIF	338
QUERY:	309	QVNVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITWLKNGVDVSTQMSKQLSLLANG	368
		||||||||||||||||+|||| ||||||||||| |++ |||||+|++ ++||||+| |||
SBJCT:	339	QVNVPPVIRVYPESQAREPGVTASLRCHAEGIPKPQLGWLKNGIDITPKLSKQLTLQANG	398
QUERY:	369	SELHISSVRYEDTGAYTCIAKNEVGVDEDISSLFIEDSARKTLANILWREEGLSVGNMFY	428
		||+|||+|||||||||||||||| ||||||||||+|||||||||||||||||| +|||||
SBJCT:	399	SEVHISNVRYEDTGAYTCIAKNEAGVDEDISSLFVEDSARKTLANILWREEGLGIGNMFY	458
QUERY:	429	VFSDDGIIVIHPVDCEIQRHLKPTEKIFMSYEEICPQREKNATQPCQWVSAVNVRNRYIY	488
		|| +||| || |++|| |||+||+||+    +|+||+ | +  | | | |||||++++||
SBJCT:	459	VFYEDGIKVIQPIECEFQRHIKPSEKLLGFQDEVCPKAEGDEVQRCVWASAVNVKDKFIY	518
QUERY:	489	VAQPALSRVLVVDIQAQKVLQSIGVDPLPAKLSYDKSHDQVWVLSWGDVHKSRPSLQVIT	548
		|||| | |||+||+|+|||+|++  ||+| || |||||||||||||| + |+ |+|||||
SBJCT:	519	VAQPTLDRVLIVDVQSQKVVQAVSTDPVPVKLHYDKSHDQVWVLSWGTLEKTSPTLQVIT	578
QUERY:	549	EASTGQSQHLIRT-----PFAGVDDFFIPPTNLIINHIRFGFIFNKSDPAVHKVDLETMM	603
		||     | | |      |  ||||||| | ||| |+||||| +| + |+ |+|||||
SBJCT:	579	LASGNVPHHTIHTQPVGKQFDRVDDFFIPTTTLIITHMRFGFILHKDEAALQKIDLETMS	638
QUERY:	604	PLKTIGLHHHGCVPQAMAHTHLGGYFFIQCRQDSPASAARQLLVDSVTDSVLGPNGDVTG	663
		+||| |  + ||||++|+||||||+|| |+ ||  + + |++|| |||||+| | ||||
SBJCT:	639	YIKTINLKDYKCVPQSLAYTHLGGYYFIGCKPDSTGAVSPQVMVDGVTDSVIGFNSDVTG	698
QUERY:	664	TPHTSPDGRFIVSAAADSPWLHVQEITVRGEIQTLYDLQINSGISDLAFQRSFTESNQYN	723
		||+ |||| ++||       + || ||+|||||  +|+  |  ||||||| ||||++|||
SBJCT:	699	TPYVSPDGHYLVSINDVKGLVRVQYITIRGEIQEAFDIYTNLHISDLAFQPSFTEAHQYN	758
QUERY:	724	IYAALHTEPDLLFLELSTGKVGMLKNLKEPPAGPAQPWGGTHRIMRDSGLFGQYLLTPAR	783
		|| +  |+ |+||+|||+||| |+|+||||      ||   +| ++|||||||||+||++
SBJCT:	739	IYGSSSTQTDVLFVELSSGKVKMIKSLKEPLKAEEWPWNRKNRQIQDSGLFGQYLMTPSK	818
QUERY:	784	ESLFLINGRQNTLRCEVSGIKGGTTVVWVGE	814
		+|||+++|| | | ||++ ++ | ||+|||+
SBJCT:	819	DSLFILDGRLNKLNCEITEVEKGNTVIWVGD	849

[0052] Amino acids 123-815 of FCTR2 also have 693 of 693 amino acid residues (100%) identical to the 693 amino acid residue protein fragment of KIAA 1061 Protein from Homo sapiens (ptnr: TREMBLNEW-ACC: BAA83013) (SEQ ID NO:48) (Table 2E).

TABLE 2E
BLASTP of FCTR2 against KIAA1061 Protein [Fragment] (SEQ ID NO:48)
ptnr:TREMBLNEW-ACC:BAA83013 KIAA1O62 PROTEIN - Homo sapiens (Human),
693 aa (fragment).
Length = 693
Score = 3623 (1275.4 bits), Expect = 0.0, P = 0.0
Identities = 693/693 (100%), Positives = 693/693 (100%)
QUERY:	123	NVLLALQTRLQPLQEGDSRQDPASQKRLLVESLFRDLDADGNGHLSSSELAQHVLKKQDL	182
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1	NVLLALQTRLQPLQEGDSRQDPASQKRLLVESLFRDLDADGNGHLSSSELAQHVLKKQDL	60
QUERY:	183	DEDLLGCSPGDLLRFDDYNSDSSLTLREFYMAFQVVQLSLAPEDRVSVTTVTVGLSTVLT	242
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	61	DEDLLGCSPGDLLRFDDYNSDSSLTLREFYMAFQVVQLSLAPEDRVSVTTVTVGLSTVLT	120
QUERY:	243	CAVHGDLRPPIIWKRNGLTLNFLDLEDINDFGEDDSLYITKVTTIHMGNYTCHASGHEQL	302
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	121	CAVHGDLRPPIIWKRNGLTLNFLDLEDINDFGEDDSLYITKVTTIHMGNYTCHASGHEQL	180
QUERY:	303	FQTHVLQVNVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITWLKNGVDVSTQMSKQL	362
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	181	FQTHVLQVNVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITWLKNGVDVSTQMSKQL	240
QUERY:	363	SLLANGSELHISSVRYEDTGAYTCIAKNEVGVDEDISSLFIEDSARKTLANILWREEGLS	422
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	241	SLLANGSELHISSVRYEDTGAYTCIAKNEVGVDEDISSLFIEDSARKTLANILWREEGLS	300
QUERY:	423	VGNMFYVFSDDGIIVIHPVDCEIQRHLKPTEKIFMSYEEICPQREKNATQPCQWVSAVNV	482
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	301	VGNMFYVFSDDGIIVIHPVDCEIQRHLKPTEKIFMSYEEICPQREKNATQPCQWVSAVNV	360
QUERY:	483	RNRYIYVAQPALSRVLVVDIQAQKVLQSIGVDPLPAKLSYDKSHDQVWVLSWGDVHKSRP	542
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	361	RNRYIYVAQPALSRVLVVDIQAQKVLQSIGVDPLPAKLSYDKSHDQVWVLSWGDVHKSRP	420
QUERY:	543	SLQVITEASTGQSQELIRTPFAGVDDFFIPPTNLIINHIRFGFIFNKSDPAVHKVDLETM	602
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	421	SLQVITEASTGQSQHLIRTPFAGVDDFFIPPTNLIINHIRFGFIFNKSDPAVHKVDLETM	480
QUERY:	603	MPLKTIGLHHHGCVPQAMAHTHLGGYFFIQCRQDSPASAARQLLVDSVTDSVLGPNGDVT	662
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	481	MPLKTIGLHEHGCVPQAMAHTHLGGYFFIQCRQDSPASAARQLLVDSVTDSVLGPNGDVT	540
QUERY:	663	GTPHTSPDGRFIVSAAADSPWLHVQEITVRGEIQTLYDLQINSGISDLAFQRSFTESNQY	722
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	541	GTPHTSPDGRFIVSAAADSPWLHVQEITVRGEIQTLYDLQINSGISDLAFQRSFTESNQY	600
QUERY:	723	NIYAALHTEPDLLFLELSTGKVGMLKNLKEPPAGPAQPWGGTHRIMRDSGLFGQYLLTPA	782
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	601	NIYAALHTEPDLLFLELSTGKVGMLKNLKEPPAGPAQPWGGTHRIMRDSGLFGQYLLTPA	660
QUERY:	783	RESLFLINGRQNTLRCEVSGIKGGTTVVWVGEV	815
		|||||||||||||||||||||||||||||||||
SBJCT:	661	RESLFLINGRQNTLRCEVSGIEGGTTVVWVGEV	693

[0053] The amino acid sequence of the FCTR2 protein has 451 of 772 amino acid residues (58%) identical to, and 586 of 772 residues (75%) positive with, the 773 amino acid residue proteins hypothetical protein DKFZp566D234.1 from Homo sapiens (fragments) (ptnr: SPTREMBL-ACC: CAB70877.1) (SEQ ID NO:49) (Table 2F).

TABLE 2F
BLASTP of FCTR2 against hypothetical protein DKFZp566D234.1 (SEQ ID NO:49)
>GI|11360192|PIR||T46283 HYPOTHETICAL PROTEIN DKFZP566D234.1 - HUMAN (FRAGMENTS)
GI|6808053|EMB|CAB70877.1| (AL137695) HYPOTHETICAL PROTEIN [HOMO SAPIENS]
LENGTH = 773
SCORE = 911 BITS (2354), EXPECT = 0.0
IDENTITIES = 451/772 (58%), POSITIVES = 586/772 (75%), GAPS = 7/772 (0%)
QUERY:	49	CVLSRKTGEPECQCLEACRPSYVPVCGSDGRFYENHCKLHRAACLLGKRITVIHSKDCFL	108
		|| ||+||+ || |++ |+  | ||||||| ||||||++||||||  ++||++|++|||
SBJCT:	2	CVTSRETGQAECACMDLCKRHYKPVCGSDGEFYENHCEVHRAACLKKQKITIVHNEDCFF	61
QUERY:	109	KGDTCTMAGYARLKNVLLALQTRLQPLQEGDSRQ-DPASQKRLLVESLFRDLDADGNGHL	167
		||| |     +++||+|| || +   +|| ++   |  |+|+|||+ +|+  ||| |  +
SBJCT:	62	KGDKCKTTECSKMKNMLLDLQNQRYIMQENENPNGDDISRKKLLVDQMFKYFDADSNDLV	121
QUERY:	168	SSSELAQHVLKKQDLDEDLLGCSPGDLLRFDDYNSDSSLTLREFYMAFQVVQLSLAPEDR	227
		+|| | |+|+++| +||  |+   ||++||+|+|  | | ||| ||||+||||  + +
SBJCT:	122	DINELTQ-VIKQEELGKDLFDCTLYVLLKYDDFNADKHLALEEFYRAFQVIQLSLPEDQK	180
QUERY:	228	XXXXXXXXXXXXXXXCAVHGDLRPPIIWKRNGLTLNFLDLEDINDFGEDDSLYITKVTTI	287
		||+ | |||||||||| + || | ||||||||+| |||||||||
SBJCT:	181	LSITAATVGQSAVLSCAIQGTLRPPIIWKRNNIILNNLGLEDINDFGDDGSLYITKVTTT	240
QUERY:	288	HMGNYTCHASGHEQLFQTHVLQVNVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITW	347
		|+|||||+| |+||++|||+ ||||||||||||||||+|||| ||||||||||| |++ |
SBJCT:	241	HVGNYTCYADGYEQVYQTHIFQVNVPPVIRVYPESQAREPGVTASLRCHAEGIPKPQLGW	300
QUERY:	348	LKNGVDVSTQMSKQLSLLANGSELHISSVRYEDTGAYTCIAKNEVGVDEDISSLFIEDSA	407
		||||+|++ ++||||+| |||||+|||+|||||||||||||||| ||||||||||+||||
SBJCT:	301	LKNGIDITPKLSKQLTLQANGSEVHISNVRYEDTGAYTCIAKNEAGVDEDISSLFVEDSA	360
QUERY:	408	RKTLANILWREEGLSVGNMFYVFSDDGIIVIHPVDCEIQRHLKPTEKIFMSYEEICPQRE	467
		|||||||||||||| +||||||| +||| || |++|| |||+||+||+    +|+||  |
SBJCT:	361	RKTLANILWREEGLGIGNMFYVFYEDGIKVIQPIECEFQRHIKPSEKLLGFQDEVCPIAE	420
QUERY:	468	KNATQPCQWVSAVNVRNRYIYVAQPALSRVLVVDIQAQKVLQSIGVDPLPAKLSYDKSHD	527
		+  | | | |||||++++|||||| | |||+||+|+|||+|++  ||+| || ||||||
SBJCT:	421	GDEVQRCVWASAVNVKDKFIYVAQPTLDRVLIVDVQSQKVVQAVSTDPVPVKLHYDKSHD	480
QUERY:	528	QVWVLSWGDVHKSRPSLQVITEASTGQSQHLIRT-----PFAGVDDFFIPPTNLIINHIR	582
		|||||||| + |+ |+||||| ||     | | |      |  ||||||| | ||| |+|
SBJCT:	481	QVWVLSWGTLEKTSPTLQVITLASGNVPHHTIHTQPVGKQFDRVDDFFIPTTTLIITHMR	540
QUERY:	583	FGFIFNKSDPAVHKVDLETMMPLKTIGLHHHGCVPQAMAHTHLGGYFFIQCRQDSPASAA	642
		|||| +| + |+ |+|||||  +||| |  + ||||++|+||||||+|| |+ ||  + +
SBJCT:	541	FGFILHKDEAALQKIDLETMSYIKTINLKDYKCVPQSLAYTHLGGYYFIGCKPDSTGAVS	600
QUERY:	643	RQLLVDSVTDSVLGPNGDVTGTPHTSPDGRFIVSAAADSPWLHVQEITVRGEIQTLYDLQ	702
		|++|| |||||+| | ||||||+ |||| ++||       + || ||+|||||  +|+
SBJCT:	601	PQVMVDGVTDSVIGFNSDVTGTPYVSPDGHYLVSINDVKGLVRVQYITIRGEIQEAFDIY	660
QUERY:	703	INSGISDLAFQRSFTESNQYNIYAALHTEPDLLFLELSTGKVGMLKNLKEPPAGPAQPWG	762
		|  ||||||| ||||++||||| +  |+ |+||+|||+||| |+|+||||      ||
SBJCT:	661	TNLHISDLAFQPSFTEAHQYNIYGSSSTQTDVLFVELSSGKVKMIKSLKEPLKAEEWPWN	720
QUERY:	763	GTHRIMRDSGLFGQYLLTPARESLFLINGRQNTLRCEVSGIKGGTTVVWVGE	814
		+| ++|||||||||+||+++|||+++|| | | ||++ ++ | ||+|||+
SBJCT:	721	RKNRQIQDSGLFGQYLMTPSKDSLFILDGRLNKLNCEITEVEKGNTVIWVGD	772

[0054] The amino acid sequence of the FCTR2 protein has 61 of 194 amino acid residues (31%) identical to, and 90 of 194 residues (45%) positive with, the 306 amino acid residue protein Follastin-Related Protein 1 Precursor from Rattus Norvegicus (ptnr: GenBank Acc:Q62632) (SEQ ID NO:50) (Table 2G).

TABLE 2G
BLASTP of FCTR2 against Follastatin-Related Protein 1 Precursor from
Rattus Norvegicus (SEQ ID NO:50)
>GI|2498392|SP|Q62632|FRP RAT FOLLISTATIN-RELATED PROTEIN 1 PRECURSOR
GI|1083669|PIR||S51361 FOLLISTATIN-RELATED PROTEIN PRECURSOR - RAT
GI|536900|GB|AAA66063.1|(U06864) FOLLISTATIN-RELATED PROTEIN PRECURSOR [RATTUS
NORVEGICUS]
LENGTH = 306
SCORE = 86.4 BITS (213), EXPECT = 1E-15
IDENTITIES = 61/194 (31%), POSITIVES = 90/194 (45%), GAPS = 26/194 (13%)
QUERY:	38	CGKKFCSRGSRCVLSRKTGEPECQCLEACRPSYVPVCGSDGRFYENHCKLERAACLLGKR	97
		|   ||  |  | ++ | ||| | |+| |+|   |||||+|+ | |||+||| ||| | +
SBJCT:	29	CANVFCGAGRECAVTEK-GEPTCLCIEQCKPHKRPVCGSNGKTYLNHCELERDACLTGSK	87
QUERY:	98	ITVIHSKDCFLKGD--------TCTMAGYARLKNVLLA-LQTRLQPLQEGDSRQDPASQK	148
		| | +   |  |           |  |    |+  ++  |+  + |    |      |
SBJCT:	88	IQVDYDGHCKEKKSVSPSASPVVCYQANRDELRRRIIQWLEAEIIP----DGWFSKGSNY	143
QUERY:	149	RLLVESLFRDLDADGNGHLSSSELAQHVLK-----------KQDLDEDLLGCSPGDLLRF	197
		+++  |+  | +|+ || |||  + | +            |+ ++ | |     |+
SBJCT:	144	SEILDKYFKSFD-NGDSHLDSSEFLKFVEQNETAVNITAYPNQENNKLLRGLCVDALIEL	202
QUERY:	198	DDYNSDSSLTLREF	211
		| |+|  |+ +||
SBJCT:	203	SDENADWKLSFQEF	216

[0055] The amino acid sequence of the FCTR2 protein has 61 of 194 amino acid residues (31%) identical to, and 89 of 194 residues (45%) positive with, the 306 amino acid residue protein Follastin-Related Protein 1 Precursor from Mus musculus (GenBank Acc:Q62356) (SEQ ID NO:51) (Table 2H).

TABLE 2H
BLASTP of FCTR2 against Follastatin-Related Protein 1 Precursor from
Mus musculus (SEQ ID NO:51)
>GI|6679871|REF|NP 032073.1|FOLLISTATIN-LIKE [MUS MUSCULUS]
GI|2498391|SP|Q62356|FRP MOUSE FOLLISTATIN-RELATED PROTEIN 1 PRECURSOR (TGF-BETA-
INDUCIBLE PROTEIN
TSC-36)
GI|481186|PIR||S38251 FOLLISTATIN-RELATED PROTEIN - MOUSE
GI|349006|GB|AAC37633.1 (M91380) TGF-BETA-INDUCIBLE PROTEIN [MUS MUSCULUS]
LENGTH = 306
SCORE = 85.2 BITS (210), EXPECT = 3E-15
IDENTITIES = 61/194 (31%), POSITIVES = 89/194 (45%), GAPS = 26/194 (13%)
QUERY:	38	CGKKFCSRGSRCVLSRKTGEPECQCLEACRPSYVPVCGSDGRFYENHCKLHRAACLLGKR	97
		|   ||  |  | ++ | ||| | |+| |+|   |||||+|+ | |||+||| ||| | +
SBJCT:	29	CANVFCGAGRECAVTEK-GEPTCLCIEQCKPHKRPVGCSNGKTYLNHCELHRDACLTGSK	87
QUERY:	98	ITVIHSKDCFLKGDT--------CTMAGYARLKNVLLA-LQTRLQPLQEGDSRQDPASQK	148
		| | +   |  |           |  |    |+  |+  |+  + |    |      |
SBJCT:	88	IQVDYDGHCKEKKSASPSASPVVCYQANRDELRRRLIQWLEAEIIP----DGWFSKGSNY	143
QUERY:	149	RLLVESLFRDLDADGNGHLSSSELAQHVLKK-----------QDLDEDLLGCSPGDLLRF	197
		+++  |+  | +|+ || |||  + | +            |+ ++ |       |+
SBJCT:	144	SEILDKYFKSFD-NGDSHLDSSEFLKFVEQNETAINITTYADQENNKLLRSLCVDALIEL	202
QUERY:	198	DDYNSDSSLTLREF	211
		| |+|  |+ +||
SBJCT:	203	SDENADWKLSFQEF	216

[0056] The amino acid sequence of the FCTR2 protein has 63 of 193 amino acid residues (32%) identical to, and 89 of 193 residues (45%) positive with, the 299 amino acid residue protein Follastatin-Related Protein from the African Clawed Frog (GenBank Acc:JGO187) (SEQ ID NO:52) (Table 21).

TABLE 21
BLASTP of FCTR2 against Follastatin-Related Protein from the African
Clawed Frog (SEQ ID NO:52)
>GI|7512162||PIR|JG0187 FOLLISTATIN-RELATED PROTEIN - AFRICAN CLAWED FROG
LENGTH = 299
SCORE = 81.8 BITS (201), EXPECT = 3E-14
IDENTITIES = 63/193 (32%), POSITIVES = 89/193 (45%), GAPS = 25/193 (12%)
QUERY:	38	CGKKFCSRGSRCVLSRKTGEPECQCLEACRPSYVPVCGSDGRFYENHCKLHRAACLLGKR	97
		|   ||  |  | ++ | |+| | |+| |+    |||||+|+ | |||+||| ||| | +
SBJCT:	28	CANVFCGAGRECAVTEK-GDPTCDCIEKCKSHKRPVCGSNGKTYLNHCELHRDACLTGSK	86
QUERY:	98	ITVIHSKDCFLK-GDT-------CTMAGYARL-KNVLLALQTRLQPLQEGDSRQDPASQK	148
		| | +   |  |  ||       |  +    + + |+  ||| + |    |      |
SBJCT:	87	IQVDYDGHCKEKTSDTPAAVPVACYQSDRDEMRRRVIHWLQTEITP----DGWFSKGSDY	148
QUERY:	149	RLLVESLFRDLDADGNGHLSSSELAQHVLKKQDL------DED----LLGCSPGDLLRFD	198
		+++  |+  | ||+ || |+||   + + |        ||+    |       |+
SBJCT:	143	SEILDRYFKKFD-DGDSHLDSAELQSFLEQSQSTNITTYKDEETNRMLKSLCVEALIELS	201
QUERY:	199	DYNSDSSLTLREF	211
		| |+|  |   ||
SBJCT:	202	DENADWKLNKNEF	214

[0057] The amino acid sequence of the FCTR2 protein has 59 of 194 amino acid residues (30%) identical to, and 90 of 194 residues (45%) positive with, the 308 amino acid residue protein Follistatin-Related Protein 1 Precursor from Homo sapiens (GenBank Acc:Q12841) (SEQ ID NO:53) (Table 2J).

TABLE 2J
BLASTP of FCTR2 against Follistatin-Related Protein 1 Precursor from
Homo sapiens (SEQ ID NO:53)
>GI|5901956|REF|NP 009016.1|FOLLISTATIN-LIKE 1 [HOMO SAPIENS]
GI|2498390|SP|Q12841|FRP HUMAN FOLLISTATIN-RELATED PROTEIN 1 PRECURSOR
GI|1082372|PIR||S51362 FOLLISTATIN-RELATED PROTEIN - HUMAN
GI|536898|GB|AAA66062.1|(U06863) FOLLISTATIN-RELATED PROTEIN PRECURSOR [HOMO SAPIENS]
GI|3184393|DBJ|BAA28707.1|(D89937) FOLLISTATIN-RELATED PROTEIN (FRP) [HOMO SAPIENS]
GI|12652619|GB|AAH00055.1|AAH00055 (BC000055) FOLLISTATIN-LIKE 1 [HOMO SAPIENS]
LENGTH = 308
SCORE = 82.9 BITS (204), EXPECT = 1E-14
IDENTITIES = 59/194 (30%), POSITIVES = 90/194 (45%), GAPS 26/194 (13%)
QUERY:	38	CGKKFCSRGSRCVLSRKTGEPECQCLEACRPSYVPVCGSDGRFYENHCKLHRAACLLGKR	97
		|   ||  |  | ++ | ||| | |+| |+|   |||||+|+ | |||+||| ||| | +
SBJCT:	31	CANVFCGAGRECAVTEK-GEPTCLCIEQCKPHVRPVCGSNGKTYLNHCELHRDACLTGSK	89
QUERY:	98	ITVIHSKDCFLKGD--------TCTMAGYARLKNVLLA-LQTRLQPLQEGDSRQDPASQK	148
		| | +   |  |           |  +    |+  ++  |+  + |    |      |
SBJCT:	90	IQVDYDGHCKEKKSVSPSASPVVCYQSNRDELRRRIIQWLEAEIIP----DGWFSKGSNY	145
QUERY:	149	RLLVESLFRDLDADGNGHLSSSELAQHVLKK-----------QDLDEDLLGCSPGDLLRF	197
		+++  |++ | +|+  | |||  + | +            |+ ++ | |     |+
SBJCT:	146	SEILDKYFKNFD-NGDSRLDSSEFLKFVEQNETAINITTYPDQENNKLLRGLCVDALIEL	204
QUERY:	198	DDYNSDSSLTLREF	211
		| |+|  |+ +||
SBJCT:	205	SDENADWKLSFQEF	218

[0058] The amino acid sequence of the FCTR2 protein has 35 of 69 amino acid residues (50%) identical to, and 45 of 69 residues (64%) positive with, the 315 amino acid residue Flik protein [Gallus gallus] (EMBL Acc:CAB42968.1) (SEQ ID NO:54) (Table 2K).

TABLE 2K
BLASTP of FCTR2 against Flik protein [Gallus gallus](SEQ ID NO:54)
>GI|4837645|EMB|CAB42968.1|(AJ238977) FLIK PROTEIN [GALLUS GALLUS]
LENGTH = 315
SCORE = 79.8 BITS (196), EXPECT = 1E-13
IDENTITIES = 35/69 (50%), POSITIVES = 45/69 (64%), GAPS = 1/69 (1%)
QUERY:	38	CGKKFCSRGSRCVLSRKTGEPECQCLEACRPSYVPVCGSDGRFYENHCKLHRAACLLGKR	97
		|   || ||+ | ++ | ||| | |+| |+|   |||||+|+ | |||+||| ||| | +
SBJCT:	31	CANVFCGRGAECAVTEK-GEPTCLCIEQCKPHGRPVCGSNGKTYLNHCELHRDACLTGSK	89
QUERY:	98	ITVIHSKDC	106
		||++|
SBJCT:	90	IQVDYDGHC	98

[0059] The amino acid sequence of the FCTR2 protein has 49 of 152 amino acid residues (32%) identical to, and 65 of 152 residues (42%) positive with a 272-420 amino acid fragment and, 31 of 83 residues (37%) identical to and 44 of 83 residues (52%) positive with a 248-329 amino acid fragment, both of the 1375 amino acid residue Frazzled gene protein [Drosophila melanogaster] (GenBankAcc:T13822) (SEQ ID NO:55) (Table 2L).

TABLE 2L
BLASTP of FCTR2 against Frazzled gene protein [Drosophila melanogaster]
(SEQ ID NO:55)
>GI|75118611|PIR||T-13822 FRAZZLED GENE PROTEIN - FRUIT FLY (DROSOPHILA MELANOGASTER)
GI|1621115|GB|AAC47314.1|(U71001) FRAZZLED [DROSOPHILA MELANOGASTER]
LENGTH = 1375
SCORE = 69.4 BITS (169), EXPECT = 2E-10
IDENTITIES = 49/152 (32%), POSITIVES = 65/152 (42%), GAPS = 4/152 (2%)
QUERY:	243	CAVHGDLRPPIIWKRNGLTLNFLDLEDINDFGEDDSLYITKVTTIHMGNYTCHASGH-EQ	301
		|  +|  +| | | |||+ |+| ||+         || |+    |  ||| | ||   +
SBJCT:	272	CVANGVPKPQIKWLRNGMDLDFNDLDSRFSIVGTGSLQISSAEDIDSGNYQCRASNTVDS	331
QUERY:	302	LFQTHVLQVNVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITWLKNGVDVSTQMSKQ	361
		|     +||  ||     |+           |+|   | | | | |||||  ++     |
SBJCT:	332	LDAQATVQVQEPPKFIKAPKDTTAHEXDEPELKCDIWGKPKPVIRWLKNGDLITPNDYMQ	391
QUERY:	362	LSLLANGSELHISSVRYEDTGAYTCIAKNEVG	393
		| +|  | |  +   | | + |+  |  |
SBJCT:	392	---LVDGHNLKILGLLNSDAGMFQCVGTNAAG	420
SCORE = 52.9 BITS (126), EXPECT = lE-05
IDENTITIES = 31/83 (37%), POSITIVES = 44/83 (52%), GAPS = 2/83 (2%)
QUERY:	311	NVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITWLKNGVDVS-TQMSKQLSLLANGS	369
		+| |   | |  +    |   +| | | |+| |+| ||+||+|+    +  + |++  ||
SBJCT:	248	SVAPSFLVGPSPKTVREGDTVTLDCVANGVPKPQIKWLRNGMDLDFNDLDSRFSIVGTGS	307
QUERY:	370	ELHISSVRYEDTGAYTCIAKNEV	392
		| |||    |+| | | | | |
SBJCT:	308	-LQISSAEDIDSGNYQCRASNTV	329

[0060] The amino acid sequence of the FCTR2 protein has 53 of 177 amino acid residues (29%) identical to, and 78 of 177 residues (43%) positive with a 366-539 amino acid fragment, 51 of 170 residues (30%) identical to and 74 of 170 residues (43%) positive with a 276-438 amino acid fragment, 46 of 165 amino acid residues (27%) identical to, and 74 of 165 amino acid residues positive with a 185-341 amino acid fragment, 48 of 167 amino acid residues (28%) identical to and 70 of 167 amino acid residues (41%) positive with a 77-243 amino acid fragment, and 28 of 84 amino acid residues (33%) and 37 of 84 amino acid residues positive with a 56-139 amino acid fragment all of the protein 1395 residue Roundabout 1 protein [Drosophila melanogaster] (GenBankAcc:AAC38849.1) (SEQ ID NO:56) (Table 2M).

Table 2M
BLASTP of FCTR2 against Roundabout 1 protein [Drosophila melanogaster]
(SEQ ID NO:56)
>GI|2804782|GB|AAC38849.1|(AF040989) ROUNDABOUT 1 [DROSOPHILA MELANOGASTER]
LENGTH = 1395
SCORE = 69.8 BITS (170), EXPECT = lE-lO
IDENTITIES = 53/177 (29%), POSITIVES = 78/177 (43%), GAPS = 11/177 (6%)
QUERY:	243	CAVHGDLRPPIIWKRNGL-TLNFLDLEDINDF-GEDDSLYITKVTTIHMGNYTCHA----	296
		|   |+  | + | + |+ || | +||||||+   | +| ||       | | | |
SBJCT:	366	CMASGNPPPSVFWTKEGVSTLMFPNSSHGRQYVAADGTLQITDVRQEDEGYYVCSAFSVV	425
QUERY:	297	--SGHEQLFQTHVLQVNVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITWLKNGVDV	354
		|      |   +    ||+|++ | +|    |  |+| | | | | ||| |  +|  |
SBJCT:	426	DSSTVRVFLQVSSVDERPPPIIQIGPANQTLPKGSVATLPCRATGNPSPRIKWFHDGHAV	485
QUERY:	355	STQMSKQLSLLANGSELHISSVRYEDTGAYTCIAKNEVGVDEDISSLFIEDSARKTL	411
		|   + |++  || | +  ++  |+| ||| |  | |     ++| +|     +|
SBJCT:	486	--QAGNRYSII-QGSSLRVDDLQLSDSGTYTCTASGERGETSWAATLTVEKPGSTSL	539
SCORE = 56.3 BITS (135), EXPECT = 1E-06
IDENTITIES = 51/170 (30%), POSITIVES = 74/170 (43%), GAPS = 12/170 (7%)
QUERY:	243	CAVHGDLRPPIIWKRNGLTLNFLDLEDINDFGEDDSLYITKVTTIHMGNYTCHASGH-EQ	301
		|+| ||  | ++||+    +       ++|   + || |+ +|    | | | |  +  |
SBJCT:	276	CSVGGDPPPKVLWKKEEGNIPVSRARILHD---EKSLEISNITPTDEGTYVCEAHNNVGQ	332
QUERY:	302	LFQTHVLQVNVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITWLKNGVDVSTQM---	358
		+     | |+ ||     | ++         | | | | | | + | | |  ||| |
SBJCT:	333	ISARASLIVHAPPNFTKRPSNKKVGLNGVVQLPCMASGNPPPSVFWTKEG--VSTLMFPN	390
QUERY:	359	-SKQLSLLANGSELHISSVRYEDTGAYTCIAKNEVGVDEDISSLFIEDSA	407
		|     +|    | |+ || || | | | | +   ||     +|++ |+
SBJCT:	391	SSHGRQYVAADGTLQITDVRQEDEGYYVCSAFSV--VDSSTVRVFLQVSS	438
SCORE = 51.7 BITS (123), EXPECT = 3E-05
IDENTITIES = 46/165 (27%), POSITIVES = 74/165 (43%), GAPS = 20/165 (12%)
QUERY:	251	PPIIWKRNGLTINFLDLEDINDFG--------EDDSLYITKVTTIHMGNYTCHASG----	298
		| +|| ++|+ |+  ||+ ++ ||        +  +| |+ |  |  ||| | |
SBJCT:	185	PTLIWIKDGVPLD--DLKAMS-FGASSRVRIVDGGNLLISNVEPIDEGNYKCIAQNLVGT	241
QUERY:	299	HEQLFQTHVLQVNVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITWLKNGVDVSTQM	358
		|  +   ++||   |     |+ |    |  |+  |   | | |++ | |   ++
SBJCT:	242	RESSYAKLIVQVK--PYFMKEPKDQVMLYGQTATFHCSVGGDPPPKVLWKKEEGNIPVSR	299
QUERY:	359	SKQLSLIANGSELHISSVRYEDTGAYTCIAKNEVGVDEDISSLFI	403
		++   +| +   | ||++   | | | | | | ||     +|| +
SBJCT:	300	AR---ILHDEKSLEISNITPTDEGTYVCEAHNNVGQISARASLIV	341
SCORE = 44.0 BITS (103), EXPECT = 0.007
IDENTITIES = 48/167 (28%), POSITIVES = 70/167 (41%), GAPS = 13/167 (7%)
QUERY:	243	CAVHGDLRPPIIWKRNGLTLNFLDLEDINDFGEDDSLYITKVTTIHM----GNYTCHASG	298
		| | |   | | | ++|  ++  + +      +| +|+ +           | | | |
SBJCT:	77	CKVEGKPEPTIEWFKDGEPVSTNEKKSHRVQFKDGALFFYRTMQGKKEQDGGEYWCVAKN	136
QUERY:	299	H-EQLFQTHV-LQVNV-PPVIRVYPESQAQEPGVAASLRCH-AEGIPMPRITWLKNGVDV	354
		|    |  ||+ |     || |+      |  | | |   +||| | + |+|+|| +
SBJCT:	137	RVGQAVSRHASLQIAVLRDDFRVEPKDTRVAKGETALLECGPPKGIPEPTLIWIKDGVPL	196
QUERY:	355	STQMSKQLSL-----LANGSELHISSVRYEDTGAYTCIAKNEVGVDE	396
		+          + +|  | ||+|   | | | |||+| ||  |
SBJCT:	197	DDLKAMSFGASSRVRIVDGGNLLISNVEPIDEGNYKCIAQNLVGTRE	243
SCORE = 42.9 BITS (100), EXPECT = 0.014
IDENTITIES = 28/84 (33%), POSITIVES = 37/84 (43%), GAPS = 4/84 (4%)
QUERY:	314	PVIRVYPESQAQEPGVAASLRCHAEGIPMPRITWLKNGVDVSTQMSKQLSLLANGSELH-	372
		| |  +|     +    |+| |  || | | | | |+|  |||   |   +      |
SBJCT:	56	PRIIEHPTDLVVKKNEPATLNCKVEGKPEPTIEWFKDGEPVSTNEKKSHRVQFKDGALFF	115
QUERY:	373	---ISSVRYEDTGAYTCIAKNEVG	393
		+   + +| | | |+||| ||
SBJCT:	116	YRTMQGKKEQDGGEYWCVAKNRVG	139

[0061] The amino acid sequence of the FCTR2 protein has 55 of 157 amino acid residues (35%) identical to, and 75 of 157 residues (47%) positive with a 620-775 amino acid fragment, 49 of 163 residues (30%) identical to and 71 of 163 residues (43%) positive with a 335-492 amino acid fragment, 32 of 85 amino acid residues (37%) identical to, and 48 of 85 amino acid residues (55%) positive with a 1305-1388 amino acid fragment, 37 of 143 amino acid residues (25%) identical to and 60 of 143 amino acid residues (41%) positive with a 183-319 amino acid fragment, 43 of 174 amino acid residues (24%) and 70 of 174 amino acid residues (39%) positive with a 711-884 amino acid fragment, and 46 of 165 residues (27%) identical to and 69 of 165 residues positive with a 831-884 amino acid fragment all of the protein 1395 residue Down Syndrome Cell Adhesion Molecule Precursor (CHD2) from Homo Sapiens (GenBankAcc:060469) (SEQ ID NO:57) (Table 2N).

TABLE 2N
BLASTP of FCTR2 against Down Syndrome Cell Adhesion Molecule Precursor
>gi|12643619|sp|O60469|DSCA Human DOWN SYNDROME CELL ADHESION MOLECULE PRECURSOR (CHD2)
GI|67400131|GB|AAF27525.1|AF217525 1 (AF217525) DOWN SYNDROME CELL ADHESION
MOLECULE [HOMO SAPIENS]
LENGTH = 2012
SCORE = 70.6 BITS (172), EXPECT = 6E−11
IDENTITIES = 55/157 (35%), POSITIVES = 75/157 (47%), GAPS = 7/157 (4%)
QUERY:	245	VHGDLRPPIIWKRNGLTLNFLDLEDINDFGEDDSLYITKVTTIHMGNYTCHASGHEQLFQ	304	(SEQ ID NO:57)
		| |||   | |+++|  +       |++     || |+ ++ +| ||||| |       +
SBJCT:	620	VSGDLPITITWQKDGRPIPGSLGVTIDNIDFTSSLRISNLSLMHNGNYTCIARNEAAAVE	679
QUERY:	305	THV-LQVNVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITW-LKNGVDVST----QM	358
		| | |||   | |  |    | |  | | ||| |+| | |    |  |       +
SBJCT:	680	HQSQLIVRVPPKFVVQPRDQDGIYGKAVILNCSAEGYPVPTIVWKFSKGAGVPQFQPIAL	739
QUERY:	359	SKQLSLLANGSELHISSVRYEDTGAYTCIAKNEVGVD 395
		+ ++ +|+||| | |  |  ||+| | |   |+|| |
SBJCT:	740	NGRIQVLSNGS-LLIKHVVEEDSGYYLCKVSNDVGAD 775
SCORE = 50.6 BITS (120), EXPECT = 7E−05
IDENTITIES = 49/163 (30%), POSITIVES = 71/163 (43%), GAPS = 16/163 (9%)
QUERY:	243	CAVHGDLRPPIIWKRNGLTLNFLDLEDINDFGEDDSLYITKVTTIHMGNYTCHASGHEQL	302
		|+| |     + | |||  ||      |     ++ | +  +     | | |     +
SBJCT:	335	CSVTGTEDQELSWYRNGEILNPGKNVRITGINHEN-LIMDHMVKSDGGAYQCFVRKDKLS	393
QUERY:	303	FQTH---VLQVNVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITW-------LKNGV	352
		| +   ||+   | +|  + | +   |    || |+ +| |+| |||       || |
SBJCT:	394	AQDYVQVVLEDGTPKIISAFSE-KVVSPAEPVSLMCNVKGTPLPTITWTLDDDPILKGG-	451
QUERY:	353	DVSTQMSKQLSLLAN-GSELHISSVRYEDTGAYTCIAKNEVGV 394
		| ++|+ ++   |  | |+||| +  | | | | | |  ||
SBJCT:	452	--SHRISQMITSEGNVVSYLNISSSQVRDGGVYRCTANNSAGV 492
SCORE = 47.9 BITS (113), EXPECT = 5E−04
IDENTITIES = 32/85 (37%), POSITIVES = 48/85 (55%), GAPS = 6/85 (7%)
QUERY:	333	LRCHAEGIPMPRITWLK--NGVDVSTQMSKQLSLLANGSELHISSVRYEDTGAYTCIAKN	390
		| | | | | | + |+|  ||      +  + |+ +||| + | +|+ ||+| |+||| |
SBJCT:	1305	LPCKAVGDPSPAVKWMKDSNGTPSLVTIDGRRSIFSNGSFI-IRTVKAEDSGYYSCIANN	1363
QUERY:	391	EVGVDEDISSLFIE---DSARKTLA 412
		| || | +| ++   |  | |++
SBJCT:	1364	NWGSDEIILNLQVQVPPDQPRLTVS 1388
SCORE = 42.9 BITS (100), EXPECT = 0.015
IDENTITIES = 37/143 (25%), POSITIVES = 60/143 (41%), GAPS = 6/143 (4%)
QUERY:	270	INDFGEDDSLYITKVTTIHMGNYTCHASGHEQLFQTHVLQVNVPPVIRVYPESQAQEPGV	329
		| |   +| ||  +  | |        |   +|| +     |  | |    + +    |
SBJCT:	183	IKDVQNEDGLYNYRCITRHRYTGETRQSNSARLFVSD--PANSAPSILDGFDHRKAMAGQ	240
QUERY:	330	AASLRCHAEGIPMPRITWLKNGVDVSTQMSKQLSLLANGSELHISSVRYEDTGAYTCIAK	389
		| | | | | |   |||+  ++  ++| +      |  | | ++|  |+|+| |
SBJCT:	241	RVELPCKALGHPEPDYRWLKD--NMPLELSGRFQKTVTG--LLIENIRPSDSGSYVCEVS	296
QUERY:	390	NEVGVDEDISSLFIEDSARKTLA 412
		|  |  + |  |+++   + |++
SBJCT:	297	NRYGTAKVIGRLYVKQPLKATIS 319
SCORE = 41.3 BITS (96), EXPECT = 0.047
IDENTITIES = 43/174 (24%), POSITIVES = 70/174 (39%), GAPS = 11/174 (6%)
QUERY:	243	CAVHGDLRPPIIWK--RNGLTLNF--LDLEDINDFGEDDSLYITKVTTIHMGNYTCHASG	298
		|+  |   | |+||  +      |  + |        + || |  |     | | |  |
SBJCT:	711	CSAEGYPVPTIVWKFSKGAGVPQFQPIALNGRIQVLSNGSLLIKHVVEEDSGYYLCKVSN	770
QUERY:	299	H--EQLFQTHVLQVNVPPVIRVYPESQAQEPGVAASLRCHAEGIPMPRITWLKNGVDVST	356
		+ ++  | | +| +|  || +     |    + | | |     + | |    ++
SBJCT:	771	DVGADVSKSMYLTVKIPAMITSYPNTTLATQGQKKEMSCTAHGEKPIIVRWEKEDRIINP	830
QUERY:	357	QMSKQLSLLANGSELHISSVRY-----EDTGAYTCIAKNEVGVDEDISSLFIED 405
		+|++ |       |  ||+++      ||+| ++| | || | |  |  | +++
SBJCT:	831	EMARYLVSTKEVGEEVISTLQILPTVREDSGFFSCHAINSYGEDRGIIQLTVQE 884
SCORE = 40.6 BITS (94), EXPECT = 0.074
IDENTITIES = 46/165 (27%), POSITIVES = 69/165 (40%), GAPS = 7/165 (4%)
QUERY:	243	CAVHGDLRPPIIWKRNGLTLNFLDLEDINDFGEDDSLYITKVTT-IHMGNYTCHASGHEQ	301
		| | |     | | +|   | |   +    |  + +| ++ |   +  | |||+     |
SBJCT:	525	CRVIGYPYYSIKWYKNSNLLPFNHRQVA--FENNGTLKLSDVQKEVDEGEYTCNVLVQPQ	582
QUERY:	302	LFQTHVLQVN--VPPVIRVYPESQAQEPGVAASLRCHAEGIPMP-RITWLKNGVDVSTQM	358
		|  +  + |   ||| |+ + |      |    + |      +|  ||| |+|  +   +
SBJCT:	583	LSTSQSVHVTVKVPPFIQPF-EFPRFSIGQRVFIPCVVVSGDLPITITWQKDGRPIPGSL	641
QUERY:	359	SKQLSLLANGSELHISSVRYEDTGAYTCIAKNEVGVDEDISSLFI	403
		+  +   | | ||++     | |||||+||    |  | | +
SBJCT:	642	GVTIDNIDFTSSLRISNLSLMHNGNYTCIARNEAAAVEHQSQLIV	686

[0062] The amino acid sequence of the FCTR2 protein has 55 of 194 amino acid residues (28%) identical to, and 86 of 194 residues (44%) positive with Limbic System-Associated Membrane Protein Precursor (LSAMP) from Homo sapiens (SWISSPROT Acc:Q13449) (SEQ ID NO:58) (Table 2O).

TABLE 2O
BLASTP of FCTR2 against Limbic System-Associated
Membrane Protein (SEQ ID NO:58) Precursor
PTNR:SWISSPROT-ACC:Q13449 LIMBIC SYSTEM-ASSOCIATED
MEMBRANE PROTEIN PRECURSOR (LSAMP) - HOMO SAPIENS
(HUMAN), 338 AA.
LENGTH = 338
SCORE = 191 (67.2 BITS),
EXPECT = 6.7E−12,
P = 7E−12
IDENTITIES = 55/194 (28%),
POSITIVES = 86/194 (44%)

[0063] The amino acid sequence of the FCTR2 protein has 68 of 190 amino acid residues (35%) identical to, and 92 of 190 residues (48%) positive with Putative Neuronal Cell Adhesion Molecule, Short Form from Mus musculus (SPTREMBL Acc:070246) (SEQ ID NO:59) (Table 2P).

TABLE 2P
BLASTP of FCTR2 against Putative Neuronal Cell
Adhesion Molecule, Short (SEQ ID NO:59) Form from
Mus musculus
PTNR:SPTREMBL-ACC:070246 PUTATIVE NEURONAL CELL
ADHESION MOLECULE (PUNC) (PUTATIVE NEURONAL CELL
ADHESION MOLECULE, SHORT FORM) - MUS MUSCULUS
(MOUSE), 793 AA
LENGTH = 793
SCORE = 203 (71.5 BITS),
EXPECT = 7.0E−12,
SUM P(2) = 7.0E−12
IDENTITIES = 68/190 (35%),
POSITIVES = 92/190 (48%)

[0064] The amino acid sequence of the FCTR2 protein has 58 of 199 amino acid residues (29%) identical to, and 91 of 199 residues (45%) positive with CHLAMP, G11-Isoform Precursor from Gallus gallus (SPTREMBL Acc: 002869) (SEQ ID NO:60) (Table 2Q).

TABLE 2Q
BLASTP of FCTR2 against CHLAMP,G11-Isoform
Precursor from Gallus gallus (SEQ ID NO:60)
PTNR:SPTREMBL-ACC:002869 CHLAMP, G11-ISOFORM
PRECURSOR - GALLUS GALLUS (CHICKEN), 350 AA.
LENGTH = 350
SCORE = 191 (67.2 BITS),
EXPECT = 7.7E−12,
P = 7.7E−12
IDENTITIES = 58/199 (29%),
POSITIVES = 91/199 (45%)

[0065] The amino acid sequence of the FCTR2 protein has 55 of 194 amino acid residues (28%) identical to, and 86 of 194 residues (44%) positive with Limbic System-Associated Membrane Protein Precursor (LSAMP) from Rattus norvegicus (SWISSPROT Acc:Q62813) (SEQ ID NO:61) (Table 2R).

TABLE 2R
BLASTP of FCTR2 against Limbic System-Associated
Membrane Protein Precursor (LSAMIP) from
Rattus norvegicus (SEQ ID NO:61)
PTNR:SWISSPROT-ACC:Q62813 LIMBIC SYSTEM-ASSOCIATED
MEMBRANE PROTEIN PRECURSOR (LSANP) - RATTUS
NORVEGICUS (RAT), 338 AA.
LENGTH = 338
SCORE = 188 (66.2 BITS),
EXPECT = 1.5E−11,
P = 1.5E−11
IDENTITIES = 55/194 (28%),
POSITIVES = 86/194 (44%)

[0066] FCTR2 protein has similarity to cell adhesion molecules, follistatin, roundabout and frazzled (see BlastP results). These genes are involved in neuronal development and reproductive physiology. Frazzled encodes a Drosophila member of the DCC immunoglobulin subfamily and is required for CNS and motor axon guidance (Cell 87:197-204(1996)). Characterization of a rat C6 glioma-secreted follistatin-related protein (FRP) and cloning and sequence of the human homologue is described in Eur. J. Biochem. 225:937-946(1994). This protein may modulate the action of some growth factors on cell proliferation and differentiation. FRP binds heparin. The follistatin-related protein is a secreted protein and has one follistatin-like domain. The cloning and early dorsal axial expression of Flik, a chick follistatin-related gene and evidence for involvement in dorsalization/neural induction is presented in Dev. Biol. 178:327-342(1996). Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors, as shown in Cell 92:205-215(1998). cDNA cloning and structural analysis of the human limbic-system-associated membrane protein (LAMP) is described in Gene 170:189-195(1996). LAMP, a protein of the OBCAM family that contains three immunoglobulin-like C2-type domains, mediates selective neuronal growth and axon targeting. LAMP contributes to the guidance of developing axons and remodeling of mature circuits in the limbic system. This protein is essential for normal growth of the hippocampal mossy fiber projection. LAMP is attached to the membrane by a GPI-Anchor. It is expressed on limbic neurons and fiber tracts as well as in single layers of the superior colliculus, spinal chord and cerbellum. Characterization of the human full-length PTK7 cDNA encoding a receptor protein tyrosine kinase-like molecule closely related to chick KLG is disclosed in J. Biochem. 119:235-239(1996). Based upon homology, FCTR2 proteins and each homologous protein or peptide may share at least some activity.

[0067] Functions and therapeutic uses:

[0068] The OMIM gene map has identified this region which the invention maps to (5q21-5q3 1) as associated with susceptibility to the following diseases (OMIM Ids are underlined):

[0069] Allergy and asthma

[0070] Hemangioma,

[0071] capillary infantile Schistosoma mansoni infection, susceptibility/resistance to Spinocerebellar ataxia

[0072] Bronchial asthma

[0073] Plasmodium falciparum parasitemia,

[0074] intensity of Corneal dystrophy, Groenouw type I, 121900; Corneal dystrophy,lattice type I, 122200;

[0075] Reis-Bucklers corneal dystrophy;Corneal dystrophy, Avellino type Eosinophilia, familial Myelodysplastic syndrome;

[0076] Myelogenous leukemia, Acute Cutis laxa, recessive, type I, Deafness, autosomal dominant nonsyndromic sensorineural, 1 Contractural arachnodactyly, Congenital Neonatal alloimmune thrombocytopenia;

[0077] Glycoprotein Ia deficiency Male infertility;

[0078] Charcot-Marie-Tooth neuropathy, Demyelinating Gardner syndrome;

[0079] Adenomatous polyposis coli;

[0080] Colorectal cancer;

[0081] Desmoid disease, hereditary, 135290;

[0082] Turcot syndrome,276300;

[0083] Adenomatous polyposis coli, attenuated

[0084] Colorectal cancer

[0085] Therefore the invention is implicated in at least all of the above mentioned diseases and may have therapeutic uses for these diseases.

[0086] This sequence has similarity to cell adhesion molecules, follistatin, roundabout and frazzled (see BlastP results). These genes are involved in neuronal development and reproductive physiology. Therefore the invention is also implicated in disorders such as or therapeutic uses for:

[0087] Neurodegenerative disorders, nerve trauma, epilepsy, mental health conditions

[0088] Tissue regeneration in vivo and in vitro

[0089] Female reproductive system disorders and pregnancy

[0090] FCTR3

[0091] FCTR3, is an amino acid type II membrane, neurestin-like protein. The FCTR3a nucleic acid of 1430 nucleotides (also designated 10129612.0.118) is shown in Table 3A. An ORF was identified beginning with an ATG initiation codon at nucleotides 69-71 and ending with a TAG codon at nucleotides 1212-1214. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 3A, and the start and stop codons are in bold letters.

TABLE 3A
FCTR3a Nucleotide Sequence
AAAAAAGGCGGGGGGTGGACTTAGCAGTGTAATTTGAGACCGGTGGTAAGGATTGGAGCGAGCTAGAGATGCTGCACGCTGCTA (SEQ ID NO:5)
ACAAGGGAAGGAAGCCTTCAGCTGAGGCAGGTCGTCCCATTCCACCTACATCCTCGCCTAGTCTCCTCCCATCTGCTCAGCTGC
CTAGCTCCCATAATCCTCCACCAGTTAGCTGCCAGATGCCATTGCTAGACAGCAACACCTCCCATCAAATCATGGACACCAACC
CTGATGAGGAATTCTCCCCCAATTCATACCTGCTCAGAGCATGCTCAGGGCCCCAGCAAGCCTCCAGCAGTGGCCCTCCGAACC
ACCACAGCCAGTCGACTCTGAGGCCCCCTCTCCCACCCCCTCACAACCACACGCTGTCCCATCACCACTCGTCCGCCAACTCCC
TCAACAGGAACTCACTGACCAATCGGCGGAGTCAGATCCACGCCCCGGCCCCAGCGCCCAATGACCTGGCCACCACACCAGAGT
CCGTTCAGCTTCAGGACAGCTGGGTGCTAAACAGCAACGTGCCACTGGAGACCCGGCACTTCCTCTTCAAGACCTCCTCGGGGA
GCACACCCTTGTTCAGCAGCTCTTCCCCGGGATACCCTTTGACCTCAGGAACGGTTTACACGCCCCCGCCCCGCCTGCTGCCCA
GGAATACTTTCTCCAGGAAGGCTTTCAAGCTGAAGAAGCCCTCCAAATACTGCAGCTGGAAATGTGCTGCCCTCTCCGCCATTG
CCGCGGCCCTCCTCTTGGCTATTTTGCTGGCGTATTTCATAGTGCCCTGGTCGTTGAAAAACAGCAGCATAGACAGTGGTGAAG
CAGAAGTTGGTCGGCGGGTAACACAAGAAGTCCCACCAGGGGTGTTTTGGAGGTCACAAATTCACATCAGTCAGCCCCAGTTCT
TAAAGTTCAACATCTCCCTCGGGAAGGACGCTCTCTTTGGTGTTTACATAAGAAGAGGACTTCCACCATCTCATGCCCAGTATG
ACTTCATGGAACGTCTGGACGGGAAGGAGAAGTGGAGTGTGGTTGAGTCTCCCAGGGAACGCCGGAGCATACAGACCTTGGTTC
AGAATGAAGCCGTGTTTGTGCAGTACCTGGATGTGGGCCTGTGGCATCTGGCCTTCTACAATGATGGAAAAGACAAAGAGATGG
TTTCCTTCAATACTGTTGTCCTAGATGGGACCATCTAGTTGCAGAAAAACAAGCTCAGGGCGCCCACTGATTTGACATTATGAT
TCAGTGCAGGACTGTCCACGTAACTGCCATGGGAATGGTGAATGTGTGTCCGGGGTGTGTCACTGTTTCCCAGGATTTCTAGGA
GCAGACTGTGCTAAAGACCTTCCTGCCTTGACTTTCTGCAAGACAATCATTAATAAAGCTGCTCTGTAAATACTAAAAAAAAAA
CA

[0092] The FCTR3 polypeptide (SEQ ID NO:5) encoded by SEQ ID NO:5 is 381 amino acid residues and is presented using the one-letter code in Table 3B.

TABLE 3B
Encoded FCTR3a protein sequence.
MLHAANKGRKPSAEAGRPIPPTSSPSLLPSAQLPSSHNPPPVSCQMPLLDSNTSHQIMDTNPDEEFSPNSYLLRACSGPQQASS (SEQ ID NO:6)
SGPPNHHSQSTLRPPLPPPHNHTLSHHHSSANSLNRNSLTNRRSQIHAPAPAPNDLATTPESVQLQDSWVLNSNVPLETRHFLF
KTSSGSTPLFSSSSPGYPLTSGTVYTPPPRLLPRNTFSRKAFKLKKPSKYCSWKCAALSAIAAALLLAILLAYFIVPWSLKNSS
IDSGEAEVGRRVTQEVPPGVFWRSQIHISQPQFLKFNISLGKDALFGVYIRRGLPPSHAQYDFMERLDGKEKWSVVESPRERRS
IQTLVQNEAVFVQYLDVGLWHLAFYNDGKDKEMVSFNTVVLDGTI

[0093] In an alternative embodiment, the 5′ end of the FCTR3a nucleic acid could be extended as it is in the 9826 bp FCTR3b (also referred to herein as 10129612.0.405) shown in Table 3C. An ORF was identified beginning with an ATG initiation codon at nucleotides 280-282 and ending with a TAA codon at nucleotides 8479-8481. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 3C, and the start and stop codons are in bold letters. Italicized bases 1-201 refer to a variable 5′ region that will be further discussed below.

TABLE 3C
FCTR3b Nucleotide Sequence
TTTAAATCCTCATACCTTAAAGGAGATGTGTATATAAGGGAGTTGGAACCAGCATTAGATGAGTTGACAAAAATGCACTT (SEQ ID NO:7)
TCAGTTCTAGAGGTCTGGGAAGTCCAAGAACAAGGTGCTGGCAGATTGGATTCCCCGTGAGGGCTTTCTTCCTGGCTTGA
AGTTGGCTGCTTTCCTGCTGAGACTTCTCATGGCAGAGACTGAGGGTGGCAAAGTGACAAGTGCCAAAACTCAGGCCTGA
CTTTTCTGAAAACATCAGCATTCTGCCATATCTGGAATAATGGATGTAAAGGACCGGCGACACCGCTCTTTGACCAGAGG
ACGCTGTGGCAAAGAGTGTCGCTACACAAGCTCCTCTCTGGACAGTGAGGACTGCCGGGTGCCCACACAGAAATCCTACA
GCTCCAGTGAGACTCTGAAGGCCTATGACCATGACAGCAGGATGCACTATGGAAACCGAGTCACAGACCTCATCCACCGG
GAGTCAGATGAGTTTCCTAGACAAGGAACCAACTTCACCCTTGCCGAACTGGGCATCTGTGAGCCCTCCCCACACCGAAG
CGGCTACTGCTCCGACATGGGGATCCTTCACCAGGGCTACTCCCTTAGCACAGGGTCTGACGCCGACTCCGACACCGAGG
GAGGGATGTCTCCAGAACACGCCATCAGACTGTGGGGCAGAGGGATAAAATCCAGGCGCAGTTCCGGCCTGTCCAGTCGT
GAAAACTCGGCCCTTACCCTGACTGACTCTGACAACGAAAACAAATCAGATGATGAGAACGGTCGTCCCATTCCACCTAC
ATCCTCGCCTAGTCTCCTCCCATCTGCTCAGCTGCCTAGCTCCCATAATCCTCCACCAGTTAGCTGCCAGATGCCATTGC
TAGACAGCAACACCTCCCATCAAATCATGGACACCAACCCTGATGAGGAATTCTCCCCCAATTCATACCTGCTCAGAGCA
TGCTCAGGGCCCCAGCAAGCCTCCAGCAGTGGCCCTCCGAACCACCACAGCCAGTCGACTCTGAGGCCCCCTCTCCCACC
CCCTCACAACCACACGCTGTCCCATCACCACTCGTCCGCCAACTCCCTCAACAGGAACTCACTGACCAATCGGCGGAGTC
AGATCCACGCCCCGGCCCCAGCGCCCAATGACCTGGCCACCACACCAGAGTCCGTTCAGCTTCAGGACAGCTGGGTGCTA
AACAGCAACGTGCCACTGGAGACCCGGCACTTCCTCTTCAAGACCTCCTCGGGGAGCACACCCTTGTTCAGCAGCTCTTC
CCCGGGATACCCTTTGACCTCAGGAACGGTTTACACGCCCCCGCCCCGCCTGCTGCCCAGGAATACTTTCTCCAGGAAGG
CTTTCAAGCTGAAGAAGCCCTCCAAATACTGCAGCTGGAAATGTGCTGCCCTCTCCGCCATTGCCGCGGCCCTCCTCTTG
GCTATTTTGCTGGCGTATTTCATAGTGCCCTGGTCGTTGAAAAACAGCAGCATAGACAGTGGTGAAGCAGAAGTTGGTCG
GCGGGTAACACAAGAAGTCCCACCAGGGGTGTTTTGGAGGTCACAAATTCACATCAGTCAGCCCCAGTTCTTAAAGTTCA
ACATCTCCCTCGGGAAGGACGCTCTCTTTGGTGTTTACATAAGAAGAGGACTTCCACCATCTCATGCCCAGTATGACTTC
ATGGAACGTCTGGACGGGAAGGAGAAGTGGAGTGTGGTTGAGTCTCCCAGGGAACGCCGGAGCATACAGACCTTGGTTCA
GAATGAAGCCGTGTTTGTGCAGTACCTGGATGTGGGCCTGTGGCATCTGGCCTTCTACAATGATGGAAAAGACAAAGAGA
TGGTTTCCTTCAATACTGTTGTCCTAGATTCAGTGCAGGACTGTCCACGTAACTGCCATGGGAATGGTGAATGTGTGTCC
GGGGTGTGTCACTGTTTCCCAGGATTTCTAGGAGCAGACTGTGCTAAAGCTGCCTGCCCTGTCCTGTGCAGTGGGAATGG
ACAATATTCTAAAGGGACGTGCCAGTGCTACAGCGGCTGGAAAGGTGCAGAGTGCGACGTGCCCATGAATCAGTGCATCG
ATCCTTCCTGCGGGGGCCACGGCTCCTGCATTGATGGGAACTGTGTCTGCTCTGCTGGCTACAAAGGCGAGCACTGTGAG
GAAGTTGATTGCTTGGATCCCACCTGCTCCAGCCACGGAGTCTGTGTGAATGGAGAATGCCTGTGCAGCCCTGGCTGGGG
TGGTCTGAACTGTGAGCTGGCGAGGGTCCAGTGCCCAGACCAGTGCAGTGGGCATGGCACGTACCTGCCTGACACGGGCC
TCTGCAGCTGCGATCCCAACTGGATGGGTCCCGACTGCTCTGTTGAAGTTGTGCTCAGTAGACTGTGGCACTCACGCGTC
TGCATCGGGGGAGCCTGCCGCTGTGAAGAGGGCTGGACAGGCGCAGCGTGTGACCAGCGCGTGTGCCACCCCCGCTGCAT
TGAGCACGGGACCTGTAAAGATGGCAAATGTGAATGCCGAGAGGGCTGGAATGGTGAACACTGCACCATTGGTAGGCAAA
CGGCAGGCACCGAAACAGATGGCTGCCCTGACTTGTGCAACGGTAACGGGAGATGCACACTGGGTCAGAACAGCTGGCAG
TGTGTCTGCCAGACCGGCTGGAGAGGGCCCGGATGCAACGTTGCCATGGAAACTTCCTGTGCTGATAACAAGGATAATGA
GGGAGATGGCCTGGTGGATTGTTTGGACCCTGACTGCTGCCTGCAGTCAGCCTGTCAGAACAGCCTGCTCTGCCGGGGGT
CCCGGGACCCACTGGACATCATTCAGCAGGGCCAGACGGATTGGCCCGCAGTGAAGTCCTTCTATGACCGTATCAAGCTC
TTGGCAGGCAAGGATAGCACCCACATCATTCCTGGAGAGAACCCTTTCAACAGCAGCTTGGTTTCTCTCATCCGAGGCCA
AGTAGTAACTACAGATGGAACTCCCCTGGTCGGTGTGAACGTGTCTTTTGTCAAGTACCCAAAATACGGCTACACCATCA
CCCGCCAGGATGGCACGTTCGACCTGATCGCAAATGGAGGTGCTTCCTTGACTCTACACTTTGAGCGAGCCCCGTTCATG
AGCCAGGAGCGCACTGTGTGGCTGCCGTGGAACAGCTTTTACGCCATGGACACCCTGGTGATGAAGACCGAGGAGAACTC
CATCCCCAGCTGTGACCTCAGTGGCTTTGTCCGGCCTGATCCAATCATCATCTCCTCCCCACTGTCCACCTTCTTTAGTG
CTGCCCCTGGGCAGAATCCCATCGTGCCTGAGACCCAGGTTCTTCATGAAGAAATCGAGCTCCCTGGTTCCAATGTGAAA
CTTCGCTATCTGAGCTCTAGAACTGCAGGGTACAAGTCACTGCTGAAGATCACCATGACCCAGTCCACAGTGCCCCTGAA
CCTCATTAGGGTTCACCTGATGGTGGCTGTCGAGGGGCATCTCTTCCAGAAGTCATTCCAGGCTTCTCCCAACCTGGCCT
CCACCTTCATCTGGGACAAGACAGATGCGTATGGCCAAAGGGTGTATGGACTCTCAGATGCTGTTGTGTCTGTCGGGTTT
GAATATGAGACCTGTCCCAGTCTAATTCTCTGGGAGAAAAGGACAGCCCTCCTTCAGGGATTCGAGCTGGACCCCTCCAA
CCTCGGTGGCTGGTCCCTAGACAAACACCACATCCTCAATGTTAAAAGTGGAATCCTACACAAAGGCACTGGGGAAAACC
AGTTCCTGACCCAGCAGCCTGCCATCATCACCAGCATCATGGGCAATGGTCGCCGCCGGAGCATTTCCTGTCCCAGCTGC
AACGGCCTTGCTGAAGGCAACAAGCTGCTGGCCCCAGTGGCTCTGGCTGTTGGAATCGATGGGAGCCTCTATGTGGGTGA
CTTCAATTACATCCGACGCATCTTTCCCTCTCGAAATGTGACCAGCATCTTGGAGTTACGAAATAAAGAGTTTAAACATA
GCAACAACCCAGCACACAAGTACTACTTGGCAGTGGACCCCGTGTCCGGCTCGCTCTACGTGTCCGACACCAACAGCAGG
AGAATCTACCGCGTCAAGTCTCTGAGTGGAACCAAAGACCTGGCTGGGAATTCGGAAGTTGTGGCAGGGACGGGAGAGCA
GTGTCTACCCTTTGATGAAGCCCGCTGCGGGGATGGAGGGAAGGCCATAGATGCAACCCTGATGAGCCCGAGAGGTATTG
CAGTAGACAAGAATGGGCTCATGTACTTTGTCGATGCCACCATGATCCGGAAGGTTGACCAGAATGGAATCATCTCCACC
CTGCTGGGCTCCAATGACCTCACTGCCGTCCGGCCGCTGAGCTGTGATTCCAGCATGGATGTAGCCCAGGTTCGTCTGGA
GTGGCCAACAGACCTTGCTGTCAATCCCATGGATAACTCCTTGTATGTTCTAGAGAACAATGTCATCCTTCGAATCACCG
AGAACCACCAAGTCAGCATCATTGCGGGACGCCCCATGCACTGCCAAGTTCCTGGCATTGACTACTCACTCAGCAAACTA
GCCATTCACTCTGCCCTGGAGTCAGCCAGTGCCATTGCCATTTCTCACACTGGGGTCCTCTACATCACTGAGACAGATGA
GAAGAAGATTAACCGTCTACGCCAGGTAACAACCAACGGGGAGATCTGCCTTTTAGCTGGGGCAGCCTCGGACTGCGACT
GCAAAAACGATGTCAATTGCAACTGCTATTCAGGAGATGATGCCTACGCGACTGATGCCATCTTGAATTCCCCATCATCC
TTAGCTGTAGCTCCAGATGGTACCATTTACATTGCAGACCTTGGAAATATTCGGATCAGGGCGGTCAGCAAGAACAAGCC
TGTTCTTAATGCCTTCAACCAGTATGAGGCTGCATCCCCCGGAGAGCAGGAGTTATATGTTTTCAACGCTGATGGCATCC
ACCAATACACTGTGAGCCTGGTGACAGGGGAGTACTTGTACAATTTCACATATAGTACTGACAATGATGTCACTGAATTG
ATTGACAATAATGGGAATTCCCTGAAGATCCGTCGGGACAGCAGTGGCATGCCCCGTCACCTGCTCATGCCTGACAACCA
GATCATCACCCTCACCGTGGGCACCAATGGAGGCCTCAAAGTCGTGTCCACACAGAACCTGGAGCTTGGTCTCATGACCT
ATGATGGCAACACTGGGCTCCTGGCCACCAAGAGCGATGAAACAGGATGGACGACTTTCTATGACTATGACCACGAAGGC
CGCCTGACCAACGTGACGCGCCCCACGGGGGTGGTAACCAGTCTGCACCGGGAAATGGAGAAATCTATTACCATTGACAT
TGAGAACTCCAACCGTGATGATGACGTCACTGTCATCACCAACCTCTCTTCAGTAGAGGCCTCCTACACAGTGGTACAAG
ATCAAGTTCGGAACAGCTACCAGCTCTGTAATAATGGTACCCTGAGGGTGATGTATGCTAATGGGATGGGTATCAGCTTC
CACAGCGAGCCCCATGTCCTAGCGGGCACCATCACCCCCACCATTGGACGCTGCAACATCTCCCTGCCTATGGAGAATGG
CTTAAACTCCATTGAGTGGCGCCTAAGAAAGGAACAGATTAAAGGCAAAGTCACCATCTTTGGCAGGAAGCTCCGGGTCC
ATGGAAGAAATCTCTTGTCCATTGACTATGATCGAAATATTCGGACTGAAAAGATCTATGATGACCACCGGAAGTTCACC
CTGAGGATCATTTATGACCAGGTGGGCCGCCCCTTCCTCTGGCTGCCCAGCAGCGGGCTGGCAGCTGTCAACGTGTCATA
CTTCTTCAATGGGCGCCTGGCTGGGCTTCAGCGTGGGGCCATGAGCGAGAGGACAGACATCGACAAGCAAGGCCGCATCG
TGTCCCGCATGTTCGCTGACGGGAAAGTGTGGAGCTACTCCTACCTTGACAAGTCCATGGTCCTCCTGCTTCAGAGCCAA
CGTCAGTATATATTTGAGTATGACTCCTCTGACCGCCTCCTTGCCGTCACCATGCCCAGCGTGGCCCGGCACAGCATGTC
CACACACACCTCCATCGGCTACATCCGTAATATTTACAACCCGCCTGAAAGCAATGCTTCGGTCATCTTTGACTACAGTG
ATGACGGCCGCATCCTGAAGACCTCCTTTTTGGGCACCGGACGCCAGGTGTTCTACAAGTATGGGAAACTCTCCAAGTTA
TCAGAGATTGTCTACGACAGTACCGCCGTCACCTTCGGGTATGACGAGACCACTGGTGTCTTGAAGATGGTCAACCTCCA
AAGTGGGGGCTTCTCCTGCACCATCAGGTACCGGAAGATTGGCCCCCTGGTGGACAAGCAGATCTACAGGTTCTCCGAGG
AAGGCATGGTCAATGCCAGGTTTGACTACACCTATCATGACAACAGCTTCCGCATCGCAAGCATCAAGCCCGTCATAAGT
GAGACTCCCCTCCCCGTTGACCTCTACCGCTATGATGAGATTTCTGGCAAGGTGGAACACTTTGGTAAGTTTGGAGTCAT
CTATTATGACATCAACCAGATCATCACCACTGCCGTGATGACCCTCAGCAAACACTTCGACACCCATGGGCGGATCAAGG
AGGTCCAGTATGAGATGTTCCGGTCCCTCATGTACTGGATGACGGTGCAATATGACAGCATGGGCAGGGTGATCAAGAGG
GAGCTAAAACTGGGGCCCTATGCCAATACCACGAAGTACACCTATGACTACGATGGGGACGGGCAGCTCCAGAGCGTGGC
CGTCAATGACCGCCCGACCTGGCGCTACAGCTATGACCTTAATGGGAATCTCCACTTACTGAACCCAGGCAACAGTGTGC
GCCTCATGCCCTTGCGCTATGACCTCCGGGATCGGATAACCAGACTCGGGGATGTGCAGTACAAAATTGACGACGATGGC
TATCTGTGCCAGAGAGGGTCTGACATCTTCGAATACAATTCCAAGGGCCTCCTAACAAGAGCCTACAACAAGGCCAGCGG
GTGGAGTGTCCAGTACCGCTATGATGGCGTAGGACGGCGGGCTTCCTACAAGACCAACCTGGGCCACCACCTGCAGTACT
TCTACTCTGACCTCCACAACCCGACGCGCATCACCCATGTCTACAATCACTCCAACTCGGAGATTACCTCACTGTACTAC
GACCTCCAGGGCCACCTCTTTGCCATGGAGAGCAGCAGTGGGGAGGAGTACTATGTTGCCTCTGATAACACAGGGACTCC
TCTGGCTGTGTTCAGCATCAACGGCCTCATGATCAAACAGCTGCAGTACACGGCCTATGGGGAGATTTATTATGACTCCA
ACCCCGACTTCCAGATGGTCATTGGCTTCCATGGGGGACTCTATGACCCCCTGACCAAGCTGGTCCACTTCACTCAGCGT
GATTATGATGTGCTGGCAGGACGATGGACCTCCCCAGACTATACCATGTGGAAAAACGTGGGCAAGGAGCCGGCCCCCTT
TAACCTGTATATGTTCAAGAGCAACAATCCTCTCAGCAGTGAGCTAGATTTGAAGAACTACGTGACAGATGTGAAAAGCT
GGCTTGTGATGTTTGGATTTCAGCTTAGCAACATCATTCCTGGCTTCCCGAGAGCCAAAATGTATTTCGTGCCTCCTCCC
TATGAATTGTCAGAGAGTCAAGCAAGTGAGAATGGACAGCTCATTACAGGTGTCCAACAGACAACAGAGAGACATAACCA
GGCCTTCATGGCTCTGGAAGGACAGGTCATTACTAAAAAGCTCCACGCCAGCATCCGAGAGAAAGCAGGTCACTGGTTTG
CCACCACCACGCCCATCATTGGCAAAGGCATCATGTTTGCCATCAAAGAAGGGCGGGTGACCACGGGCGTGTCCAGCATC
GCCAGCGAAGATAGCCGCAAGGTGGCATCTGTGCTGAACAACGCCTACTACCTGGACAAGATGCACTACAGCATCGAGGG
CAAGGACACCCACTACTTTGTGAAGATTGGCTCAGCCGATGGCGACCTGGTCACACTACGCACCACCATCGGCCGCAAGG
TGCTAGAGAGCGGGGTGAACGTGACCGTGTCCCAGCCCACGCTGCTGGTCAACGGCAGGACTCGAAGGTTCACGAACATT
GAGTTCCAGTACTCCACGCTGCTGCTCAGCATCCGCTATGGCCTCACCCCCGACACCCTGGACGAAGAGAAGGCCCGCGT
CCTGGACCAGGCGAGACAGAGGGCCCTGGGCACGGCCTGGGCCAAGGAGCAGCAGAAAGCCAGGGACGGGAGAGAGGGGA
GCCGCCTGTGGACTGAGGGCGAGAAGCAGCAGCTTCTGAGCACCGGGCGCGTGCAAGGGTACGAGGGATATTACGTGCTT
CCCGTGGAGCAATACCCAGAGCTTGCAGACAGTAGCAGCAACATCCAGTTTTTAAGACAGAATGAGATGGGAAAGAGGTA
ACAAAATAATCTGCTGCCATTCCTTGTCTGAATGGCTCAGCAGGAGTAACTGTTATCTCCTCTCCTAAGGAGATGAAGAC
CTAACAGGGGCACTGCGGCTGGGCTGCTTTAGGAGACCAAGTGGCAAGAAAGCTCACATTTTTTGAGTTCAAATGCTACT
GTCCAAGCGAGAAGTCCCTCATCCTGAAGTAGACTAAAGCCCGGCTGAAAATTCCGAGGAAAACAAAACAAACGAATGAA
TGAACAGACACACACAATGTTCCAAGTTCCCCTAAAATATGACCCACTTGTTCTGGGTCTACGCAGAAAAGAGACGCAAA
GTGTCCAAAAGGAACAAAAGAACAAAAACGAATAAGCAAAGAAGAAAACAAACAAAAACAAAACAAAACAAACACACGGA
CCGATAAACAAAGAAGCGAAGATAAGAAAGAAGGCCTCATATCCAATTACCTCACTCATTCACATGTGAGCGACACGCAG
ACATCCGCGAGGGCCAGCGTCACCAGACCAGCTGCGGGACAAACCACTCAGACTGCTTGTAGGACAAATACTTCTGACAT
TTTCGTTTAAGCAAATACAGGTGCATTTAAAACACGACTTTGGGGGTGATTTGTGTGTAGCGCCTGGGGAGGGGGGATAA
AAGAGGAGGAGTGAGCACTGGAAATACTTTTTAAAGAAAAAAAAACATGAGGGAATAAAAGAAATTCCTATCAAAAATCA
AAGTGAAATAATACCATCCAGCACTTAACTCTCAGGTCCCAACTAAGTCTGGCCTGAGCTAATTTATTTGAGCGCAGAGT
GTAAAATTTAATTCAAAATGGTGGCTATAATCACTACAGATAAATTTCATACTCTTTTGTCTTTGGAGATTCCATTGTGG
ACAGTAATACGCAGTTACAGGGTGTAGTCTGTTTAGATTCCGTAGTTCGTGGGTATCAGTTTCGGTAGAGGTGCAGCATC
GTGACACTTTTGCTAACAGGTACCACTTCTGATCACCCTGTACATACATGAGCCGAAAGGCACAATCACTGTTTCAGATT
TAAAATTATTAGTGTGTTTGTTTGGTCCAGAAACTGAGACAATCACATGACAGTCACCACGAGGAGAGAAAATTTAAAAA
ATAAAAATAAAAACAAAAAAAATTTTAAAAATTAAAAAAACAAAAATAAAGTCTAATAAGAACTTTGGTACAGGAACTTT
TTTGTAATATACATGTATGAATTGTTCATCGAGTTTTTATATTAATTTTAATTTGCTGCTAAGCAAAGACTAGGGACAGG
CAAAGATAATTTATGGCAAAGTGTTTAAATTGTTTATACATAAATAAAGTCTCTAAAACTCCTGTG

[0094] The FCTR3b polypeptide (SEQ ID NO:8) encoded by SEQ ID NO:7 is 2733 amino acid residues and is presented using the one-letter code in Table 3D. The protein has a predicted molecular weight of 303424.3 daltons.

TABLE 3D
Encoded FCTR3b protein sequence.
MDVKDRRHRSLTRGRCGKECRYTSSSLDSEDCRVPTQKSYSSSETLKAYDHDSRMHYGNRVTDLIHRESDEFPRQGTNFTLAE (SEQ ID NO:8)
LGICEPSPHRSGYCSDMGILHQGYSLSTGSDADSDTEGGMSPEHAIRLWGRGIKSRRSSGLSSRENSALTLTDSDNENKSDDE
NGRPIPPTSSPSLLPSAQLPSSHNPPPVSCQMPLLDSNTSHQIMDTNPDEEFSPNSYLLRACSGPQQASSSGPPNHHSQSTLR
PPLPPPHNHTLSHHHSSANSLNRNSLTNRRSQIHAPAPAPNDLATTPESVQLQDSWVLNSNVPLETRHFLFKTSSGSTPLFSS
SSPGYPLTSGTVYTPPPRLLPRNTFSRKAFKLKKPSKYCSWKCAALSAIAAALLLAILLAYFIVPWSLKNSSIDSGEAEVGRR
VTQEVPPGVFWRSQIHISQPQFLKFNISLGKDALFGVYIRRGLPPSHAQYDFMERLDGKEKWSVVESPRERRSIQTLVQNEAV
FVQYLDVGLWHLAFYNDGKDKEMVSFNTVVLDSVQDCPRNCHGNGECVSGVCHCFPGFLGADCAKAACPVLCSGNGQYSKGTC
QCYSGWKGAECDVPMNQCIDPSCGGHGSCIDGNCVCSAGYKGEHCEEVDCLDPTCSSHGVCVNGECLCSPGWGGLNCELARVQ
CPDQCSGHGTYLPDTGLCSCDPNWMGPDCSVEVCSVDCGTHGVCIGGACRCEEGWTGAACDQRVCHPRCIEHGTCKDGKCECR
EGWNGEHCTIGRQTAGTETDGCPDLCNGNGRCTLGQNSWQCVCQTGWRGPGCNVAMETSCADNKDNEGDGLVDCLDPDCCLQS
ACGNSLLCRGSRDPLDIIQQGQTDWPAVKSFYDRIKLLAGKDSTHIIPGENPFNSSLVSLIRGQVVTTDGTPLVGVNVSFVKY
PKYGYTITRQDGTFDLIANGGASLTLHFERAPFMSQERTVWLPWNSFYAMDTLVMKTEENSIPSCDLSGFVRPDPIIISSPLS
TFFSAAPGQNPIVPETQVLHEEIELPGSNVKLRYLSSRTAGYKSLLKITMTQSTVPLNLIRVHLMVAVEGHLFQKSFQASPNL
ASTFIWDKTDAYGQRVYGLSDAVVSVGFEYETCPSLILWEKRTALLQGFELDPSNLGGWSLDKHHILNVKSGILHKGTGENQF
LTQQPAIITSIMGNGRRRSISCPSCNGLAEGNKLLAPVALAVGIDGSLYVGDFNYIRRIFPSRNVTSILELRNKEFKHSNNPA
HKYYLAVDPVSGSLYVSDTNSRRIYRVKSLSGTKDLAGNSEVVAGTGEQCLPFDEARCGDGGKAIDATLMSPRGIAVDKNGLM
YFVDATMIRKVDQNGIISTLLGSNDLTAVRPLSCDSSMDVAQVRLEWPTDLAVNPMDNSLYVLENNVILRITENHQVSIIAGR
PMHCQVPGIDYSLSKLAIHSALESASAIAISHTGVLYITETDEKKINRLRQVTTNGEICLLAGAASDCDCKNDVNCNCYSGDD
AYATDAILNSPSSLAVAPDGTIYIADLGNIRIRAVSKNKPVLNAFNQYEAASPGEQELYVFNADGIHQYTVSLVTGEYLYNFT
YSTDNDVTELIDNNGNSLKIRRDSSGMPRHLLMPDNQIITLTVGTNGGLKVVSTQNLELGLMTYDGNTGLLATKSDETGWTTF
YDYDHEGRLTNVTRPTGVVTSLHREMEKSITIDIENSNRDDDVTVITNLSSVEASYTVVQDQVRNSYQLCNNGTLRVMYANGM
GISFHSEPHVLAGTATPTIGRCNISLPMENGLNSIEWRLRKEQIKGKVTIFGRKLRVHGRNLLSIDYDRNIRTEKIYDDHRKF
TLRIIYDQVGRPFLWLPSSGLAAVNVSYFFNGRLAGLQRGAMSERTDIDKQGRIVSRMFADGKVWSYSYLDKSMVLLLQSQRQ
YIFEYDSSDRLLAVTMPSVARHSMSTHTSIGYIRNIYNPPESNASVIFDYSDDGRILKTSFLGTGRQVFYKYGKLSKLSEIVY
DSTAVTFGYDETTGVLKMVNLQSGGFSCTIRYRKIGPLVDKQIYRFSEEGMVNARFDYTYHDNSFRIASIKPVISETPLPVDL
YRYDEISGKVEHFGKFGVIYYDINQIITTAVMTLSKHFDTHGRIKEVQYEMFRSLMYWMTVQYDSMGRVIKRELKLGPYANTT
KYTYDYDGDGQLQSVAVNDRPTWRYSYDLNGNLHLLNPGNSVRLMPLRYDLRDRITRLGDVQYKIDDDGYLCQRGSDIFEYNS
KGLLTRAYNKASGWSVQYRYDGVGRRASYKTNLGHHLQYFYSDLHNPTRITHVYNHSNSEITSLYYDLQGHLFAMESSSGEEY
YVASDNTGTPLAVFSINGLMIKQLQYTAYGEIYYDSNPDFQMVIGFHGGLYDPLTKLVHFTQRDYDVLAGRWTSPDYTMWKNV
GKEPAPFNLYMFKSNNPLSSELDLKNYVTDVKSWLVMFGFQLSNIIPGFPRAKMYFVPPPYELSESQASENGQLITGVQQTTE
RHNQAFMALEGQVITKKLHASIREKAGHWFATTTPIIGKGIMFAIKEGRVTTGVSSIASEDSRKVASVLNNAYYLDKMHYSIE
GKDTHYFVKIGSADGDLVTLGTTIGRKVLESGVNVTVSQPTLLVNGRTRRFTNIEFQYSTLLLSIRYGLTPDTLDEEKARVLD
QARQRALGTAWAKEQQKARDGREGSRLWTEGEKQQLLSTGRVQGYEGYYVLPVEQYPELADSSSNIQFLRQNEMGKR

[0095] In further alternative embodiments the italicized bases in the 5′ end of the FCTR3b sequence in table 3C is a variable region. This region can be substituted for in other embodiments of FCTR3. The nucleotide sequence for 9823 bp FCTR3c (also referred to herein as 10129612.0.154) has the same nucleotide sequence as FCTR3b except that the italicized region is replaced with the 201 base sequence shown in Table 3E. An ORF for the total FCTR3c nucleotide sequence was identified beginning with an ATG initiation codon at nucleotides 277-280 and ending with a TAG codon at nucleotides 8473-8475. This is the same open reading frame that is shown in Table 3C, with the corresponding base numbers for FCTR3c. This open reading frame will translate the same amino acid sequence as shown in Table 3C for FCTR3b.

TABLE 3E
Encoded FCTR3c 5′end nucleotide sequence.
GCTCCAAAGCGAGCTGGGACCGAAGACTCTAGGCTAAGTTATCTATGTAGATGGTGTCAGGGAGCGAAGCTACTGACCGA (SEQ ID NO:9)
GCTGCTGTTACATCCAGCTTTTTAATTGCCTAAGCGGTCTGGGGCTTGCTTCGTCATTTGGCTTTGCTGTGGAGCACTCC
TGTAAAGCCAGCTGAATTGTACATCGAAGATCCACCCTTTT

[0096] In yet another embodiment, the italicized region shown in the 5′ end of the sequence in Table 3C can be replaced with the sequence shown in Table 3F to form 9823 bp FCTR3d (also referred to herein as 10129612.0.67). An ORF was identified beginning with an ATG initiation codon at nucleotides 277-280 and ending with a TAG codon at nucleotides 8473-8475. This is the same open reading frame that is shown in Table 3C, with the corresponding base numbers for FCTR3d. This open reading frame will translate the same amino acid sequence as shown in Table 3D for FCTR3b.

TABLE 3F
Encoded FCTR3d 5′ end nucleotide sequence.
GCTCCAAAGCGAGCTGGGACCGAAGACTCTAGGCTA (SEQ ID NO:10)
AGTTATCTATGTAGATGGTGTCAGGGAGCGAAGCTA
CTGACCGAGCTGCTGTTACATCCAGCTTTTTAATTG
CCTAAGCGGTCTGGGGCTTGCTTCGTCATTTGGCTT
TGCTGTGGAGCACTCCTGTAAAGCCAGCTGAATTGT
ACATCGAAGATCCACCCTTTT

[0097] In yet another embodiment, the italicized region shown in the 5′ end of the sequence in Table 3C can be replaced with the sequence shown in Table 3G to form 9765 bp FCTR3e (also referred to as 10129612.0.258). An ORF was identified beginning with an ATG initiation codon at nucleotides 210-212 and ending with a TAG codon at nucleotides 8408-8410. This is the same open reading frame that is shown in Table 3C, with the corresponding base numbers for FCTR3e. This open reading frame will translate the same amino acid sequence as shown in Table 3D for FCTR3b.

TABLE 3G
Encoded FCTR3e 5′ end nucleotide sequence.
CCAGCATTAGATGAGTTGACAAAAATGCAGTTTCAG (SEQ ID NO:11)
CTCTGAAGGTCTGAAAGATTCTGCTGCAACTAAAGC
TCTGAAGATTCTGCTACAACTATGACATCCATTTTC
TCCCACTTCAGACAGGATGAATACAA

[0098] In yet another embodiment another FCTR3a homolog, FCTR3f (also referred to as 10129612.0.352) was found having the 9729bp sequence shown in Table 3H. An ORF was identified beginning with an ATG initiation codon at nucleotides 210-212 and ending with a TAG codon at nucleotides 8382-8384. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 3G, and the start and stop codons are in bold letters.

TABLE 3H
Encoded FCTR3f nucleotide sequence.
CCAGCATTAGATGAGTTGACAAAAATGCAGTTTCAGCTCTGAAGGTCTGAAAGATTCTGCTGCAACTAAAGCTCTGAAGA (SEQ ID NO:12)
TTCTGCTACAACTATGACATCCATTTTCTCCCACTTCAGACAGGATGAATACAAGGTGGCAAAGTGACAAGTGCCAAAAC
TCAGGCCTGACTTTCCTGAAAACATCAGCATTCTGCCATATCTGGAATAATGGATGTAAAGGACCGGCGACACCGCTCTT
TGACCAGAGGACGCTGTGGCAAAGAGTGTCGCTACACAAGCTCCTCTCTGGACAGTGAGGACTGCCGGGTGCCCACACAG
AAATCCTACAGCTCCAGTGAGACTCTGAAGGCCTATGACCATGACAGCAGGATGCACTATGGAAACCGAGTCACAGACCT
CATCCACCGGGAGTCAGATGAGTTTCCTAGACAAGGAACCAACTTCACCCTTGCCGAACTGGGCATCTGTGAGCCCTCCC
CACACCGAAGCGGCTACTGCTCCGACATGGGGATCCTTCACCAGGGCTACTCCCTTAGCACAGGGTCTGACGCCGACTCC
GACACCGAGGGAGGGATGTCTCCAGAACACGCCATCAGACTGTGGGGCAGAGGGATAAAATCCAGGCGCAGTTCCGGCCT
GTCCAGTCGTGAAAACTCGGCCCTTACCCTGACTGACTCTGACAACGAAAACAAATCAGATGATGAGAACGGTCGTCCCA
TTCCACCTACATCCTCGCCTAGTCTCCTCCCATCTGCTCAGCTGCCTAGCTCCCATAATCCTCCACCAGTTAGCTGCCAG
ATGCCATTGCTAGACAGCAACACCTCCCATCAAATCATGGACACCAACCCTGATGAGGAATTCTCCCCCAATTCATACCT
GCTCAGAGCATGCTCAGGGCCCCAGCAAGCCTCCAGCAGTGGCCCTCCGAACCACCACAGCCAGTCGACTCTGAGGCCCC
CTCTCCCACCCCCTCACAACCACACGCTGTCCCATCACCACTCGTCCGCCAACTCCCTCAACAGGAACTCACTGACCAAT
CGGCGGAGTCAGATCCACGCCCCGGCCCCAGCGCCCAATGACCTGGCCACCACACCAGAGTCCGTTCAGCTTCAGGACAG
CTGGGTGCTAAACAGCAACGTGCCACTGGAGACCCGGCACTTCCTCTTCAAGACCTCCTCGGGGAGCACACCCTTGTTCA
GCAGCTCTTCCCCGGGATACCCTTTGACCTCAGGAACGGTTTACACGCCCCCGCCCCGCCTGCTGCCCAGGAATACTTTC
TCCAGGAAGGCTTTCAAGCTGAAGAAGCCCTCCAAATACTGCAGCTGGAAATGTGCTGCCCTCTCCGCCATTGCCGCGGC
CCTCCTCTTGGCTATTTTGCTGGCGTATTTCATAGTGCCCTGGTCGTTGAAAAACAGCAGCATAGACAGTGGTGAAGCAG
AAGTTGGTCGGCGGGTAACACAAGAAGTCCCACCAGGGGTGTTTTGGAGGTCACAAATTCACATCAGTCAGCCCCAGTTC
TTAAAGTTCAACATCTCCCTCGGGAAGGACGCTCTCTTTGGTGTTTACATAAGAAGAGGACTTCCACCATCTCATGCCCA
GTATGACTTCATGGAACGTCTGGACGGGAAGGAGAAGTGGAGTGTGGTTGAGTCTCCCAGGGAACGCCGGAGCATACAGA
CCTTGGTTCAGAATGAAGCCGTGTTTGTGCAGTACCTGGATGTGGGCCTGTGGCATCTGGCCTTCTACAATGATGGAAAA
GACAAAGAGATGGTTTCCTTCAATACTGTTGTCCTAGATTCAGTGCAGGACTGTCCACGTAACTGCCATGGGAATGGTGA
ATGTGTGTCCGGGGTGTGTCACTGTTTCCCAGGATTTCTAGGAGCAGACTGTGCTAAAGCTGCCTGCCCTGTCCTGTGCA
GTGGGAATGGACAATATTCTAAAGGGACGTGCCAGTGCTACAGCGGCTGGAAAGGTGCAGAGTGCGACGTGCCCATGAAT
CAGTGCATCGATCCTTCCTGCGGGGGCCACGGCTCCTGCATTGATGGGAACTGTGTCTGCTCTGCTGGCTACAAAGGCGA
GCACTGTGAGGAAGTTGATTGCTTGGATCCCACCTGCTCCAGCCACGGAGTCTGTGTGAATGGAGAATGCCTGTGCAGCC
CTGGCTGGGGTGGTCTGAACTGTGAGCTGGCGAGGGTCCAGTGCCCAGACCAGTGCAGTGGGCATGGCACGTACCTGCCT
GACACGGGCCTCTGCAGCTGCGATCCCAACTGGATGGGTCCCGACTGCTCTGTTGAAGTGTGCTCAGTAGACTGTGGCAC
TCACGGCGTCTGCATCGGGGGAGCCTGCCGCTGTGAAGAGGGCTGGACAGGCGCAGCGTGTGACCAGCGCGTGTGCCACC
CCCGCTGCATTGAGCATGGGACCTGTAAAGATGGCAAATGTGAATGCCGAGAGGGCTGGAATGGTGAACACTGCACCATT
GATGGCTGCCCTGACTTGTGCAACGGTAACGGGAGATGCACACTGGGTCAGAACAGCTGGCAGTGTGTCTGCCAGACCGG
CTGGAGAGGGCCCGGATGCAACGTTGCCATGGAAACTTCCTGTGCTGATAACAAGGATAATGAGGGAGATGGCCTGGTGG
ATTGTTTGGACCCTGACTGCTGCCTGCAGTCAGCCTGTCAGAACAGCCTGCTCTGCCGGGGGTCCCGGGACCCACTGGAC
ATCATTCAGCAGGGCCAGACGGATTGGCCCGCAGTGAAGTCCTTCTATGACCGTATCAAGCTCTTGGCAGGCAAGGATAG
CACCCACATCATTCCTGGAGAGAACCCTTTCAACAGCAGCTTGGTTTCTCTCATCCGAGGCCAAGTAGTAACTACAGATG
GAACTCCCCTGGTCGGTGTGAACGTGTCTTTTGTCAAGTACCCAAAATACGGCTACACCATCACCCGCCAGGATGGCACG
TTCGACCTGATCGCAAATGGAGGTGCTTCCTTGACTCTACACTTTGAGCGAGCCCCGTTCATGAGCCAGGAGCGCACTGT
GTGGCTGCCGTGGAACAGCTTTTACGCCATGGACACCCTGGTGATGAAGACCGAGGAGAACTCCATCCCCAGCTGTGACC
TCAGTGGCTTTGTCCGGCCTGATCCAATCATCATCTCCTCCCCACTGTCCACCTTCTTTAGTGCTGCCCCTGGGCAGAAT
CCCATCGTGCCTGAGACCCAGGTTCTTCATGAAGAAATCGAGCTCCCTGGTTCCAATGTGAAACTTCGCTATCTGAGCTC
TAGAACTGCAGGGTACAAGTCACTGCTGAAGATCACCATGACCCAGTCCACAGTGCCCCTGAACCTCATTAGGGTTCACC
TGATGGTGGCTGTCGAGGGGCATCTCTTCCAGAAGTCATTCCAGGCTTCTCCCAACCTGGCCTCCACCTTCATCTGGGAC
AAGACAGATGCGTATGGCCAAAGGGTGTATGGACTCTCAGATGCTGTTGTGTCTGTCGGGTTTGAATATGAGACCTGTCC
CAGTCTAATTCTCTGGGAGAAAAGGACAGCCCTCCTTCAGGGATTCGAGCTGGACCCCTCCAACCTCGGTGGCTGGTCCC
TAGACAAACACCACATCCTCAATGTTAAAAGTGGAATCCTACACAAAGGCACTGGGGAAAACCAGTTCCTGACCCAGCAG
CCTGCCATCATCACCAGCATCATGGGCAATGGTCGCCGCCGGAGCATTTCCTGTCCCAGCTGCAACGGCCTTGCTGAAGG
CAACAAGCTGCTGGCCCCAGTGGCTCTGGCTGTTGGAATCGATGGGAGCCTCTATGTGGGTGACTTCAATTACATCCGAC
GCATCTTTCCCTCTCGAAATGTGACCAGCATCTTGGAGTTACGAAATAAAGAGTTTAAACATAGCAACAACCCAGCACAC
AAGTACTACTTGGCAGTGGACCCCGTGTCCGGCTCGCTCTACGTGTCCGACACCAACAGCAGGAGAATCTACCGCGTCAA
GTCTCTGAGTGGAACCAAAGACCTGGCTGGGAATTCGGAAGTTGTGGCAGGGACGGGAGAGCAGTGTCTACCCTTTGATG
AAGCCCGCTGCGGGGATGGAGGGAAGGCCATAGATGCAACCCTGATGAGCCCGAGAGGTATTGCAGTAGACAAGAATGGG
CTCATGTACTTTGTCGATGCCACCATGATCCGGAAGGTTGACCAGAATGGAATCATCTCCACCCTGCTGGGCTCCAATGA
CCTCACTGCCGTCCGGCCGCTGAGCTGTGATTCCAGCATGGATGTAGCCCAGGTTCGTCTGGAGTGGCCAACAGACCTTG
CTGTCAATCCCATGGATAACTCCTTGTATGTTCTAGAGAACAATGTCATCCTTCGAATCACCGAGAACCACCAAGTCAGC
ATCATTGCGGGACGCCCCATGCACTGCCAAGTTCCTGGCATTGACTACTCACTCAGCAAACTAGCCATTCACTCTGCCCT
GGAGTCAGCCAGTGCCATTGCCATTTCTCACACTGGGGTCCTCTACATCACTGAGACAGATGAGAAGAAGATTAACCGTC
TACGCCAGGTAACAACCAACGGGGAGATCTGCCTTTTAGCTGGGGCAGCCTCGGACTGCGACTGCAAAAACGATGTCAAT
TGCAACTGCTATTCAGGAGATGATGCCTACGCGACTGATGCCATCTTGAATTCCCCATCATCCTTAGCTGTAGCTCCAGA
TGGTACCATTTACATTGCAGACCTTGGAAATATTCGGATCAGGGCGGTCAGCAAGAACAAGCCTGTTCTTAATGCCTTCA
ACCAGTATGAGGCTGCATCCCCCGGAGAGCAGGAGTTATATGTTTTCAACGCTGATGGCATCCACCAATACACTGTGAGC
CTGGTGACAGGGGAGTACTTGTACAATTTCACATATAGTACTGACAATGATGTCACTGAATTGATTGACAATAATGGGAA
TTCCCTGAAGATCCGTCGGGACAGCAGTGGCATGCCCCGTCACCTGCTCATGCCTGACAACCAGATCATCACCCTCACCG
TGGGCACCAATGGAGGCCTCAAAGTCGTGTCCACACAGAACCTGGAGCTTGGTCTCATGACCTATGATGGCAACACTGGG
CTCCTGGCCACCAAGAGCGATGAAACAGGATGGACGACTTTCTATGACTATGACCACGAAGGCCGCCTGACCAACGTGAC
GCGCCCCACGGGGGTGGTAACCAGTCTGCACCGGGAAATGGAGAAATCTATTACCATTGACATTGAGAACTCCAACCGTG
ATGATGACGTCACTGTCATCACCAACCTCTCTTCAGTAGAGGCCTCCTACACAGTGGTACAAGATCAAGTTCGGAACAGC
TACCAGCTCTGTAATAATGGTACCCTGAGGGTGATGTATGCTAATGGGATGGGTATCAGCTTCCACAGCGAGCCCCATGT
CCTAGCGGGCACCATCACCCCCACCATTGGACGCTGCAACATCTCCCTGCCTATGGAGAATGGCTTAAACTCCATTGAGT
GGCGCCTAAGAAAGGAACAGATTAAAGGCAAAGTCACCATCTTTGGCAGGAAGCTCCGGGTCCATGGAAGAAATCTCTTG
TCCATTGACTATGATCGAAATATTCGGACTGAAAAGATCTATGATGACCACCGGAAGTTCACCCTGAGGATCATTTATGA
CCAGGTGGGCCGCCCCTTCCTCTGGCTGCCCAGCAGCGGGCTGGCAGCTGTCAACGTGTCATACTTCTTCAATGGGCGCC
TGGCTGGGCTTCAGCGTGGGGCCATGAGCGAGAGGACAGACATCGACAAGCAAGGCCGCATCGTGTCCCGCATGTTCGCT
GACGGGAAAGTGTGGAGCTACTCCTACCTTGACAAGTCCATGGTCCTCCTGCTTCAGAGCCAACGTCAGTATATATTTGA
GTATGACTCCTCTGACCGCCTCCTTGCCGTCACCATGCCCAGCGTGGCCCGGCACAGCATGTCCACACACACCTCCATCG
GCTACATCCGTAATATTTACAACCCGCCTGAAAGCAATGCTTCGGTCATCTTTGACTACAGTGATGACGGCCGCATCCTG
AAGACCTCCTTTTTGGGCACCGGACGCCAGGTGTTCTACAAGTATGGGAAACTCTCCAAGTTATCAGAGATTGTCTACGA
CAGTACCGCCGTCACCTTCGGGTATGACGAGACCACTGGTGTCTTGAAGATGGTCAACCTCCAAAGTGGGGGCTTCTCCT
GCACCATCAGGTACCGGAAGATTGGCCCCCTGGTGGACAAGCAGATCTACAGGTTCTCCGAGGAAGGCATGGTCAATGCC
AGGTTTGACTACACCTATCATGACAACAGCTTCCGCATCGCAAGCATCAAGCCCGTCATAAGTGAGACTCCCCTCCCCGT
TGACCTCTACCGCTATGATGAGATTTCTGGCAAGGTGGAACACTTTGGTAAGTTTGGAGTCATCTATTATGACATCAACC
AGATCATCACCACTGCCGTGATGACCCTCAGCAAACACTTCGACACCCATGGGCGGATCAAGGAGGTCCAGTATGAGATG
TTCCGGTCCCTCATGTACTGGATGACGGTGCAATATGACAGCATGGGCAGGGTGATCAAGAGGGAGCTAAAACTGGGGCC
CTATGCCAATACCACGAAGTACACCTATGACTACGATGGGGACGGGCAGCTCCAGAGCGTGGCCGTCAATGACCGCCCGA
CCTGGCGCTACAGCTATGACCTTAATGGGAATCTCCACTTACTGAACCCAGGCAACAGTGTGCGCCTCATGCCCTTGCGC
TATGACCTCCGGGATCGGATAACCAGACTCGGGGATGTGCAGTACAAAATTGACGACGATGGCTATCTGTGCCAGAGAGG
GTCTGACATCTTCGAATACAATTCCAAGGGCCTCCTAACAAGAGCCTACAACAAGGCCAGCGGGTGGAGTGTCCAGTACC
GCTATGATGGCGTAGGACGGCGGGCTTCCTACAAGACCAACCTGGGCCACCACCTGCAGTACTTCTACTCTGACCTCCAC
AACCCGACGCGCATCACCCATGTCTACAATCACTCCAACTCGGAGATTACCTCACTGTACTACGACCTCCAGGGCCACCT
CTTTGCCATGGAGAGCAGCAGTGGGGAGGAGTACTATGTTGCCTCTGATAACACAGGGACTCCTCTGGCTGTGTTCAGCA
TCAACGGCCTCATGATCAAACAGCTGCAGTACACGGCCTATGGGGAGATTTATTATGACTCCAACCCCGACTTCCAGATG
GTCATTGGCTTCCATGGGGGACTCTATGACCCCCTGACCAAGCTGGTCCACTTCACTCAGCGTGATTATGATGTGCTGGC
AGGACGATGGACCTCCCCAGACTATACCATGTGGAAAAACGTGGGCAAGGAGCCGGCCCCCTTTAACCTGTATATGTTCA
AGAGCAACAATCCTCTCAGCAGTGAGCTAGATTTGAAGAACTACGTGACAGATGTGAAAAGCTGGCTTGTGATGTTTGGA
TTTCAGCTTAGCAACATCATTCCTGGCTTCCCGAGAGCCAAAATGTATTTCGTGCCTCCTCCCTATGAATTGTCAGAGAG
TCAAGCAAGTGAGAATGGACAGCTCATTACAGGTGTCCAACAGACAACAGAGAGACATAACCAGGCCTTCATGGCTCTGG
AAGGACAGGTCATTACTAAAAAGCTCCACGCCAGCATCCGAGAGAAAGCAGGTCACTGGTTTGCCACCACCACGCCCATC
ATTGGCAAAGGCATCATGTTTGCCATCAAAGAAGGGCGGGTGACCACGGGCGTGTCCAGCATCGCCAGCGAAGATAGCCG
CAAGGTGGCATCTGTGCTGAACAACGCCTACTACCTGGACAAGATGCACTACAGCATCGAGGGCAAGGACACCCACTACT
TTGTGAAGATTGGCTCAGCCGATGGCGACCTGGTCACACTAGGCACCACCATCGGCCGCAAGGTGCTAGAGAGCGGGGTG
AACGTGACCGTGTCCCAGCCCACGCTGCTGGTCAACGGCAGGACTCGAAGGTTCACGAACATTGAGTTCCAGTACTCCAC
GCTGCTGCTCAGCATCCGCTATGGCCTCACCCCCGACACCCTGGACGAAGAGAAGGCCCGCGTCCTGGACCAGGCGAGAC
AGAGGGCCCTGGGCACGGCCTGGGCCAAGGAGCAGCAGAAAGCCAGGGACGGGAGAGAGGGGAGCCGCCTGTGGACTGAG
GGCGAGAAGCAGCAGCTTCTGAGCACCGGGCGCGTGCAAGGGTACGAGGGATATTACGTGCTTCCCGTGGAGCAATACCC
AGAGCTTGCAGACAGTAGCAGCAACATCCAGTTTTTAAGACAGAATGAGATGGGAAAGAGGTAACAAAATAATCTGCTGC
CATTCCTTGTCTGAATGGCTCAGCAGGAGTAACTGTTATCTCCTCTCCTAAGGAGATGAAGACCTAACAGGGGCACTGCG
GCTGGGCTGCTTTAGGAGACCAAGTGGCAAGAAAGCTCACATTTTTTGAGTTCAAATGCTACTGTCCAAGCGAGAAGTCC
CTCATCCTGAAGTAGACTAAAGCCCGGCTGAAAATTCCGAGGAAAACAAAACAAACGAATGAATGAACAGACACACACAA
TGTTCCAAGTTCCCCTAAAATATGACCCACTTGTTCTGGGTCTACGCAGAAAAGAGACGCAAAGTGTCCAAAAGGAACAA
AAGAACAAAAACGAATAAGCAAAGAAGAAAACAAACAAAAACAAAACAAAACAAACACACGGACCGATAAACAAAGAAGC
GAAGATAAGAAAGAAGGCCTCATATCCAATTACCTCACTCATTCACATGTGAGCGACACGCAGACATCCGCGAGGGCCAG
CGTCACCAGACCAGCTGCGGGACAAACCACTCAGACTGCTTGTAGGACAAATACTTCTGACATTTTCGTTTAAGCAAATA
CAGGTGCATTTAAAACACGACTTTGGGGGTGATTTGTGTGTAGCGCCTGGGGAGGGGGGATAAAAGAGGAGGAGTGAGCA
CTGGAAATACTTTTTAAAGAAAAAAAAACATGAGGGAATAAAAGAAATTCCTATCAAAAATCAAAGTGAAATAATACCAT
CCAGCACTTAACTCTCAGGTCCCAACTAAGTCTGGCCTGAGCTAATTTATTTGAGCGCAGAGTGTAAAATTTAATTCAAA
ATGGTGGCTATAATCACTACAGATAAATTTCATACTCTTTTGTCTTTGGAGATTCCATTGTGGACAGTAATACGCAGTTA
CAGGGTGTAGTCTGTTTAGATTCCGTAGTTCGTGGGTATCAGTTTCGGTAGAGGTGCAGCATCGTGACACTTTTGCTAAC
AGGTACCACTTCTGATCACCCTGTACATACATGAGCCGAAAGGCACAATCACTGTTTCAGATTTAAAATTATTAGTGTGT
TTGTTTGGTCCAGAAACTGAGACAATCACATGACAGTCACCACGAGGAGAGAAAATTTAAAAAATAAAAATAAAAACAAA
AAAAATTTTAAAAATTAAAAAAACAAAAATAAAGTCTAATAAGAACTTTGGTACAGGAACTTTTTTGTAATATACATGTA
TGAATTGTTCATCGAGTTTTTATATTAATTTTAATTTGCTGCTAAGCAAAGACTAGGGACAGGCAAAGATAATTTATGGC
AAAGTGTTTAAATTGTTTATACATAAATAAAGTCTCTAAAACTCCTGTG

[0099] The FCTR3f polypeptide (SEQ ID NO: 13) encoded by SEQ ID NO:12 is 2724 amino acid residues long and is presented using the one-letter code in Table 3I. This sequence differs from FCTR3b in that it is missing amino acids 758-766 from that polypeptide.

TABLE 3I
Encoded FCTR3f protein sequence.
MDVKDRRHRSLTRGRCGKECRYTSSSLDSEDCRVPT (SEQ ID NO:13)
QKSYSSSETLKAYDHDSRMHYGNRVTDLIHRESDEF
PRQGTNFTLAELGICEPSPHRSGYCSDMGILHQGYS
LSTGSDADSDTEGGMSPEHAIRLWGRGIKSRRSSGL
SSRENSALTLTDSDNENKSDDENGRPIPPTSSPSLL
PSAQLPSSHNPPPVSCQMPLLDSNTSHQIMDTNPDE
EFSPNSYLLRACSGPQQASSSGPPNHHSQSTLRPPL
PPPHNHTLSHHHSSANSLNRNSLTNRRSQIHAPAPA
PNDLATTPESVQLQDSWVLNSNVPLETRHFLFKTSS
GSTPLFSSSSPGYPLTSGTVYTPPPRLLPRNTFSRK
AFKLKKPSKYCSWKCAALSAIAAALLLAILLAYFIV
PWSLKNSSIDSGEAEVGRRVTQEVPPGVFWRSQIHI
SQPQFLKFNISLGKDALFGVYIRRGLPPSHAQYDFM
ERLDGKEKWSVVESPRERRSIQTLVQNEAVFVQYLD
VGLWHLAFYNDGKDKEMVSFNTVVLDSVQDCPRNCH
GNGECVSGVCHCFPGFLGADCAKAACPVLCSGNGQY
SKGTCQCYSGWKGAECDVPMNQCIDPSCGGHGSCID
GNCVCSAGYKGEHCEEVDCLDPTCSSHGVCVNGECL
CSPGWGGLNCELARVQCPDQCSGHGTYLPDTGLCSC
DPNWMGPDCSVEVCSVDCGTHGVCIGGACRCEEGWT
GAACDQRVCHPRCIEHGTCKDGKCECREGWNGEHCT
IDGCPDLCNGNGRCTLGQNSWQCVCQTGWRGPGCNV
AMETSCADNKDNEGDGLVDCLDPDCCLQSACQNSLL
CRGSRDPLDIIQQGQTDWPAVKSFYDRIKLLAGKDS
THIIPGENPFNSSLVSLIRGQVVTTDGTPLVGVNVS
FVKYPKYGYTITRQDGTFDLIANGGASLTLHFERAP
FMSQERTVWLPWNSFYAMDTLVMKTEENSIPSCDLS
GFVRPDPIIISSPLSTFFSAAPGQNPIVPETQVLHE
EIELPGSNVKLRYLSSRTAGYKSLLKITMTQSTVPL
NLIRVHLMVAVEGHLFQKSFQASPNLASTFIWDKTD
AYGQRVYGLSDAVVSVGFEYETCPSLILWEKRTALL
QGFELDPSNLGGWSLDKHHILNVKSGILHKGTGENQ
FLTQQPAIITSIMGNGRRRSISCPSCNGLAEGNKLL
APVALAVGIDGSLYVGDFNYIRRIFPSRNVTSILEL
RNKEFKHSNNPAHKYYLAVDPVSGSLYVSDTNSRRI
YRVKSLSGTKDLAGNSEVVAGTGEQCLPFDEARCGD
GGKAIDATLMSPRGIAVDKNGLMYFVDATMIRKVDQ
NGIISTLLGSNDLTAVRPLSCDSSMDVAQVRLEWPT
DLAVNPMDNSLYVLENNVILRITENHQVSIIAGRPM
HCQVPGIDYSLSKLAIHSALESASAIAISHTGVLYI
TETDEKKINRLRQVTTNGEICLLAGAASDCDCKNDV
NCNCYSGDDAYATDAILNSPSSLAVAPDGTIYIADL
GNIRIRAVSKNKPVLNAFNQYEAASPGEQELYVFNA
DGIHQYTVSLVTGEYLYNFTYSTDNDVTELIDNNGN
SLKIRRDSSGMPRHLLMPDNQIITLTVGTNGGLKVV
STQNLELGLMTYDGNTGLLATKSDETGWTTFYDYDH
EGRLTNVTRPTGVVTSLHREMEKSITIDIENSNRDD
DVTVITNLSSVEASYTVVQDQVRNSYQLCNNGTLRV
MYANGMGISFHSEPHVLAGTITPTIGRCNISLPMEN
GLNSIEWRLRKEQIKGKVTIFGRKLRVHGRNLLSID
YDRNIRTEKIYDDHRKFTLRIIYDQVGRPFLWLPSS
GLAAVNVSYFFNGRLAGLQRGAMSERTDIDKQGRIV
SRMFADGKVWSYSYLDKSMVLLLQSQRQYIFEYDSS
DRLLAVTMPSVARHSMSTHTSIGYIRNIYNPPESNA
SVIFDYSDDGRILKTSFLGTGRQVFYKYGKLSKLSE
IVYDSTAVTFGYDETTGVLKMVNLQSGGFSCTIRYR
KIGPLVDKQIYRFSEEGMVNARFDYTYHDNSFRIAS
IKPVISETPLPVDLYRYDEISGKVEHFGKFGVIYYD
INQIITTAVMTLSKHFDTHGRIKEVQYEMFRSLMYW
MTVQYDSMGRVIKRELKLGPYANTTKYTYDYDGDGQ
LQSVAVNDRPTWRYSYDLNGNLHLLNPGNSVRLMPL
RYDLRDRITRLGDVQYKIDDDGYLCQRGSDIFEYNS
KGLLTRAYNKASGWSVQYRYDGVGRRASYKTNLGHH
LQYFYSDLHNPTRITHVYNHSNSEITSLYYDLQGHL
FAMESSSGEEYYVASDNTGTPLAVFSINGLMIKQLQ
YTAYGEIYYDSNPDFQMVIGFHGGLYDPLTKLVHFT
QRDYDVLAGRWTSPDYTMWKNVGKEPAPFNLYMFKS
NNPLSSELDLKNYVTDVKSWLVMFGFQLSNIIPGFP
RAKMYFVPPPYELSESQASENGQLITGVQQTTERHN
QAFMALEGQVITKKLHASIREKAGHWFATTTPIIGK
GIMFAIKEGRVTTGVSSIASEDSRKVASVLNNAYYL
DKMHYSIEGKDTHYFVKIGSADGDLVTLGTTIGRKV
LESGVNVTVSQPTLLVNGRTRRFTNIEFQYSTLLLS
IRYGLTPDTLDEEKARVLDQARQRALGTAWAKEQQK
ARDGREGSRLWTEGEKQQLLSTGRVQGYEGYYVLPV
EQYPELADSSSNIQFLRQNEMGKR

[0100] In a BLASTN search it was found that the FCTR3a nucleic acid has homology to three fragments of Mus musculus odd Oz/ten-m homolog 2. It has 634 of 685 bases (92%) identical to bases 614-1298, 365 of 406 bases (89%) identical to bases 1420-1825, and 93 of 103 bases (90%) identical to bases 1823-1925 of Mus musculus odd Oz/ten-m homolog 2 (GenBank Acc: NM—011856.2) (Table 3J).

TABLE 3J
BLASTN of FCTR3a against Mus musculus odd Oz/ten-m homolog 2 (SEQ ID NO:62)
>GI|7657414|REF|NM 011856.2| MUS MUSCULUS ODD OZ/TEN-M HOMOLOG 2 (DROSOPHILA)
(ODZ2), MRNA
LENGTH = 8797
SCORE = 954 BITS (481), EXPECT = 0.0
IDENTITIES = 634/685 (92%)
STRAND = PLUS/PLUS
QUERY:	114	GGTCGTCCCATTCCACCTACATCCTCGCCTAGTCTCCTCCCATCTGCTCAGCTGCCTAGC	173
		||||||||||||||||||||||||||| |||| |||||||||||||||||||||||||||
SBJCT:	614	GGTCGTCCCATTCCACCTACATCCTCGTCTAGCCTCCTCCCATCTGCTCAGCTGCCTAGC	673
QUERY:	174	TCCCATAATCCTCCACCAGTTAGCTGCCAGATGCCATTGCTAGACAGCAACACCTCCCAT	233
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	674	TCCCATAATCCTCCACCAGTTAGCTGCCAGATGCCATTGCTAGACAGCAACACCTCCCAT	733
QUERY:	234	CAAATCATGGACACCAACCCTGATGAGGAATTCTCCCCCAATTCATACCTGCTCAGAGCA	293
		|| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	734	CAGATCATGGACACCAACCCTGATGAGGAATTCTCCCCCAATTCATACCTGCTCAGAGCA	793
QUERY:	294	TGCTCAGGGCCCCAGCAAGCCTCCAGCAGTGGCCCTCCGAACCACCACAGCCAGTCGACT	353
		|||||||||||||||||||||||||||||||||||||| ||||||||||||||||| ||
SBJCT:	794	TGCTCAGGGCCCCAGCAAGCCTCCAGCAGTGGCCCTCCAAACCACCACAGCCAGTCAACA	853
QUERY:	354	CTGAGGCCCCCTCTCCCACCCCCTCACAACCACACGCTGTCCCATCACCACTCGTCCGCC	413
		|||||||||||||| ||||||||||| |||||||| |||||||| |||||||| || |||
SBJCT:	854	CTGAGGCCCCCTCTGCCACCCCCTCATAACCACACCCTGTCCCACCACCACTCCTCGGCC	913
QUERY:	414	AACTCCCTCAACAGGAACTCACTGACCAATCGGCGGAGTCAGATCCACGCCCCGGCCCCA	473
		||||||||||||||||||||||||||||||||||||||||| ||||||||||| || ||
SBJCT:	914	AACTCCCTCAACAGGAACTCACTGACCAATCGGCGGAGTCAAATCCACGCCCCAGCTCCT	973
QUERY:	474	GCGCCCAATGACCTGGCCACCACACCAGAGTCCGTTCAGCTTCAGGACAGCTGGGTGCTA	533
		|||||||| |||||||||||||| |||||||| |||||||| ||||| |||||||||||
SBJCT:	974	GCGCCCAACGACCTGGCCACCACCCCAGAGTCTGTTCAGCTCCAGGATAGCTGGGTGCTG	33
QUERY:	534	AACAGCAACGTGCCACTGGAGACCCGGCACTTCCTCTTCAAGACCTCCTCGGGGAGCACA	593
		||||| ||||| ||||||||||| ||||||||||| ||||| || || || || ||||||
SBJCT:	1034	AACAGTAACGTCCCACTGGAGACTCGGCACTTCCTTTTCAAAACGTCGTCTGGAAGCACA	93
QUERY:	594	CCCTTGTTCAGCAGCTCTTCCCCGGGATACCCTTTGACCTCAGGAACGGTTTACACGCCC	653
		||| |||||||||||||||| ||||||||||||||||||||||| || ||||| || ||
SBJCT:	1094	CCCCTGTTCAGCAGCTCTTCTCCGGGATACCCTTTGACCTCAGGGACCGTTTATACACCA	1153
QUERY:	654	CCGCCCCGCCTGCTGCCCAGGAATACTTTCTCCAGGAAGGCTTTCAAGCTGAAGAAGCCC	713
		|| ||||||||||||||  ||||||| |||||||||||||| ||||||||||||||| ||
SBJCT:	1154	CCACCCCGCCTGCTGCCACGGAATACATTCTCCAGGAAGGCCTTCAAGCTGAAGAAACCC	1213
QUERY:	714	TCCAAATACTGCAGCTGGAAATGTGCTGCCCTCTCCGCCATTGCCGCGGCCCTCCTCTTG	773
		|||||||||||||| ||||||||||||||||| || ||||| ||||| ||||||||||||
SBJCT:	1214	TCCAAATACTGCAGTTGGAAATGTGCTGCCCTGTCTGCCATCGCCGCCGCCCTCCTCTTG	1273
QUERY:	774	GCTATTTTGCTGGCGTATTTCATAG 798
		|| ||||||||||| ||||||||||
SBJCT:	1274	GCCATTTTGCTGGCATATTTCATAG 1298
SCORE = 480 BITS (242), EXPECT = E-132
IDENTITIES = 365/406 (89%)
STRAND = PLUS/PLUS
QUERY:	797	AGTGCCCTGGTCGTTGAAAAACAGCAGCATAGACAGTGGTGAAGCAGAAGTTGGTCGGCG	856
		|||||||||||| |||||||||||||||||||||||||| ||||||||||||||||||||
SBJCT:	1420	AGTGCCCTGGTCATTGAAAAACAGCAGCATAGACAGTGGCGAAGCAGAAGTTGGTCGGCG	1479
QUERY:	857	GGTAACACAAGAAGTCCCACCAGGGGTGTTTTGGAGGTCACAAATTCACATCAGTCAGCC	916
		||| ||||| ||||||||||||||||||||||||||||| || |||||||||||||||||
SBJCT:	1480	GGTGACACAGGAAGTCCCACCAGGGGTGTTTTGGAGGTCCCAGATTCACATCAGTCAGCC	1539
QUERY:	917	CCAGTTCTTAAAGTTCAACATCTCCCTCGGGAAGGACGCTCTCTTTGGTGTTTACATAAG	976
		|| ||||||||||||||||||||||| || ||||| || ||||| ||||| || |||||
SBJCT:	1540	TCAATTCTTAAAGTTCAACATCTCCCTGGGCAAGGATGCCCTCTTCGGTGTCTATATAAG	1599
QUERY:	977	AAGAGGACTTCCACCATCTCATGCCCAGTATGACTTCATGGAACGTCTGGACGGGAAGGA	36
		|||||||| ||||| ||||||||||||||||||||||||||||| ||||| || |||||
SBJCT:	1600	GAGAGGACTACCACCGTCTCATGCCCAGTATGACTTCATGGAACGCCTGGATGGAAAGGA	1659
QUERY:	1037	GAAGTGGAGTGTGGTTGAGTCTCCCAGGGAACGCCGGAGCATACAGACCTTGGTTCAGAA	96
		||| ||||| ||||| ||||| |||||||||||||||||||| |||||  |||| |||||
SBJCT:	1660	GAAATGGAGCGTGGTCGAGTCGCCCAGGGAACGCCGGAGCATCCAGACTCTGGTGCAGAA	1719
QUERY:	1097	TGAAGCCGTGTTTGTGCAGTACCTGGATGTGGGCCTGTGGCATCTGGCCTTCTACAATGA	1156
		|| || ||||||||||||||| ||||||||||||||||||| |||||||||||||||||
SBJCT:	1720	CGAGGCTGTGTTTGTGCAGTACTTGGATGTGGGCCTGTGGCACCTGGCCTTCTACAATGA	1779
QUERY:	1157	TGGAAAAGACAAAGAGATGGTTTCCTTCAATACTGTTGTCCTAGAT 1202
		|| || ||||| |||||||| |||||||| ||||||||| |||||
SBJCT:	1780	CGGCAAGGACAAGGAGATGGTCTCCTTCAACACTGTTGTCTTAGAT 1825
SCORE = 125 BITS (63), EXPECT = 7E-26
IDENTITIES = 93/ 3 (90%)
STRAND = PLUS/PLUS
QUERY:	1258	GATTCAGTGCAGGACTGTCCACGTAACTGCCATGGGAATGGTGAATGTGTGTCCGGGGTG	1317
		||||||||||||||||||||||| ||||| || ||||| |||||||| ||||| ||  ||
SBJCT:	1823	GATTCAGTGCAGGACTGTCCACGGAACTGTCACGGGAACGGTGAATGCGTGTCTGGACTG	1882
QUERY:	1318	TGTCACTGTTTCCCAGGATTTCTAGGAGCAGACTGTGCTAAAG 1360
		|||||||||||||||||||| ||||| ||||||||||||||||
SBJCT:	1883	TGTCACTGTTTCCCAGGATTCCTAGGTGCAGACTGTGCTAAAG 1925

[0101] In another BLASTN search it was found that the FCTR3a nucleic acid has homology to three fragments of Gallus gallus mRNA for teneurin-2. It has 541 of 629 bases (86%) identical to bases 502-1130, 302 of 367 bases (82%) identical to bases 1330-1696, and 87 of 103 bases (84%) identical to bases 1711-1813 of Gallus gallus mRNA for teneurin-2 (EMBL Acc: AJ245711.1) (Table 3K).

TABLE 3K
BLASTN of FCTR3a against Gallus gallus mRNA for teneurin-2 (SEQ ID NO:63)
>GI|60l0048|EMB|AJ245711.1|GGA245711 GALLUS GALLUS MRNA FOR TENEURIN-2, SHORT
SPLICE VARIANT (TEN2 GENE)
LENGTH = 2496
SCORE = 549 BITS (277), EXPECT = E-153
IDENTITIES = 541/629 (86%)
STRAND = PLUS/PLUS
QUERY:	114	GGTCGTCCCATTCCACCTACATCCTCGCCTAGTCTCCTCCCATCTGCTCAGCTGCCTAGC	173
		||||||||||||||||||||||||||| |||| || |||||||||||||||||||| ||
SBJCT:	502	GGTCGTCCCATTCCACCTACATCCTCGTCTAGCCTTCTCCCATCTGCTCAGCTGCCCAGT	561
QUERY:	174	TCCCATAATCCTCCACCAGTTAGCTGCCAGATGCCATTGCTAGACAGCAACACCTCCCAT	233
		|| ||||||||||||||||||||||||||||||||||||||||||||||| || ||||||
SBJCT:	562	TCTCATAATCCTCCACCAGTTAGCTGCCAGATGCCATTGCTAGACAGCAATACGTCCCAT	621
QUERY:	234	CAAATCATGGACACCAACCCTGATGAGGAATTCTCCCCCAATTCATACCTGCTCAGAGCA	293
		||||||||||||||||| ||||| ||||| ||||| || ||||||||||| || ||||||
SBJCT:	622	CAAATCATGGACACCAATCCTGACGAGGAGTTCTCTCCTAATTCATACCTACTAAGAGCA	681
QUERY:	294	TGCTCAGGGCCCCAGCAAGCCTCCAGCAGTGGCCCTCCGAACCACCACAGCCAGTCGACT	353
		|| |||||||| ||||| || ||||||||||||||| | ||||| ||||||||||| ||
SBJCT:	682	TGTTCAGGGCCACAGCAGGCATCCAGCAGTGGCCCTTCAAACCATCACAGCCAGTCAACG	741
QUERY:	354	CTGAGGCCCCCTCTCCCACCCCCTCACAACCACACGCTGTCCCATCACCACTCGTCCGCC	413
		|||||||| |||||||| || |||||||||||| ||||||||||||| |||||||| |||
SBJCT:	742	CTGAGGCCACCTCTCCCCCCTCCTCACAACCACTCGCTGTCCCATCATCACTCGTCTGCC	801
QUERY:	414	AACTCCCTCAACAGGAACTCACTGACCAATCGGCGGAGTCAGATCCACGCCCCGGCCCCA	473
		|||||||||||||||||||| || ||||| || || |  ||||||||||| || || ||
SBJCT:	802	AACTCCCTCAACAGGAACTCGCTCACCAACCGCCGCAACCAGATCCACGCGCCTGCTCCC	861
QUERY:	474	GCGCCCAATGACCTGGCCACCACACCAGAGTCCGTTCAGCTTCAGGACAGCTGGGTGCTA	533
		|| |||||||||||||| ||||| || ||||| || ||||| |||||||||||||||||
SBJCT:	862	GCTCCCAATGACCTGGCGACCACGCCTGAGTCTGTGCAGCTGCAGGACAGCTGGGTGCTC	921
QUERY:	534	AACAGCAACGTGCCACTGGAGACCCGGCACTTCCTCTTCAAGACCTCCTCGGGGAGCACA	593
		|||||||||||||| ||||||||| |||| ||| | || ||||| || || || |  ||
SBJCT:	922	AACAGCAACGTGCCGCTGGAGACCAGGCATTTCTTGTTTAAGACATCTTCTGGAACGACT	981
QUERY:	594	CCCTTGTTCAGCAGCTCTTCCCCGGGATACCCTTTGACCTCAGGAACGGTTTACACGCCC	653
		||  ||||||| ||||||||||| || |||||  ||||||||||||| ||||| || ||
SBJCT:	982	CCGCTGTTCAGTAGCTCTTCCCCTGGCTACCCACTGACCTCAGGAACAGTTTATACTCCA	1041
QUERY:	654	CCGCCCCGCCTGCTGCCCAGGAATACTTTCTCCAGGAAGGCTTTCAAGCTGAAGAAGCCC	713
		|| ||| | ||| | || || ||||| || |||||||| || ||||||||||| ||||||
SBJCT:	1042	CCTCCCAGGCTGTTACCTAGAAATACATTTTCCAGGAATGCATTCAAGCTGAAAAAGCCC	1101
QUERY:	714	TCCAAATACTGCAGCTGGAAATGTGCTGC 742
		||||| || || |||||||||||||||||
SBJCT:	1102	TCCAAGTATTGTAGCTGGAAATGTGCTGC 1130
SCORE = 212 BITS (107), EXPECT = 4E-52
IDENTITIES = 302/367 (82%)
STRAND = PLUS/PLUS
QUERY:	819	AGCAGCATAGACAGTGGTGAAGCAGAAGTTGGTCGGCGGGTAACACAAGAAGTCCCACCA	878
		||||||||||| ||||| ||| |||||||||| ||   ||| || ||||| || || ||
SBJCT:	1330	AGCAGCATAGATAGTGGAGAAACAGAAGTTGGCCGCAAGGTCACCCAAGAGGTGCCCCCT	1389
QUERY:	879	GGGGTGTTTTGGAGGTCACAAATTCACATCAGTCAGCCCCAGTTCTTAAAGTTCAACATC	938
		|| ||||| ||| |||| || || || ||||| ||||| |||||| | |||||||||||
SBJCT:	1390	GGAGTGTTCTGGCGGTCTCAGATCCATATCAGCCAGCCACAGTTCCTGAAGTTCAACATA	1449
QUERY:	939	TCCCTCGGGAAGGACGCTCTCTTTGGTGTTTACATAAGAAGAGGACTTCCACCATCTCAT	998
		||||| |||||||| ||||| || |||||||| |||||||||||||| |||||||| |||
SBJCT:	1450	TCCCTAGGGAAGGATGCTCTTTTCGGTGTTTATATAAGAAGAGGACTCCCACCATCACAT	1509
QUERY:	999	GCCCAGTATGACTTCATGGAACGTCTGGACGGGAAGGAGAAGTGGAGTGTGGTTGAGTCT	1058
		|| |||||||| |||||||||||  |||| ||||| ||||| ||||||||||| || ||
SBJCT:	1510	GCACAGTATGATTTCATGGAACGCTTGGATGGGAAAGAGAAATGGAGTGTGGTGGAATCC	1569
QUERY:	1059	CCCAGGGAACGCCGGAGCATACAGACCTTGGTTCAGAATGAAGCCGTGTTTGTGCAGTAC	1118
		||  ||||||| || || || |||||  | ||||||||||| || |||||||| ||||||
SBJCT:	1570	CCACGGGAACGGCGAAGTATTCAGACTCTTGTTCAGAATGAGGCTGTGTTTGTTCAGTAC	1629
QUERY:	1119	CTGGATGTGGGCCTGTGGCATCTGGCCTTCTACAATGATGGAAAAGACAAAGAGATGGTT	1178
		||||||||||  ||||||| ||||| || ||||||||||| || ||||||||  ||||
SBJCT:	1630	TTGGATGTGGGTTTGTGGCACCTGGCGTTTTACAATGATGGCAAGGACAAAGAAGTGGTC	1689
QUERY:	1179	TCCTTCA 1185
		|||||||
SBJCT:	1690	TCCTTCA 1696
SCORE = 77.8 BITS (39), EXPECT = 1E-11
IDENTITIES = 87/103 (84%)
STRAND = PLUS/PLUS
QUERY:	1258	GATTCAGTGCAGGACTGTCCACGTAACTGCCATGGGAATGGTGAATGTGTGTCCGGGGTG	1317
		||||||||||| |||||||||||||| || ||||| ||||| || ||||| || || ||
SBJCT:	1711	GATTCAGTGCAAGACTGTCCACGTAATTGTCATGGCAATGGCGAGTGTGTTTCTGGTGTC	1770
QUERY:	1318	TGTCACTGTTTCCCAGGATTTCTAGGAGCAGACTGTGCTAAAG 1360
		|| |||||||| || |||||||  |||||||| ||||||||||
SBJCT:	1771	TGCCACTGTTTTCCCGGATTTCATGGAGCAGATTGTGCTAAAG 1813

[0102] In this search it was also found that the fragments of FCTR3bcd and e nucleic acids had homology to three fragments of Homo sapiens mRNA for KIAA1127 protein. It has 5537 of 5538 bases (99%) identical to bases 1-5538, 705 of 714 bases (98%) identical to bases 5609-6322, and 176 of 176 bases (100%) identical to bases 6385-6560 of Homo sapiens mRNA for KIAA1 127 protein (GenBank Acc: AB032953) (Table 3L).

TABLE 3L
BLASTN of FCTR3b, c, d, and e against Homo sapiens KIAA1127 mRNA (SEQ ID NO:
64)
>GI|6329762|AB032953.1|AB032953 HOMO SAPIENS MRNA FOR KIAA1127 PROTEIN,
PARTIAL CDS
LENGTH = 6560
SCORE = 1.097E+04 BITS (5534), EXPECT = 0.0
IDENTITIES = 5537/5538 (99%)
STRAND = PLUS/PLUS
QUERY:	3267	CACCTTCTTTAGTGCTGCCCCTGGGCAGAATCCCATCGTGCCTGAGACCCAGGTTCTTCA	3326
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1	CACCTTCTTTAGTGCTGCCCCTGGGCAGAATCCCATCGTGCCTGAGACCCAGGTTCTTCA	60
QUERY:	3327	TGAAGAAATCGAGCTCCCTGGTTCCAATGTGAAACTTCGCTATCTGAGCTCTAGAACTGC	3386
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	61	TGAAGAAATCGAGCTCCCTGGTTCCAATGTGAAACTTCGCTATCTGAGCTCTAGAACTGC	120
QUERY:	3387	AGGGTACAAGTCACTGCTGAAGATCACCATGACCCAGTCCACAGTGCCCCTGAACCTCAT	3446
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	121	AGGGTACAAGTCACTGCTGAAGATCACCATGACCCAGTCCACAGTGCCCCTGAACCTCAT	180
QUERY:	3447	TAGGGTTCACCTGATGGTGGCTGTCGAGGGGCATCTCTTCCAGAAGTCATTCCAGGCTTC	3506
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	181	TAGGGTTCACCTGATGGTGGCTGTCGAGGGGCATCTCTTCCAGAAGTCATTCCAGGCTTC	240
QUERY:	3507	TCCCAACCTGGCCTCCACCTTCATCTGGGACAAGACAGATGCGTATGGCCAAAGGGTGTA	3566
		|||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	241	TCCCAACCTGGCCTACACCTTCATCTGGGACAAGACAGATGCGTATGGCCAAAGGGTGTA	300
QUERY:	3567	TGGACTCTCAGATGCTGTTGTGTCTGTCGGGTTTGAATATGAGACCTGTCCCAGTCTAAT	3626
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	301	TGGACTCTCAGATGCTGTTGTGTCTGTCGGGTTTGAATATGAGACCTGTCCCAGTCTAAT	360
QUERY:	3627	TCTCTGGGAGAAAAGGACAGCCCTCCTTCAGGGATTCGAGCTGGACCCCTCCAACCTCGG	3686
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	361	TCTCTGGGAGAAAAGGACAGCCCTCCTTCAGGGATTCGAGCTGGACCCCTCCAACCTCGG	420
QUERY:	3687	TGGCTGGTCCCTAGACAAACACCACATCCTCAATGTTAAAAGTGGAATCCTACACAAAGG	3746
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	421	TGGCTGGTCCCTAGACAAACACCACATCCTCAATGTTAAAAGTGGAATCCTACACAAAGG	480
QUERY:	3747	CACTGGGGAAAACCAGTTCCTGACCCAGCAGCCTGCCATCATCACCAGCATCATGGGCAA	3806
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	481	CACTGGGGAAAACCAGTTCCTGACCCAGCAGCCTGCCATCATCACCAGCATCATGGGCAA	540
QUERY:	3807	TGGTCGCCGCCGGAGCATTTCCTGTCCCAGCTGCAACGGCCTTGCTGAAGGCAACAAGCT	3866
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	541	TGGTCGCCGCCGGAGCATTTCCTGTCCCAGCTGCAACGGCCTTGCTGAAGGCAACAAGCT	600
QUERY:	3867	GCTGGCCCCAGTGGCTCTGGCTGTTGGAATCGATGGGAGCCTCTATGTGGGTGACTTCAA	3926
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	601	GCTGGCCCCAGTGGCTCTGGCTGTTGGAATCGATGGGAGCCTCTATGTGGGTGACTTCAA	660
QUERY:	3927	TTACATCCGACGCATCTTTCCCTCTCGAAATGTGACCAGCATCTTGGAGTTACGAAATAA	3986
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	661	TTACATCCGACGCATCTTTCCCTCTCGAAATGTGACCAGCATCTTGGAGTTACGAAATAA	720
QUERY:	3987	AGAGTTTAAACATAGCAACAACCCAGCACACAAGTACTACTTGGCAGTGGACCCCGTGTC	4046
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	721	AGAGTTTAAACATAGCAACAACCCAGCACACAAGTACTACTTGGCAGTGGACCCCGTGTC	780
QUERY:	4047	CGGCTCGCTCTACGTGTCCGACACCAACAGCAGGAGAATCTACCGCGTCAAGTCTCTGAG	4106
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	781	CGGCTCGCTCTACGTGTCCGACACCAACAGCAGGAGAATCTACCGCGTCAAGTCTCTGAG	840
QUERY:	4107	TGGAACCAAAGACCTGGCTGGGAATTCGGAAGTTGTGGCAGGGACGGGAGAGCAGTGTCT	4166
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	841	TGGAACCAAAGACCTGGCTGGGAATTCGGAAGTTGTGGCAGGGACGGGAGAGCAGTGTCT	900
QUERY:	4167	ACCCTTTGATGAAGCCCGCTGCGGGGATGGAGGGAAGGCCATAGATGCAACCCTGATGAG	4226
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	901	ACCCTTTGATGAAGCCCGCTGCGGGGATGGAGGGAAGGCCATAGATGCAACCCTGATGAG	960
QUERY:	4227	CCCGAGAGGTATTGCAGTAGACAAGAATGGGCTCATGTACTTTGTCGATGCCACCATGAT	4286
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	961	CCCGAGAGGTATTGCAGTAGACAAGAATGGGCTCATGTACTTTGTCGATGCCACCATGAT	1020
QUERY:	4287	CCGGAAGGTTGACCAGAATGGAATCATCTCCACCCTGCTGGGCTCCAATGACCTCACTGC	4346
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1021	CCGGAAGGTTGACCAGAATGGAATCATCTCCACCCTGCTGGGCTCCAATGACCTCACTGC	1080
QUERY:	4347	CGTCCGGCCGCTGAGCTGTGATTCCAGCATGGATGTAGCCCAGGTTCGTCTGGAGTGGCC	4406
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1081	CGTCCGGCCGCTGAGCTGTGATTCCAGCATGGATGTAGCCCAGGTTCGTCTGGAGTGGCC	1140
QUERY:	4407	AACAGACCTTGCTGTCAATCCCATGGATAACTCCTTGTATGTTCTAGAGAACAATGTCAT	4466
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1141	AACAGACCTTGCTGTCAATCCCATGGATAACTCCTTGTATGTTCTAGAGAACAATGTCAT	1200
QUERY:	4467	CCTTCGAATCACCGAGAACCACCAAGTCAGCATCATTGCGGGACGCCCCATGCACTGCCA	4526
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1201	CCTTCGAATCACCGAGAACCACCAAGTCAGCATCATTGCGGGACGCCCCATGCACTGCCA	1260
QUERY:	4527	AGTTCCTGGCATTGACTACTCACTCAGCAAACTAGCCATTCACTCTGCCCTGGAGTCAGC	4586
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1261	AGTTCCTGGCATTGACTACTCACTCAGCAAACTAGCCATTCACTCTGCCCTGGAGTCAGC	1320
QUERY:	4587	CAGTGCCATTGCCATTTCTCACACTGGGGTCCTCTACATCACTGAGACAGATGAGAAGAA	4646
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1321	CAGTGCCATTGCCATTTCTCACACTGGGGTCCTCTACATCACTGAGACAGATGAGAAGAA	1380
QUERY:	4647	GATTAACCGTCTACGCCAGGTAACAACCAACGGGGAGATCTGCCTTTTAGCTGGGGCAGC	4706
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1381	GATTAACCGTCTACGCCAGGTAACAACCAACGGGGAGATCTGCCTTTTAGCTGGGGCAGC	1440
QUERY:	4707	CTCGGACTGCGACTGCAAAAACGATGTCAATTGCAACTGCTATTCAGGAGATGATGCCTA	4766
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1441	CTCGGACTGCGACTGCAAAAACGATGTCAATTGCAACTGCTATTCAGGAGATGATGCCTA	1500
QUERY:	4767	CGCGACTGATGCCATCTTGAATTCCCCATCATCCTTAGCTGTAGCTCCAGATGGTACCAT	4826
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1501	CGCGACTGATGCCATCTTGAATTCCCCATCATCCTTAGCTGTAGCTCCAGATGGTACCAT	1560
QUERY:	4827	TTACATTGCAGACCTTGGAAATATTCGGATCAGGGCGGTCAGCAAGAACAAGCCTGTTCT	4886
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1561	TTACATTGCAGACCTTGGAAATATTCGGATCAGGGCGGTCAGCAAGAACAAGCCTGTTCT	1620
QUERY:	4887	TAATGCCTTCAACCAGTATGAGGCTGCATCCCCCGGAGAGCAGGAGTTATATGTTTTCAA	4946
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1621	TAATGCCTTCAACCAGTATGAGGCTGCATCCCCCGGAGAGCAGGAGTTATATGTTTTCAA	1680
QUERY:	4947	CGCTGATGGCATCCACCAATACACTGTGAGCCTGGTGACAGGGGAGTACTTGTACAATTT	5006
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1681	CGCTGATGGCATCCACCAATACACTGTGAGCCTGGTGACAGGGGAGTACTTGTACAATTT	1740
QUERY:	5007	CACATATAGTACTGACAATGATGTCACTGAATTGATTGACAATAATGGGAATTCCCTGAA	5066
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1741	CACATATAGTACTGACAATGATGTCACTGAATTGATTGACAATAATGGGAATTCCCTGAA	1800
QUERY:	5067	GATCCGTCGGGACAGCAGTGGCATGCCCCGTCACCTGCTCATGCCTGACAACCAGATCAT	5126
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1801	GATCCGTCGGGACAGCAGTGGCATGCCCCGTCACCTGCTCATGCCTGACAACCAGATCAT	1860
QUERY:	5127	CACCCTCACCGTGGGCACCAATGGAGGCCTCAAAGTCGTGTCCACACAGAACCTGGAGCT	5186
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1861	CACCCTCACCGTGGGCACCAATGGAGGCCTCAAAGTCGTGTCCACACAGAACCTGGAGCT	1920
QUERY:	5187	TGGTCTCATGACCTATGATGGCAACACTGGGCTCCTGGCCACCAAGAGCGATGAAACAGG	5246
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1921	TGGTCTCATGACCTATGATGGCAACACTGGGCTCCTGGCCACCAAGAGCGATGAAACAGG	1980
QUERY:	5247	ATGGACGACTTTCTATGACTATGACCACGAAGGCCGCCTGACCAACGTGACGCGCCCCAC	5306
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1981	ATGGACGACTTTCTATGACTATGACCACGAAGGCCGCCTGACCAACGTGACGCGCCCCAC	2040
QUERY:	5307	GGGGGTGGTAACCAGTCTGCACCGGGAAATGGAGAAATCTATTACCATTGACATTGAGAA	5366
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2041	GGGGGTGGTAACCAGTCTGCACCGGGAAATGGAGAAATCTATTACCATTGACATTGAGAA	2100
QUERY:	5367	CTCCAACCGTGATGATGACGTCACTGTCATCACCAACCTCTCTTCAGTAGAGGCCTCCTA	5426
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2101	CTCCAACCGTGATGATGACGTCACTGTCATCACCAACCTCTCTTCAGTAGAGGCCTCCTA	2160
QUERY:	5427	CACAGTGGTACAAGATCAAGTTCGGAACAGCTACCAGCTCTGTAATAATGGTACCCTGAG	5486
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2161	CACAGTGGTACAAGATCAAGTTCGGAACAGCTACCAGCTCTGTAATAATGGTACCCTGAG	2220
QUERY:	5487	GGTGATGTATGCTAATGGGATGGGTATCAGCTTCCACAGCGAGCCCCATGTCCTAGCGGG	5546
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2221	GGTGATGTATGCTAATGGGATGGGTATCAGCTTCCACAGCGAGCCCCATGTCCTAGCGGG	2280
QUERY:	5547	CACCATCACCCCCACCATTGGACGCTGCAACATCTCCCTGCCTATGGAGAATGGCTTAAA	5606
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2281	CACCATCACCCCCACCATTGGACGCTGCAACATCTCCCTGCCTATGGAGAATGGCTTAAA	2340
QUERY:	6627	TGGGCGGATCAAGGAGGTCCAGTATGAGATGTTCCGGTCCCTCATGTACTGGATGACGGT	6686
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3361	TGGGCGGATCAAGGAGGTCCAGTATGAGATGTTCCGGTCCCTCATGTACTGGATGACGGT	3420
QUERY:	6687	GCAATATGACAGCATGGGCAGGGTGATCAAGAGGGAGCTAAAACTGGGGCCCTATGCCAA	6746
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3421	GCAATATGACAGCATGGGCAGGGTGATCAAGAGGGAGCTAAAACTGGGGCCCTATGCCAA	3480
QUERY:	6747	TACCACGAAGTACACCTATGACTACGATGGGGACGGGCAGCTCCAGAGCGTGGCCGTCAA	6806
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3481	TACCACGAAGTACACCTATGACTACGATGGGGACGGGCAGCTCCAGAGCGTGGCCGTCAA	3540
QUERY:	6807	TGACCGCCCGACCTGGCGCTACAGCTATGACCTTAATGGGAATCTCCACTTACTGAACCC	6866
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3541	TGACCGCCCGACCTGGCGCTACAGCTATGACCTTAATGGGAATCTCCACTTACTGAACCC	3600
QUERY:	6867	AGGCAACAGTGTGCGCCTCATGCCCTTGCGCTATGACCTCCGGGATCGGATAACCAGACT	6926
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3601	AGGCAACAGTGTGCGCCTCATGCCCTTGCGCTATGACCTCCGGGATCGGATAACCAGACT	3660
QUERY:	6927	CGGGGATGTGCAGTACAAAATTGACGACGATGGCTATCTGTGCCAGAGAGGGTCTGACAT	6986
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3661	CGGGGATGTGCAGTACAAAATTGACGACGATGGCTATCTGTGCCAGAGAGGGTCTGACAT	3720
QUERY:	6987	CTTCGAATACAATTCCAAGGGCCTCCTAACAAGAGCCTACAACAAGGCCAGCGGGTGGAG	7046
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3721	CTTCGAATACAATTCCAAGGGCCTCCTAACAAGAGCCTACAACAAGGCCAGCGGGTGGAG	3780
QUERY:	7047	TGTCCAGTACCGCTATGATGGCGTAGGACGGCGGGCTTCCTACAAGACCAACCTGGGCCA	7106
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3781	TGTCCAGTACCGCTATGATGGCGTAGGACGGCGGGCTTCCTACAAGACCAACCTGGGCCA	3840
QUERY:	7107	CCACCTGCAGTACTTCTACTCTGACCTCCACAACCCGACGCGCATCACCCATGTCTACAA	7166
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3841	CCACCTGCAGTACTTCTACTCTGACCTCCACAACCCGACGCGCATCACCCATGTCTACAA	3900
QUERY:	7167	TCACTCCAACTCGGAGATTACCTCACTGTACTACGACCTCCAGGGCCACCTCTTTGCCAT	7226
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3901	TCACTCCAACTCGGAGATTACCTCACTGTACTACGACCTCCAGGGCCACCTCTTTGCCAT	3960
QUERY:	7227	GGAGAGCAGCAGTGGGGAGGAGTACTATGTTGCCTCTGATAACACAGGGACTCCTCTGGC	7286
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3961	GGAGAGCAGCAGTGGGGAGGAGTACTATGTTGCCTCTGATAACACAGGGACTCCTCTGGC	4020
QUERY:	7287	TGTGTTCAGCATCAACGGCCTCATGATCAAACAGCTGCAGTACACGGCCTATGGGGAGAT	7346
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4021	TGTGTTCAGCATCAACGGCCTCATGATCAAACAGCTGCAGTACACGGCCTATGGGGAGAT	4080
QUERY:	7347	TTATTATGACTCCAACCCCGACTTCCAGATGGTCATTGGCTTCCATGGGGGACTCTATGA	7406
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4081	TTATTATGACTCCAACCCCGACTTCCAGATGGTCATTGGCTTCCATGGGGGACTCTATGA	4140
QUERY:	7407	CCCCCTGACCAAGCTGGTCCACTTCACTCAGCGTGATTATGATGTGCTGGCAGGACGATG	7466
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4141	CCCCCTGACCAAGCTGGTCCACTTCACTCAGCGTGATTATGATGTGCTGGCAGGACGATG	4200
QUERY:	7467	GACCTCCCCAGACTATACCATGTGGAAAAACGTGGGCAAGGAGCCGGCCCCCTTTAACCT	7526
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4201	GACCTCCCCAGACTATACCATGTGGAAAAACGTGGGCAAGGAGCCGGCCCCCTTTAACCT	4260
QUERY:	7527	GTATATGTTCAAGAGCAACAATCCTCTCAGCAGTGAGCTAGATTTGAAGAACTACGTGAC	7586
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4261	GTATATGTTCAAGAGCAACAATCCTCTCAGCAGTGAGCTAGATTTGAAGAACTACGTGAC	4320
QUERY:	7587	AGATGTGAAAAGCTGGCTTGTGATGTTTGGATTTCAGCTTAGCAACATCATTCCTGGCTT	7646
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4321	AGATGTGAAAAGCTGGCTTGTGATGTTTGGATTTCAGCTTAGCAACATCATTCCTGGCTT	4380
QUERY:	7647	CCCGAGAGCCAAAATGTATTTCGTGCCTCCTCCCTATGAATTGTCAGAGAGTCAAGCAAG	7706
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4381	CCCGAGAGCCAAAATGTATTTCGTGCCTCCTCCCTATGAATTGTCAGAGAGTCAAGCAAG	4440
QUERY:	7707	TGAGAATGGACAGCTCATTACAGGTGTCCAACAGACAACAGAGAGACATAACCAGGCCTT	7766
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4441	TGAGAATGGACAGCTCATTACAGGTGTCCAACAGACAACAGAGAGACATAACCAGGCCTT	4500
QUERY:	7767	CATGGCTCTGGAAGGACAGGTCATTACTAAAAAGCTCCACGCCAGCATCCGAGAGAAAGC	7826
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4501	CATGGCTCTGGAAGGACAGGTCATTACTAAAAAGCTCCACGCCAGCATCCGAGAGAAAGC	4560
QUERY:	7827	AGGTCACTGGTTTGCCACCACCACGCCCATCATTGGCAAAGGCATCATGTTTGCCATCAA	7886
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4561	AGGTCACTGGTTTGCCACCACCACGCCCATCATTGGCAAAGGCATCATGTTTGCCATCAA	4620
QUERY:	7887	AGAAGGGCGGGTGACCACGGGCGTGTCCAGCATCGCCAGCGAAGATAGCCGCAAGGTGGC	7946
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4621	AGAAGGGCGGGTGACCACGGGCGTGTCCAGCATCGCCAGCGAAGATAGCCGCAAGGTGGC	4680
QUERY:	7947	ATCTGTGCTGAACAACGCCTACTACCTGGACAAGATGCACTACAGCATCGAGGGCAAGGA	8006
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4681	ATCTGTGCTGAACAACGCCTACTACCTGGACAAGATGCACTACAGCATCGAGGGCAAGGA	4740
QUERY:	8007	CACCCACTACTTTGTGAAGATTGGCTCAGCCGATGGCGACCTGGTCACACTAGGCACCAC	8066
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4741	CACCCACTACTTTGTGAAGATTGGCTCAGCCGATGGCGACCTGGTCACACTAGGCACCAC	4800
QUERY:	8067	CATCGGCCGCAAGGTGCTAGAGAGCGGGGTGAACGTGACCGTGTCCCAGCCCACGCTGCT	8126
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4801	CATCGGCCGCAAGGTGCTAGAGAGCGGGGTGAACGTGACCGTGTCCCAGCCCACGCTGCT	4860
QUERY:	8127	GGTCAACGGCAGGACTCGAAGGTTCACGAACATTGAGTTCCAGTACTCCACGCTGCTGCT	8186
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4861	GGTCAACGGCAGGACTCGAAGGTTCACGAACATTGAGTTCCAGTACTCCACGCTGCTGCT	4920
QUERY:	8187	CAGCATCCGCTATGGCCTCACCCCCGACACCCTGGACGAAGAGAAGGCCCGCGTCCTGGA	8246
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4921	CAGCATCCGCTATGGCCTCACCCCCGACACCCTGGACGAAGAGAAGGCCCGCGTCCTGGA	4980
QUERY:	8247	CCAGGCGAGACAGAGGGCCCTGGGCACGGCCTGGGCCAAGGAGCAGCAGAAAGCCAGGGA	8306
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	4981	CCAGGCGAGACAGAGGGCCCTGGGCACGGCCTGGGCCAAGGAGCAGCAGAAAGCCAGGGA	5040
QUERY:	8307	CGGGAGAGAGGGGAGCCGCCTGTGGACTGAGGGCGAGAAGCAGCAGCTTCTGAGCACCGG	8366
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5041	CGGGAGAGAGGGGAGCCGCCTGTGGACTGAGGGCGAGAAGCAGCAGCTTCTGAGCACCGG	5100
QUERY:	8367	GCGCGTGCAAGGGTACGAGGGATATTACGTGCTTCCCGTGGAGCAATACCCAGAGCTTGC	8426
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5101	GCGCGTGCAAGGGTACGAGGGATATTACGTGCTTCCCGTGGAGCAATACCCAGAGCTTGC	5160
QUERY:	8427	AGACAGTAGCAGCAACATCCAGTTTTTAAGACAGAATGAGATGGGAAAGAGGTAACAAAA	8486
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5161	AGACAGTAGCAGCAACATCCAGTTTTTAAGACAGAATGAGATGGGAAAGAGGTAACAAAA	5220
QUERY:	8487	TAATCTGCTGCCATTCCTTGTCTGAATGGCTCAGCAGGAGTAACTGTTATCTCCTCTCCT	8546
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5221	TAATCTGCTGCCATTCCTTGTCTGAATGGCTCAGCAGGAGTAACTGTTATCTCCTCTCCT	5280
QUERY:	8547	AAGGAGATGAAGACCTAACAGGGGCACTGCGGCTGGGCTGCTTTAGGAGACCAAGTGGCA	8606
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5281	AAGGAGATGAAGACCTAACAGGGGCACTGCGGCTGGGCTGCTTTAGGAGACCAAGTGGCA	5340
QUERY:	8607	AGAAAGCTCACATTTTTTGAGTTCAAATGCTACTGTCCAAGCGAGAAGTCCCTCATCCTG	8666
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5341	AGAAAGCTCACATTTTTTGAGTTCAAATGCTACTGTCCAAGCGAGAAGTCCCTCATCCTG	5400
QUERY:	8667	AAGTAGACTAAAGCCCGGCTGAAAATTCCGAGGAAAACAAAACAAACGAATGAATGAACA	8726
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5401	AAGTAGACTAAAGCCCGGCTGAAAATTCCGAGGAAAACAAAACAAACGAATGAATGAACA	5460
QUERY:	8727	GACACACACAATGTTCCAAGTTCCCCTAAAATATGACCCACTTGTTCTGGGTCTACGCAG	8786
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5461	GACACACACAATGTTCCAAGTTCCCCTAAAATATGACCCACTTGTTCTGGGTCTACGCAG	5520
QUERY:	8787	AAAAGAGACGCAAAGTGT 8804
		||||||||||||||||||
SBJCT:	5521	AAAAGAGACGCAAAGTGT 5538
SCORE = 1362 BITS (687), EXPECT = 0.0
IDENTITIES = 705/714 (98%)
STRAND = PLUS/PLUS
QUERY:	8875	CACGGACCGATAAACAAAGAAGCGAAGATAAGAAAGAAGGCCTCATATCCAATTACCTCA	8934
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5609	CACGGACCGATAAACAAAGAAGCGAAGATAAGAAAGAAGGCCTCATATCCAATTACCTCA	5668
QUERY:	8935	CTCATTCACATGTGAGCGACACGCAGACATCCGCGAGGGCCAGCGTCACCAGACCAGCTG	8994
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5669	CTCATTCACATGTGAGCGACACGCAGACATCCGCGAGGGCCAGCGTCACCAGACCAGCTG	5728
QUERY:	8995	CGGGACAAACCACTCAGACTGCTTGTAGGACAAATACTTCTGACATTTTCGTTTAAGCAA	9054
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5729	CGGGACAAACCACTCAGACTGCTTGTAGGACAAATACTTCTGACATTTTCGTTTAAGCAA	5788
QUERY:	9055	ATACAGGTGCATTTAAAACACGACTTTGGGGGTGATTTGTGTGTAGCGCCTGGGGAGGGG	9114
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5789	ATACAGGTGCATTTAAAACACGACTTTGGGGGTGATTTGTGTGTAGCGCCTGGGGAGGGG	5848
QUERY:	9115	GGATAAAAGAGGAGGAGTGAGCACTGGAAATACTTTTTAAAGNNNNNNNNNCATGAGGGA	9174
		|||||||||||||||||||||||||||||||||||||||||| |||||||||
SBJCT:	5849	GGATAAAAGAGGAGGAGTGAGCACTGGAAATACTTTTTAAAGAAAAAAAAACATGAGGGA	5908
QUERY:	9175	ATAAAAGAAATTCCTATCAAAAATCAAAGTGAAATAATACCATCCAGCACTTAACTCTCA	9234
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5909	ATAAAAGAAATTCCTATCAAAAATCAAAGTGAAATAATACCATCCAGCACTTAACTCTCA	5968
QUERY:	9235	GGTCCCAACTAAGTCTGGCCTGAGCTAATTTATTTGAGCGCAGAGTGTAAAATTTAATTC	9294
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	5969	GGTCCCAACTAAGTCTGGCCTGAGCTAATTTATTTGAGCGCAGAGTGTAAAATTTAATTC	6028
QUERY:	9295	AAAATGGTGGCTATAATCACTACAGATAAATTTCATACTCTTTTGTCTTTGGAGATTCCA	9354
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	6029	AAAATGGTGGCTATAATCACTACAGATAAATTTCATACTCTTTTGTCTTTGGAGATTCCA	6088
QUERY:	9355	TTGTGGACAGTAATACGCAGTTACAGGGTGTAGTCTGTTTAGATTCCGTAGTTCGTGGGT	9414
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	6089	TTGTGGACAGTAATACGCAGTTACAGGGTGTAGTCTGTTTAGATTCCGTAGTTCGTGGGT	6148
QUERY:	9415	ATCAGTTTCGGTAGAGGTGCAGCATCGTGACACTTTTGCTAACAGGTACCACTTCTGATC	9474
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	6149	ATCAGTTTCGGTAGAGGTGCAGCATCGTGACACTTTTGCTAACAGGTACCACTTCTGATC	6208
QUERY:	9475	ACCCTGTACATACATGAGCCGAAAGGCACAATCACTGTTTCAGATTTAAAATTATTAGTG	9534
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	6209	ACCCTGTACATACATGAGCCGAAAGGCACAATCACTGTTTCAGATTTAAAATTATTAGTG	6268
QUERY:	9535	TGTTTGTTTGGTCCAGAAACTGAGACAATCACATGACAGTCACCACGAGGAGAG 9588
		||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	6269	TGTTTGTTTGGTCCAGAAACTGAGACAATCACATGACAGTCACCACGAGGAGAG 6322
SCORE = 349 BITS (176), EXPECT = 2E-92
IDENTITIES = 176/176 (100%)
STRAND = PLUS/PLUS
QUERY:	9651	GTCTAATAAGAACTTTGGTACAGGAACTTTTTTGTAATATACATGTATGAATTGTTCATC	9710
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	6385	GTCTAATAAGAACTTTGGTACAGGAACTTTTTTGTAATATACATGTATGAATTGTTCATC	6444
QUERY:	9711	GAGTTTTTATATTAATTTTAATTTGCTGCTAAGCAAAGACTAGGGACAGGCAAAGATAAT	9770
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	6445	GAGTTTTTATATTAATTTTAATTTGCTGCTAAGCAAAGACTAGGGACAGGCAAAGATAAT	6504
QUERY:	9771	TTATGGCAAAGTGTTTAAATTGTTTATACATAAATAAAGTCTCTAAAACTCCTGTG 9826
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	6505	TTATGGCAAAGTGTTTAAATTGTTTATACATAAATAAAGTCTCTAAAACTCCTGTG 6560

[0103] In this search it was also found that the FCTR3bcd and e nucleic acids had homology to five fragments of Mus musculus mRNA for Ten-m2. It has 5498 of 6108 bases (90%) identical to bases 2504-8610, 1095 of 1196 bases (91%) identical to bases 103-1298, 1000 of 1088 bases (91%) identical to bases 1420-2540, 81 of 89 bases (91%) identical to bases 8655-8743, and 30 of 32 bases (93%) identical to bases 7-38 of Mus musculus mRNA for Ten-m2 (Table 3M).

TABLE 3M
BLASTN of FCTR3b, c, d, and e against Mus musculus mRNA for Ten-m2 (SEQ ID
NO:65) Mrna
>GI|4760777|DBJ|AB025411.1|AB025411 MUS MUSCULUS MRNA FOR TEN-M2, COMPLETE
CDS
LENGTH = 8797
SCORE = 7263 BITS (3664), EXPECT = 0.0
IDENTITIES = 5498/6108 (90%), GAPS = 1/6108 (0%)
STRAND = PLUS/PLUS
QUERY:	2578	GATGGCTGCCCTGACTTGTGCAACGGTAACGGGAGATGCACACTGGGTCAGAACAGCTGG	2637
		|||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2504	GATGGCTGCCCTGATTTGTGCAACGGTAACGGGAGATGCACACTGGGTCAGAACAGCTGG	2563
QUERY:	2638	CAGTGTGTCTGCCAGACCGGCTGGAGAGGGCCCGGATGCAACGTTGCCATGGAAACTTCC	2697
		|||||||||||||||||||||||||||||||| ||||||||||||||||||||||| |||
SBJCT:	2564	CAGTGTGTCTGCCAGACCGGCTGGAGAGGGCCTGGATGCAACGTTGCCATGGAAACCTCC	2623
QUERY:	2698	TGTGCTGATAACAAGGATAATGAGGGAGATGGCCTGGTGGATTGTTTGGACCCTGACTGC	2757
		|| |||||||||||||||||||||||||||||||||||||| ||  ||||||||||||||
SBJCT:	2624	TGCGCTGATAACAAGGATAATGAGGGAGATGGCCTGGTGGACTGCCTGGACCCTGACTGC	2683
QUERY:	2758	TGCCTGCAGTCAGCCTGTCAGAACAGCCTGCTCTGCCGGGGGTCCCGGGACCCACTGGAC	2817
		||||| |||||||||||||||||||||||||||||||||||||| ||||||||  |||||
SBJCT:	2684	TGCCTACAGTCAGCCTGTCAGAACAGCCTGCTCTGCCGGGGGTCTCGGGACCCCTTGGAC	2743
QUERY:	2818	ATCATTCAGCAGGGCCAGACGGATTGGCCCGCAGTGAAGTCCTTCTATGACCGTATCAAG	2877
		||||||||||| || ||||| || ||||| ||||||||||||||||||||||| ||||||
SBJCT:	2744	ATCATTCAGCAAGGTCAGACAGACTGGCCTGCAGTGAAGTCCTTCTATGACCGCATCAAG	2803
QUERY:	2878	CTCTTGGCAGGCAAGGATAGCACCCACATCATTCCTGGAGAGAACCCTTTCAACAGCAGC	2937
		||||||||||||||||| ||||||||||||||||||||||| ||||| ||||| ||||||
SBJCT:	2804	CTCTTGGCAGGCAAGGACAGCACCCACATCATTCCTGGAGACAACCCCTTCAATAGCAGC	2863
QUERY:	2938	TTGGTTTCTCTCATCCGAGGCCAAGTAGTAACTACAGATGGAACTCCCCTGGTCGGTGTG	2997
		|||| ||||| |||||||||||||||||||| |  ||||| |||||| |||| ||||||
SBJCT:	2864	CTGGTGTCTCTGATCCGAGGCCAAGTAGTAACCATGGATGGGACTCCCTTGGTGGGTGTG	2923
QUERY:	2998	AACGTGTCTTTTGTCAAGTACCCAAAATACGGCTACACCATCACCCGCCAGGATGGCACG	3057
		|| |||||||||||||||||||||||||| |||||||||||||| |||||||||||||||
SBJCT:	2924	AATGTGTCTTTTGTCAAGTACCCAAAATATGGCTACACCATCACTCGCCAGGATGGCACG	2983
QUERY:	3058	TTCGACCTGATCGCAAATGGAGGTGCTTCCTTGACTCTACACTTTGAGCGAGCCCCGTTC	3117
		|| |||||||| || ||||| ||| || |||||||||| ||||||||||||||||| |||
SBJCT:	2984	TTTGACCTGATTGCCAATGGGGGTTCTGCCTTGACTCTTCACTTTGAGCGAGCCCCTTTC	3043
QUERY:	3118	ATGAGCCAGGAGCGCACTGTGTGGCTGCCGTGGAACAGCTTTTACGCCATGGACACCCTG	3177
		||||||||||||||||| ||||||||||| ||||||||||| || |||||||||||||||
SBJCT:	3044	ATGAGCCAGGAGCGCACAGTGTGGCTGCCATGGAACAGCTTCTATGCCATGGACACCCTG	3103
QUERY:	3178	GTGATGAAGACCGAGGAGAACTCCATCCCCAGCTGTGACCTCAGTGGCTTTGTCCGGCCT	3237
		|| |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3104	GTAATGAAGACCGAGGAAAACTCCATCCCCAGCTGTGACCTCAGTGGCTTTGTCCGGCCA	3163
QUERY:	3238	GATCCAATCATCATCTCCTCCCCACTGTCCACCTTCTTTAGTGCTGCCCCTGGGCAGAAT	3297
		|||||||||||||||||||| || |||||||||||||| || ||| ||||||    |||
SBJCT:	3164	GATCCAATCATCATCTCCTCTCCTCTGTCCACCTTCTTCAGCGCTTCCCCTGCCTCGAAC	3223
QUERY:	3298	CCCATCGTGCCTGAGACCCAGGTTCTTCATGAAGAAATCGAGCTCCCTGGTTCCAATGTG	3357
		||||| |||||||||||||||||||||||||||||||| |||||||||||| ||||||||
SBJCT:	3224	CCCATTGTGCCTGAGACCCAGGTTCTTCATGAAGAAATTGAGCTCCCTGGTACCAATGTG	3283
QUERY:	3358	AAACTTCGCTATCTGAGCTCTAGAACTGCAGGGTACAAGTCACTGCTGAAGATCACCATG	3417
		|| || || ||||| |||||||||||||||||||| ||||| ||||||||||||||||||
SBJCT:	3284	AAGCTCCGTTATCTCAGCTCTAGAACTGCAGGGTATAAGTCGCTGCTGAAGATCACCATG	3343
QUERY:	3418	ACCCAGTCCACAGTGCCCCTGAACCTCATTAGGGTTCACCTGATGGTGGCTGTCGAGGGG	3477
		|| ||||||||||||||| |||||||||| ||||||||| |||||||| ||||| |||||
SBJCT:	3344	ACGCAGTCCACAGTGCCCTTGAACCTCATCAGGGTTCACTTGATGGTTGCTGTAGAGGGG	3403
QUERY:	3478	CATCTCTTCCAGAAGTCATTCCAGGCTTCTCCCAACCTGGCCTCCACCTTCATCTGGGAC	3537
		|||||||||||||||||||||||||||||||||||||| |||| ||| ||||||||||||
SBJCT:	3404	CATCTCTTCCAGAAGTCATTCCAGGCTTCTCCCAACCTAGCCTACACATTCATCTGGGAC	3463
QUERY:	3538	AAGACAGATGCGTATGGCCAAAGGGTGTATGGACTCTCAGATGCTGTTGTGTCTGTCGGG	3597
		||||||||||| |||||||||||||| ||||| || || ||||||||||||||||| |||
SBJCT:	3464	AAGACAGATGCTTATGGCCAAAGGGTTTATGGCCTATCGGATGCTGTTGTGTCTGTTGGG	3523
QUERY:	3598	TTTGAATATGAGACCTGTCCCAGTCTAATTCTCTGGGAGAAAAGGACAGCCCTCCTTCAG	3657
		||||||||||||||||| |||||||| || || |||||||||||||||||||| ||||||
SBJCT:	3524	TTTGAATATGAGACCTGCCCCAGTCTCATCCTGTGGGAGAAAAGGACAGCCCTGCTTCAG	3583
QUERY:	3658	GGATTCGAGCTGGACCCCTCCAACCTCGGTGGCTGGTCCCTAGACAAACACCACATCCTC	3717
		||||||||||||||||| |||||||| || ||||||||||| ||||||||||||| ||||
SBJCT:	3584	GGATTCGAGCTGGACCCTTCCAACCTTGGAGGCTGGTCCCTGGACAAACACCACACCCTC	3643
QUERY:	3718	AATGTTAAAAGTGGAATCCTACACAAAGGCACTGGGGAAAACCAGTTCCTGACCCAGCAG	3777
		||||| ||||| ||||| ||||||||||| || ||||| |||||||||||||||||||||
SBJCT:	3644	AATGTGAAAAGCGGAATACTACACAAAGGGACAGGGGAGAACCAGTTCCTGACCCAGCAG	3703
QUERY:	3778	CCTGCCATCATCACCAGCATCATGGGCAATGGTCGCCGCCGGAGCATTTCCTGTCCCAGC	3837
		|||||||||||||| |||||||||||||| ||||||||| | ||||| ||||||||||||
SBJCT:	3704	CCTGCCATCATCACGAGCATCATGGGCAACGGTCGCCGCAGAAGCATCTCCTGTCCCAGC	3763
QUERY:	3838	TGCAACGGCCTTGCTGAAGGCAACAAGCTGCTGGCCCCAGTGGCTCTGGCTGTTGGAATC	3897
		||||| |||||||||||||||||||| ||| | ||||| ||||| |||||||| || |||
SBJCT:	3764	TGCAATGGCCTTGCTGAAGGCAACAAACTGTTAGCCCCTGTGGCCCTGGCTGTGGGGATC	3823
QUERY:	3898	GATGGGAGCCTCTATGTGGGTGACTTCAATTACATCCGACGCATCTTTCCCTCTCGAAAT	3957
		||||||||||||| ||| ||||||||||| || |||| ||||||||||||||||||||||
SBJCT:	3824	GATGGGAGCCTCTTTGTTGGTGACTTCAACTATATCCGGCGCATCTTTCCCTCTCGAAAT	3883
QUERY:	3958	GTGACCAGCATCTTGGAGTTACGAAATAAAGAGTTTAAACATAGCAACAACCCAGCACAC	4017
		|||||||| |||||||||||||||||||||||||||||||||||||||| ||||| ||||
SBJCT:	3884	GTGACCAGTATCTTGGAGTTACGAAATAAAGAGTTTAAACATAGCAACAGCCCAGGACAC	3943
QUERY:	4018	AAGTACTACTTGGCAGTGGACCCCGTGTCCGGCTCGCTCTACGTGTCCGACACCAACAGC	4077
		|||||||||||||| |||||||||||| | ||||| |||||||| || ||||||||||||
SBJCT:	3944	AAGTACTACTTGGCTGTGGACCCCGTGACTGGCTCACTCTACGTCTCTGACACCAACAGT	4003
QUERY:	4078	AGGAGAATCTACCGCGTCAAGTCTCTGAGTGGAACCAAAGACCTGGCTGGGAATTCGGAA	4137
		| ||||||||||| |||||||||||||| ||| |||||||||||||||| |||||||||
SBJCT:	4004	CGCCGAATCTACCGAGTCAAGTCTCTGAGCGGAGCCAAAGACCTGGCTGGAAATTCGGAA	4063
QUERY:	4138	GTTGTGGCAGGGACGGGAGAGCAGTGTCTACCCTTTGATGAAGCCCGCTGCGGGGATGGA	4197
		|||||||||||||| || || || |||||||||||||||||||||||||| |||||||||
SBJCT:	4064	GTTGTGGCAGGGACTGGCGAACAATGTCTACCCTTTGATGAAGCCCGCTGTGGGGATGGA	4123
QUERY:	4198	GGGAAGGCCATAGATGCAACCCTGATGAGCCCGAGAGGTATTGCAGTAGACAAGAATGGG	4257
		||||||||  | || || |||||||||||||| |||||||||||||||||||||||||||
SBJCT:	4124	GGGAAGGCTGTGGACGCCACCCTGATGAGCCCCAGAGGTATTGCAGTAGACAAGAATGGG	4183
QUERY:	4258	CTCATGTACTTTGTCGATGCCACCATGATCCGGAAGGTTGACCAGAATGGAATCATCTCC	4317
		|| ||||||||||| ||||||||||||||||||||||| ||||| || ||||||||||||
SBJCT:	4184	CTTATGTACTTTGTTGATGCCACCATGATCCGGAAGGTGGACCAAAACGGAATCATCTCC	4243
QUERY:	4318	ACCCTGCTGGGCTCCAATGACCTCACTGCCGTCCGGCCGCTGAGCTGTGATTCCAGCATG	4377
		|||||||||||||||||||||||||| || ||||| || ||||||||||| || ||||||
SBJCT:	4244	ACCCTGCTGGGCTCCAATGACCTCACAGCTGTCCGACCACTGAGCTGTGACTCGAGCATG	4303
QUERY:	4378	GATGTAGCCCAGGTTCGTCTGGAGTGGCCAACAGACCTTGCTGTCAATCCCATGGATAAC	4437
		|| || |||||||| ||||| || ||||| |||||||| || ||||| |||||||| |||
SBJCT:	4304	GACGTGGCCCAGGTCCGTCTAGAATGGCCGACAGACCTCGCCGTCAACCCCATGGACAAC	4363
QUERY:	4438	TCCTTGTATGTTCTAGAGAACAATGTCATCCTTCGAATCACCGAGAACCACCAAGTCAGC	4497
		||| |||| ||||| |||||||| |||||||| || ||||| ||||||||||| ||||||
SBJCT:	4364	TCCCTGTACGTTCTGGAGAACAACGTCATCCTGCGGATCACGGAGAACCACCAGGTCAGC	4423
QUERY:	4498	ATCATTGCGGGACGCCCCATGCACTGCCAAGTTCCTGGCATTGACTACTCACTCAGCAAA	4557
		||||| |||||||| || ||||||||||| ||||| ||||| |||||||| |||||||||
SBJCT:	4424	ATCATCGCGGGACGGCCTATGCACTGCCAGGTTCCCGGCATCGACTACTCGCTCAGCAAA	4483
QUERY:	4558	CTAGCCATTCACTCTGCCCTGGAGTCAGCCAGTGCCATTGCCATTTCTCACACTGGGGTC	4617
		|| ||||| |||||||| ||||| |||||||| |||||||||||||||||||||||||||
SBJCT:	4484	CTCGCCATCCACTCTGCGCTGGAATCAGCCAGCGCCATTGCCATTTCTCACACTGGGGTG	4543
QUERY:	4618	CTCTACATCACTGAGACAGATGAGAAGAAGATTAACCGTCTACGCCAGGTAACAACCAAC	4677
		||||||||||||||||| || ||||||||||| ||||| |||||||| || || |||||
SBJCT:	4544	CTCTACATCACTGAGACGGACGAGAAGAAGATCAACCGCCTACGCCAAGTCACCACCAAT	4603
QUERY:	4678	GGGGAGATCTGCCTTTTAGCTGGGGCAGCCTCGGACTGCGACTGCAAAAACGATGTCAAT	4737
		|| ||||||||||| ||||| ||||| ||||| ||||| ||||||||||||||||||||
SBJCT:	4604	GGAGAGATCTGCCTCTTAGCCGGGGCGGCCTCAGACTGTGACTGCAAAAACGATGTCAAC	4663
QUERY:	4738	TGCAACTGCTATTCAGGAGATGATGCCTACGCGACTGATGCCATCTTGAATTCCCCATCA	4797
		|||| |||||| || |||||||| || ||||| || || |||||| |||| || || ||
SBJCT:	4664	TGCATCTGCTACTCGGGAGATGACGCTTACGCCACGGACGCCATCCTGAACTCGCCGTCC	4723
QUERY:	4798	TCCTTAGCTGTAGCTCCAGATGGTACCATTTACATTGCAGACCTTGGAAATATTCGGATC	4857
		|||||||| || ||||| ||||| ||||| ||||||||||||||||| ||||| ||||||
SBJCT:	4724	TCCTTAGCCGTGGCTCCGGATGGCACCATCTACATTGCAGACCTTGGGAATATCCGGATC	4783
QUERY:	4858	AGGGCGGTCAGCAAGAACAAGCCTGTTCTTAATGCCTTCAACCAGTATGAGGCTGCATCC	4917
		|||||||||||||| || || || |||||||| || |||||||||||||||||||||||
SBJCT:	4784	AGGGCGGTCAGCAAAAATAAACCCGTTCTTAACGCATTCAACCAGTATGAGGCTGCATCT	4843
QUERY:	4918	CCCGGAGAGCAGGAGTTATATGTTTTCAACGCTGATGGCATCCACCAATACACTGTGAGC	4977
		|| ||||| ||||| || || || |||||||||||||| ||||| || |||||||||||
SBJCT:	4844	CCGGGAGAACAGGAATTGTACGTGTTCAACGCTGATGGTATCCATCAGTACACTGTGAGT	4903
QUERY:	4978	CTGGTGACAGGGGAGTACTTGTACAATTTCACATATAGTACTGACAATGATGTCACTGAA	5037
		|||||||| |||||||||||||||||||||||||| || ||||||||||| ||||| ||
SBJCT:	4904	CTGGTGACTGGGGAGTACTTGTACAATTTCACATACAGCGCTGACAATGACGTCACCGAG	4963
QUERY:	5038	TTGATTGACAATAATGGGAATTCCCTGAAGATCCGTCGGGACAGCAGTGGCATGCCCCGT	5097
		||||||||||| || ||||||||||| |||||||| ||||||||||||||||||||||
SBJCT:	4964	TTGATTGACAACAACGGGAATTCCCTAAAGATCCGCCGGGACAGCAGTGGCATGCCCCGC	5023
QUERY:	5098	CACCTGCTCATGCCTGACAACCAGATCATCACCCTCACCGTGGGCACCAATGGAGGCCTC	5157
		|||||||||||||| || || ||||| |||||||| || |||||||||||||||||||||
SBJCT:	5024	CACCTGCTCATGCCGGATAATCAGATTATCACCCTTACTGTGGGCACCAATGGAGGCCTC	5083
QUERY:	5158	AAAGTCGTGTCCACACAGAACCTGGAGCTTGGTCTCATGACCTATGATGGCAACACTGGG	5217
		|||| ||||||||| |||||||||||||| || |||||||| |||||||| ||||||||
SBJCT:	5084	AAAGCCGTGTCCACTCAGAACCTGGAGCTGGGCCTCATGACTTATGATGGGAACACTGGA	5143
QUERY:	5218	CTCCTGGCCACCAAGAGCGATGAAACAGGATGGACGACTTTCTATGACTATGACCACGAA	5277
		||||| ||||||||||| |||||||| |||||||| ||||| |||||||||||||||||
SBJCT:	5144	CTCCTAGCCACCAAGAGTGATGAAACCGGATGGACAACTTTTTATGACTATGACCACGAG	5203
QUERY:	5278	GGCCGCCTGACCAACGTGACGCGCCCCACGGGGGTGGTAACCAGTCTGCACCGGGAAATG	5337
		||||| |||||||| ||||| ||||||||||| ||||| |||||||||||||||||||||
SBJCT:	5204	GGCCGTCTGACCAATGTGACCCGCCCCACGGGCGTGGTGACCAGTCTGCACCGGGAAATG	5263
QUERY:	5338	GAGAAATCTATTACCATTGACATTGAGAACTCCAACCGTGATGATGACGTCACTGTCATC	5397
		||||||||||| |||||||||||||||||||||||||| ||||||||||||||||| |||
SBJCT:	5264	GAGAAATCTATCACCATTGACATTGAGAACTCCAACCGGGATGATGACGTCACTGTGATC	5323
QUERY:	5398	ACCAACCTCTCTTCAGTAGAGGCCTCCTACACAGTGGTACAAGATCAAGTTCGGAACAGC	5457
		||||||||||| || || ||||||||||| |||||||||||||||||||| || ||||||
SBJCT:	5324	ACCAACCTCTCCTCCGTGGAGGCCTCCTATACAGTGGTACAAGATCAAGTGCGAAACAGC	5383
QUERY:	5458	TACCAGCTCTGTAATAATGGTACCCTGAGGGTGATGTATGCTAATGGGATGGGTATCAGC	5517
		||||||||||| |||||||| |||||| |||||||||| || || || |||| | |||||
SBJCT:	5384	TACCAGCTCTGCAATAATGGAACCCTGCGGGTGATGTACGCCAACGGCATGGCTGTCAGC	5443
QUERY:	5518	TTCCACAGCGAGCCCCATGTCCTAGCGGGCACCATCACCCCCACCATTGGACGCTGCAAC	5577
		|||||||| |||||||| ||||| || |||||||||||||||||||| || |||||||||
SBJCT:	5444	TTCCACAGTGAGCCCCACGTCCTCGCAGGCACCATCACCCCCACCATCGGGCGCTGCAAC	5503
QUERY:	5578	ATCTCCCTGCCTATGGAGAATGGCTTAAACTCCATTGAGTGGCGCCTAAGAAAGGAACAG	5637
		||||| ||||| |||||||||||| | |||||||| ||||||||||| || |||||||||
SBJCT:	5504	ATCTCTCTGCCCATGGAGAATGGCCTGAACTCCATCGAGTGGCGCCTGAGGAAGGAACAG	5563
QUERY:	5638	ATTAAAGGCAAAGTCACCATCTTTGGCAGGAAGCTCCGGGTCCATGGAAGAAATCTCTTG	5697
		|| ||||||||||||||||||||||| |||||||| |||||||| ||||| |||||| ||
SBJCT:	5564	ATCAAAGGCAAAGTCACCATCTTTGGGAGGAAGCTTCGGGTCCACGGAAGGAATCTCCTG	5623
QUERY:	5698	TCCATTGACTATGATCGAAATATTCGGACTGAAAAGATCTATGATGACCACCGGAAGTTC	5757
		|||||||| ||||| |||||||| || || || |||||||| |||||||||||||| |||
SBJCT:	5624	TCCATTGATTATGACCGAAATATCCGTACGGAGAAGATCTACGATGACCACCGGAAATTC	5683
QUERY:	5758	ACCCTGAGGATCATTTATGACCAGGTGGGCCGCCCCTTCCTCTGGCTGCCCAGCAGCGGG	5817
		|||||||||||||| |||||||||||||||||||||||||| ||||| || ||||| |||
SBJCT:	5684	ACCCTGAGGATCATCTATGACCAGGTGGGCCGCCCCTTCCTGTGGCTCCCGAGCAGTGGG	5743
QUERY:	5818	CTGGCAGCTGTCAACGTGTCATACTTCTTCAATGGGCGCCTGGCTGGGCTTCAGCGTGGG	5877
		|||||||| ||||| || || |||||||||||||||||| |||| || || ||||| |||
SBJCT:	5744	CTGGCAGCCGTCAATGTCTCCTACTTCTTCAATGGGCGCTTGGCCGGCCTCCAGCGAGGG	5803
QUERY:	5878	GCCATGAGCGAGAGGACAGACATCGACAAGCAAGGCCGCATCGTGTCCCGCATGTTCGCT	5937
		||||||||||||||||||||||| |||||||||||||| ||||||||||||||||||||
SBJCT:	5804	GCCATGAGCGAGAGGACAGACATTGACAAGCAAGGCCGGATCGTGTCCCGCATGTTCGCC	5863
QUERY:	5938	GACGGGAAAGTGTGGAGCTACTCCTACCTTGACAAGTCCATGGTCCTCCTGCTTCAGAGC	5997
		||||||||||| ||||| || ||||| |||||||||||||||||||| ||||| ||||||
SBJCT:	5864	GACGGGAAAGTCTGGAGTTATTCCTATCTTGACAAGTCCATGGTCCTTCTGCTACAGAGC	5923
QUERY:	5998	CAACGTCAGTATATATTTGAGTATGACTCCTCTGACCGCCTCCTTGCCGTCACCATGCCC	6057
		||||||||||| |||||||| ||||||||||| || |||||||  || ||||| ||||||
SBJCT:	5924	CAACGTCAGTACATATTTGAATATGACTCCTCCGATCGCCTCCACGCAGTCACTATGCCC	5983
QUERY:	6058	AGCGTGGCCCGGCACAGCATGTCCACACACACCTCCATCGGCTACATCCGTAATATTTAC	6117
		|| || |||||||||||||||||||| ||||||||||| || |||||||| || ||||||
SBJCT:	5984	AGTGTCGCCCGGCACAGCATGTCCACGCACACCTCCATTGGTTACATCCGAAACATTTAC	6043
QUERY:	6118	AACCCGCCTGAAAGCAATGCTTCGGTCATCTTTGACTACAGTGATGACGGCCGCATCCTG	6177
		||||| || ||||||||||| ||||||||||||||||||||||||||||||||||||||
SBJCT:	6044	AACCCACCCGAAAGCAATGCATCGGTCATCTTTGACTACAGTGATGACGGCCGCATCCTA	6103
QUERY:	6178	AAGACCTCCTTTTTGGGCACCGGACGCCAGGTGTTCTACAAGTATGGGAAACTCTCCAAG	6237
		||||| || || |||||||| || ||||||||||||||||||||||| ||||||||||||
SBJCT:	6104	AAGACATCTTTCTTGGGCACTGGGCGCCAGGTGTTCTACAAGTATGGAAAACTCTCCAAG	6163
QUERY:	6238	TTATCAGAGATTGTCTACGACAGTACCGCCGTCACCTTCGGGTATGACGAGACCACTGGT	6297
		||||||||||| ||||||||||| || ||||||||||| ||||||||||||||||| |||
SBJCT:	6164	TTATCAGAGATAGTCTACGACAGCACAGCCGTCACCTTTGGGTATGACGAGACCACCGGT	6223
QUERY:	6298	GTCTTGAAGATGGTCAACCTCCAAAGTGGGGGCTTCTCCTGCACCATCAGGTACCGGAAG	6357
		||| ||||||||||||| ||||||||||||||||||||||| |||||||||||||| |||
SBJCT:	6224	GTCCTGAAGATGGTCAATCTCCAAAGTGGGGGCTTCTCCTGTACCATCAGGTACCGAAAG	6283
QUERY:	6358	ATTGGCCCCCTGGTGGACAAGCAGATCTACAGGTTCTCCGAGGAAGGCATGGTCAATGCC	6417
		|||| ||||| |||||||||||||| ||||||||||| |||||||| ||| |||| |||
SBJCT:	6284	GTTGGGCCCCTTGTGGACAAGCAGATTTACAGGTTCTCTGAGGAAGGAATGATCAACGCC	6343
QUERY:	6418	AGGTTTGACTACACCTATCATGACAACAGCTTCCGCATCGCAAGCATCAAGCCCGTCATA	6477
		|||||||| || |||||||| ||||| ||||||||||| || |||||||| ||||||||
SBJCT:	6344	AGGTTTGATTATACCTATCACGACAATAGCTTCCGCATTGCCAGCATCAAACCCGTCATT	6403
QUERY:	6478	AGTGAGACTCCCCTCCCCGTTGACCTCTACCGCTATGATGAGATTTCTGGCAAGGTGGAA	6537
		|| ||||||||||| || |||||||||||||||||||| |||||||| ||||||||||||
SBJCT:	6404	AGCGAGACTCCCCTTCCTGTTGACCTCTACCGCTATGACGAGATTTCCGGCAAGGTGGAA	6463
QUERY:	6538	CACTTTGGTAAGTTTGGAGTCATCTATTATGACATCAACCAGATCATCACCACTGCCGTG	6597
		||||| || |||||||| ||||||| || ||||||||||||||||||||||||||||||
SBJCT:	6464	CACTTCGGCAAGTTTGGGGTCATCTACTACGACATCAACCAGATCATCACCACTGCCGTC	6523
QUERY:	6598	ATGACCCTCAGCAAACACTTCGACACCCATGGGCGGATCAAGGAGGTCCAGTATGAGATG	6657
		||||| || ||||| ||||| |||||||||||||| |||||||| || || |||||||||
SBJCT:	6524	ATGACGCTTAGCAAGCACTTTGACACCCATGGGCGCATCAAGGAAGTGCAATATGAGATG	6583
QUERY:	6658	TTCCGGTCCCTCATGTACTGGATGACGGTGCAATATGACAGCATGGGCAGGGTGATCAAG	6717
		|||||||||||||||||||||||||| |||||||||||||| ||||| ||||| ||||||
SBJCT:	6584	TTCCGGTCCCTCATGTACTGGATGACTGTGCAATATGACAGTATGGGTAGGGTCATCAAG	6643
QUERY:	6718	AGGGAGCTAAAACTGGGGCCCTATGCCAATACCACGAAGTACACCTATGACTACGATGGG	6777
		||||| || ||||| |||||||||||||| ||||| ||||||||||||||||| || |||
SBJCT:	6644	AGGGAACTGAAACTAGGGCCCTATGCCAACACCACAAAGTACACCTATGACTATGACGGG	6703
QUERY:	6778	GACGGGCAGCTCCAGAGCGTGGCCGTCAATGACCGCCCGACCTGGCGCTACAGCTATGAC	6837
		||||| ||||||||||| ||||||||||||||||| || ||||||||||| |||||||||
SBJCT:	6704	GACGGCCAGCTCCAGAGTGTGGCCGTCAATGACCGGCCTACCTGGCGCTATAGCTATGAC	6763
QUERY:	6838	CTTAATGGGAATCTCCACTTACTGAACCCAGGCAACAGTGTGCGCCTCATGCCCTTGCGC	6897
		|| |||||||| || ||| | || |||||||| |||||||  |||||||||||||| |||
SBJCT:	6764	CTCAATGGGAACCTGCACCTTCTAAACCCAGGAAACAGTGCTCGCCTCATGCCCTTACGC	6823
QUERY:	6898	TATGACCTCCGGGATCGGATAACCAGACTCGGGGATGTGCAGTACAAAATTGACGACGAT	6957
		||||||||||| || ||||||||||| || ||||| |||||||||||||| || ||||||
SBJCT:	6824	TATGACCTCCGTGACCGGATAACCAGGCTAGGGGACGTGCAGTACAAAATCGATGACGAT	6883
QUERY:	6958	GGCTATCTGTGCCAGAGAGGGTCTGACATCTTCGAATACAATTCCAAGGGCCTCCTAACA	7017
		|||||| |||||||||||||||| |||||||| |||||||| ||||||||||| || ||
SBJCT:	6884	GGCTATTTGTGCCAGAGAGGGTCAGACATCTTTGAATACAACTCCAAGGGCCTTCTGACG	6943
QUERY:	7018	AGAGCCTACAACAAGGCCAGCGGGTGGAGTGTCCAGTACCGCTATGATGGCGTAGGACGG	7077
		||||| ||||||||||||||||| ||||| || |||||||||||||| || || || ||
SBJCT:	6944	AGAGCATACAACAAGGCCAGCGGATGGAGCGTGCAGTACCGCTATGACGGAGTGGGCCGC	7003
QUERY:	7078	CGGGCTTCCTACAAGACCAACCTGGGCCACCACCTGCAGTACTTCTACTCTGACCTCCAC	7137
		||||||||||||||||||||||||||||||||||| |||||||||||||| |||||||||
SBJCT:	7004	CGGGCTTCCTACAAGACCAACCTGGGCCACCACCTACAGTACTTCTACTCCGACCTCCAC	7063
QUERY:	7138	AACCCGACGCGCATCACCCATGTCTACAATCACTCCAACTCGGAGATTACCTCACTGTAC	7197
		||||| || || ||||||||||| |||| |||||||||||| ||||| ||||| || |||
SBJCT:	7064	AACCCCACACGTATCACCCATGTTTACAACCACTCCAACTCTGAGATCACCTCGCTCTAC	7123
QUERY:	7198	TACGACCTCCAGGGCCACCTCTTTGCCATGGAGAGCAGCAGTGGGGAGGAGTACTATGTT	7257
		|| ||||||||||||||||| ||||||||||||||||| ||||| || || ||||||||
SBJCT:	7124	TATGACCTCCAGGGCCACCTATTTGCCATGGAGAGCAGTAGTGGTGAAGAATACTATGTC	7183
QUERY:	7258	GCCTCTGATAACACAGGGACTCCTCTGGCTGTGTTCAGCATCAACGGCCTCATGATCAAA	7317
		||||| || ||||| ||||| ||||||||||||| ||| ||||| ||||||||||||||
SBJCT:	7184	GCCTCAGACAACACGGGGACCCCTCTGGCTGTGTACAGTATCAATGGCCTCATGATCAAG	7243
QUERY:	7318	CAGCTGCAGTACACGGCCTATGGGGAGATTTATTATGACTCCAACCCCGACTTCCAGATG	7377
		|| ||||||||||| |||||||||||||| || ||||||||||| || ||||||||||||
SBJCT:	7244	CAACTGCAGTACACAGCCTATGGGGAGATCTACTATGACTCCAATCCAGACTTCCAGATG	7303
QUERY:	7378	GTCATTGGCTTCCATGGGGGACTCTATGACCCCCTGACCAAGCTGGTCCACTTCACTCAG	7437
		|||||||||||||| || || |||||||||||||| |||||||| |||||||| |||||
SBJCT:	7304	GTCATTGGCTTCCACGGAGGCCTCTATGACCCCCTCACCAAGCTCGTCCACTTTACTCAA	7363
QUERY:	7438	CGTGATTATGATGTGCTGGCAGGACGATGGACCTCCCCAGACTATACCATGTGGAAAAAC	7497
		||||||||||| |||||||||||||| ||||| ||||| ||||| ||||||||||| |||
SBJCT:	7364	CGTGATTATGACGTGCTGGCAGGACGGTGGACGTCCCCCGACTACACCATGTGGAGGAAC	7423
QUERY:	7498	GTGGGCAAGGAGCCGGCCCCCTTTAACCTGTATATGTTCAAGAGCAACAATCCTCTCAGC	7557
		|||||||||||||| |||||||| |||||||| |||||||||| |||||||||||| |||
SBJCT:	7424	GTGGGCAAGGAGCCAGCCCCCTTCAACCTGTACATGTTCAAGAACAACAATCCTCTGAGC	7483
QUERY:	7558	AGTGAGCTAGATTTGAAGAACTACGTGACAGATGTGAAAAGCTGGCTTGTGATGTTTGGA	7617
		| |||||| || || ||||||||||||||||| ||||| |||||||||||||||||||||
SBJCT:	7484	AATGAGCTGGACTTAAAGAACTACGTGACAGACGTGAAGAGCTGGCTTGTGATGTTTGGA	7543
QUERY:	7618	TTTCAGCTTAGCAACATCATTCCTGGCTTCCCGAGAGCCAAAATGTATTTCGTGCCTCCT	7677
		|||||||| ||||||||||||||||| ||||||||||||||||||||||| ||||||||
SBJCT:	7544	TTTCAGCTCAGCAACATCATTCCTGGATTCCCGAGAGCCAAAATGTATTTTGTGCCTCCC	7603
QUERY:	7678	CCCTATGAATTGTCAGAGAGTCAAGCAAGTGAGAATGGACAGCTCATTACAGGTGTCCAA	7737
		||||||||| ||||||||||||||||||| ||||| |||||||||||||||||||||||
SBJCT:	7604	CCCTATGAACTGTCAGAGAGTCAAGCAAGCGAGAACGGACAGCTCATTACAGGTGTCCAG	7663
QUERY:	7738	CAGACAACAGAGAGACATAACCAGGCCTTCATGGCTCTGGAAGGACAGGTCATTACTAAA	7797
		|||||||| ||||| ||||||||||||||| |||||||||||||||||||||| ||||||
SBJCT:	7664	CAGACAACTGAGAGGCATAACCAGGCCTTCCTGGCTCTGGAAGGACAGGTCATCACTAAA	7723
QUERY:	7798	AAGCTCCACGCCAGCATCCGAGAGAAAGCAGGTCACTGGTTTGCCACCACCACGCCCATC	7857
		|||||||| ||||||||||||||||||||||| ||||||||||| |||||||| ||||||
SBJCT:	7724	AAGCTCCATGCCAGCATCCGAGAGAAAGCAGGCCACTGGTTTGCTACCACCACACCCATC	7783
QUERY:	7858	ATTGGCAAAGGCATCATGTTTGCCATCAAAGAAGGGCGGGTGACCACGGGCGTGTCCAGC	7917
		|| |||||||||||||||||||||||||||||||||||||||||||| || ||||| |||
SBJCT:	7784	ATCGGCAAAGGCATCATGTTTGCCATCAAAGAAGGGCGGGTGACCACAGGAGTGTCTAGC	7843
QUERY:	7918	ATCGCCAGCGAAGATAGCCGCAAGGTGGCATCTGTGCTGAACAACGCCTACTACCTGGAC	7977
		|||||||| || || ||||||||||| ||||| ||| ||||||| ||||||||| | |||
SBJCT:	7844	ATCGCCAGTGAGGACAGCCGCAAGGTAGCATCCGTGTTGAACAATGCCTACTACTTAGAC	7903
QUERY:	7978	AAGATGCACTACAGCATCGAGGGCAAGGACACCCACTACTTTGTGAAGATTGGCTCAGCC	8037
		|||||||||||||||||||||||||||||||| ||||||||||||||||| ||| | ||
SBJCT:	7904	AAGATGCACTACAGCATCGAGGGCAAGGACACACACTACTTTGTGAAGATCGGCGCCGCG	7963
QUERY:	8038	GATGGCGACCTGGTCACACTAGGCACCACCATCGGCCGCAAGGTGCTAGAGAGCGGGGTG	8097
		||||| ||||||||||| ||||| |||||||| || ||||||||||| ||||| ||||||
SBJCT:	7964	GATGGTGACCTGGTCACGCTAGGAACCACCATTGGGCGCAAGGTGCTGGAGAGTGGGGTG	8023
QUERY:	8098	AACGTGACCGTGTCCCAGCCCACGCTGCTGGTCAACGGCAGGACTCGAAGGTTCACGAAC	8157
		|||||||| ||||| ||||||||||||||||| || |||||||||||||||||||| |||
SBJCT:	8024	AACGTGACGGTGTCACAGCCCACGCTGCTGGTGAATGGCAGGACTCGAAGGTTCACCAAC	8083
QUERY:	8158	ATTGAGTTCCAGTACTCCACGCTGCTGCTCAGCATCCGCTATGGCCTCACCCCCGACACC	8217
		|||||||||||||||||||||||||||||||| |||||||| |||||||||||||||||
SBJCT:	8084	ATTGAGTTCCAGTACTCCACGCTGCTGCTCAGTATCCGCTACGGCCTCACCCCCGACACG	8143
QUERY:	8218	CTGGACGAAGAGAAGGCCCGCGTCCTGGACCAGGCGAGACAGAGGGCCCTGGGCACGGCC	8277
		||||||||||| |||||||||||||||||||| ||| ||||||| |||||||| || |||
SBJCT:	8144	CTGGACGAAGAAAAGGCCCGCGTCCTGGACCAAGCGGGACAGAGAGCCCTGGGTACTGCC	8203
QUERY:	8278	TGGGCCAAGGAGCAGCAGAAAGCCAGGGACGGGAGAGAGGGGAGCCGCCTGTGGACTGAG	8337
		||||||||||||||||||||||||||||||||||||||||| |||||||||||||| |||
SBJCT:	8204	TGGGCCAAGGAGCAGCAGAAAGCCAGGGACGGGAGAGAGGGCAGCCGCCTGTGGACGGAG	8263
QUERY:	8338	GGCGAGAAGCAGCAGCTTCTGAGCACCGGGCGCGTGCAAGGGTACGAGGGATATTACGTG	8397
		|||||||||||||| || |||||||| || || || ||||| || ||||| ||||||||
SBJCT:	8264	GGCGAGAAGCAGCAACTCCTGAGCACGGGACGGGTACAAGGTTATGAGGGCTATTACGTA	8323
QUERY:	8398	CTTCCCGTGGAGCAATACCCAGAGCTTGCAGACAGTAGCAGCAACATCCAGTTTTTAAGA	8457
		||||| ||||| || ||||| ||||| |||||||||||||||||||||||||| ||||||
SBJCT:	8324	CTTCCGGTGGAACAGTACCCGGAGCTGGCAGACAGTAGCAGCAACATCCAGTTCTTAAGA	8383
QUERY:	8458	CAGAATGAGATGGGAAAGAGGTAACAAAATAATCTGCTGCCATTCCTTGTCTGAATGGCT	8517
		|||||||||||||||||||||||||||||||| |||||||||   ||| ||||  |||||
SBJCT:	8384	CAGAATGAGATGGGAAAGAGGTAACAAAATAACCTGCTGCCACCTCTTCTCTGGGTGGCT	8443
QUERY:	8518	CAGCAGGAGTAACTGTTATCTCCTCTCCTAAGGAGATGAAGACCTAACAGGGGCACTGCG	8577
		||||||||| |||||| | ||||||||||||||||| ||||||||||| ||||||||| |
SBJCT:	8444	CAGCAGGAGCAACTGTGACCTCCTCTCCTAAGGAGACGAAGACCTAAC-GGGGCACTGAG	8502
QUERY:	8578	GCTGGGCTGCTTTAGGAGACCAAGTGGCAAGAAAGCTCACATTTTTTGAGTTCAAATGCT	8637
		|| ||||||||||||||  |||||||||||||||||||||||||||||||||||||||||
SBJCT:	8503	GCCGGGCTGCTTTAGGATCCCAAGTGGCAAGAAAGCTCACATTTTTTGAGTTCAAATGCT	8562
QUERY:	8638	ACTGTCCAAGCGAGAAGTCCCTCATCCTGAAGTAGACTAAAGCCCGGC 8685
		|||||| |||||  ||||||||||||||||||||||||| ||||||||
SBJCT:	8563	ACTGTCTAAGCGCAAAGTCCCTCATCCTGAAGTAGACTAGAGCCCGGC 8610
SCORE = 1570 BITS (792), EXPECT = 0.0
IDENTITIES = 1095/1196 (91%)
STRAND = PLUS/PLUS
QUERY:	270	ATCTGGAATAATGGATGTAAAGGACCGGCGACACCGCTCTTTGACCAGAGGACGCTGTGG	329
		||||||||||||||||||||||||||||||||| |||||||||||||| ||||| |||||
SBJCT:	103	ATCTGGAATAATGGATGTAAAGGACCGGCGACATCGCTCTTTCACCAGGGGACGGTGTGG	162
QUERY:	330	CAAAGAGTGTCGCTACACAAGCTCCTCTCTGGACAGTGAGGACTGCCGGGTGCCCACACA	389
		|||||||||||||||||| ||||||||||||||||||||||||||||| |||||||| ||
SBJCT:	163	CAAAGAGTGTCGCTACACCAGCTCCTCTCTGGACAGTGAGGACTGCCGTGTGCCCACTCA	222
QUERY:	390	GAAATCCTACAGCTCCAGTGAGACTCTGAAGGCCTATGACCATGACAGCAGGATGCACTA	449
		||| |||||||| |||||||||||  ||||||| ||||||||||||||||| ||||||||
SBJCT:	223	GAAGTCCTACAGTTCCAGTGAGACCTTGAAGGCTTATGACCATGACAGCAGAATGCACTA	282
QUERY:	450	TGGAAACCGAGTCACAGACCTCATCCACCGGGAGTCAGATGAGTTTCCTAGACAAGGAAC	509
		|||||||||||||||||||||  | ||||||||||| ||||||||| |||||||||| ||
SBJCT:	283	TGGAAACCGAGTCACAGACCTGGTGCACCGGGAGTCCGATGAGTTTTCTAGACAAGGGAC	342
QUERY:	510	CAACTTCACCCTTGCCGAACTGGGCATCTGTGAGCCCTCCCCACACCGAAGCGGCTACTG	569
		||||||||||| || ||| |||| ||||| |||||||||||||||||||| || |||||
SBJCT:	343	AAACTTCACCCTGGCAGAATTGGGAATCTGCGAGCCCTCCCCACACCGAAGTGGTTACTG	402
QUERY:	570	CTCCGACATGGGGATCCTTCACCAGGGCTACTCCCTTAGCACAGGGTCTGACGCCGACTC	629
		||||||||||| ||||| ||||||||||||||||| ||||| |||||||| || |||||
SBJCT:	403	TTCCGACATGGGTATCCTCCACCAGGGCTACTCCCTGAGCACTGGGTCTGATGCAGACTC	462
QUERY:	630	CGACACCGAGGGAGGGATGTCTCCAGAACACGCCATCAGACTGTGGGGCAGAGGGATAAA	689
		|||||||||||||||||||||||||||||||||| ||||||||||||  ||||||||||
SBJCT:	463	GGACACCGAGGGAGGGATGTCTCCAGAACATGCCATCAGACTGTGGGGACGAGGGATAAA	522
QUERY:	690	ATCCAGGCGCAGTTCCGGCCTGTCCAGTCGTGAAAACTCGGCCCTTACCCTGACTGACTC	749
		|||||||||||| || ||| ||||||| || || |||||||||||||| |||||||||||
SBJCT:	523	ATCCAGGCGCAGCTCTGGCTTGTCCAGCCGCGAGAACTCGGCCCTTACTCTGACTGACTC	582
QUERY:	750	TGACAACGAAAACAAATCAGATGATGAGAACGGTCGTCCCATTCCACCTACATCCTCGCC	809
		|||||| ||||| ||||| ||||| || || ||||||||||||||||||||||||||| |
SBJCT:	583	TCACAATGAAAATAAATCGGATGACGACAATGGTCGTCCCATTCCACCTACATCCTCGTC	642
QUERY:	810	TAGTCTCCTCCCATCTGCTCAGCTGCCTAGCTCCCATAATCCTCCACCAGTTAGCTGCCA	869
		||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	643	TAGCCTCCTCCCATCTGCTCAGCTGCCTAGCTCCCATAATCCTCCACCAGTTAGCTGCCA	702
QUERY:	870	GATGCCATTGCTAGACAGCAACACCTCCCATCAAATCATGGACACCAACCCTGATGAGGA	929
		||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
SBJCT:	703	GATGCCATTGCTAGACAGCAACACCTCCCATCAGATCATGGACACCAACCCTGATGAGGA	762
QUERY:	930	ATTCTCCCCCAATTCATACCTGCTCAGAGCATGCTCAGGGCCCCAGCAAGCCTCCAGCAG	989
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	763	ATTCTCCCCCAATTCATACCTGCTCAGAGCATGCTCAGGGCCCCAGCAAGCCTCCAGCAG	822
QUERY:	990	TGGCCCTCCGAACCACCACAGCCAGTCGACTCTGAGGCCCCCTCTCCCACCCCCTCACAA	1049
		||||||||| ||||||||||||||||| || |||||||||||||| ||||||||||| ||
SBJCT:	823	TGGCCCTCCAAACCACCACAGCCAGTCAACACTGAGGCCCCCTCTGCCACCCCCTCATAA	882
QUERY:	1050	CCACACGCTGTCCCATCACCACTCGTCCGCCAACTCCCTCAACAGGAACTCACTGACCAA	1109
		|||||| |||||||| |||||||| || ||||||||||||||||||||||||||||||||
SBJCT:	883	CCACACCCTGTCCCACCACCACTCCTCGGCCAACTCCCTCAACAGGAACTCACTGACCAA	942
QUERY:	1110	TCGGCGGAGTCAGATCCACGCCCCGGCCCCAGCGCCCAATGACCTGGCCACCACACCAGA	1169
		|||||||||||| ||||||||||| ||| || ||||||| |||||||||||||| |||||
SBJCT:	943	TCGGCGGAGTCAAATCCACGCCCCAGCTCCTGCGCCCAACGACCTGGCCACCACCCCAGA	1002
QUERY:	1170	GTCCGTTCAGCTTCAGGACAGCTGGGTGCTAAACAGCAACGTGCCACTGGAGACCCGGCA	1229
		||| |||||||| ||||| ||||||||||| ||||| ||||| ||||||||||| |||||
SBJCT:	1003	GTCTGTTCAGCTCCAGGATAGCTGGGTGCTGAACAGTAACGTCCCACTGGAGACTCGGCA	1062
QUERY:	1230	CTTCCTCTTCAAGACCTCCTCGGGGAGCACACCCTTGTTCAGCAGCTCTTCCCCGGGATA	1289
		|||||| ||||| || || || || ||||||||| |||||||||||||||| ||||||||
SBJCT:	1063	CTTCCTTTTCAAAACGTCGTCTGGAAGCACACCCCTGTTCAGCAGCTCTTCTCCGGGATA	1122
QUERY:	1290	CCCTTTGACCTCAGGAACGGTTTACACGCCCCCGCCCCGCCTGCTGCCCAGGAATACTTT	1349
		||||||||||||||| || ||||| || || || ||||||||||||||  ||||||| ||
SBJCT:	1123	CCCTTTGACCTCAGGGACCGTTTATACACCACCACCCCGCCTGCTGCCACGGAATACATT	1182
QUERY:	1350	CTCCAGGAAGGCTTTCAAGCTGAAGAAGCCCTCCAAATACTGCAGCTGGAAATGTGCTGC	1409
		|||||||||||| |||||||||||||| ||||||||||||||||| ||||||||||||||
SBJCT:	1183	CTCCAGGAAGGCCTTCAAGCTGAAGAAACCCTCCAAATACTGCAGTTGGAAATGTGCTGC	1242
QUERY:	1410	CCTCTCCGCCATTGCCGCGGCCCTCCTCTTGGCTATTTTGCTGGCGTATTTCATAG 1465
		||| || ||||| ||||| |||||||||||||| ||||||||||| ||||||||||
SBJCT:	1243	CCTGTCTGCCATCGCCQCCGCCCTCCTCTTCGCCATTTTGCTGGCATATTTCATAG 1298
SCORE = 1455 BITS (734), EXPECT = 0.0
IDENTITIES = 1000/1088 (91%), GAPS = 3/1088 (0%)
STRAND = PLUS/PLUS
QUERY:	1464	AGTGCCCTGGTCGTTGAAAAACAGCAGCATAGACAGTGGTGAAGCAGAAGTTGGTCGGCG	1523
		|||||||||||| |||||||||||||||||||||||||| ||||||||||||||||||||
SBJCT:	1420	AGTGCCCTGCTCATTGAAAAACAGCAGCATAGACAGTGGCGAAGCAGAAGTTGGTCGGCG	1479
QUERY:	1524	GGTAACACAAGAAGTCCCACCAGGGGTGTTTTGGAGGTCACAAATTCACATCAGTCAGCC	1583
		||| ||||| ||||||||||||||||||||||||||||| || |||||||||||||||||
SBJCT:	1480	GGTGACACAGGAAGTCCCACCAGGGGTGTTTTGGAGGTCCCAGATTCACATCAGTCAGCC	1539
QUERY:	1584	CCAGTTCTTAAAGTTCAACATCTCCCTCGGGAAGGACGCTCTCTTTGGTGTTTACATAAG	1643
		|| ||||||||||||||||||||||| || ||||| || ||||| ||||| || |||||
SBJCT:	1540	TCAATTCTTAAAGTTCAACATCTCCCTGGGCAAGGATGCCCTCTTCGGTGTCTATATAAG	1599
QUERY:	1644	AAGAGGACTTCCACCATCTCATGCCCAGTATGACTTCATGGAACGTCTGGACGGGAAGGA	1703
		|||||||| ||||| ||||||||||||||||||||||||||||| ||||| || |||||
SBJCT:	1600	GAGAGGACTACCACCGTCTCATGCCCAGTATGACTTCATGGAACGCCTGGATGGAAAGGA	1659
QUERY:	1704	GAAGTGGAGTGTGGTTGAGTCTCCCAGGGAACGCCGGAGCATACAGACCTTGGTTCAGAA	1763
		||| ||||| ||||| ||||| |||||||||||||||||||| |||||  |||| |||||
SBJCT:	1660	GAAATGGAGCGTGGTCGAGTCGCCCAGGGAACGCCGGAGCATCCAGACTCTGGTGCAGAA	1719
QUERY:	1764	TGAAGCCGTGTTTGTGCAGTACCTGGATGTGGGCCTGTGGCATCTGGCCTTCTACAATGA	1823
		|| || ||||||||||||||| ||||||||||||||||||| |||||||||||||||||
SBJCT:	1720	CGAGGCTGTGTTTGTGCAGTACTTGGATGTGGGCCTGTGGCACCTGGCCTTCTACAATGA	1779
QUERY:	1824	TGGAAAAGACAAAGAGATGGTTTCCTTCAATACTGTTGTCCTAGATTCAGTGCAGGACTG	1883
		|| || ||||| |||||||| |||||||| ||||||||| |||||||||||||||||||
SBJCT:	1780	CGGCAAGGACAAGGAGATGGTCTCCTTCAACACTGTTGTCTTAGATTCAGTGCAGGACTG	1839
QUERY:	1884	TCCACGTAACTGCCATGGGAATGGTGAATGTGTGTCCGGGGTGTGTCACTGTTTCCCAGG	1943
		|||||| ||||| || ||||| |||||||| ||||| ||  |||||||||||||||||||
SBJCT:	1840	TCCACGGAACTGTCACGGGAACGGTGAATGCGTGTCTGGACTGTGTCACTGTTTCCCAGG	1899
QUERY:	1944	ATTTCTAGGAGCAGACTGTGCTAAAGCTGCCTGCCCTGTCCTGTGCAGTGGGAATGGACA	2003
		||| ||||| ||||||||||||||||||||||||||||| |||||||| || ||||||||
SBJCT:	1900	ATTCCTAGGTGCAGACTGTGCTAAAGCTGCCTGCCCTGTACTGTGCAGCGGAAATGGACA	1959
QUERY:	2004	ATATTCTAAAGGGACGTGCCAGTGCTACAGCGGCTGGAAAGGTGCAGAGTGCGACGTGCC	2063
		||||||||||| |||||||||||||||||||||||||||||||||||||| || |||||
SBJCT:	1960	GTATTCTAAAGGAACGTGCCAGTGCTACAGCGGCTGGAAAGGTGCAGAGTGTGATGTGCC	2019
QUERY:	2064	CATGAATCAGTGCATCGATCCTTCCTGCGGGGGCCACGGCTCCTGCATTGATGGGAACTG	2123
		||||| || || |||||||||||||| |||||||| |||||||||||||||||||||||
SBJCT:	2020	TATGAACCAATGTATCGATCCTTCCTGTGGGGGCCATGGCTCCTGCATTGATGGGAACTG	2079
QUERY:	2124	TGTCTGCTCTGCTGGCTACAAAGGCGAGCACTGTGAGGAAGTTGATTGCTTGGATCCCAC	2183
		|| ||  ||||||||||||| ||||||||||||||||||||||||||||||||||| ||
SBJCT:	2080	CGTGTGTGCTGCTGGCTACAAGGGCGAGCACTGTGAGGAAGTTGATTGCTTGGATCCTAC	2139
QUERY:	2184	CTGCTCCAGCCACGGAGTCTGTGTGAATGGAGAATGCCTGTGCAGCCCTGGCTGGGGTGG	2243
		|||||||||||| || ||||||||||||||||| || || |||||||| |||||||||||
SBJCT:	2140	CTGCTCCAGCCATGGTGTCTGTGTGAATGGAGAGTGTCTATGCAGCCCCGGCTGGGGTGG	2199
QUERY:	2244	TCTGAACTGTGAGCTGGCGAGGGTCCAGTGCCCAGACCAGTGCAGTGGGCATGGCACGTA	2303
		||| |||||||||||||||||||||||||||||||||||||| |||||||||||||| ||
SBJCT:	2200	TCTCAACTGTGAGCTGGCGAGGGTCCAGTGCCCAGACCAGTGTAGTGGGCATGGCACTTA	2259
QUERY:	2304	CCTGCCTGACACGGGCCTCTGCAGCTGCGATCCCAACTGGATGGGTCCCGACTGCTCTGT	2363
		||| |||||| | |||||||||||||| ||||| ||||||||||||||||||||||||||
SBJCT:	2260	CCTCCCTGACTCCGGCCTCTGCAGCTGTGATCCGAACTGGATGGGTCCCGACTGCTCTGT	2319
QUERY:	2364	TGAAGTGTGCTCAGTAGACTGTGGCACTCACGGCGTCTGCATCGGGGGAGCCTGCCGCTG	2423
		|   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2320	T---GTGTGCTCAGTAGACTGTGGCACTCACGGCGTCTGCATCGGGGGAGCCTGCCGCTG	2376
QUERY:	2424	TGAAGAGGGCTGGACAGGCGCAGCGTGTGACCAGCGCGTGTGCCACCCCCGCTGCATTGA	2483
		|||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||
SBJCT:	2377	TGAAGAGGGCTGGACAGGCGCAGCTTGTGACCAGCGCGTGTGCCACCCCCGCTGCATTGA	2436
QUERY:	2484	GCACGGGACCTGTAAAGATGGCAAATGTGAATGCCGAGAGGGCTGGAATGGTGAACACTG	2543
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2437	GCACGGGACCTGTAAAGATGGCAAATGTGAATGCCGAGAGGGCTGGAATGGTGAACACTG	2496
QUERY:	2544	CACCATTG 2551
		||||||||
SBJCT:	2497	CACCATTG 2504
SCORE = 105 BITS (53), EXPECT = 5E-19
IDENTITIES = 81/89 (91%), GAPS = 1/89 (1%)
STRAND = PLUS/PLUS
QUERY:	8711	AACGAATGAATGAACAGACACACACAATGTTCCAAGTTCCCCTAAAATATGACCCACTTG	8770
		|||||| ||||||| | ||||||| |||||| ||||||||||||||||||||||||||||
SBJCT:	8655	AACGAACGAATGAAAACACACACAAAATGTTTCAAGTTCCCCTAAAATATGACCCACTTG	8714
QUERY:	8771	TTCTGCGTCT-ACGCAGAAAAGAGACGCA 8798
		||| |||||| | ||||||||||||||||
SBJCT:	8715	TTCCGGGTCTAAGGCAGAAAAGAGACGCA 8743
SCORE = 48.1 BITS (24), EXPECT = 0.093
IDENTITIES = 30/32 (93%)
STRAND = PLUS/PLUS
QUERY:	475	CACCGGGAGTCAGATGAGTTTCCTAGACAAGG 506
		||||||||||| ||||||||| ||||||||||
SBJCT:	7	CACCGGGAGTCCGATGAGTTTTCTAGACAAGG 38

[0104] In this search it was also found that the FCTR3bcd and e nucleic acids had homology to three fragments of Rattus norvegicus neurestin alpha. It has 5498 of 6132 bases (89%) identical to bases 2527-8658, 1081 of 1196 bases (90%) identical to bases 123-1318, 996 of 1088 bases (91%) identical to bases 1440-2527 of Rattus norvegicus neurestin alpha (GenBank Acc:NM—020088.1) (Table 3N).

TABLE 3N
BLASTN of FCTR3b, c, d, and e against Rattus norvegicus Neurestin alpha mRNA (SEQ
ID NO:66)
>GI|9910319|REF|NM 020088.1| RATTUS NORVEGICUS NEURESTIN ALPHA (LOC56762),
MRNA
LENGTH = 8689
SCORE = 7129 BITS (3596), EXPECT = 0.0
IDENTITIES = 5498/6132 (89%)
STRAND = PLUS/PLUS
QUERY:	2578	GATGGCTGCCCTGACTTGTGCAACGGTAACGGGAGATGCACACTGGGTCAGAACAGCTGG	2637
		|||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2527	GATGGCTGCCCTGATTTGTGCAACGGTAACGGGAGATGCACACTGGGTCAGAACAGCTGG	2586
QUERY:	2638	CAGTGTGTCTGCCAGACCGGCTGGAGAGGGCCCGGATGCAACGTTGCCATGGAAACTTCC	2697
		|||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||
SBJCT:	2587	CAGTGTGTCTGCCAGACCGGCTGGAGAGGGCCCGGATGCAACGTTGCCATGGAAACCTCC	2646
QUERY:	2698	TGTGCTGATAACAAGGATAATGAGGGAGATGGCCTGGTGGATTGTTTGGACCCTGACTGC	2757
		|| |||||||||||||||||||||||||||||||||||||| ||  ||||||||||||||
SBJCT:	2647	TGCGCTGATAACAAGGATAATGAGGGAGATGGCCTGGTGGACTGCCTGGACCCTGACTGC	2706
QUERY:	2758	TGCCTGCAGTCAGCCTGTCAGAACAGCCTGCTCTGCCGGGGGTCCCGGGACCCACTGGAC	2817
		||||| ||||||||||||||||||||||||||||| |||||||| ||||||||  |||||
SBJCT:	2707	TGCCTCCAGTCAGCCTGTCAGAACAGCCTGCTCTGTCGGGGGTCTCGGGACCCCTTGGAC	2766
QUERY:	2818	ATCATTCAGCAGGGCCAGACGGATTGGCCCGCAGTGAAGTCCTTCTATGACCGTATCAAG	2877
		||||||||||| |||||||| || ||||| || ||||||||||||||||| |||||||||
SBJCT:	2767	ATCATTCAGCAAGGCCAGACAGACTGGCCTGCGGTGAAGTCCTTCTATGATCGCATCAAG	2826
QUERY:	2878	CTCTTGGCAGGCAAGGATAGCACCCACATCATTCCTGGAGAGAACCCTTTCAACAGCAGC	2937
		||||||||||||||||| ||||||||||||||||||||||| ||||| ||||| ||||||
SBJCT:	2804	CTCTTGGCAGGCAAGGACAGCACCCACATCATTCCTGGAGACAACCCCTTCAATAGCAGC	2886
QUERY:	2938	TTGGTTTCTCTCATCCGAGGCCAAGTAGTAACTACAGATGGAACTCCCCTGGTCGGTGTG	2997
		|||| ||||| |||||||||||||||||||| || ||||| || ||||||||| |||||
SBJCT:	2887	CTGGTGTCTCTGATCCGAGGCCAAGTAGTAACCACGGATGGGACCCCCCTGGTGGGTGTG	2946
QUERY:	2998	AACGTGTCTTTTGTCAAGTACCCAAAATACGGCTACACCATCACCCGCCAGGATGGCACG	3057
		|| |||||||||||||||||||||||||| |||||||||||||| |||||||| ||||||
SBJCT:	2947	AATGTGTCTTTTGTCAAGTACCCAAAATATGGCTACACCATCACTCGCCAGGACGGCACG	3006
QUERY:	3058	TTCGACCTGATCGCAAATGGAGGTGCTTCCTTGACTCTACACTTTGAGCGAGCCCCGTTC	3117
		|| |||||||| || ||||| ||  || |||||||||| ||||||||||||||||| |||
SBJCT:	3007	TTTGACCTGATTGCCAATGGGGGCTCTGCCTTGACTCTTCACTTTGAGCGAGCCCCTTTC	3066
QUERY:	3118	ATGAGCCAGGAGCGCACTGTGTGGCTGCCGTGGAACAGCTTTTACGCCATGGACACCCTG	3177
		||||||| ||||||||| || |||| ||||||||||||||| || |||||||||||||||
SBJCT:	3067	ATGAGCCGGGAGCGCACAGTATGGCCGCCGTGGAACAGCTTCTATGCCATGGACACCCTG	3126
QUERY:	3178	GTGATGAAGACCGAGGAGAACTCCATCCCCAGCTGTGACCTCAGTGGCTTTGTCCGGCCT	3237
		|| |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	3127	GTAATGAAGACGGAGGAGAACTCCATCCCCAGCTGTGACCTCAGTGGCTTTGTCCGGCCT	3186
QUERY:	3238	GATCCAATCATCATCTCCTCCCCACTGTCCACCTTCTTTAGTGCTGCCCCTGGGCAGAAT	3297
		||||| |||||||||||||| || |||||||||||||| || ||| |||||| |  |||
SBJCT:	3187	GATCCGATCATCATCTCCTCTCCTCTGTCCACCTTCTTCAGCGCTTCCCCTGCGGCGAAC	3246
QUERY:	3298	CCCATCGTGCCTGAGACCCAGGTTCTTCATGAAGAAATCGAGCTCCCTGGTTCCAATGTG	3357
		||||| |||||||||||||||||||||||||| || ||||||||||||||  |||| |||
SBJCT:	3247	CCCATTGTGCCTGAGACCCAGGTTCTTCATGAGGAGATCGAGCTCCCTGGCACCAACGTG	3306
QUERY:	3358	AAACTTCGCTATCTGAGCTCTAGAACTGCAGGGTACAAGTCACTGCTGAAGATCACCATG	3417
		|| || || || || ||||| ||||| |||||||||||||||||||||||||||||||||
SBJCT:	3307	AAGCTCCGTTACCTCAGCTCCAGAACAGCAGGGTACAAGTCACTGCTGAAGATCACCATG	3366
QUERY:	3418	ACCCAGTCCACAGTGCCCCTGAACCTCATTAGGGTTCACCTGATGGTGGCTGTCGAGGGG	3477
		||||||||||| |||||| ||||||||||  |||||||| ||||||| || || |||||
SBJCT:	3367	ACCCAGTCCACGGTGCCCTTGAACCTCATCCGGGTTCACTTGATGGTTGCCGTGGAGGGG	3426
QUERY:	3478	CATCTCTTCCAGAAGTCATTCCAGGCTTCTCCCAACCTGGCCTCCACCTTCATCTGGGAC	3537
		||||||||||||||||| ||||||||||||||||||||||||| ||| ||||||||||||
SBJCT:	3427	CATCTCTTCCAGAAGTCGTTCCAGGCTTCTCCCAACCTGGCCTACACATTCATCTGGGAC	3486
QUERY:	3538	AAGACAGATGCGTATGGCCAAAGGGTGTATGGACTCTCAGATGCTGTTGTGTCTGTCGGG	3597
		|||||||| || |||||||||||||| ||||| || || ||||||||||||||||| |||
SBJCT:	3487	AAGACAGACGCTTATGGCCAAAGGGTTTATGGCCTATCGGATGCTGTTGTGTCTGTTGGA	3546
QUERY:	3598	TTTGAATATGAGACCTGTCCCAGTCTAATTCTCTGGGAGAAAAGGACAGCCCTCCTTCAG	3657
		||||||||||||||||| |||||||| || || ||||| |||||||||||||| ||||||
SBJCT:	3547	TTTGAATATGAGACCTGCCCCAGTCTCATCCTGTGGGAAAAAAGGACAGCCCTACTTCAA	3606
QUERY:	3658	GGATTCGAGCTGGACCCCTCCAACCTCGGTGGCTGGTCCCTAGACAAACACCACATCCTC	3717
		||||||||||||||||| |||||||| |||||||||||||| || || ||||||| ||||
SBJCT:	3607	GGATTCGAGCTGGACCCTTCCAACCTTGGTGGCTGGTCCCTGGATAAGCACCACACCCTC	3666
QUERY:	3718	AATGTTAAAAGTGGAATCCTACACAAAGGCACTGGGGAAAACCAGTTCCTGACCCAGCAG	3777
		||||| ||||| ||||| |||| ||||||||| ||||| |||||||||||||||||||||
SBJCT:	3667	AATGTGAAAAGCGGAATACTACTCAAAGGCACAGGGGAGAACCAGTTCCTGACCCAGCAG	3726
QUERY:	3778	CCTGCCATCATCACCAGCATCATGGGCAATGGTCGCCGCCGGAGCATTTCCTGTCCCAGC	3837
		|| ||||||||||||||||||||||| || ||||||||| | ||||| ||||||||||||
SBJCT:	3727	CCCGCCATCATCACCAGCATCATGGGTAACGGTCGCCGCAGAAGCATCTCCTGTCCCAGC	3786
QUERY:	3838	TGCAACGGCCTTGCTGAAGGCAACAAGCTGCTGGCCCCAGTGGCTCTGGCTGTTGGAATC	3897
		||||| |||||||||||||||||||| ||| ||||||| ||||| |||||||| || |||
SBJCT:	3787	TGCAATGGCCTTGCTGAAGGCAACAAACTGTTGGCCCCCGTGGCCCTGGCTGTGGGGATC	3846
QUERY:	3898	GATGGGAGCCTCTATGTGGGTGACTTCAATTACATCCGACGCATCTTTCCCTCTCGAAAT	3957
		||||||||||||| ||| |||||||||||||| ||||| |||||||| || |||||||||
SBJCT:	3847	GATGGGAGCCTCTTTGTCGGTGACTTCAATTATATCCGGCGCATCTTCCCTTCTCGAAAT	3906
QUERY:	3958	GTGACCAGCATCTTGGAGTTACGAAATAAAGAGTTTAAACATAGCAACAACCCAGCACAC	4017
		|||||||| |||||||||||||||||||||||||||||||||||||||| ||||| ||||
SBJCT:	3907	GTGACCAGTATCTTGGAGTTACGAAATAAAGAGTTTAAACATAGCAACAGCCCAGGACAC	3966
QUERY:	4018	AAGTACTACTTGGCAGTGGACCCCGTGTCCGGCTCGCTCTACGTGTCCGACACCAACAGC	4077
		|||||||||||||| |||||||| ||| | ||||||||||| || || |||||||||||
SBJCT:	3944	AAGTACTACTTGGCTGTGGACCCTGTGACTGGCTCGCTCTATGTCTCTGACACCAACAGT	4026
QUERY:	4078	AGGAGAATCTACCGCGTCAAGTCTCTGAGTGGAACCAAAGACCTGGCTGGGAATTCGGAA	4137
		|  | |||||||| ||||||||||| || ||| ||||||||||||||||||||||||||
SBJCT:	4027	CGCCGGATCTACCGAGTCAAGTCTCTAAGCGGAGCCAAAGACCTGGCTGGGAATTCGGAA	4086
QUERY:	4138	GTTGTGGCAGGGACGGGAGAGCAGTGTCTACCCTTTGATGAAGCCCGCTGCGGGGATGGA	4197
		|||||||| ||||| || || || |||||||||||||||||||||||||| ||||||||
SBJCT:	4087	GTTGTGGCCGGGACTGGCGAACAATGTCTACCCTTTGATGAAGCCCGCTGTGGGGATGGC	4146
QUERY:	4198	GGGAAGGCCATAGATGCAACCCTGATGAGCCCGAGAGGTATTGCAGTAGACAAGAATGGG	4257
		||||||||  | ||||| |||||||||||||| ||||||||||||||||||||||| |||
SBJCT:	4147	GGGAAGGCTGTGGATGCCACCCTGATGAGCCCTAGAGGTATTGCAGTAGACAAGAACGGG	4206
QUERY:	4258	CTCATGTACTTTGTCGATGCCACCATGATCCGGAAGGTTGACCAGAATGGAATCATCTCC	4317
		|| ||||| ||||| ||||||||||||||||||||||| ||||| |||||||||||||||
SBJCT:	4207	CTTATGTATTTTGTTGATGCCACCATGATCCGGAAGGTCGACCAAAATGGAATCATCTCC	4266
QUERY:	4318	ACCCTGCTGGGCTCCAATGACCTCACTGCCGTCCGGCCGCTGAGCTGTGATTCCAGCATG	4377
		|||||||||||||||||||||||||| || ||||| || ||||||||||| || ||||||
SBJCT:	4267	ACCCTGCTGGGCTCCAATGACCTCACAGCTGTCCGACCACTGAGCTGTGACTCTAGCATG	4326
QUERY:	4378	GATGTAGCCCAGGTTCGTCTGGAGTGGCCAACAGACCTTGCTGTCAATCCCATGGATAAC	4437
		|| || |||||||| ||||| || ||||| ||||||||||| ||||| |||||||| ||
SBJCT:	4327	GACGTGGCCCAGGTCCGTCTAGAATGGCCGACAGACCTTGCGGTCAACCCCATGGACAAT	4386
QUERY:	4438	TCCTTGTATGTTCTAGAGAACAATGTCATCCTTCGAATCACCGAGAACCACCAAGTCAGC	4497
		||| |||| || || |||||||| |||||||| || ||||||||||| ||||| ||||||
SBJCT:	4387	TCCCTGTACGTCCTGGAGAACAACGTCATCCTGCGGATCACCGAGAATCACCAGGTCAGC	4446
QUERY:	4498	ATCATTGCGGGACGCCCCATGCACTGCCAAGTTCCTGGCATTGACTACTCACTCAGCAAA	4557
		||||| |||||||| |||||||||||||| ||||| ||||| |||||||| ||||||||
SBJCT:	4447	ATCATCGCGGGACGGCCCATGCACTGCCAGGTTCCCGGCATCGACTACTCGCTCAGCAAG	4506
QUERY:	4558	CTAGCCATTCACTCTGCCCTGGAGTCAGCCAGTGCCATTGCCATTTCTCACACTGGGGTC	4617
		|| ||||| |||||||| |||||||||||||| ||||| |||||||||||||||||||||
SBJCT:	4507	CTCGCCATCCACTCTGCTCTGGAGTCAGCCAGCGCCATCGCCATTTCTCACACTGGGGTG	4566
QUERY:	4618	CTCTACATCACTGAGACAGATGAGAAGAAGATTAACCGTCTACGCCAGGTAACAACCAAC	4677
		||||||||||| ||||| || ||||||||||| ||||| |||||||| || || ||||||
SBJCT:	4567	CTCTACATCACCGAGACGGACGAGAAGAAGATCAACCGCCTACGCCAAGTCACCACCAAC	4626
QUERY:	4678	GGGGAGATCTGCCTTTTAGCTGGGGCAGCCTCGGACTGCGACTGCAAAAACGATGTCAAT	4737
		|| ||||||||||| ||||| ||||||||||| ||||| ||||||||||| || |||||
SBJCT:	4627	GGAGAGATCTGCCTCTTAGCCGGGGCAGCCTCAGACTGTGACTGCAAAAATGACGTCAAC	4686
QUERY:	4738	TGCAACTGCTATTCAGGAGATGATGCCTACGCGACTGATGCCATCTTGAATTCCCCATCA	4797
		|||| ||||||||| |||||||| || ||||| || |||||||||||||| ||||| ||
SBJCT:	4687	TGCATCTGCTATTCGGGAGATGACGCATACGCCACGGATGCCATCTTGAACTCCCCGTCC	4746
QUERY:	4798	TCCTTAGCTGTAGCTCCAGATGGTACCATTTACATTGCAGACCTTGGAAATATTCGGATC	4857
		||||||||||| ||||| ||||| ||||| ||||| |||||||| || ||||| ||||||
SBJCT:	4747	TCCTTAGCTGTGGCTCCGGATGGCACCATCTACATCGCAGACCTCGGGAATATCCGGATC	4806
QUERY:	4858	AGGGCGGTCAGCAAGAACAAGCCTGTTCTTAATGCCTTCAACCAGTATGAGGCTGCATCC	4917
		|||||||||||||| ||||| ||||||||||| || |||||||||||||||||||| ||
SBJCT:	4807	AGGGCGGTCAGCAAAAACAAACCTGTTCTTAACGCGTTCAACCAGTATGAGGCTGCGTCT	4866
QUERY:	4918	CCCGGAGAGCAGGAGTTATATGTTTTCAACGCTGATGGCATCCACCAATACACTGTGAGC	4977
		|| ||||| |||||  | || || |||||||| ||||| ||||| || ||||| |||||
SBJCT:	4867	CCGGGAGAACAGGAACTGTACGTGTTCAACGCCGATGGTATCCATCAGTACACCGTGAGC	4926
QUERY:	4978	CTGGTGACAGGGGAGTACTTGTACAATTTCACATATAGTACTGACAATGATGTCACTGAA	5037
		|||||||| ||||||||||| ||||||||||| || ||  |||||||||||||||| ||
SBJCT:	4927	CTGGTGACCGGGGAGTACTTATACAATTTCACCTACAGCGCTGACAATGATGTCACCGAG	4986
QUERY:	5038	TTGATTGACAATAATGGGAATTCCCTGAAGATCCGTCGGGACAGCAGTGGCATGCCCCGT	5097
		||||||||||| || ||||||||||| |||||||| |||||||||||||||||||||||
SBJCT:	4987	TTGATTGACAACAACGGGAATTCCCTAAAGATCCGCCGGGACAGCAGTGGCATGCCCCGA	5046
QUERY:	5098	CACCTGCTCATGCCTGACAACCAGATCATCACCCTCACCGTGGGCACCAATGGAGGCCTC	5157
		||||||||||||||||| || |||||||||||||| || ||||||||||| |||||||||
SBJCT:	5047	CACCTGCTCATGCCTGATAATCAGATCATCACCCTTACGGTGGGCACCAACGGAGGCCTC	5106
QUERY:	5158	AAAGTCGTGTCCACACAGAACCTGGAGCTTGGTCTCATGACCTATGATGGCAACACTGGG	5217
		|||| |||||| || |||||||||||||| || |||||||| |||||||| ||||||||
SBJCT:	5107	AAAGCCGTGTCAACGCAGAACCTGGAGCTGGGCCTCATGACTTATGATGGGAACACTGGA	5166
QUERY:	5218	CTCCTGGCCACCAAGAGCGATGAAACAGGATGGACGACTTTCTATGACTATGACCACGAA	5277
		||||| |||||||||||||||||||| |||||||| ||||| |||||||||||||||||
SBJCT:	5167	CTCCTAGCCACCAAGAGCGATGAAACCGGATGGACAACTTTTTATGACTATGACCACGAG	5226
QUERY:	5278	GGCCGCCTGACCAACGTGACGCGCCCCACGGGGGTGGTAACCAGTCTGCACCGGGAAATG	5337
		||||| |||||||| ||||| ||||||||||||||||| ||||| |||||||||||||||
SBJCT:	5227	GGCCGTCTGACCAATGTGACTCGCCCCACGGGGGTGGTGACCAGCCTGCACCGGGAAATG	5286
QUERY:	5338	GAGAAATCTATTACCATTGACATTGAGAACTCCAACCGTGATGATGACGTCACTGTCATC	5397
		|||||||| || ||| |||||||||||||||||||||||||| | || |||||||| ||
SBJCT:	5287	GAGAAATCCATCACCGTTGACATTGAGAACTCCAACCGTGATAACGATGTCACTGTGATT	5346
QUERY:	5398	ACCAACCTCTCTTCAGTAGAGGCCTCCTACACAGTGGTACAAGATCAAGTTCGGAACAGC	5457
		||||||||||||||||| |||||||||||||| ||||||||||||||||| |||||||||
SBJCT:	5347	ACCAACCTCTCTTCAGTGGAGGCCTCCTACACCGTGGTACAAGATCAAGTGCGGAACAGC	5406
QUERY:	5458	TACCAGCTCTGTAATAATGGTACCCTGAGGGTGATGTATGCTAATGGGATGGGTATCAGC	5517
		||||||||||| |  || || |||||| | || ||||| || || || |||||  |||||
SBJCT:	5407	TACCAGCTCTGCAGCAACGGGACCCTGCGCGTCATGTACGCCAACGGCATGGGCGTCAGC	5466
QUERY:	5518	TTCCACAGCGAGCCCCATGTCCTAGCGGGCACCATCACCCCCACCATTGGACGCTGCAAC	5577
		||||||||||||||||| ||||| || |||||| ||||||||||||| || ||||| |||
SBJCT:	5467	TTCCACAGCGAGCCCCACGTCCTCGCAGGCACCCTCACCCCCACCATCGGGCGCTGTAAC	5526
QUERY:	5578	ATCTCCCTGCCTATGGAGAATGGCTTAAACTCCATTGAGTGGCGCCTAAGAAAGGAACAG	5637
		||||||||||| |||||||| ||| | |||||||| ||||||||||| || |||||||||
SBJCT:	5527	ATCTCCCTGCCCATGGAGAACGGCCTGAACTCCATCGAGTGGCGCCTGAGGAAGGAACAG	5586
QUERY:	5638	ATTAAAGGCAAAGTCACCATCTTTGGCAGGAAGCTCCGGGTCCATGGAAGAAATCTCTTG	5697
		|||||||||||||||||||||||||| |||||||| |||||||| ||||| || ||| ||
SBJCT:	5587	ATTAAAGGCAAAGTCACCATCTTTGGGAGGAAGCTTCGGGTCCACGGAAGGAACCTCCTG	5646
QUERY:	5698	TCCATTGACTATGATCGAAATATTCGGACTGAAAAGATCTATGATGACCACCGGAAGTTC	5757
		|||||||| ||||| |||||||| || ||||| ||||||||||| |||||||||||||||
SBJCT:	5647	TCCATTGATTATGACCGAAATATCCGCACTGAGAAGATCTATGACGACCACCGGAAGTTC	5706
QUERY:	5758	ACCCTGAGGATCATTTATGACCAGGTGGGCCGCCCCTTCCTCTGGCTGCCCAGCAGCGGG	5817
		||||||||||||||||||||||||||||||||||||||||| ||||| |||||||| ||
SBJCT:	5707	ACCCTGAGGATCATTTATGACCAGGTGGGCCGCCCCTTCCTGTGGCTCCCCAGCAGTGGA	5766
QUERY:	5818	CTGGCAGCTGTCAACGTGTCATACTTCTTCAATGGGCGCCTGGCTGGGCTTCAGCGTGGG	5877
		||||| || ||||| || || ||||||||||| ||||||||||| || || ||||| |||
SBJCT:	5767	CTGGCGGCCGTCAATGTCTCCTACTTCTTCAACGGGCGCCTGGCCGGCCTCCAGCGCGGG	5826
QUERY:	5878	GCCATGAGCGAGAGGACAGACATCGACAAGCAAGGCCGCATCGTGTCCCGCATGTTCGCT	5937
		||||||||||||||||||||||| |||||||||||||| || |||||||| ||||||||
SBJCT:	5827	GCCATGAGCGAGAGGACAGACATTGACAAGCAAGGCCGGATTGTGTCCCGAATGTTCGCC	5886
QUERY:	5938	GACGGGAAAGTGTGGAGCTACTCCTACCTTGACAAGTCCATGGTCCTCCTGCTTCAGAGC	5997
		||||||||||| |||||||| |||||||||||||||||||||||||||||||| ||||||
SBJCT:	5887	GACGGGAAAGTCTGGAGCTATTCCTACCTTGACAAGTCCATGGTCCTCCTGCTGCAGAGC	5946
QUERY:	5998	CAACGTCAGTATATATTTGAGTATGACTCCTCTGACCGCCTCCTTGCCGTCACCATGCCC	6057
		|| |||||||| |||||||| ||||||||||||||||||||||  || ||||||||||||
SBJCT:	5924	CAGCGTCAGTACATATTTGAATATGACTCCTCTGACCGCCTCCACGCAGTCACCATGCCC	5983
QUERY:	6058	AGCGTGGCCCGGCACAGCATGTCCACACACACCTCCATCGGCTACATCCGTAATATTTAC	6117
		|| || |||||||||||||||||||| ||||||||||| ||||||||||| || ||||||
SBJCT:	6007	AGTGTCGCCCGGCACAGCATGTCCACGCACACCTCCATTGGCTACATCCGGAACATTTAC	6066
QUERY:	6118	AACCCGCCTGAAAGCAATGCTTCGGTCATCTTTGACTACAGTGATGACGGCCGCATCCTG	6177
		||||| || |||||||| || |||||||||||||||||||||||||||||||||||||||
SBJCT:	6067	AACCCACCGGAAAGCAACGCCTCGGTCATCTTTGACTACAGTGATGACGGCCGCATCCTG	6126
QUERY:	6178	AAGACCTCCTTTTTGGGCACCGGACGCCAGGTGTTCTACAAGTATGGGAAACTCTCCAAG	6237
		||||| || ||  |||||||||| |||||||||||||| ||||| || ||||| ||||||
SBJCT:	6127	AAGACGTCTTTCCTGGGCACCGGGCGCCAGGTGTTCTATAAGTACGGAAAACTCTCCAAG	6186
QUERY:	6238	TTATCAGAGATTGTCTACGACAGTACCGCCGTCACCTTCGGGTATGACGAGACCACTGGT	6297
		||||| ||||| ||||||||||| || |||||||||||||| ||||||||||||||||||
SBJCT:	6187	TTATCGGAGATCGTCTACGACAGCACTGCCGTCACCTTCGGCTATGACGAGACCACTGGC	6246
QUERY:	6298	GTCTTGAAGATGGTCAACCTCCAAAGTGGGGGCTTCTCCTGCACCATCAGGTACCGGAAG	6357
		||| |||||||||| || |||||||| |||||||||||||| |||||||||||||| |||
SBJCT:	6247	GTCCTGAAGATGGTGAATCTCCAAAGCGGGGGCTTCTCCTGTACCATCAGGTACCGAAAG	6306
QUERY:	6358	ATTGGCCCCCTGGTGGACAAGCAGATCTACAGGTTCTCCGAGGAAGGCATGGTCAATGCC	6417
		| || ||||| |||||||||||||| ||||||||||| |||||||||||| |||| |||
SBJCT:	6307	GTCGGGCCCCTCGTGGACAAGCAGATTTACAGGTTCTCTGAGGAAGGCATGATCAACGCC	6366
QUERY:	6418	AGGTTTGACTACACCTATCATGACAACAGCTTCCGCATCGCAAGCATCAAGCCCGTCATA	6477
		||||| || |||||||| || |||||||||||||||||||| |||||||||||||||||
SBJCT:	6367	AGGTTCGATTACACCTACCACGACAACAGCTTCCGCATCGCCAGCATCAAGCCCGTCATC	6426
QUERY:	6478	AGTGAGACTCCCCTCCCCGTTGACCTCTACCGCTATGATGAGATTTCTGGCAAGGTGGAA	6537
		|||||||||||||| |||||||||||||||||||| ||||||||||||||||||||||||
SBJCT:	6427	AGTGAGACTCCCCTTCCCGTTGACCTCTACCGCTACGATGAGATTTCTGGCAAGGTGGAA	6486
QUERY:	6538	CACTTTGGTAAGTTTGGAGTCATCTATTATGACATCAACCAGATCATCACCACTGCCGTG	6597
		||||| || ||||| || |||||||| || |||||||||||||||||||||||||||||
SBJCT:	6487	CACTTCGGCAAGTTCGGGGTCATCTACTACGACATCAACCAGATCATCACCACTGCCGTC	6546
QUERY:	6598	ATGACCCTCAGCAAACACTTCGACACCCATGGGCGGATCAAGGAGGTCCAGTATGAGATG	6657
		||||| |||||||| ||||| |||||||||||||| |||||||| || ||||||||||||
SBJCT:	6547	ATGACACTCAGCAAGCACTTTGACACCCATGGGCGCATCAAGGAAGTGCAGTATGAGATG	6606
QUERY:	6658	TTCCGGTCCCTCATGTACTGGATGACGGTGCAATATGACAGCATGGGCAGGGTGATCAAG	6717
		||||||||||||||||||||||||||||||||||||||||| ||||||||||| ||||||
SBJCT:	6607	TTCCGGTCCCTCATGTACTGGATGACGGTGCAATATGACAGTATGGGCAGGGTCATCAAG	6666
QUERY:	6718	AGGGAGCTAAAACTGGGGCCCTATGCCAATACCACGAAGTACACCTATGACTACGATGGG	6777
		||||| || |||||||||||||||||||| ||||| |||||||||||||||||||| |||
SBJCT:	6667	AGGGAACTGAAACTGGGGCCCTATGCCAACACCACAAAGTACACCTATGACTACGACGGG	6726
QUERY:	6778	GACGGGCAGCTCCAGAGCGTGGCCGTCAATGACCGCCCGACCTGGCGCTACAGCTATGAC	6837
		||||| ||||||||||| ||||||||||||||||| || |||||||| || |||||||||
SBJCT:	6727	GACGGCCAGCTCCAGAGTGTGGCCGTCAATGACCGGCCTACCTGGCGTTATAGCTATGAC	6786
QUERY:	6838	CTTAATGGGAATCTCCACTTACTGAACCCAGGCAACAGTGTGCGCCTCATGCCCTTGCGC	6897
		|| |||||||| || ||| | || |||||||| |||||||  ||||||||||| || |||
SBJCT:	6787	CTCAATGGGAACCTGCACCTGCTAAACCCAGGAAACAGTGCTCGCCTCATGCCGTTACGC	6846
QUERY:	6898	TATGACCTCCGGGATCGGATAACCAGACTCGGGGATGTGCAGTACAAAATTGACGACGAT	6957
		||||||||||| || ||||||||||| || ||||| |||||||||||||| || || |||
SBJCT:	6847	TATGACCTCCGTGACCGGATAACCAGGCTAGGGGACGTGCAGTACAAAATCGATGATGAT	6906
QUERY:	6958	GGCTATCTGTGCCAGAGAGGGTCTGACATCTTCGAATACAATTCCAAGGGCCTCCTAACA	7017
		|||||| | ||||||||||| ||||||||||| |||||||| ||||||||||| |||||
SBJCT:	6907	GGCTATTTATGCCAGAGAGGATCTGACATCTTTGAATACAACTCCAAGGGCCTTCTAACG	6966
QUERY:	7018	AGAGCCTACAACAAGGCCAGCGGGTGGAGTGTCCAGTACCGCTATGATGGCGTAGGACGG	7077
		||||| |||||||||||||||||||||||||| ||||||||||||||||||||  | ||
SBJCT:	6967	AGAGCGTACAACAAGGCCAGCGGGTGGAGTGTGCAGTACCGCTATGATGGCGTGAGCCGC	7026
QUERY:	7078	CGGGCTTCCTACAAGACCAACCTGGGCCACCACCTGCAGTACTTCTACTCTGACCTCCAC	7137
		||||||||||||||||||||||||||||||||||| ||||||||||| || |||||||||
SBJCT:	7027	CGGGCTTCCTACAAGACCAACCTGGGCCACCACCTACAGTACTTCTATTCCGACCTCCAC	7086
QUERY:	7138	AACCCGACGCGCATCACCCATGTCTACAATCACTCCAACTCGGAGATTACCTCACTGTAC	7197
		|||| || || ||||||||||| |||| |||||||||||| ||||| |||||||| |||
SBJCT:	7087	CACCCCACACGTATCACCCATGTTTACAACCACTCCAACTCTGAGATCACCTCACTCTAC	7146
QUERY:	7198	TACGACCTCCAGGGCCACCTCTTTGCCATGGAGAGCAGCAGTGGGGAGGAGTACTATGTT	7257
		|| ||||||||||||||||||||||||||||||||||| |||||||| |||||||||||
SBJCT:	7147	TATGACCTCCAGGGCCACCTCTTTGCCATGGAGAGCAGTAGTGGGGAAGAGTACTATGTT	7206
QUERY:	7258	GCCTCTGATAACACAGGGACTCCTCTGGCTGTGTTCAGCATCAACGGCCTCATGATCAAA	7317
		||||| |||||||| ||||||||||||||||| || || ||||| ||||||||||||||
SBJCT:	7207	GCCTCAGATAACACCGGGACTCCTCTGGCTGTTTTTAGTATCAATGGCCTCATGATCAAG	7266
QUERY:	7318	CAGCTGCAGTACACGGCCTATGGGGAGATTTATTATGACTCCAACCCCGACTTCCAGATG	7377
		|| || || ||||| ||||||||||||||||| ||||||||||| || ||||| ||||||
SBJCT:	7267	CAACTCCAATACACAGCCTATGGGGAGATTTACTATGACTCCAATCCAGACTTTCAGATG	7326
QUERY:	7378	GTCATTGGCTTCCATGGGGGACTCTATGACCCCCTGACCAAGCTGGTCCACTTCACTCAG	7437
		||||| |||||||| || || ||||| |||||||| |||||||| || ||||| || |||
SBJCT:	7327	GTCATCGGCTTCCACGGAGGCCTCTACGACCCCCTCACCAAGCTCGTTCACTTTACGCAG	7386
QUERY:	7438	CGTGATTATGATGTGCTGGCAGGACGATGGACCTCCCCAGACTATACCATGTGGAAAAAC	7497
		||||||||||| |||||||||||||| ||||| ||||| ||||| ||||||||||| ||
SBJCT:	7387	CGTGATTATGACGTGCTGGCAGGACCGTGGACGTCCCCCGACTACACCATGTGGAGGAAT	7446
QUERY:	7498	GTGGGCAAGGAGCCGGCCCCCTTTAACCTGTATATGTTCAAGAGCAACAATCCTCTCAGC	7557
		|||||||||||||| |||||||| |||||||| |||||||||| ||||||||| |||||
SBJCT:	7447	GTGGGCAAGGAGCCAGCCCCCTTCAACCTGTACATGTTCAAGAACAACAATCCACTGAGC	7506
QUERY:	7558	AGTGAGCTAGATTTGAAGAACTACGTGACAGATGTGAAAAGCTGGCTTGTGATGTTTGGA	7617
		| |||||| ||||| ||||||||||||||||| ||||| |||||||| ||||||||||||
SBJCT:	7507	AATGAGCTGGATTTAAAGAACTACGTGACAGACGTGAAGAGCTGGCTCGTGATGTTTGGA	7566
QUERY:	7618	TTTCAGCTTAGCAACATCATTCCTGGCTTCCCGAGAGCCAAAATGTATTTCGTGCCTCCT	7677
		|||||||| ||||||||||||||||| ||||| ||||||||||||||||| ||||||||
SBJCT:	7567	TTTCAGCTCAGCAACATCATTCCTGGATTCCCAAGAGCCAAAATGTATTTTGTGCCTCCC	7626
QUERY:	7678	CCCTATGAATTGTCAGAGAGTCAAGCAAGTGAGAATGGACAGCTCATTACAGGTGTCCAA	7737
		||||||||| |||||||||| |||||||||||||||||||||||||||||||||||||
SBJCT:	7627	CCCTATGAACTGTCAGAGAGCCAAGCAAGTGAGAATGGACAGCTCATTACAGGTGTCCAG	7686
QUERY:	7738	CAGACAACAGAGAGACATAACCAGGCCTTCATGGCTCTGGAAGGACAGGTCATTACTAAA	7797
		|||||||||||||| ||||||||||||||  ||||||| ||||||||||||||  |||||
SBJCT:	7687	CAGACAACAGAGAGGCATAACCAGGCCTTTCTGGCTCTAGAAGGACAGGTCATCTCTAAA	7746
QUERY:	7798	AAGCTCCACGCCAGCATCCGAGAGAAAGCAGGTCACTGGTTTGCCACCACCACGCCCATC	7857
		|||||||| ||  |||||||||||||||||||| |||||||||| || ||||||||||||
SBJCT:	7747	AAGCTCCATGCAGGCATCCGAGAGAAAGCAGGCCACTGGTTTGCTACGACCACGCCCATC	7806
QUERY:	7858	ATTGGCAAAGGCATCATGTTTGCCATCAAAGAAGGGCGGGTGACCACGGGCGTGTCCAGC	7917
		|| ||||||||||||||||| |||||||||||||||||||||||||| |||||||| |||
SBJCT:	7807	ATCGGCAAAGGCATCATGTTCGCCATCAAAGAAGGGCGGGTGACCACAGGCGTGTCTAGC	7866
QUERY:	7918	ATCGCCAGCGAAGATAGCCGCAAGGTGGCATCTGTGCTGAACAACGCCTACTACCTGGAC	7977
		|||||||| || || ||||||||||| ||||| ||| ||||||||||||||||| |||||
SBJCT:	7867	ATCGCCAGTGAGGACAGCCGCAAGGTAGCATCCGTGTTGAACAACGCCTACTACTTGGAC	7926
QUERY:	7978	AAGATGCACTACAGCATCGAGGGCAAGGACACCCACTACTTTGTGAAGATTGGCTCAGCC	8037
		|||||||||||||||||||||||||||||||| |||||||| |||||||| ||  ||||
SBJCT:	7927	AAGATGCACTACAGCATCGAGGGCAAGGACACACACTACTTCGTGAAGATCGGTGCAGCG	7986
QUERY:	8038	GATGGCGACCTGGTCACACTAGGCACCACCATCGGCCGCAAGGTGCTAGAGAGCGGGGTG	8097
		|| || |||||||| || || || |||||||| || ||||||||||| ||||||||||||
SBJCT:	7987	GACGGTGACCTGGTTACGCTGGGGACCACCATTGGGCGCAAGGTGCTGGAGAGCGGGGTG	8046
QUERY:	8098	AACGTGACCGTGTCCCAGCCCACGCTGCTGGTCAACGGCAGGACTCGAAGGTTCACGAAC	8157
		|||||||||||||| ||||||||||||||||| ||||||||||||||||||||||| |||
SBJCT:	8047	AACGTGACCGTGTCACAGCCCACGCTGCTGGTGAACGGCAGGACTCGAAGGTTCACCAAC	8106
QUERY:	8158	ATTGAGTTCCAGTACTCCACGCTGCTGCTCAGCATCCGCTATGGCCTCACCCCCGACACC	8217
		||||| ||||||||||||||||||||||||||||| ||||| |||||||||||||||||
SBJCT:	8107	ATTGAATTCCAGTACTCCACGCTGCTGCTCAGCATACGCTACGGCCTCACCCCCGACACA	8166
QUERY:	8218	CTGGACGAAGAGAAGGCCCGCGTCCTGGACCAGGCGAGACAGAGGGCCCTGGGCACGGCC	8277
		||||| |||||||||||||||||||||||||| ||| |||||||||||||||| || |||
SBJCT:	8167	CTGGATGAAGAGAAGGCCCGCGTCCTGGACCAAGCGCGACAGAGGGCCCTGGGTACTGCC	8226
QUERY:	8278	TGGGCCAAGGAGCAGCAGAAAGCCAGGGACGGGAGAGAGGGGAGCCGCCTGTGGACTGAG	8337
		||||||||||||||||||||||||||||||||||||||||| ||||| |||||||| |||
SBJCT:	8227	TGGGCCAAGGAGCAGCAGAAAGCCAGGGACGGGAGAGAGGGCAGCCGTCTGTGGACGGAG	8286
QUERY:	8338	GGCGAGAAGCAGCAGCTTCTGAGCACCGGGCGCGTGCAAGGGTACGAGGGATATTACGTG	8397
		|||||||||||||| || |||||||| || || |||||||| || ||||| ||||||||
SBJCT:	8287	GGCGAGAAGCAGCAACTCCTGAGCACGGGACGGGTGCAAGGTTATGAGGGCTATTACGTG	8346
QUERY:	8398	CTTCCCGTGGAGCAATACCCAGAGCTTGCAGACAGTAGCAGCAACATCCAGTTTTTAAGA	8457
		||||| ||||| || ||||||||||| |||||||||||||||||||||||||| ||||||
SBJCT:	8347	CTTCCGGTGGAACAGTACCCAGAGCTGGCAGACAGTAGCAGCAACATCCAGTTCTTAAGA	8406
QUERY:	8458	CAGAATGAGATGGGAAAGAGGTAACAAAATAATCTGCTGCCATTCCTTGTCTGAATGGCT	8517
		|||||||||||||||||||||||||||||||| |||||||||   ||| ||||  |||||
SBJCT:	8407	CAGAATGAGATGGGAAAGAGGTAACAAAATAACCTGCTGCCACCTCTTCTCTGGGTGGCT	8466
QUERY:	8518	CAGCAGGAGTAACTGTTATCTCCTCTCCTAAGGAGATGAAGACCTAACAGGGGCACTGCG	8577
		||||||||| |||||| | ||||||||||||||||| ||||||||||||||||||||| |
SBJCT:	8467	CAGCAGGAGCAACTGTGACCTCCTCTCCTAAGGAGACGAAGACCTAACGGGGGCACTGAG	8526
QUERY:	8578	GCTGGGCTGCTTTAGGAGACCAAGTGGCAAGAAAGCTCACATTTTTTGAGTTCAAATGCT	8637
		|| ||||||||||||||  |||||||||||||||||||||||||||||||||||||||||
SBJCT:	8527	GCCGGGCTGCTTTAGGACCCCAAGTGGCAAGAAAGCTCACATTTTTTGAGTTCAAATGCT	8586
QUERY:	8638	ACTGTCCAAGCGAGAAGTCCCTCATCCTGAAGTAGACTAAAGCCCGGCTGAAAATTCCGA	8685
		||||||||||||  ||||||||||||||||||||||||| ||| ||||   |||||| ||
SBJCT:	8587	ACTGTCCAAGCGCAAAGTCCCTCATCCTGAAGTAGACTAGAGCTCGGCCACAAATTCTGA	8610
QUERY:	8698	GGAAAACAAAAC 8709
		||||||||||||
SBJCT:	8647	GGAAAACAAAAC 8658
SCORE = 1459 BITS (736), EXPECT = 0.0
IDENTITIES = 1081/1196 (90%)
STRAND = PLUS/PLUS
QUERY:	270	ATCTGGAATAATGGATGTAAAGGACCGGCGACACCGCTCTTTGACCAGAGGACGCTGTGG	329
		||||| |||||||||||| ||||| |||||||| |||||||||||||| ||||| |||||
SBJCT:	123	ATCTGCAATAATGGATGTGAAGGATCGGCGACATCGCTCTTTGACCAGGGGACGGTGTGG	182
QUERY:	330	CAAAGAGTGTCGCTACACAAGCTCCTCTCTGGACAGTGAGGACTGCCGGGTGCCCACACA	389
		||| |||||||||||||| ||||||||||||||||||||||||||||| |||||||| ||
SBJCT:	183	CAAGGAGTGTCGCTACACCAGCTCCTCTCTGGACAGTGAGGACTGCCGTGTGCCCACGCA	242
QUERY:	390	GAAATCCTACAGCTCCAGTGAGACTCTGAAGGCCTATGACCATGACAGCAGGATGCACTA	449
		||| |||||||| ||||||||||| |||||||| ||||||||||||||||| ||||||||
SBJCT:	243	GAAGTCCTACAGTTCCAGTGAGACCCTGAAGGCTTATGACCATGACAGCAGAATGCACTA	302
QUERY:	450	TGGAAACCGAGTCACAGACCTCATCCACCGGGAGTCAGATGAGTTTCCTAGACAAGGAAC	509
		|||||||||||||||||||||  | ||||||||||| ||||||||| ||||||||||  |
SBJCT:	303	TGGAAACCGAGTCACAGACCTGGTGCACCGGGAGTCCGATGAGTTTTCTAGACAAGGGGC	362
QUERY:	510	CAACTTCACCCTTGCCGAACTGGGCATCTGTGAGCCCTCCCCACACCGAAGCGGCTACTG	569
		|| |||||||| || ||| |||| ||||| |||||||||||||||||||| || |||||
SBJCT:	363	TAATTTCACCCTGGCAGAATTGGGAATCTGCGAGCCCTCCCCACACCGAAGTGGTTACTG	422
QUERY:	570	CTCCGACATGGGGATCCTTCACCAGGGCTACTCCCTTAGCACAGGGTCTGACGCCGACTC	629
		||||||||||||||||| ||||||||||||||||| ||||| |||||||| || |||||
SBJCT:	423	TTCCGACATGGGGATCCTCCACCAGGGCTACTCCCTGAGCACTGGGTCTGATGCGGACTC	482
QUERY:	630	CGACACCGAGGGAGGGATGTCTCCAGAACACGCCATCAGACTGTGGGGCAGAGGGATAAA	689
		||||||||||||||||||||||||||||| |||||||||||||||||  ||||||||||
SBJCT:	483	GGACACCGAGGGAGGGATGTCTCCAGAACATGCCATCAGACTGTGGGGACGAGGGATAAA	542
QUERY:	690	ATCCAGGCGCAGTTCCGGCCTGTCCAGTCGTGAAAACTCGGCCCTTACCCTGACTGACTC	749
		||| |||||||| || ||| ||||||| || || ||||| |||||||| |||||||| ||
SBJCT:	543	ATCGAGGCGCAGCTCTGGCTTGTCCAGCCGCGAGAACTCAGCCCTTACTCTGACTGATTC	602
QUERY:	750	TGACAACGAAAACAAATCAGATGATGAGAACGGTCGTCCCATTCCACCTACATCCTCGCC	809
		|||||| ||||| ||||| ||||| || || ||||| ||||||||||||||||||||| |
SBJCT:	603	TGACAATGAAAATAAATCGGATGACGACAATGGTCGACCCATTCCACCTACATCCTCGTC	662
QUERY:	810	TAGTCTCCTCCCATCTGCTCAGCTGCCTAGCTCCCATAATCCTCCACCAGTTAGCTGCCA	869
		||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	663	TAGCCTCCTCCCATCTGCTCAGCTGCCTAGCTCCCATAATCCTCCACCAGTTAGCTGCCA	722
QUERY:	870	GATGCCATTGCTAGACAGCAACACCTCCCATCAAATCATGGACACCAACCCTGATGAGGA	929
		||||||||||||||||||||||||||||||||| ||||||||||||||||| ||||||||
SBJCT:	723	GATGCCATTGCTAGACAGCAACACCTCCCATCAGATCATGGACACCAACCCCGATGAGGA	782
QUERY:	930	ATTCTCCCCCAATTCATACCTGCTCAGAGCATGCTCAGGGCCCCAGCAAGCCTCCAGCAG	989
		||||||||| ||||||||||||||||||||||||||||||||||||||||||||||| ||
SBJCT:	783	ATTCTCCCCTAATTCATACCTGCTCAGAGCATGCTCAGGGCCCCAGCAAGCCTCCAGTAG	842
QUERY:	990	TGGCCCTCCGAACCACCACAGCCAGTCGACTCTGAGGCCCCCTCTCCCACCCCCTCACAA	1049
		||||||||||||||||||||||||||| || |||||||||||||| ||||| ||||| ||
SBJCT:	843	TGGCCCTCCGAACCACCACAGCCAGTCAACGCTGAGGCCCCCTCTGCCACCTCCTCATAA	902
QUERY:	1050	CCACACGCTGTCCCATCACCACTCGTCCGCCAACTCCCTCAACAGGAACTCACTGACCAA	1109
		|||||| |||||||| |||||||| || ||||||||||||||||| ||||||||||||||
SBJCT:	903	CCACACCCTGTCCCACCACCACTCCTCTGCCAACTCCCTCAACAGAAACTCACTGACCAA	962
QUERY:	1110	TCGGCGGAGTCAGATCCACGCCCCGGCCCCAGCGCCCAATGACCTGGCCACCACACCAGA	1169
		|||||||||||| ||||||||||| || || || |||||||||||||||||||| || ||
SBJCT:	963	TCGGCGGAGTCAAATCCACGCCCCAGCTCCTGCACCCAATGACCTGGCCACCACGCCAGA	1022
QUERY:	1170	GTCCGTTCAGCTTCAGGACAGCTGGGTGCTAAACAGCAACGTGCCACTGGAGACCCGGCA	1229
		|||||||||||| ||||||||||||||||| ||||| |||||||| |||||||| |||||
SBJCT:	1023	GTCCGTTCAGCTCCAGGACAGCTGGGTGCTGAACAGTAACGTGCCGCTGGAGACGCGGCA	1082
QUERY:	1230	CTTCCTCTTCAAGACCTCCTCGGGGAGCACACCCTTGTTCAGCAGCTCTTCCCCGGGATA	1289
		||||||||||||||| ||||| || ||||||||| |||||||||||||||| || |||||
SBJCT:	1083	CTTCCTCTTCAAGACGTCCTCCGGAAGCACACCCCTGTTCAGCAGCTCTTCTCCAGGATA	1142
QUERY:	1290	CCCTTTGACCTCAGGAACGGTTTACACGCCCCCGCCCCGCCTGCTGCCCAGGAATACTTT	1349
		||| ||||||||||| || ||||| || || || ||||||||||||||  ||||||| ||
SBJCT:	1143	CCCCTTGACCTCAGGGACCGTTTATACACCACCACCCCGCCTGCTGCCACGGAATACATT	1202
QUERY:	1350	CTCCAGGAAGGCTTTCAAGCTGAAGAAGCCCTCCAAATACTGCAGCTGGAAATGTGCTGC	1409
		||| |||||||| |||||||||||||| ||||||||||||||||| |||||||| || ||
SBJCT:	1203	CTCTAGGAAGGCCTTCAAGCTGAAGAAACCCTCCAAATACTGCAGTTGGAAATGCGCCGC	1262
QUERY:	1410	CCTCTCCGCCATTGCCGCGGCCCTCCTCTTGGCTATTTTGCTGGCGTATTTCATAG 1465
		||| || ||||||||||| ||||||||  ||||| |||||||||| ||||||||||
SBJCT:	1263	CCTGTCTGCCATTGCCGCTGCCCTCCTTCTGGCCATTTTGCTGGCCTATTTCATAG 1318
SCORE = 1427 BITS (720), EXPECT = 0.0
IDENTITIES = 996/1088 (91%)
STRAND = PLUS/PLUS
QUERY:	1464	AGTGCCCTGGTCGTTGAAAAACAGCAGCATAGACAGTGGTGAAGCAGAAGTTGGTCGGCG	1523
		|||||||||||||||||||||||||||||||||||| || || |||||||| ||||| ||
SBJCT:	1440	AGTGCCCTGGTCGTTGAAAAACAGCAGCATAGACAGCGGCGAGGCAGAAGTCGGTCGACG	1499
QUERY:	1524	GGTAACACAAGAAGTCCCACCAGGGGTGTTTTGGAGGTCACAAATTCACATCAGTCAGCC	1583
		||| ||||| ||||||||||||||||||||||||||||| || |||||||||||||||||
SBJCT:	1500	GGTGACACAGGAAGTCCCACCAGGGGTGTTTTGGAGGTCCCAGATTCACATCAGTCAGCC	1559
QUERY:	1584	CCAGTTCTTAAAGTTCAACATCTCCCTCGGGAAGGACGCTCTCTTTGGTGTTTACATAAG	1643
		|||||||||||||||||||||||||| |||||||| || ||||| || || ||||||||
SBJCT:	1560	TCAGTTCTTAAAGTTCAACATCTCCCTGGGGAAGGATGCCCTCTTCGGCGTCTACATAAG	1619
QUERY:	1644	AAGAGGACTTCCACCATCTCATGCCCAGTATGACTTCATGGAACGTCTGGACGGGAAGGA	1703
		||||||||| |||||||||||||| |||||||||||||||||||| |||||||| |||||
SBJCT:	1620	AAGAGGACTGCCACCATCTCATGCACAGTATGACTTCATGGAACGCCTGGACGGAAAGGA	1679
QUERY:	1704	GAAGTGGAGTGTGGTTGAGTCTCCCAGGGAACGCCGGAGCATACAGACCTTGGTTCAGAA	1763
		||||||||||||||| ||||| |||||||||||||||||||| |||||| |||| |||||
SBJCT:	1680	GAAGTGGAGTGTGGTCGAGTCACCCAGGGAACGCCGGAGCATCCAGACCCTGGTGCAGAA	1739
QUERY:	1764	TGAAGCCGTGTTTGTGCAGTACCTGGATGTGGGCCTGTGGCATCTGGCCTTCTACAATGA	1823
		|| || ||||| ||||||||| ||||||||||||||||||| || ||||||||||||||
SBJCT:	1740	CGAGGCTGTGTTCGTGCAGTACTTGGATGTGGGCCTGTGGCACCTCGCCTTCTACAATGA	1799
QUERY:	1824	TGGAAAAGACAAAGAGATGGTTTCCTTCAATACTGTTGTCCTAGATTCAGTGCAGGACTG	1883
		|| || ||||| |||||||| ||||||||||| |||||| |||||||||||||||||||
SBJCT:	1800	CGGCAAGGACAAGGAGATGGTCTCCTTCAATACGGTTGTCTTAGATTCAGTGCAGGACTG	1859
QUERY:	1884	TCCACGTAACTGCCATGGGAATGGTGAATGTGTGTCCGGGGTGTGTCACTGTTTCCCAGG	1943
		|||||| |||||||| ||||| || ||||| ||||| ||  |||||||||||||||||||
SBJCT:	1860	TCCACGAAACTGCCACGGGAACGGCGAATGCGTGTCTGGACTGTGTCACTGTTTCCCAGG	1919
QUERY:	1944	ATTTCTAGGAGCAGACTGTGCTAAAGCTGCCTGCCCTGTCCTGTGCAGTGGGAATGGACA	2003
		||| ||||| |||||||| |||||||||||||||||||| ||||||||||||||||||||
SBJCT:	1920	ATTCCTAGGTGCAGACTGCGCTAAAGCTGCCTGCCCTGTTCTGTGCAGTGGGAATGGACA	1979
QUERY:	2004	ATATTCTAAAGGGACGTGCCAGTGCTACAGCGGCTGGAAAGGTGCAGAGTGCGACGTGCC	2063
		||||| |||||||| |||||||||||||| ||||||||||| ||||| ||||| |||||
SBJCT:	1980	GTATTCCAAAGGGACATGCCAGTGCTACAGTGGCTGGAAAGGAGCAGAATGCGATGTGCC	2039
QUERY:	2064	CATGAATCAGTGCATCGATCCTTCCTGCGGGGGCCACGGCTCCTGCATTGATGGGAACTG	2123
		|||||| |||||||||||||||||||| ||||||||||||||||||||||||||||||||
SBJCT:	2040	CATGAACCAGTGCATCGATCCTTCCTGTGGGGGCCACGGCTCCTGCATTGATGGGAACTG	2099
QUERY:	2124	TGTCTGCTCTGCTGGCTACAAAGGCGAGCACTGTGAGGAAGTTGATTGCTTGGATCCCAC	2183
		|| ||  | ||||||||||| ||||||||||| || ||||| |||||||||||||| ||
SBJCT:	2100	CGTGTGTGCAGCTGGCTACAAGGGCGAGCACTGCGAAGAAGTGGATTGCTTGGATCCAAC	2159
QUERY:	2184	CTGCTCCAGCCACGGAGTCTGTGTGAATGGAGAATGCCTGTGCAGCCCTGGCTGGGGTGG	2243
		|||||||||||| || ||||||||||| ||||| || || |||||||| |||||||| ||
SBJCT:	2160	CTGCTCCAGCCATGGTGTCTGTGTGAACGGAGAGTGTCTATGCAGCCCCGGCTGGGGCGG	2219
QUERY:	2244	TCTGAACTGTGAGCTGGCGAGGGTCCAGTGCCCAGACCAGTGCAGTGGGCATGGCACGTA	2303
		|| ||||| |||||||||||||||||||||||||||||||| |||||||||||||| ||
SBJCT:	2220	GCTCAACTGCGAGCTGGCGAGGGTCCAGTGCCCAGACCAGTGTAGTGGGCATGGCACTTA	2279
QUERY:	2304	CCTGCCTGACACGGGCCTCTGCAGCTGCGATCCCAACTGGATGGGTCCCGACTGCTCTGT	2363
		||| |||||| | |||||||||| ||| ||||| || |||||||||||||||||||||||
SBJCT:	2280	CCTCCCTGACTCTGGCCTCTGCAACTGTGATCCGAATTGGATGGGTCCCGACTGCTCTGT	2339
QUERY:	2364	TGAAGTGTGCTCAGTAGACTGTGGCACTCACGGCGTCTGCATCGGGGGAGCCTGCCGCTG	2423
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2340	TGAAGTGTGCTCAGTAGACTGTGGCACTCACGGCGTCTGCATCGGGGGAGCCTGCCGCTG	2399
QUERY:	2424	TGAAGAGGGCTGGACAGGCGCAGCGTGTGACCAGCGCGTGTGCCACCCCCGCTGCATTGA	2483
		||||||||||||||||||||| || |||||||||||||||||||||||||||||||||||
SBJCT:	2400	TGAAGAGGGCTGGACAGGCGCGGCTTGTGACCAGCGCGTGTGCCACCCCCGCTGCATTGA	2459
QUERY:	2484	GCACGGGACCTGTAAAGATGGCAAATGTGAATGCCGAGAGGGCTGGAATGGTGAACACTG	2543
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2460	GCACGGGACCTGTAAAGATGGCAAATGTGAATGCCGAGAGGGCTGGAATGGTGAACACTG	2519
QUERY:	2544	CACCATTG 2551
		||||||||
SBJCT:	2520	CACCATTG 2527

[0105] In this search it was also found that the FCTR3bcd and e nucleic acid had homology to six fragments of Gallus gallus partial mRNA for teneurin-2. It has 2780 of 3449 bases (80%) identical to bases 3386-6834, 1553 of 1862 bases (83%) identical to bases 1414-3275, 540 of 628 bases (85%) identical to bases 587-1214, 593 of 725 bases (81%) identical to bases 7084-7808, 429 of 515 bases (83%) identical to bases 7895-8409, and 397 of 475 bases (83%) identical to bases 20-494 of Gallus gallus partial mRNA for teneurin-2. (EMBL Acc: GGA278031) (Table 3O).

TABLE 30
BLASTN of FCTR3b,c,d, and e against Gallus gallus Teneurin-2 mRNA
(SEQ ID NO:67)
>GI|10241573|EMB|AJ279031.1|GGA279031 GALLUS GALLUS PARTIAL MRNA FOR
TENEURIN-2 (TEN2 GENE), LONG SPLICE
VARIANT
LENGTH = 8409
SCORE = 1532 BITS (773), EXPECT = 0.0
IDENTITIES = 2780/3449 (80%)
STRAND = PLUS/PLUS
QUERY:	3458	TGATGGTGGCTGTCGAGGGGCATCTCTTCCAGAAGTCATTCCAGGCTTCTCCCAACCTGG	3517
		||||||| || || || |||||||| || || || ||||| | ||| ||||||||| |||
SBJCT:	3386	TGATGGTAGCAGTAGAAGGGCATCTATTTCAAAAATCATTTCTGGCATCTCCCAACTTGG	3445
QUERY:	3518	CCTCCACCTTCATCTGGGACAAGACAGATGCGTATGGCCAAAGGGTGTATGGACTCTCAG	3577
		| |  || |||||||||||||| |||||||| ||||| || ||| |||||  | ||||
SBJCT:	3446	CTTATACATTCATCTGGGACAAAACAGATGCATATGGTCAGAAGGTTTATGGGTTGTCAG	3505
QUERY:	3578	ATGCTGTTGTGTCTGTCGGGTTTGAATATGAGACCTGTCCCAGTCTAATTCTCTGGGAGA	3637
		||||||| || ||||| || |||||||||||||| ||||||||| | ||||| |||||||
SBJCT:	3506	ATGCTGTAGTTTCTGTGGGTTTTGAATATGAGACTTGTCCCAGTTTGATTCTGTGGGAGA	3565
QUERY:	3638	AAAGGACAGCCCTCCTTCAGGGATTCGAGCTGGACCCCTCCAACCTCGGTGGCTGGTCCC	3697
		||||||| || || || || ||||| ||||| || || ||||| || || || |||||
SBJCT:	3566	AAAGGACTGCGCTGCTGCAAGGATTTGAGCTAGATCCTTCCAATCTAGGAGGATGGTCTT	3625
QUERY:	3698	TAGACAAACACCACATCCTCAATGTTAAAAGTGGAATCCTACACAAAGGCACTGGGGAAA	3757
		| || ||||| ||  | || ||||| || ||||| ||  | |||||||||| ||| ||||
SBJCT:	3626	TGGATAAACATCATGTACTGAATGTCAAGAGTGGTATATTGCACAAAGGCAATGGAGAAA	3685
QUERY:	3758	ACCAGTTCCTGACCCAGCAGCCTGCCATCATCACCAGCATCATGGGCAATGGTCGCCGCC	3817
		| ||||| || || |||||||| ||  | || |||||||| ||||| ||||| |||||
SBJCT:	3686	ATCAGTTTCTAACTCAGCAGCCAGCTGTGATAACCAGCATTATGGGGAATGGGCGCCGAA	3745
QUERY:	3818	GGAGCATTTCCTGTCCCAGCTGCAACGGCCTTGCTGAAGGCAACAAGCTGCTGGCCCCAG	3877
		| ||||| |||||||| ||||| || || ||||| | ||| || |||||  ||||||| |
SBJCT:	3746	GAAGCATATCCTGTCCTAGCTGCAATGGTCTTGCAGAAGGAAATAAGCTTTTGGCCCCTG	3805
QUERY:	3878	TGGCTCTGGCTGTTGGAATCGATGGGAGCCTCTATGTGGGTGACTTCAATTACATCCGAC	3937
		| || ||||| || ||||| ||||| ||||||| ||| || || || |||||||| || |
SBJCT:	3806	TAGCACTGGCAGTGGGAATTGATGGAAGCCTCTTTGTTGGAGATTTTAATTACATTCGGC	3865
QUERY:	3938	GCATCTTTCCCTCTCGAAATGTGACCAGCATCTTGGAGTTACGAAATAAAGAGTTTAAAC	3997
		| ||||| || ||  | |||||||| ||||| |||||| |  ||||||||||||||||||
SBJCT:	3866	GTATCTTCCCATCCAGGAATGTGACTAGCATATTGGAGCTGAGAAATAAAGAGTTTAAAC	3925
QUERY:	3998	ATAGCAACAACCCAGCACACAAGTACTACTTGGCAGTGGACCCCGTGTCCGGCTCGCTCT	4057
		|||||||||| || || ||||| |||||  |||| ||||||||||| || ||||| || |
SBJCT:	3926	ATAGCAACAATCCTGCTCACAAATACTATCTGGCCGTGGACCCCGTTTCGGGCTCCCTGT	3985
QUERY:	4058	ACGTGTCCGACACCAACAGCAGGAGAATCTACCGCGTCAAGTCTCTGAGTGGAACCAAAG	4117
		|||| || |||||||||||| |  | || |||   ||||| ||||| | ||| || ||||
SBJCT:	3986	ACGTATCAGACACCAACAGCCGACGGATATACAAAGTCAAATCTCTTACTGGCACGAAAG	4045
QUERY:	4118	ACCTGGCTGGGAATTCGGAAGTTGTGGCAGGGACGGGAGAGCAGTGTCTACCCTTTGATG	4177
		|||||||||| ||||| ||||| || || ||||| |||||||| || || ||||||||||
SBJCT:	4046	ACCTGGCTGGTAATTCTGAAGTGGTAGCGGGGACTGGAGAGCAATGCCTGCCCTTTGATG	4105
QUERY:	4178	AAGCCCGCTGCGGGGATGGAGGGAAGGCCATAGATGCAACCCTGATGAGCCCGAGAGGTA	4237
		||||| | || || ||||||||||| ||  | || |||||||| ||||| ||  |||| |
SBJCT:	4106	AAGCCAGATGTGGAGATGGAGGGAAAGCAGTGGACGCAACCCTAATGAGTCCTCGAGGAA	4165
QUERY:	4238	TTGCAGTAGACAAGAATGGGCTCATGTACTTTGTCGATGCCACCATGATCCGGAAGGTTG	4297
		||||||| || ||| |||| |||||||| ||||| |||||||| ||||| || || || |
SBJCT:	4166	TTGCAGTGGATAAGTATGGACTCATGTATTTTGTTGATGCCACTATGATTCGAAAAGTGG	4225
QUERY:	4298	ACCAGAATGGAATCATCTCCACCCTGCTGGGCTCCAATGACCTCACTGCCGTCCGGCCGC	4357
		| ||||||||||| || || || |||||||||||||||||||| ||||||||||| || |
SBJCT:	4226	ATCAGAATGGAATTATATCAACTCTGCTGGGCTCCAATGACCTAACTGCCGTCCGACCTC	4285
QUERY:	4358	TGAGCTGTGATTCCAGCATGGATGTAGCCCAGGTTCGTCTGGAGTGGCCAACAGACCTTG	4417
		| |||||||||||||||||||||||   |||||| || ||||||||||| || || || |
SBJCT:	4286	TAAGCTGTGATTCCAGCATGGATGTCAGCCAGGTACGGCTGGAGTGGCCTACTGATCTCG	4345
QUERY:	4418	CTGTCAATCCCATGGATAACTCCTTGTATGTTCTAGAGAACAATGTCATCCTTCGAATCA	4477
		||||| |||||||||| |||||  | ||||| |||||||||||||| ||  | || ||||
SBJCT:	4346	CTGTCGATCCCATGGACAACTCACTTTATGTCCTAGAGAACAATGTTATTTTACGGATCA	4405
QUERY:	4478	CCGAGAACCACCAAGTCAGCATCATTGCGGGACGCCCCATGCACTGCCAAGTTCCTGGCA	4537
		| || ||||| ||||| ||||| ||||| |||||||||||||||||||| |||||||| |
SBJCT:	4406	CAGAAAACCATCAAGTTAGCATTATTGCTGGACGCCCCATGCACTGCCAGGTTCCTGGTA	4465
QUERY:	4538	TTGACTACTCACTCAGCAAACTAGCCATTCACTCTGCCCTGGAGTCAGCCAGTGCCATTG	4597
		| |||||||| || |||||||| || ||||| || || || || ||||||||||||||||
SBJCT:	4466	TAGACTACTCTCTTAGCAAACTGGCTATTCATTCCGCACTTGAATCAGCCAGTGCCATTG	4525
QUERY:	4598	CCATTTCTCACACTGGGGTCCTCTACATCACTGAGACAGATGAGAAGAAGATTAACCGTC	4657
		|||| || ||||| || || || ||||||| |||||||||||| || || ||||| || |
SBJCT:	4526	CCATCTCACACACAGGAGTTCTTTACATCAGTGAGACAGATGAAAAAAAAATTAATCGGC	4585
QUERY:	4658	TACGCCAGGTAACAACCAACGGGGAGATCTGCCTTTTAGCTGGGGCAGCCTCGGACTGCG	4717
		||||||||||||| ||||| || || || |||||| | || |||||||| || ||||| |
SBJCT:	4586	TACGCCAGGTAACTACCAATGGAGAAATATGCCTTCTTGCAGGGGCAGCTTCAGACTGTG	4645
QUERY:	4718	ACTGCAAAAACGATGTCAATTGCAACTGCTATTCAGGAGATGATGCCTACGCGACTGATG	4777
		| |||||||| |||||||| || || |||||||| || |||||||  || || |||||||
SBJCT:	4646	ATTGCAAAAATGATGTCAACTGTAATTGCTATTCTGGGGATGATGGGTATGCCACTGATG	4705
QUERY:	4778	CCATCTTGAATTCCCCATCATCCTTAGCTGTAGCTCCAGATGGTACCATTTACATTGCAG	4837
		||||||| ||||| ||||| ||||||||||| || |||||||||||||| ||||| || |
SBJCT:	4706	CCATCTTAAATTCACCATCTTCCTTAGCTGTGGCCCCAGATGGTACCATCTACATAGCTG	4765
QUERY:	4838	ACCTTGGAAATATTCGGATCAGGGCGGTCAGCAAGAACAAGCCTGTTCTTAATGCCTTCA	4897
		| || |||||||| || || ||||| ||||| || |||| |||  |||||||| | || |
SBJCT:	4766	ATCTCGGAAATATCCGCATTAGGGCTGTCAGTAAAAACAGGCCCATTCTTAATTCTTTTA	4825
QUERY:	4898	ACCAGTATGAGGCTGCATCCCCCGGAGAGCAGGAGTTATATGTTTTCAACGCTGATGGCA	4957
		|||| ||||| |||||||| || ||||| |||||| | ||||| ||||| |||||||| |
SBJCT:	4826	ACCAATATGAAGCTGCATCTCCAGGAGAACAGGAGCTGTATGTCTTCAATGCTGATGGGA	4885
QUERY:	4958	TCCACCAATACACTGTGAGCCTGGTGACAGGGGAGTACTTGTACAATTTCACATATAGTA	5017
		| ||||| |||||| | ||||| || || ||||||||||||||||||||||| ||||| |
SBJCT:	4886	TTCACCAGTACACTCTCAGCCTTGTTACCGGGGAGTACTTGTACAATTTCACCTATAGCA	4945
QUERY:	5018	CTGACAATGATGTCACTGAATTGATTGACAATAATGGGAATTCCCTGAAGATCCGTCGGG	5077
		||| || |||||||| ||  |||| ||||  ||||| || ||| ||||| |||||||||
SBJCT:	4946	GTGATAACGATGTCACCGAGGTGATGGACAGCAATGGCAACTCCTTGAAGGTCCGTCGGG	5005
QUERY:	5078	ACAGCAGTGGCATGCCCCGTCACCTGCTCATGCCTGACAACCAGATCATCACCCTCACCG	5137
		|   ||| || |||||||| ||  | || |||||||| || |||||  |||| ||  |||
SBJCT:	5006	ATGCCAGCGGAATGCCCCGCCATTTACTGATGCCTGATAATCAGATTGTCACGCTGGCCG	5065
QUERY:	5138	TGGGCACCAATGGAGGCCTCAAAGTCGTGTCCACACAGAACCTGGAGCTTGGTCTCATGA	5197
		| ||||| ||||| || |||||| | || || || |||| |||||| |||||  | ||||
SBJCT:	5066	TTGGCACTAATGGTGGACTCAAACTAGTCTCAACGCAGACCCTGGAACTTGGATTAATGA	5125
QUERY:	5198	CCTATGATGGCAACACTGGGCTCCTGGCCACCAAGAGCGATGAAACAGGATGGACGACTT	5257
		| ||| | || |||| ||| ||| | || || ||||| ||||||||||||||||| || |
SBJCT:	5126	CTTATAACGGAAACAGTGGTCTCTTAGCAACGAAGAGTGATGAAACAGGATGGACAACAT	5185
QUERY:	5258	TCTATGACTATGACCACGAAGGCCGCCTGACCAACGTGACGCGCCCCACGGGGGTGGTAA	5317
		| ||||||||||| || ||||| ||||||||||| || || || ||||| || |||||||
SBJCT:	5186	TTTATGACTATGATCATGAAGGGCGCCTGACCAATGTAACACGTCCCACTGGAGTGGTAA	5245
QUERY:	5318	CCAGTCTGCACCGGGAAATGGAGAAATCTATTACCATTGACATTGAGAACTCCAACCGTG	5377
		| || || || || |||||||| || ||||||||||| ||||||||||| || || || |
SBJCT:	5246	CTAGCCTTCATCGAGAAATGGAAAAGTCTATTACCATCGACATTGAGAATTCTAATCGGG	5305
QUERY:	5378	ATGATGACGTCACTGTCATCACCAACCTCTCTTCAGTAGAGGCCTCCTACACAGTGGTAC	5437
		||||||| ||||| |||||||| || ||||| || || ||||| ||||| ||||| || |
SBJCT:	5306	ATGATGATGTCACGGTCATCACAAATCTCTCCTCTGTGGAGGCTTCCTATACAGTTGTTC	5365
QUERY:	5438	AAGATCAAGTTCGGAACAGCTACCAGCTCTGTAATAATGGTACCCTGAGGGTGATGTATG	5497
		||||||||||  |||||||||||||||||||||||||||||||  |||| ||||||||||
SBJCT:	5366	AAGATCAAGTGAGGAACAGCTACCAGCTCTGTAATAATGGTACTTTGAGAGTGATGTATG	5425
QUERY:	5498	CTAATGGGATGGGTATCAGCTTCCACAGCGAGCCCCATGTCCTAGCGGGCACCATCACCC	5557
		| ||||| ||| |||| ||||| |||||||| || |||||||| || || ||  | || |
SBJCT:	5426	CCAATGGCATGAGTATTAGCTTTCACAGCGAACCTCATGTCCTGGCTGGGACAGTAACTC	5485
QUERY:	5558	CCACCATTGGACGCTGCAACATCTCCCTGCCTATGGAGAATGGCTTAAACTCCATTGAGT	5617
		||||||| ||||| || || || || || || ||||||||||| || ||||| ||||| |
SBJCT:	5486	CCACCATAGGACGATGTAATATTTCTCTACCAATGGAGAATGGTTTGAACTCAATTGAAT	5545
QUERY:	5618	GGCGCCTAAGAAAGGAACAGATTAAAGGCAAAGTCACCATCTTTGGCAGGAAGCTCCGGG	5677
		|||| || || || |||||||||||||||||||| ||  | ||||| || |||||| |||
SBJCT:	5546	GGCGTCTGAGGAAAGAACAGATTAAAGGCAAAGTGACTGTGTTTGGAAGAAAGCTCAGGG	5605
QUERY:	5678	TCCATGGAAGAAATCTCTTGTCCATTGACTATGATCGAAATATTCGGACTGAAAAGATCT	5737
		| |||||||| ||| |  |||||||||| || || || ||||| || || ||||| ||||
SBJCT:	5606	TTCATGGAAGGAATTTGCTGTCCATTGATTACGACCGGAATATACGCACAGAAAAAATCT	5665
QUERY:	5738	ATGATGACCACCGGAAGTTCACCCTGAGGATCATTTATGACCAGGTGGGCCGCCCCTTCC	5797
		| ||||| ||||| ||||||||||||||||| ||||| || ||| |||| || |||||||
SBJCT:	5666	ACGATGATCACCGCAAGTTCACCCTGAGGATAATTTACGATCAGCTGGGACGGCCCTTCC	5725
QUERY:	5798	TCTGGCTGCCCAGCAGCGGGCTGGCAGCTGTCAACGTGTCATACTTCTTCAATGGGCGCC	5857
		||||||||||||||||||| ||||| || ||||||||||| || |||||||| |||||||
SBJCT:	5726	TCTGGCTGCCCAGCAGCGGCCTGGCTGCCGTCAACGTGTCCTATTTCTTCAACGGGCGCC	5785
QUERY:	5858	TGGCTGGGCTTCAGCGTGGGGCCATGAGCGAGAGGACAGACATCGACAAGCAAGGCCGCA	5917
		|||||||||||||||| || ||||||||||| |||||||||||||||||||||||| | |
SBJCT:	5786	TGGCTGGGCTTCAGCGCGGAGCCATGAGCGAAAGGACAGACATCGACAAGCAAGGCAGGA	5845
QUERY:	5918	TCGTGTCCCGCATGTTCGCTGACGGGAAAGTGTGGAGCTACTCCTACCTTGACAAGTCCA	5977
		|| | || |||||||| || || ||||| || ||||| ||| ||||||| || || ||||
SBJCT:	5846	TCATATCGCGCATGTTTGCAGATGGGAAGGTTTGGAGTTACACCTACCTAGAAAAATCCA	5905
QUERY:	5978	TGGTCCTCCTGCTTCAGAGCCAACGTCAGTATATATTTGAGTATGACTCCTCTGACCGCC	6037
		|||| || |||||||||||||| || ||||| || ||||||||||| || || ||||| |
SBJCT:	5906	TGGTACTACTGCTTCAGAGCCAGCGGCAGTACATCTTTGAGTATGATTCTTCAGACCGGC	5965
QUERY:	6038	TCCTTGCCGTCACCATGCCCAGCGTGGCCCGGCACAGCATGTCCACACACACCTCCATCG	6097
		||| ||| || || ||||| || || || ||||| |||||||| || ||||| ||  | |
SBJCT:	5966	TCCATGCTGTTACTATGCCTAGTGTTGCTCGGCATAGCATGTCAACTCACACGTCTGTTG	6025
QUERY:	6098	GCTACATCCGTAATATTTACAACCCGCCTGAAAGCAATGCTTCGGTCATCTTTGACTACA	6157
		|||||||  | |||||||| || || ||||||||||| || || || || ||||| ||||
SRJCT:	6026	GCTACATTAGGAATATTTATAATCCTCCTGAAAGCAACGCATCAGTGATTTTTGATTACA	6085
QUERY:	6158	GTGATGACGGCCGCATCCTGAAGACCTCCTTTTTGGGCACCGGACGCCAGGTGTTCTACA	6217
		||||||| ||  | ||  |||| || || ||||| || || || || || || || ||||
SBJCT:	6086	GTGATGATGGGAGGATTTTGAAAACATCATTTTTAGGTACTGGTCGACAAGTCTTTTACA	6145
QUERY:	6218	AGTATGGGAAACTCTCCAAGTTATCAGAGATTGTCTACGACAGTACCGCCGTCACCTTCG	6277
		||||||| || || ||||| ||||| || ||||| || |||||||| || || || || |
SBJCT:	6146	AGTATGGAAAGCTATCCAAATTATCTGAAATTGTTTATGACAGTACTGCGGTTACTTTTG	6205
QUERY:	6278	GGTATGACGAGACCACTGGTGTCTTGAAGATGGTCAACCTCCAAAGTGGGGGCTTCTCCT	6337
		| ||||| || || || |||||| | || ||||| ||  | |||||||| || || || |
SBJCT:	6206	GATATGATGAAACTACAGGTGTCCTAAAAATGGTGAATTTGCAAAGTGGAGGATTTTCTT	6265
QUERY:	6338	GCACCATCAGGTACCGGAAGATTGGCCCCCTGGTGGACAAGCAGATCTACAGGTTCTCCG	6397
		| || ||| | || || || |||||||| || || ||||| || |||||||| ||||| |
SBJCT:	6266	GTACAATCCGCTATCGTAAAATTGGCCCTCTTGTTGACAAACAAATCTACAGATTCTCTG	6325
QUERY:	6398	AGGAAGGCATGGTCAATGCCAGGTTTGACTACACCTATCATGACAACAGCTTCCGCATCG	6457
		| ||||| ||||||||||| |||||||| || || ||||| ||||| || || ||||| |
SBJCT:	6326	AAGAAGGTATGGTCAATGCAAGGTTTGATTATACATATCACGACAATAGTTTTCGCATTG	6385
QUERY:	6458	CAAGCATCAAGCCCGTCATAAGTGAGACTCCCCTCCCCGTTGACCTCTACCGCTATGATG	6517
		|||||||||| ||| |||||||||||||||| || || ||||| || ||||| |||||||
SBJCT:	6386	CAAGCATCAAACCCATCATAAGTGAGACTCCTCTTCCAGTTGATCTTTACCGTTATGATG	6445
QUERY:	6518	AGATTTCTGGCAAGGTGGAACACTTTGGTAAGTTTGGAGTCATCTATTATGACATCAACC	6577
		||||||||||||| || || || ||||| || |||||||| || |||||||| || || |
SBJCT:	6446	AGATTTCTGGCAAAGTTGAGCATTTTGGCAAATTTGGAGTTATTTATTATGATATAAATC	6505
QUERY:	6578	AGATCATCACCACTGCCGTGATGACCCTCAGCAAACACTTCGACACCCATGGGCGGATCA	6637
		| || || || || || || ||||| || || || ||||| || ||||| || || || |
SBJCT:	6506	AAATTATTACTACAGCAGTTATGACACTGAGTAAGCACTTTGATACCCACGGACGCATTA	6565
QUERY:	6638	AGGAGGTCCAGTATGAGATGTTCCGGTCCCTCATGTACTGGATGACGGTGCAATATGACA	6697
		| || || || |||||||||||||| ||||| |||||||||||||| |||||||||||||
SBJCT:	6566	AAGAAGTTCAATATGAGATGTTCCGATCCCTGATGTACTGGATGACTGTGCAATATGACA	6625
QUERY:	6698	GCATGGGCAGGGTGATCAAGAGGGAGCTAAAACTGGGGCCCTATGCCAATACCACGAAGT	6757
		||||||| || || |  || || || || ||||| ||||| |||||||| || || ||||
SBJCT:	6626	GCATGGGAAGAGTAACTAAAAGAGAACTGAAACTTGGGCCGTATGCCAACACAACCAAGT	6685
QUERY:	6758	ACACCTATGACTACGATGGGGACGGGCAGCTCCAGAGCGTGGCCGTCAATGACCGCCCGA	6817
		| |||||||| || ||||| || |||||  | || ||||| || || |||||  | || |
SBJCT:	6686	ATACCTATGATTATGATGGAGATGGGCAATTGCAAAGCGTAGCAGTAAATGATAGGCCTA	6745
QUERY:	6818	CCTGGCGCTACAGCTATGACCTTAATGGGAATCTCCACTTACTGAACCCAGGCAACAGTG	6877
		||||||| ||||| |||||||| ||||| ||||| ||| | ||||| || || |||||||
SBJCT:	6746	CCTGGCGTTACAGTTATGACCTGAATGGAAATCTTCACCTCCTGAATCCTGGAAACAGTG	6805
QUERY:	6878	TGCGCCTCATGCCCTTGCGCTATGACCTC 6906
		| ||  | |||||| ||||||| ||||||
SBJCT:	6806	TTCGATTGATGCCCCTGCGCTACGACCTC 6834
SCORE = 1241 BITS (626), EXPECT = 0.0
IDENTITIES = 1553/1862 (83%)
STRAND = PLUS/PLUS
QUERY:	1486	AGCAGCATAGACAGTGGTGAAGCAGAAGTTGGTCGGCGGGTAACACAAGAAGTCCCACCA	1545
		||||||||||| ||||| ||| |||||||||| ||   ||| || ||||| || || ||
SBJCT:	1414	AGCAGCATAGATAGTGGAGAAACAGAAGTTGGCCGCAAGGTCACCCAAGAGGTGCCCCCT	1473
QUERY:	1546	GGGGTGTTTTGGAGGTCACAAATTCACATCAGTCAGCCCCAGTTCTTAAAGTTCAACATC	1605
		|| ||||| ||| |||| || || || ||||| ||||| |||||| | |||||||||||
SBJCT:	1474	GGAGTGTTCTGGCGGTCTCAGATCCATATCAGCCAGCCACAGTTCCTGAAGTTCAACATA	1533
QUERY:	1606	TCCCTCGGGAAGGACGCTCTCTTTGGTGTTTACATAAGAAGAGGACTTCCACCATCTCAT	1665
		||||| |||||||| ||||| || |||||||| |||||||||||||| |||||||| |||
SBJCT:	1534	TCCCTAGGGAAGGATGCTCTTTTCGGTGTTTATATAAGAAGAGGACTCCCACCATCACAT	1593
QUERY:	1666	GCCCAGTATGACTTCATGGAACGTCTGGACGGGAAGGAGAAGTGGAGTGTGGTTGAGTCT	1725
		|| |||||||| |||||||||||  |||| ||||| ||||| ||||||||||| || ||
SBJCT:	1594	GCACAGTATQATTTCATGGAACGCTTGGATGGGAAAGAGAAATGGAGTGTGGTGGAATCC	1653
QUERY:	1726	CCCAGGGAACGCCGGAGCATACAGACCTTGGTTCAGAATGAAGCCGTGTTTGTGCAGTAC	1785
		||  ||||||| || || || |||||  | ||||||||||| || |||||||| ||||||
SBJCT:	1654	CCACGGGAACGGCGAAGTATTCAGACTCTTGTTCAGAATGAGGCTGTGTTTGTTCAGTAC	1713
QUERY:	1786	CTGGATGTGGGCCTGTGGCATCTGGCCTTCTACAATGATGGAAAAGACAAAGAGATGGTT	1845
		||||||||||  ||||||| ||||| || ||||||||||| || ||||||||  ||||
SBJCT:	1714	TTGGATGTGGGTTTGTGGCACCTGGCGTTTTACAATGATGGCAAGGACAAAGAAGTGGTC	1773
QUERY:	1846	TCCTTCAATACTGTTGTCCTAGATTCAGTGCAGGACTGTCCACGTAACTGCCATGGGAAT	1905
		||||||| ||| ||| |  | ||||||||||| |||||||||||||| || ||||| |||
SBJCT:	1774	TCCTTCAGTACAGTTATTTTGGATTCAGTGCAAGACTGTCCACGTAATTGTCATGGCAAT	1833
QUERY:	1906	GGTGAATGTGTGTCCGGGGTGTGTCACTGTTTCCCAGGATTTCTAGGAGCAGACTGTGCT	1965
		|| || ||||| || || || || |||||||| || |||||||  |||||||| ||||||
SBJCT:	1834	GGCGAGTGTGTTTCTGGTGTCTGCCACTGTTTTCCCGGATTTCATGGAGCAGATTGTGCT	1893
QUERY:	1966	AAAGCTGCCTGCCCTGTCCTGTGCAGTGGGAATGGACAATATTCTAAAGGGACGTGCCAG	2025
		|||||||||||||| || ||||||||||| ||||| || || || ||||| || |||  |
SBJCT:	1894	AAAGCTGCCTGCCCGGTGCTGTGCAGTGGCAATGGTCAGTACTCCAAAGGAACCTGCTTG	1953
QUERY:	2026	TGCTACAGCGGCTGGAAAGGTGCAGAGTGCGACGTGCCCATGAATCAGTGCATCGATCCT	2085
		|||||||| |||||||||||| | || || || || ||||| |  ||||| || |||||
SBJCT:	1954	TGCTACAGTGGCTGGAAAGGTCCGGAATGTGATGTACCCATCAGCCAGTGTATTGATCCC	2013
QUERY:	2086	TCCTGCGGGGGCCACGGCTCCTGCATTGATGGGAACTGTGTCTGCTCTGCTGGCTACAAA	2145
		|| || || || || || |||||||| || |||||||||||||| ||   |||||| |||
SBJCT:	2014	TCGTGTGGAGGTCATGGTTCCTGCATCGAAGGGAACTGTGTCTGTTCCATTGGCTATAAA	2073
QUERY:	2146	GGCGAGCACTGTGAGGAAGTTGATTGCTTGGATCCCACCTGCTCCAGCCACGGAGTCTGT	2205
		|| ||  |||||||||||||||||||||| ||||| || |||||||  ||||| ||||||
SBJCT:	2074	GGAGAAAACTGTGAGGAAGTTGATTGCTTAGATCCAACATGCTCCAATCACGGGGTCTGT	2133
QUERY:	2206	GTGAATGGAGAATGCCTGTGCAGCCCTGGCTGGGGTGGTCTGAACTGTGAGCTGGCGAGG	2265
		||||| |||||||| || |||||||| |||||||||||  | |||||||||||  | ||
SBJCT:	2134	GTGAACGGAGAATGTCTCTGCAGCCCAGGCTGGGGTGGAATAAACTGTGAGCTTCCCAGA	2193
QUERY:	2266	GTCCAGTGCCCAGACCAGTGCAGTGGGCATGGCACGTACCTGCCTGACACGGGCCTCTGC	2325
		| ||||||||||||||||||||||||||||||||| |||||| ||||||| || |||||
SBJCT:	2194	GCCCAGTGCCCAGACCAGTGCAGTGGGCATGGCACATACCTGTCTGACACCGGTCTCTGT	2253
QUERY:	2326	AGCTGCGATCCCAACTGGATGGGTCCCGACTGCTCTGTTGAAGTGTGCTCAGTAGACTGT	2385
		||||||||||||||||||||||||||||||||||| |||||||||||||| |||||||||
SBJCT:	2254	AGCTGCGATCCCAACTGGATGGGTCCCGACTGCTCCGTTGAAGTGTGCTCTGTAGACTGT	2313
QUERY:	2386	GGCACTCACGGCGTCTGCATCGGGGGAGCCTGCCGCTGTGAAGAGGGCTGGACAGGCGCA	2445
		||||| || || || ||||| || ||||| || ||||||||||| || |||||||| |
SBJCT:	2314	GGCACCCATGGGGTGTGCATTGGCGGAGCGTGTCGCTGTGAAGAAGGGTGGACAGGAGTG	2373
QUERY:	2446	GCGTGTGACCAGCGCGTGTGCCACCCCCGCTGCATTGAGCACGGGACCTGTAAAGATGGC	2505
		|||||||||||||| ||||| || ||||| || |  |||||||| || |||||||||||
SBJCT:	2374	GCGTGTGACCAGCGTGTGTGTCATCCCCGGTGTACAGAGCACGGAACTTGTAAAGATGGG	2433
QUERY:	2506	AAATGTGAATGCCGAGAGGGCTGGAATGGTGAACACTGCACCATTGGTAGGCAAACGGCA	2565
		|||||||||||| |||||||||||||||| || |||||||||||||||||||||||| ||
SBJCT:	2434	AAATGTGAATGCAGAGAGGGCTGGAATGGGGAGCACTGCACCATTGGTAGGCAAACGACA	2493
QUERY:	2566	GGCACCGAAACAGATGGCTGCCCTGACTTGTGCAACGGTAACGGGAGATGCACACTGGGT	2625
		||||||||||||||||||||||||||||||||||| || |||||||| ||||| |||||
SBJCT:	2494	GGCACCGAAACAGATGGCTGCCCTGACTTGTGCAATGGCAACGGGAGGTGCACGCTGGGC	2553
QUERY:	2626	CAGAACAGCTGGCAGTGTGTCTGCCAGACCGGCTGGAGAGGGCCCGGATGCAACGTTGCC	2685
		|||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||
SBJCT:	2554	CAGAACAGCTGGCAGTGTGTCTGCCAGACCGGCTGGAGAGGGCCTGGATGCAACGTTGCC	2613
QUERY:	2686	ATGGAAACTTCCTGTGCTGATAACAAGGATAATGAGGGAGATGGCCTGGTGGATTGTTTG	2745
		|||||||| |||||||| |||||||||||||| |||||||||||| |||| || ||  |
SBJCT:	2614	ATGGAAACCTCCTGTGCCGATAACAAGGATAACGAGGGAGATGGCTTGGTTGACTGCCTA	2673
QUERY:	2746	GACCCTGACTGCTGCCTGCAGTCAGCCTGTCAGAACAGCCTGCTCTGCCGGGGGTCCCGG	2805
		| ||| || |||||||| |||||  | ||||| ||||||||||| |||||||| |||||
SBJCT:	2674	GTCCCAGATTGCTGCCTCCAGTCCACTTGTCAAAACAGCCTGCTGTGCCGGGGTTCCCGC	2733
QUERY:	2806	GACCCACTGGACATCATTCAGCAGGGCCAGACGGATTGGCCCGCAGTGAAGTCCTTCTAT	2865
		|| || || |||||||| || ||| ||||  | | ||  || || |||||||| ||||||
SBJCT:	2734	GATCCTCTTGACATCATACAACAGAGCCATTCTGGTTCACCAGCTGTGAAGTCATTCTAT	2793
QUERY:	2866	GACCGTATCAAGCTCTTGGCAGGCAAGGATAGCACCCACATCATTCCTGGAGAGAACCCT	2925
		|| || ||||||||||| |  || ||||| ||||| || |||||||| ||||| || ||
SBJCT:	2794	GATCGAATCAAGCTCTTAGTGGGGAAGGACAGCACTCATATCATTCCAGGAGAAAATCCC	2853
QUERY:	2926	TTCAACAGCAGCTTGGTTTCTCTCATCCGAGGCCAAGTAGTAACTACAGATGGAACTCCC	2985
		|||||||||||| | || ||||| ||  |||||||||| || |||||||||||||| ||
SBJCT:	2854	TTCAACAGCAGCCTTGTGTCTCTTATAAGAGGCCAAGTGGTGACTACAGATGGAACGCCT	2913
QUERY:	2986	CTGGTCGGTGTGAACGTGTCTTTTGTCAAGTACCCAAAATACGGCTACACCATCACCCGC	3045
		|| || || || |||||||| ||||||||||| ||||| || ||||| |||||||| ||
SBJCT:	2914	CTAGTTGGGGTCAACGTGTCATTTGTCAAGTATCCAAAGTATGGCTATACCATCACTCGT	2973
QUERY:	3046	CAGGATGGCACGTTCGACCTGATCGCAAATGGAGGTGCTTCCTTGACTCTACACTTTGAG	3105
		|||||||||| ||| ||| || | || || || ||  | ||| | ||| | ||||||||
SBJCT:	2974	CAGGATGGCATGTTTGACTTGGTTGCTAACGGTGGATCATCCCTAACTTTGCACTTTGAA	3033
QUERY:	3106	CGAGCCCCGTTCATGAGCCAGGAGCGCACTGTGTGGCTGCCGTGGAACAGCTTTTACGCC	3165
		|| ||||| || ||||| |||||  | || || |||||||||||||||||||| || |||
SBJCT:	3034	CGGGCCCCATTTATGAGTCAGGAAAGGACAGTATGGCTGCCGTGGAACAGCTTCTATGCC	3093
QUERY:	3166	ATGGACACCCTGGTGATGAAGACCGAGGAGAACTCCATCCCCAGCTGTGACCTCAGTGGC	3225
		|||||||| || || ||||| || |||||||||||||| ||||||||||| |||||||||
SBJCT:	3094	ATGGACACGCTTGTAATGAAAACAGAGGAGAACTCCATTCCCAGCTGTGATCTCAGTGGC	3153
QUERY:	3226	TTTGTCCGGCCTGATCCAATCATCATCTCCTCCCCACTGTCCACCTTCTTTAGTGCTGCC	3285
		|||||| | ||||||||| ||||||| || || |||||||| || ||||| |||| |||
SBJCT:	3154	TTTGTCAGACCTGATCCAGTCATCATTTCATCACCACTGTCAACTTTCTTCAGTGATGCT	3213
QUERY:	3286	CCTGGGCAGAATCCCATCGTGCCTGAGACCCAGGTTCTTCATGAAGAAATCGAGCTCCCT	3345
		||||| |  ||||| || || || || ||||||||||||||||||||||| ||| |||||
SBJCT:	3214	CCTGGCCGAAATCCTATTGTACCAGAAACCCAGGTTCTTCATGAAGAAATTGAGGTCCCT	3273
QUERY:	3346	GG 3347
		||
SBJCT:	3274	GG 3275
SCORE = 547 BITS (276), EXPECT = E − 152
IDENTITIES = 540/628 (85%)
STRAND = PLUS/PLUS
QUERY:	782	GTCGTCCCATTCCACCTACATCCTCGCCTAGTCTCCTCCCATCTGCTCAGCTGCCTAGCT	841
		|||||||||||||||||||||||||| |||| || |||||||||||||||||||| || |
SBJCT:	587	GTCGTCCCATTCCACCTACATCCTCGTCTAGCCTTCTCCCATCTGCTCAGCTGCCCAGTT	646
QUERY:	842	CCCATAATCCTCCACCAGTTAGCTGCCAGATGCCATTGCTAGACAGCAACACCTCCCATC	901
		| ||||||||||||||||||||||||||||||||||||||||||||||| || |||||||
SBJCT:	647	CTCATAATCCTCCACCAGTTAGCTGCCAGATGCCATTGCTAGACAGCAATACGTCCCATC	706
QUERY:	902	AAATCATGGACACCAACCCTGATGAGGAATTCTCCCCCAATTCATACCTGCTCAGAGCAT	961
		|||||||||||||||| ||||| ||||| ||||| || ||||||||||| || |||||||
SBJCT:	707	AAATCATGGACACCAATCCTGACGAGGAGTTCTCTCCTAATTCATACCTACTAAGAGCAT	766
QUERY:	962	GCTCAGGGCCCCAGCAAGCCTCCAGCAGTGGCCCTCCGAACCACCACAGCCAGTCGACTC	1021
		| |||||||| ||||| || ||||||||||||||| | ||||| ||||||||||| || |
SBJCT:	767	GTTCAGGGCCACAGCAGGCATCCAGCAGTGGCCCTTCAACCATCACAGCCAGTCAACGC	826
QUERY:	1022	TGAGGCCCCCTCTCCCACCCCCTCACAACCACACGCTGTCCCATCACCACTCGTCCGCCA	1081
		||||||| |||||||| || |||||||||||| ||||||||||||| |||||||| ||||
SBJCT:	827	TGAGGCCACCTCTCCCCCCTCCTCACAACCACTCGCTGTCCCATCATCACTCGTCTGCCA	886
QUERY:	1082	ACTCCCTCAACAGGAACTCACTGACCAATCGGCGGAGTCAGATCCACGCCCCGGCCCCAG	1141
		||||||||||||||||||| || ||||| || || |  ||||||||||| || || || |
SBJCT:	887	ACTCCCTCAACAGGAACTCGCTCACCAACCGCCGCAACCAGATCCACGCGCCTGCTCCCG	946
QUERY:	1142	CGCCCAATGACCTGGCCACCACACCAGAGTCCGTTCAGCTTCAGGACAGCTGGGTGCTAA	1201
		| |||||||||||||| ||||| || ||||| || ||||| ||||||||||||||||| |
SBJCT:	947	CTCCCAATGACCTGGCGACCACGCCTGAGTCTGTGCAGCTGCAGGACAGCTGGGTGCTCA	1006
QUERY:	1202	ACAGCAACGTGCCACTGGAGACCCGGCACTTCCTCTTCAAGACCTCCTCGGGGAGCACAC	1261
		||||||||||||| ||||||||| |||| ||| | || ||||| || || || |  || |
SBJCT:	1007	ACAGCAACGTGCCGCTGGAGACCAGGCATTTCTTGTTTAAGACATCTTCTGGAACGACTC	1066
QUERY:	1262	CCTTGTTCAGCAGCTCTTCCCCGGGATACCCTTTGACCTCAGGAACGGTTTACACGCCCC	1321
		|  ||||||| ||||||||||| || |||||  ||||||||||||| ||||| || || |
SBJCT:	1067	CGCTGTTCAGTAGCTCTTCCCCTGGCTACCCACTGACCTCAGGAACAGTTTATACTCCAC	1126
QUERY:	1322	CGCCCCGCCTGCTGCCCAGGAATACTTTCTCCAGGAAGGCTTTCAAGCTGAAGAAGCCCT	1381
		| ||| | ||| | || || ||||| || |||||||| || ||||||||||| |||||||
SBJCT:	1127	CTCCCAGGCTGTTACCTAGAAATACATTTTCCAGGAATGCATTCAAGCTGAAAAGCCCT	1186
QUERY:	1382	CCAAATACTGCAGCTGGAAATGTGCTGC	1409
		|||| || || |||||||||||||||||
SBJCT:	1187	CCAAGTATTGTAGCTGGAAATGTGCTGC	1214
SCORE = 391 BITS (197), EXPECT = E − 105
IDENTITIES = 593/725 (81%)
STRAND = PLUS/PLUS
QUERY:	7156	CATGTCTACAATCACTCCAACTCGGAGATTACCTCACTGTACTACGACCTCCAGGGCCAC	7215
		|||||||||||||| ||||| || || |||||||| ||||| || || || || ||||||
SBJCT:	7084	CATGTCTACAATCATTCCAATTCAGAAATTACCTCTCTGTATTATGATCTGCAAGGCCAC	7143
QUERY:	7216	CTCTTTGCCATGGAGAGCAGCAGTGGGGAGGAGTACTATGTTGCCTCTGATAACACAGGG	7275
		|||||||| |||||||| ||||||||||| || || ||||| ||||| |||||||| ||
SBJCT:	7144	CTCTTTGCAATGGAGAGTAGCAGTGGGGAAGAATATTATGTCGCCTCCGATAACACGGGC	7203
QUERY:	7276	ACTCCTCTGGCTGTGTTCAGCATCAACGGCCTCATGATCAAACAGCTGCAGTACACGGCC	7335
		||||| || || || ||||||||||| |||||||||||||||||||| |||||||| ||
SBJCT:	7204	ACTCCGCTAGCCGTATTCAGCATCAATGGCCTCATGATCAAACAGCTTCAGTACACTGCA	7263
QUERY:	7336	TATGGGGAGATTTATTATGACTCCAACCCCGACTTCCAGATGGTCATTGGCTTCCATGGG	7395
		|| || ||||||||||||||||| ||||| || |||||| |||| ||||| ||||||||
SBJCT:	7264	TACGGAGAGATTTATTATGACTCAAACCCTGATTTCCAGCTGGTTATTGGGTTCCATGGA	7323
QUERY:	7396	GGACTCTATGACCCCCTGACCAAGCTGGTCCACTTCACTCAGCGTGATTATGATGTGCTG	7455
		|| || ||||| ||  | ||||| || ||||| || || ||  | || || ||||| ||
SBJCT:	7324	GGGCTGTATGATCCTTTAACCAAACTCGTCCATTTTACCCAAAGGGACTACGATGTCCTT	7383
QUERY:	7456	GCAGGACGATGGACCTCCCCAGACTATACCATGTGGAAAAACGTGGGCAAGGAGCCGGCC	7515
		|| ||||| ||||| || || || || || |||||||||||| | || |  || || ||
SBJCT:	7384	GCTGGACGCTGGACATCTCCTGATTACACAATGTGGAAAAACATTGGTAGAGAACCTGCT	7443
QUERY:	7516	CCCTTTAACCTGTATATGTTCAAGAGCAACAATCCTCTCAGCAGTGAGCTAGATTTGAAG	7575
		||||| || ||||| ||||||||||| ||||| |||||||||| ||| || ||| | |||
SBJCT:	7444	CCCTTCAATCTGTACATGTTCAAGAGTAACAACCCTCTCAGCAATGAACTGGATCTAAAG	7503
QUERY:	7576	AACTACGTGACAGATGTGAAAAGCTGGCTTGTGATGTTTGGATTTCAGCTTAGCAACATC	7635
		|| || || |||||||| ||||||||||| |||||||| ||||||||||||||||||||
SBJCT:	7504	AATTATGTAACAGATGTCAAAAGCTGGCTGGTGATGTTCGGATTTCAGCTTAGCAACATT	7563
QUERY:	7636	ATTCCTGGCTTCCCGAGAGCCAAAATGTATTTCGTGCCTCCTCCCTATGAATTGTCAGAG	7695
		|||||||||||||| ||||| |||||||| || ||| | ||||| || ||  || || | |||
SBJCT:	7564	ATTCCTGGCTTCCCTAGAGCAAAAATGTACTTTGTGTCACCTCCATACGAGCTGACTGAG	7623
QUERY:	7696	AGTCAAGCAAGTGAGAATGGACAGCTCATTACAGGTGTCCAACAGACAACAGAGAGACAT	7755
		||||||||  |||| ||||||||||| |||||||| ||||| ||||||||||| |||||
SBJCT:	7624	AGTCAAGCGTGTGAAAATGGACAGCTAATTACAGGAGTCCAGCAGACAACAGAAAGACAC	7683
QUERY:	7756	AACCAGGCCTTCATGGCTCTGGAAGGACAGGTCATTACTAAAAAGCTCCACGCCAGCATC	7815
		|| || || ||||||||||| || |||||||||||  ||||||   | || ||||| ||
SBJCT:	7684	AATCAAGCTTTCATGGCTCTTGAGGGACAGGTCATATCTAAAAGATTACATGCCAGTATT	7743
QUERY:	7816	CGAGAGAAAGCAGGTCACTGGTTTCCCACCACCACGCCCATCATTGGCAAAGGCATCATG	7875
		|||| |||||||| ||||||||||| || | ||| || || ||||| ||||| ||||||
SBJCT:	7744	AGAGAAAAAGCAGGCCACTGGTTTGCAACAAGCACTCCTATTATTGGGAAAGGAATCATG	7803
QUERY:	7876	TTTGC 7880
		|||||
SBJCT:	7804	TTTGC 7808
SCORE = 339 BITS (171), EXPECT = 2E − 89
IDENTITIES = 429/515 (83%)
STRAND = PLUS/PLUS
QUERY:	7967	ACTACCTGGACAAGATGCACTACAGCATCGAGGGCAAGGACACCCACTACTTTGTGAAGA	8026
		|||||||||| || |||||||||||||||||||| ||||| || ||||||||||| ||||
SBJCT:	7895	ACTACCTGGAAAAAATGCACTACAGCATCGAGGGGAAGGATACTCACTACTTTGTCAAGA	7954
QUERY:	8027	TTGGCTCAGCCGATGGCGACCTGGTCACACTAGGCACCACCATCGGCCGCAAGGTGCTAG	8086
		| |||||||||||| ||||||| ||||| || |  |  |||| |||  | ||||| || |
SBJCT:	7955	TAGGCTCAGCCGATAGCGACCTCGTCACCCTCGCGATGACCAGCGGGAGGAAGGTCCTGG	8014
QUERY:	8087	AGAGCGGGGTGAACGTGACCGTGTCCCAGCCCACGCTGCTGGTCAACGGCAGGACTCGAA	8146
		| ||||| || ||||||||||| |||||||| || || ||  ||||||| |||||||||
SBJCT:	8015	ACAGCGGAGTAAACGTGACCGTCTCCCAGCCAACCCTCCTTATCAACGGAAGGACTCGAC	8074
QUERY:	8147	GGTTCACGAACATTGAGTTCCAGTACTCCACGCTGCTGCTCAGCATCCGCTATGGCCTCA	8206
		||||||| ||||| ||||| ||||| ||||| |||||| ||| ||||||||| || ||||
SBJCT:	8075	GGTTCACAAACATCGAGTTTCAGTATTCCACCCTGCTGATCAACATCCGCTACGGGCTCA	8134
QUERY:	8207	CCCCCGACACCCTGGACGAAGAGAAGGCCCGCGTCCTGGACCAGGCGAGACAGAGGGCCC	8266
		|| ||||||| ||||| || |||||||| || || || ||||||||  | ||| | ||||
SBJCT:	8135	CCGCCGACACGCTGGATGAGGAGAAGGCACGAGTGCTAGACCAGGCTCGGCAGCGAGCCC	8194
QUERY:	8267	TGGGCACGGCCTGGGCCAAGGAGCAGCAGAAAGCCAGGGACGGGAGAGAGGGGAGCCGCC	8326
		||||  ||||||||||||| ||||||||||| ||  |||| ||  | ||||| ||||||
SBJCT:	8195	TGGGGTCGGCCTGGGCCAAAGAGCAGCAGAAGGCACGGGATGGCCGCGAGGGCAGCCGCG	8254
QUERY:	8327	TGTGGACTGAGGGCGAGAAGCAGCAGCTTCTGAGCACCGGCGCGTGCAAGGGTACGAGG	8386
		| ||||| || || |||||||| |||||||||| ||| ||  | || ||||| |||||||
SBJCT:	8255	TATGACAGACGGAGAGAAGCAACAGCTTCTGAACACGGGAAGGGTTCAAGGTTACGAGG	8314
QUERY:	8387	GATATTACGTGCTTCCGTGGAGCAGTACCCAGAGCTAGCAGACAGTAGCAGCAACATCC	8446
		||||||| ||  | || |||||||| ||||||||||| ||||||||||||||||||||||
SBJCT:	8315	GATATTATGTCTTGCCTGTGGAGCAGTACCCAGAGCTAGCAGACAGTAGCAGCAACATCC	8374
QUERY:	8447	AGTTTTTAAGACAGAATGAGATGGGAAAGAGGTAA 8481
		||||||||||||||||||| |||||||||||||||
SBJCT:	8375	ACTTTTTAAGACAGAATGAAATGGGAAAGAGGTAA 8409
SCORE = 323 BITS (163), EXPECT = 1E − 84
IDENTITIES = 397/475 (83%)
STRAND = PLUS/PLUS
QUERY:	299	GACACCGCTCTTTGACCAGAGGACGCTGTGGCAAAGAGTGTCGCTACACAAGCTCCTCTC	358
		|||||||||||||||| ||||| || || || || ||||||||||| || || || || |
SBJCT:	20	GACACCCCTCTTTGACGAGAGGCCGGTGCGGGAAGGAGTGTCGCTATACTAGTTCTTCAC	79
QUERY:	359	TGGACAGTGAGGACTGCCGGGTGCCCACACAGAAATCCTACAGCTCCAGTGAGACTCTGA	418
		| |||||||| |||||| | || ||  | ||||| |||||||||||||||||||| ||||
SBJCT:	80	TCGACAGTGAAGACTGCAGAGTACCAGCTCAGAAGTCCTACAGCTCCAGTGAGACCCTGA	139
QUERY:	419	AGGCCTATGACCATGACAGCAGGATGCACTATGGAAACCGAGTCACAGACCTCATCCACC	478
		| || |||| ||||||||  ||||||||||| ||||| |||||  |||||||  | |||
SBJCT:	140	AAGCATATGGCCATGACACGAGGATGCACTACGGAAATCCAGTTTCAGACCTGGTTCACA	199
QUERY:	479	GGGAGTCAGATGAGTTTCCTAGACAAGGAACCAACTTCACCCTTGCCGAACTGGGCATCT	538
		||||||| ||||||||||| || |||||||| |||||||||||||| |||||||| ||||
SBJCT:	200	GGGAGTCGGATGAGTTTCCAAGGCAAGGAACGAACTTCACCCTTGCAGAACTGGGAATCT	259
QUERY:	539	GTGAGCCCTCCCCACACCGAAGCCGCTACTGCTCCGACATGGGGATCCTTCACCAGGGCT	598
		|||||||||| || || ||||| ||||||||||| ||||| || || || || || ||||
SBJCT:	260	GTGAGCCCTCTCCCCATCGAAGTGGCTACTGCTCGGACATAGGAATACTCCATCAAGGCT	319
QUERY:	599	ACTCCCTTAGCACACGGTCTGACGCCGACTCCGACACCGAGGGAGGGATGTCTCCAGAAC	658
		| ||| | ||||| || ||||| || ||||| ||||| ||||| |||||||||||||| |
SBJCT:	320	ATTCCTTGAGCACTGGCTCTGATGCTGACTCAGACACGGAGGGCGGGATGTCTCCAGAGC	379
QUERY:	659	ACGCCATCAGACTGTGGGGCAGAGGGATAAAATCCAGGCGCAGTTCCGGCCTGTCCAGTC	718
		|||| ||||| |||||||| |||||||| |||||||| || ||||| |||||||| ||||
SBJCT:	380	ACGCGATCAGGCTGTGGGGAAGAGGGATCAAATCCAGCCGAAGTTCTGGCCTGTCAAGTC	439
QUERY:	719	GTGAAAACTCGGCCCTTACCCTGACTGACTCTGACAACGAAAACAAATCAGATGA 773
		||||||||||||| || || || |||||||| ||||| || ||||| ||||||||
SBJCT:	440	GTGAAAACTCGGCTCTCACGCTCACTGACTCCGACAATGAGAACAAGTCAGATGA 494

[0106] The full FCTR3a amino acid sequence also has 342 of 383 amino acid residues (89%) identical to, and 342 of 383 residues (89%) positive with, the 276 amino acid residue Odd Oz/ten-m homolog 2 (Drosophila) (GenBank Acc: NP—035986.2) (SEQ ID NO:68) (Table 3P).

TABLE 3P
BLASTP of FCTR3a against Odd Oz/ten-m homolog 2-(SEQ ID NO:68)
>GI|7657415|REF|NP 035986.2| ODD OZ/TEN-M HOMOLOG 2 (DROSOPHILA); ODD OZ/TEN-
M HOMOLOG 3
(DROSOPHILA) [MUS MUSCULUS]
GI|4760778|DBJ|BAA77397.1| (AB025411) TEN-M2 [MUS MUSCULUS]
LENGTH = 2764
SCORE = 495 BITS (1274), EXPECT = E − 139
IDENTITIES = 342/383 (89%), POSITIVES = 342/383 (89%), GAPS = 41/383 (10%)
QUERY:	37	HNPPPVSCQMPLLDSNTSHQIMDTNPDEEFSPNSYLLRACSGPQQASSSGPPNHIHSQSTL	96
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	189	HNPPPVSCQMPLLDSNTSHQIMDTNPDEEFSPNSYLLRACSGPQQASSSGPPNHHSQSTL	248
QUERY:	97	RPPLPPPHNHTLSHHHSSANSLNRNSLTNRRSQIHAPAPAPNDLATTPESVQLQDSWVLN	156
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	249	RPPLPPPHNHTLSHHHSSANSLNRNSLTNRRSQIHAPAPAPNDLATTPESVQLQDSWVLN	308
QUERY:	157	SNVPLETRHFLFKTSSGSTPLFSSSSPGYPLTSGTVYTPPPRLLPRNTFSRKAFLKKPS	216
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	309	SNVPLETRHFLFKTSSGSTPLFSSSSPGYPLTSGTVYTPPPRLLPPNTFSRKAFKLKKPS	368
QUERY:	217	KYCSWKCAALSAIAAALLLAILLAYFI---------------------------------	243
		|||||||||||||||||||||||||||
SBJCT:	369	KYCSWKCAALSAIAAALLLAILLAYFIAMHLLGLNWQLQPADGHTFNNGVRTGLPGNDDV	428
QUERY:	244	--------VPWSLKNSSIDSGEAEVGRRVTQEVPPGVFWRSQIHISQPQFLKFNISLGKD	295
		||||||||||||||||||||||||||||||||||||||||||
SBJCT:	429	ATVPSGGKVPWSLKNSSIDSGEAEVGRRVTQEVPPGVFWRSQIHISQPQFLKFNISLGKD	488
QUERY:	296	ALFGVYIRRGLPPSHAQYDFMERLDGKEKWSVVESPRERRSIQTLVQNEAVFVQYLDVGL	355
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	489	ALFGVYIRRGLPPSHAQYDFMERLDGKEKWSVVESPRERRSIQTLVQNEAVFVQYLDVGL	548
QUERY:	356	WHLAFYNDGKDKEMVSFNTVVLD 378
		|||||||||||||||||||||||
SBJCT:	549	WHLAFYNDGKDKEMVSFNTVVLD 571

[0107] The full FCTR3b amino acid sequence has 2442 of 2802 amino acid residues (87%) identical to, and 2532 of 2802 residues (90%/O) positive with, the 2802 amino acid residue teneurin-2 [Gallus gallus] (GenBank Acc: AJ279031) (SEQ ID NO:69) (Table 3Q).

TABLE 3Q
BLASTP of FCTR3a against Teneurin-2-(SEQ ID NO:69
>GI|10241574|EMB|CAC09416.1| (AJ279031) TENEURIN-2 [GALLUS GALLUS]
LENGTH = 2802
SCORE = 4853 BITS (12589), EXPECT = 0.0
IDENTITIES = 2510/2802 (87%), POSITIVES = 2600/2802 (90%) , GAPS = 69/2802 (2%)
QUERY:	1	MDVRDRRHRSLTRGRCGKECRYTSSSLDSEDCRVPTQKSYSSSETLKAYDEDSRMRYGNR	60
		||+|||||||||||||||||||||||||||||||| ||||||||||||| || |||||||
SBJCT:	1	MDIKDRRHRSLTRGRCGKECRYTSSSLDSEDCRVPAQKSYSSSETLKAYGEDTRMHYGNR	60
QUERY:	61	VTDLIHRESDEFPRQGTNFTLLGICEPSPERSGYCSDMGILEQGYSLSTGSDADSDTE	120
		|+||+||||||||||||||||||||||||||||||||||+||||||||||||||||||||
SBJCT:	61	VSDLVHRESDEFPRQGTNFTLAELGICEPSPHRSGYCSDIGILEQGYSLSTGSDADSDTE	120
QUERY:	121	GGMSPEAIRLWGRGIKSRRSSGLSSRENSALTLTDSDNENKSDDENG------------	168
		|||||||||||||||||| ||||||||||||||||||||||||| ||
SBJCT:	121	GGMSPEHAIRLWGRGIKSSRSSGLSSRENSALTLTDSDNENKSDEENDFETHLSEKLKDR	180
QUERY:	169	----------------RPIPPTSSPSLLPSAQLPSSHNPPPVSCQMPLLDSNTSEQIMDT	212
		|||||||| |||||||||||||||||||||||||||||||
SBJCT:	181	QTSWQQLAETKNSLIRRPIPPTSSSSLLPSAQLPSSENPPPVSCQMPLLDSNTSHQIMDT	240
QUERY:	213	NPDEEFSPNSYLLRACSGPQQASSSGPPNHHSQSTLRPPLPPPHWHTLSHHHSSANSLNR	272
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	241	NPDEEFSPNSYLLRACSGPQQASSSGPSNESQSTLRPPLPPPHNHSLSHHHSSANSLNR	300
QUERY:	273	XXXXXXXXQIHAPAPAPNDLATTPESVQLQDSWVLNSNVPLETREFLFKXXXXXXXXXXX	332
		|||||||||||||||||||||||||||||||||||||||||
SBJCT:	301	NSLTNRRNQIHAPAPAPNDLATTPESVQLQDSWVLNSNVPLETRHFLFKTSSGTTPLFSS	360
QUERY:	333	XXXXYPLTSGTVYTPPPRLLPRNTFSRXAFKLKKPSKYCSWKCXKCXXXXXXXXXXXXXX	392
		||||||||||||||||||||||| |||||||||||||||
SBJCT:	361	SSPGYPLTSGTVYTPPPRLLPRNTFSRNAFKLKKPSKYCSWKCAALSAIAAAVLLAILLA	420
QUERY:	393	YFIV-----------------------------------------PWSLKNSSIDSGEAE	411
		|||                                          ||  +|||||||| |
SBJCT:	421	YFIAHLLGLNWQLQPADGETFSNGLRPGAAGAEDGAAAPPAGRGPWVTRNSSIDSGETE	480
QUERY:	412	VGRRVTQEVPPGVFWRSQIEISQPQFLKFNISLGKDALFGVYIRRGLPPSHAQYDFMERL	471
		|||+||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	481	VGRKVTQEVPPGVFWRSQIEISQPQFLKFNISLGKDALFGVYIRRGLPPSHAQYDFMERL	540
QUERY:	472	DGKEKWSVVESPRERRSIQTLVQNEAVFVQYLDVGLWHLAFYNDGKDKEMVSFNTVVLDS	531
		|||||||||||||||||||||||||||||||||||||||||||||||||+|||+||+|||
SBJCT:	541	DGKERWSVVESPRERRSIQTLVQNEAVFVQYLDVGLWHLAFYNDGKDKEVVSFSTVILDS	600
QUERY:	532	VQDCPRNCHGNGECVSGVCHCFPGFLGADCAAACPVLCSGNGQYSKGTCQCYSGWKGAE	591
		||||||||||||||||||||||||| ||||||||||||||||||||||| ||||||| |
SBJCT:	601	VQDCPRNCHGNGECVSGVCHCFPGFHGADCAKAACPVLCSGNGQYSKGTCLCYSGWKGPE	660
QUERY:	592	CDVPMNQCIDPSCGGHGSCIDGNCVCSAGYKGEHCEEVDCLDPTCSSHGVNGECLCSP	651
		||||++|||||||||||||+|||||| |||||+||||||||||||+|||||||||||||
SBJCT:	661	CDVPISQCIDPSCGGHGSCIEGNCVCSIGYKGENCEEVDCLDPTCSNHGVCVNGECLCSP	720
QUERY:	652	GWGNCELRVQCPDQCSGHGTYLPDTGLCSCDPNMGPDCSVEVCSVDCGTHGVCIGG	711
		||||+|||| | ||||||||||||| ||||||||||||||||||||||||||||||||||
SBJCT:	721	GWGGINCELPRAQCPDQCSGEGTYLSDTGLCSCDPMGPDCSVEVCSVDCGTHGVCIGG	780
QUERY:	712	ACRCEEGWTGAACDQRVCHPRCIEHGTCKDGKCECREGWNGEHCTIGRQTAGTETDGCPD	771
		|||||||||| ||||||||||| ||||||||||||||||||||||||||| |||||||||
SBJCT:	781	ACRCEEGWTGVACDQRVCHPRCTEHGTCKDKCECREGWNGEECTIGRQTTGTETDGCPD	840
QUERY:	772	LCNGNGRCTLGQNSWQCVCQTGWRGPGCNVAMETSCADNKDNEGDGLVDCLDPDCCLQSA	831
		||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||
SBJCT:	841	LCNGNGRCTLGQNSWQCVCQTGWRGPGCNVAMETSCADNKDNEGDGLVDCLVPDCCLQST	900
QUERY:	832	CQNSLLCRGSRDPLDIIQQGQTDWPAVKSFYDRIKLLAGKDSTHIIPGENPFNSSLVSLI	891
		|||||||||||||||||||  +  ||||||||||||| ||||||||||||||||||||||
SBJCT:	901	CQNSLLCRGSRDPLDIIQQSHSGSPAVKSFYDRIKLLVGKDSTHIIPGENPFNSSLVSLI	960
QUERY:	892	RGQVVTTDGTPLVGVSFVKYPKYGYTITRQDGTFDLIANGGASLTLHFERAPFMSQER	951
		|||||||||||||||||||||||||||||||||| |||+||||+||||||||||||||||
SBJCT:	961	RGQVVTTDGTPLVGVNVSFVKYPKYGYTITRQDGMFDLVANGGSSLTLHFERAPFMSQER	1020
QUERY:	952	TVWLPWNSFYAMDTLVMKTEENSIPSCDLSGFVRPDPIIISSPLSTFFSAAPGQNPIVPE	1011
		|||||||||||||||||||||||||||||||||||||+||||||||||| |||+||||||
SBJCT:	1021	TVWLPWNSFYAMDTLVMKTEENSIPSCDLSGFVRPDPVIISSPLSTFFSDAPGRNPIVPE	1080
QUERY:	1012	TQVLHEEIELPGSNVKLRYLSSRTAGYKSLLKITMTQSTVPLNLIRVHLMVAVEGHLFQK	1071
		|||||||||+|||++|| ||||||||||||||| |||| ||||||+||||||||||||||
SBJCT:	1081	TQVHEEIEVPGSSIKLIYLSSRTAGYRSLLKIIMTQSLVPLNLIKVHLMVAVEGHLFQK	1140
QUERY:	1072	SFQASPNASTFIWDKTDAYGQRVYGLSDAVVSVGFEYETCPSLILWEKRTALLQGFELD	1131
		|| |||||| ||||||||||||+|||||||||||||||||||||||||||||||||||||
SBJCT:	1141	SFLASPNLAYTFIWDKTDAYGQKVYGLSDAVVSVGFEYETCPSLILWEKRTALLQGFELD	1200
QUERY:	1132	PSNLGGWSLDKHHILNVKSGILEKGTGENQFLTQQPAIITSIMGNGRRRSISCPSCNGLA	1191
		|||||||||||||+||||||||||| |||||||||||+||||||||||||||||||||||
SBJCT:	1201	PSNLGGWSLDKEHVLNVKSGILHKGNGENQFLTQQPAVITSIMGNGRRRSISCPSCNGLA	1260
QUERY:	1192	EGNKLLAPVALAVGIDGSLYVGDFNYIRRIFPSRNVTSILELRNKEFKHSNNPAHKYYLA	1251
		|||||||||||||||||||+||||||||||||||||||||||||||||||||||||||||
SBJCT:	1261	EGNKLLAPVALAVGIDGSLFVGDFNYIRRIFPSRNVTSILELRNKEFKHSNNPAHKYYLA	1320
QUERY:	1252	VDPVSGSLYVSDTNSRRIYRVKSLSGTKDLAGNSEVVAGTGEQCLPFDEARCGDGGKAID	1311
		|||||||||||||||||||+||||+|||||||||||||||||||||||||||||||||+|
SBJCT:	1321	VDPVSGSLYVSDTNSRRIYKVKSLTGTKDLAGNSEVVAGTGEQCLPFDEARCGDGGKAVD	1380
QUERY:	1312	ATLMSPRGIAVDKNGLMYFVDATMIRKVDQNGIISTLLGSNDLTAVRPLSCDSSMDVAQV	1371
		||||||||||||| |||||||||||||||||||||||||||||||||||||||||||+||
SBJCT:	1381	ATLMSPRGIAVDKYGLMYFVDATMIRKVDQNGIISTLLGSNDLTAVRPLSCDSSMDVSQV	1440
QUERY:	1372	RLEWPTDLAVNPMDNSLYVLENNVILRITENHQVSIIAGRPNHCQVPGIDYSLSKXXXXX	1431
		||||||||||+||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1441	RLEWPTDLAVDPMDNSLYVLENNVILRITENHQVSIIAGRPMHCQVPGIDYSLSKLAIHS	1500
QUERY:	1432	XXXXXXXXXXXXTGVLYITETDEKKINRLRQVTTNGEICLLAGAASXXXXXXXXXXXXYS	1491
		||||||+|||||||||||||||||||||||||||            ||
SBJCT:	1501	ALESASAIAISHTGVLYISETDEKKIRLRQVTTNGEICLLAGAASDCDCKNDVNCNCYS	1560
QUERY:	1492	GDDAYATDAILNSPSSLAVAPDGTIYIADLGNIRIRAVSKNKPVLNAFNQYEAASPGEQE	1551
		||| |||||||||||||||||||||||||||||||||||||+|+||+|||||||||||||
SBJCT:	1561	GDDGYATDAILNSPSSLAVAPDGTIYIADLGNIRIRAVSKNRPILNSFNQYEAASPGEQE	1620
QUERY:	1552	LYVFNADGIHQYTVSLVTGEYLYNFTYSTDNDVTELIDNNGNSLKIRRDSSGMPRHLLMP	1611
		|||||||||||||+||||||||||||||+||||||++|+||||||+|||+||||||||||
SBJCT:	1621	LYVFNADGIHQYTLSLVTGEYLYNFTYSSDNDVTEVMDSNGNSLKVRRDASGMPRHLLMP	1680
QUERY:	1612	DNQIITLTVGTNGGLKVVSTQNLELGLMTYDGNTGLLATKSDETGWTTFYDYDHEGRLTN	1671
		||||+|| ||||||||+|||| ||||||||+||+||||||||||||||||||||||||||
SBJCT:	1681	DNQIVTLAVGTNGGLKLVSTQTLELGLMTYNGNSGLLATKSDETGWTTFYDYDHEGRLTN	1740
QUERY:	1672	VTRPTGVVTSLHREMEKSITIDIENSNRDDDVTVITNLSSVEASYTVVQDQVRNSYQLCN	1731
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1741	VTRPTGVVSLHREMEKSITIDIENSNRDDDVTVITNLSSVEASYTVVQDQVRNSYQLCN	1800
QUERY:	1732	NGTLRVMYANGMGISFHSEPHVLAGTITPTIGRCNISLPMENGLNSIEWRLRKEQIKGKV	1791
		|||||||||||| |||||||||||||+|||||||||||||||||||||||||||||||||
SBJCT:	1801	NGTLRVMYANGMSISFHSEPHVLAGTVTPTIGRCNISLPMENGLNSIEWRLRKEQIKGKV	1860
QUERY:	1792	TIFGRKLRVHGRNLLSIDYDRNIRTEKIYDDHKFTLRIIYDQVGRPFLWLPSSGLAAVN	1851
		|+|||||||||||||||||||||||||||||||||||||||||+||||||||||||||||
SBJCT:	1861	TVFGRKLRVHGRNLLSIDYDRNIRTEKIYDDHRKFTLRIIYDQLGRPFLWLPSSGLAAVN	1920
QUERY:	1852	VSYFFNGRLAGLQRGAMSERTDIDKQGRIVSRMFADGKVWSYSYLDKSMVLLLQSQRQYI	1911
		||||||||||||||||||||||||||||||+||||||||||||+||+|||||||||||||
SBJCT:	1921	VSYFFNGRLAGLQRGAMSERTDIDKQGRIISRMFADGKVWSYTYLEKSMVLLLQSQRQYI	1980
QUERY:	1912	FEYDSSDRLLAVTMPSVARXSMSTHTSIGYIRNIYNPPESNASVIFDYSDDGRILKTSFL	1971
		||||||||| |||||||||||||||||+||||||||||||||||||||||||||||||||
SRJCT:	1981	FEYDSSDRLHAVTMPSVARHSMSTHTSVGYIRNIYNPPESNASVIFDYSDDGRILKTSFL 2040
QUERY:	1972	GTGRQVFYKYGKLSKLSEIVYDSTAVTFGYDETTGVLKMVNLQSGGFSCTIRYRKIGPLV	2031
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2041	GTGRQVFYKYGKLSKLSEIVYDSTAVTFGYDETTGVLKMVNLQSGGFSCTIRYRKIGPLV	2100
QUERY:	2032	DKQIYRFSEEGMVNARFDYTYHDNSFRIASIKPVISETPLPVDLYRYDEISGKVEHFGKF	2091
		|||||||||||||||||||||||||||||||||+||||||||||||||||||||||||||
SBJCT:	2101	DKQIYRFSEEGMVNARFDYTYHDNSFRIASIKPIISETPLPVDLYRYDEISGKVEHFGKF	2160
QUERY:	2092	GVIYYDINQIITTAVMTLSKFDTHGRIEVQYEMFRSLMYWMTVQYDSMGRVIKRELKL	2151
		||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
SBJCT:	2161	GVIYYDINQIITTAVMTLSKHFDTHGRIKEVQYEMFRSLMYWMTVQYDSMGRVTKRELKL	2220
QUERY:	2152	GPYANTTKYTYDYDGDGQLQSVAVNDRPTWRYSYDXXXXXXXXXXXXSVRLMPLRYDLRD	2211
		|||||||||||||||||||||||||||||||||||            |||||||||||||
SBJCT:	2221	GPYANTTKYTYDYDGDGQLQSVAVNDRPTWRYSYDLNGNLHLLNPGNSVRLMPLRYDLRD	2280
QUERY:	2212	RITRLGDVQYKIDDDGYLCQRGSDIFEYNSKGLLTRAYNKASGWSVQYRYDGVGRRASYK	2271
		|||||||+ |||||||+|||||||+||||||||||||||||+||+|||||||+||||| |
SBJCT:	2281	RITRLGDIPYKIDDDGFLCQRGSDVFEYNSKGLLTRAYNKANGWNVQYRYDGLGRRASCK	2340
QUERY:	2272	TNLGHHLQYFYSDLHNPTRITHVYNHSNSEITSLYYDLQGHLFAMESSSGEEYYVASDN	2331
		|||||||||||+|||||||+||||||||||||||||||||||||||||||||||||||||
SBJCT:	2341	TNLGHHLQYFYADLHNPTRVHVYNHSNSEITSLYYDLQGHLFAMESSSGEEYYVASDNT	2400
QUERY:	2332	GTPLAVFSINGLMIKQLQYTAYGEIYYDSNPDFQMVIGFHGGLYDPLTKLVHFTQRDYDV	2391
		||||||||||||||||||||||||||||||||||+|||||||||||||||||||||||||
SBJCT:	2401	GTPLAVFSINGLMIKQLQYTAYGEIYYDSNPDFQLVIGFHGGLYDPLTKLVHFTQRDYDV	2460
QUERY:	2392	LAGRWTSPDYTMWKNVGKEPAPFNLYMFKSNNPLSSELDLKYVTDVKSWLVMFGFQLSN	2451
		|||||||||||||||+|+|||||||||||||||||+||||||||||||||||||||||||
SBJCT:	2461	LAGRWTSPDYTMWKNIGREPAPFNLYMFKSNNPLSNELDLKNYVTDVKSWLVMFGFQLSN	2520
QUERY:	2452	IIPGFPRAKMYFVPPPYELSESQASENGQLITGVQQTTERHNQAFMALEGQVITKKLHAS	2511
		||||||||||||| |||||+|||| ||||||||||||||||||||||||||||+|+||||
SBJCT:	2521	IIPGFPRAKMYFVSPPYELTESQACENGQLITGVQQTTERHNQAFMALEGQVISKRLHAS	2580
QUERY:	2512	IREKAGRWFATTTPIIGKGIMFAIKEGRVTTGVSSIASEDSRKVASVLNNAYYLDKMHYS	2571
		|||||||||||+|||||||||||+|+||||||+||||++||||+|||||+|+||+|||||
SBJCT:	2581	IREKAGHWFATSTPIIGKGIMFAVKKGRVTTGISSIATDDSRKIASVLNSAHYLEKMHYS	2640
QUERY:	2572	IEGKDTHYFVKIGSADGDLVTLGTTIGRKVLESGVNVTVSQPTLLVNGRTRRFTNIEFQY	2631
		|||||||||||||||| |||||  | |||||+|||||||||||||+||||||||||||||
SBJCT:	2641	IEGKDTHYFVKIGSADSDLVTLAMTSGRKVLDSGVNVTVSQPTLLINGRTRRFTNIEFQY	2700
QUERY:	2632	STLLLSIRYGLTPDTLDEEKARVLDQARQRALGTAWAKEQQKARDGREGSRLWTEGEKQQ	2691
		||||++|||||| ||||||||||||||||||||+|||||||||||||||||+||+|||||
SBJCT:	2701	STLLINIRYGLTADTLDEEKARVLDQARQRLGSAWAKEQQKARGREGSRVWTDGEKQQ	2760
QUERY:	2692	LLSTGRVQGYEGYYVLPVEQYPELADSSSNIQFLRQNEMGKR 2733
		||+|||||||||||||||||||||||||||||||||||||||
SBJCT:	2761	LLNTGRVQGYEGYYVLPVEQYPELADSSSNIQFLRQNEMGKR 2802

[0108] The FCTR3bcde and f amino acid sequences have 1524 of 2352 amino acid residues (64%) identical to, and 1881 of 2532 residues (79%) positive with, the amino acid residues 429-2771, 93 of 157 residues (59%) identical to and 118 of 157 residues (74%) positive with amino acid residues 1-155, and 59 of 152 residues (38%) identical to and 68 of 152 residues (43%/O) positive with amino acid residues 211-361 of Ten-m4 [Mus musculus] (ptnr: GenBank Acc: BAA77399.1) (SEQ ID NO:70) (Table 3R).

TABLE 3R
BLASTP of FCTR3b, c, d, e, and f against Mus musculus Ten-m4 - (SEQ ID NO:70)
>GI|4760782|DBJ|BAA77399.1| (AB025413) TEN-M4 [MUS MUSCULUS]
LENGTH = 2771
SCORE = 3089 BITS (8008), EXPECT = 0.0
IDENTITIES = 1524/2352 (64%), POSITIVES = 1881/2352 (79%), GAPS = 28/2352 (1%)
QUERY:	401	KNSSIDSGEAEVGRRVTQEVPPGVFWRSQIHISQPQFLKFNISLGKDALFGVYIRRGLPP	460
		++| ||||| +|||| +|++||| |||||+ |  |  ||||+|||| || |+| |+||||
SBJCT:	429	EDSFIDSGEIDVGRRASQKIPPGTFWRSQVFIDHPVHLKFNVSLGKAALVGIYGRKGLPP	488
QUERY:	461	SHAQYDFMERLDGK-----EKWSVESPR3RRSIQTLVQNEAVFVQYLDVGLWHLAFYND	515
		|| |+||+| |||+     |  |+    |+ |       +|  |+|||| |+||||||||
SBJCT:	489	SHTQFDFVELLDGRRLLTQEARSLEGPQRQSRGPVPPSSHETGFIQYLDSGIWHLAFYND	548
QUERY:	516	GKDKEMVSFNTLDSVQDCPENCHGNGECVSGVCECFPGFLGADCAKAACPVLCSGNGQ	575
		||+ |+||| |  ++|| +|| ||+|||+|+|| |||| |||| || +|+||||||||||
SBJCT:	549	GKESEVVSFLTTAIESVDNCPSNCYGNGDCISGTCHCFLGFLGPDCGRASCPVLCSGNGQ	608
QUERY:	576	YSKGTCQCYSGWKGAECDVPMMQCIDPSCGGHGSCIDGNCVCSAGYKGEHCEEVDCLDPT	635
		| || | |+||||||||||| ||||| +|  ||+|| | |+|+ ||||| ||||||+|||
SBJCT:	609	YMKGRCLCESGWKGAECDVPTNQCIDVACSSEGTCIMGTCICNPGYKGESCEEVDCMDPT	668
QUERY:	636	CSSHGVCVNGECLCSPGWGGLNCELARVQCPDQCSGEGTYLPDTGLCSCDPNWMGPDCSV	695
		||| |||| ||| || |||| |||  |  | ||||||||+|||||||+|||+| | |||+
SBJCT:	669	CSSRGVCVRGECHCSVGWGGTNCETPRATCLDQCSGHGTFLPDTGLCNCDPSWTGHDCSI	728
QUERY:	696	EVCSVDCGTHGVCIGGACRCEEGWTGAACDQRVCHPRCIEHGTCKDGKCECREGWNGEHC	755
		|+|+ ||| ||||+|| ||||+|| ||||||| ||||| |||||+||||||  |||||||
SBJCT:	729	EICAADCGGHGVCVGGTCRCEDGWMGAACDQRACHPRCAEHGTCRDGKCECSPGWNGEHC	788
		*********
QUERY:	756	TIGRQTAGTETDGCPDLCNGNGRCTLGQNSWQCVCQTGWRGPGCNVAMETSCADNKDNEG	815
		||         +||| ||||||||||  | | |||| ||+ +||| | | |||+|
SBJCT:	789	TIAHYLDRVVKEGCPGLCNGNGRCTLDLNGWHCVCQLGWRGTGCDTSMETGCGDGKDNDG	848
QUERY:	816	DGLVDCLDPDCCLQSACQNSLLCRGSRDPLDIIQQGQT--DWPAVKSFYDRIXLLAGKDS	873
		||||||+||||||  |  + || || |||||||+ |       +  |||||| | |+||
SBJCT:	849	DGLVDCMDPDCCLQPLCHVNPLCLGSPDPLDIIQETQAPVSQQNLNPFYDRIKFLVGRDS	908
QUERY:	874	THIIPGENPFNSSLVSLIRGQVVTTDGTPLVGVNVSFVKYPKYGYTITRQDGTFDLIANG	933
		|| |||||||+     +|||||+|+|||||||||+||+  | +||||+||||+|||+ ||
SBJCT:	909	THSIPGENPFDGGHACVIRGQVMTSDGTPLVGVNISFINNPLFGYTISRQDGSFDLVTNG	968
QUERY:	934	GASLTLHFERAPFMSQERTVWLPNNSFYAMDTLVMKTEENSIPSCDLSGFVRPDPIIISS	993
		| |+ | ||||||++|| |+||||+ |+ |+|+||+ ||| ||||||| | ||+|++  |
SBJCT:	969	GISIILRFERAPFITQEHTLWLPWDRFFVMETIVMRHEENEIPSCDLSNFARPNPVVSPS	1028
QUERY:	994	PLSTFFSAAPGQNPIVPETQVLHEEIELPGSNVKLRYLSSRTAGYKSLLKITMTQSTVPL	1053
		||++| |+   + ||||| | | ||| + |  ++| |||||| ||||+|+|++|  |+|
SBJCT:	1029	PLTSFASSCAEKGPIVPEIQALQEEIVIAGCKMRLSYLSSRTPGYKSVLRISLTHPTIPF	1088
QUERY:	1054	NLIRVHLMVAVEGHLFQKSFQASPNLASTFIWDKTDAYGQRVYGLSDAVVSVGFEYETCP	1113
		||++||||||||| ||+| | |+|+|+  ||||||| | |+|+| |+| ||||+|||+||
SBJCT:	1089	NLMKVHLMVAVEGRLFRKWFAAAPDLSYYFIWDKTDVYNQKVFGFSEAFVSVGYEYESCP	1148
QUERY:	1114	SLILWEKRTALLQGFELDPSNLGGWSLDKHHILNVKSGILHKGTGENQFLTQQPAIITSI	1173
		|||||||||+|||+|+| | |||||||||| ||++||||||| |||||++||| +| ||
SBJCT:	1149	DLILWEKRTAVLQGYEIDASKLGGWSLDKHHALNIQSGILHKGNGENQFVSQQPPVIGSI	1208
QUERY:	1174	MGNGRRRSISCPSCNGLAEGNKLLAPVALAVGIDGSLYVGDFNYIRRIFPSRNVTSILEL	1233
		||||||||||||||||||+||||||||||  | |||||||||||||||||| |||+|||+
SBJCT:	1209	MGNGRRRSISCPSCNGLADGNKLLAPVALTCGSDGSLYVGDFNYIRRIFPSGNVTNILEM	1268
QUERY:	1234	RNKEWKHSNNPAHKYYLAVDPVSGSLYVSDTNSRRIYRVKSLSGTKDLAGNSEVVAGTGE	1293
		|||+|+||++|||||||| ||+||++++|||||||+++||| +  |||  |||||||||+
SBJCT:	1269	RNKDFRBSHSPABKYYLATDPMSGAVFLSDTNSRRVFKVKSTTVUEDLVKNSEVVAGTGD	1328
QUERY:	1294	QCLPFDEARCGDGGKAIDATLMSPRGIAVDKNGLMYFVDATMIRKVDQNGIISTLLGSND	1353
		||||||+ |||||||| +||| +|||| ||| ||+|||| ||||+|||||||||||||||
SBJCT:	1329	QCLPFDDTRCGDGGATEATLTNPRGITVDKFGLIYFVDGTMIRRVDQNGIISTLLGSND	1388
QUERY:	1354	LTAVRPLSCDSSMDVAQVRLEWPTDLAVNPMDNSLYVLENNVILRITENEQVSIIAGRPM	1413
		||+ ||||||| |+++|||||||||||+||||||||||+|||+|+|+||||| |+|||||
SBJCT:	1389	LTSARPLSCDSVMEISQVRLEWPTDLAINPMDNSLYVLDNNVVLQISENHQVRIVAGRPM	1448
QUERY:	1414	HCQVPGID-YSLSKXXXXXXXXXXXXXXXXXXGVLYITETDEKKINRLRQVTTGEICLL	1472
		|||||||| + |||                  ||||| |||||||||+|||||+||| |+
SBJCT:	1449	HCQVPGIDHFLLSKVAIHATLESATALAVSHNGVLYIAETDEKKINRIRQVTTSGEISLV	1508
QUERY:	1473	AGAASXXXXXXXXXXXXXYSGDDAYATDAILNSPSSLAVAPDGTIYIADLGNIRIRAVSKN	1532
		||| |             +|||| || || ||+|||||  || +|+||||||||| + ||
SBJCT:	1509	AGAPSGCDCKNDANCDCFSGDDGYAKDAKLNTPSSLAVCADGELYVADLGNIRIRFIRKN	1568
QUERY:	1533	KPVLNAFNQYEAASPGEQELYVFNADGIHQYTVSLVTGEYLYNFTYSTDNDVTELIDNNG	1592
		|| ||  | || +|| +||||+|+  | | || || ||+|||||||+ | |+| + ||||
SBJCT:	1569	KPFLNTQNMYELSSPIDQELYLFDTSGKHLYTQSLPTGDYLYNFTYTGDGDITEITDNNG	1628
QUERY:	1593	NSLKIRRDSSGMPRHLLMPDNQIITLTVGTNGGLKVVSTQNLELGLMTYDGNTGLLATKS	1652
		| + +||||+|||  |++|| |+  +|+|||  |+ |+||  || +||| ||+|||||||
SBJCT:	1629	NMVNVRRDSTGMPLWLVVPDGQVYWVTMGTNSALRSVTTQGHELAMMTYHGNSGLLATKS	1688
QUERY:	1653	DETGWTTFYDYDHEGRLTNVTRPTGVVTSLEREMEICSITIDIENSNEDDDVTVITNLSSV	1712
		+| ||||||+||  ||||||| ||| |+|  + + |+ + +| |++ ||||+ ||||+
SBJCT:	1689	NENGWTTFYEYDSFGRLTNVTFPTGQVSSFRSDTDSSVHVQVETSSK-DDVTITTNLSAS	1747
QUERY:	1713	EASYTVVQDQVRNSYQLCNNGTLRVMYANGMGISFHSEPHVLAGTITPTIGRCNISLPME	1772
		| ||++|||||||| +  +|+||++ |||| ++  +|||+||||+ ||+|+ |++||++
SBJCT:	1748	GAFYTLLQDQVRNSYYIGADGSLRLLLANGNEVALQTEPHLLAGTVNPTVGKRNVTLPID	1807
QUERY:	1773	NGLNSIEWRLRKEQIKGKVTIFGRKLRVHGRNLLSIDYDRNIRTEKIYDDHRKFTLRIIY	1832
		|||| +||| |||| +|+||+|||+|||| |||||+|+||  ||||||||||||||||+|
SBJCT:	1808	NGLNLVEWRQRKEQARGQVTVFGRRLRVENRNLLSLDFDRVTRTERIYDDHRRFTLRILY	1867
QUERY:	1833	DQVGRPFLWLPSSGLAAVNVSYFFNGRLAGLQRGAI4SERTDIDKQGRIVSRMFADGKVWS	1892
		|| ||| || ||| |  |||+|   | +||+||| |||| + |+ ||| ||+|||||+||
SBJCT:	1868	DQAGRPSLWSPSSRLNGVNVTYSPGGHIAGIQRGIMSERMEYDQAGRITSRIFADGKMWS	1927
QUERY:	1893	YSYLDESMVLLLQSQRQYIFEYDSSDRLLAVTMPSVARESMSTHTSIGYIRNIYNPPESN	1952
		|+||+||||| | ||||||||+| +||| +||||+||| ++ |  |+|| |||| ||| |
SBJCT:	1928	YTYLEKSMVLHLHSQRQYIFEFDKNDRLSSVTMPNVARQTLETIRSVGYYRNIYQPPEGN	1987
QUERY:	1953	ASVIFDYSDDGRILKTSFLGTGRQVFYKYGKLSKLSEIVYDSTAVTFGYDETTGVLKNVN	2012
		|||| |+++|| +| | +|||||+| |||||||||+| +||+| |||| |+|| ||
SBJCT:	1988	ASVIQDFTEDGHLLHTFYLGTGRRVIYKYGKLSKLAETLYDTTKVSFTYDETAGMLKTVN	2047
QUERY:	2013	LQSGGFSCTIRYRKIGPLVDKQIYRFSEEGMVNARFDYTYRDNSFRIASIKPVISETPLP	2072
		||+ ||+||||||+||||+|+||+||+||||||||||| | |||||+ |++ ||+|||||
SBJCT:	2048	LQNEGFTCTIRYRQIGPLIDRQIFRFTEEGMVNARFDYNYDNSFRVTSMQAVINETPLP	2106
QUERY:	2073	VDLYRYDEISGKVEHFGKFGVIYYDINQIITTAVMTLSKHFDTHGRIKEVQYEMFRSLMY	2132
		+||||||++||| | ||||||||||||||||||||| +|||| +||+||||||+||||||
SBJCT:	2107	IDLYRYDDVSGKTEQFGKfGVIYYDINQIITTAVMTHTKHFDAYGRMKEVQYEIFRSLMY	2166
QUERY:	2133	WMTVQYDSMGRVIKRELKLGPYANTTKYTYDYDGDGQLQSVAVNDRPTWRYSYDXXXXXX	2192
		|||||||+||||+|+|||+|||||||+|+|+|| |||||+|++||+| ||||||
SBJCT:	2167	WMTVQYDNMGRVVKKELKVGPYANTTRYSYEYDADGQLQTVSINDKPLWRYSYDLNGNLH	2226
QUERY:	2193	XXXXXXSVRLMPLRYDLRDRITRLGDVQYKIDDDGYLCQRGSDIFEYNSKGLLTRAYNKA	2252
		| || |||||||||||||||||||+|+||+| ||| |+||||| ||| +|||+|
SBJCT:	2227	LLSPGNSARLTPLRYDLRDRITRLGDVQYKMDEDGFLRQRGGDVFEYNSAGLLIKAYNRA	2286
QUERY:	2253	SGWSVQYRYDGVGRRASYKTNLGHHLQYFYSDLHMPTRITHVYNHSNSEITSLYYDLQGE	2312
		|||||+|||||+||| | |++  ||||+||+|| |||++||+||||+|||||||||||||
SBJCT:	2287	SGWSVRYRYDGLCRRVSSKSSESHHLQFFYADLTNPTKVTELYNHSSSEITSLYYDLQGE	2346
QUERY:	2313	LFAMESSSGEEYYVASDNTGTPLAVFSINGLMIKQLQYTAYGEIYYDSNPDFQMVIGFEG	2372
		||||| |||+|+|+| || ||||||||  ||||||+ |||||||| |+||+||++||+||
SBJCT:	2347	LFAMELSSGDEFYIACDNIGTPLAVFSGTGLMIKQILYTAYGEIYMDTNPNFQIIIGYEG	2406
QUERY:	2373	GLYDPLTKLVHFTQRDYDVLAGRWTSPDYTMWKNVGKEP-APFNLYMFKSNNPLSSELDL	2431
		|||||||||||  +||||||||||||||+ +|| +      ||+|||||+|||+|+  |+
SBJCT:	2407	GLYDPLTKLVENGRRDYDVLAGRWTSPDHELWKRLSSNSIVPFHLYMFKNNNPISNSQDI	2466
QUERY:	2432	KNYVTDVKSWLVMFGFQLSNIIPGFPRARMYFVPPPYELSESQAS----ENGQLITGVQQ	2487
		| ++||| |||+ ||||| |+|||+|+     + | |||  +|      +| + | |||
SBJCT:	2467	KCFMTDVNSWLLTFGFQLHNVIPGYPKPDTDAMEPSYELVETQMKTQEWDNSKSILGVQC	2526
QUERY:	2488	TTERHNQAFMALE------GQVITKKLHASIREKAGEWFATTTPIIGKGIMFAIKEGRVT	2541
		++  +||+ ||      |  ||    |   +|    ||++  | |||+ ||+|+||||
SBJCT:	2527	EVQKQLKAFVTLERFDQLYGSTITSCQQAPETKK----FASSGSIFGKGVKFALKDGRVT	2582
QUERY:	2542	TGVSSIASEDSRKVASVLNNAYYLDKMHYSIEGKDTHYFVKIGSADGDLVTLGTTIGRKV	2601
		| + |+|+|| |++|++||||+||+ +|++|+| ||||||| | ++|||  || + ||+
SBJCT:	2583	TDIISVANEDGRRIAAILNNAHYLENLHFTIDGVDTEYFVKPGPSEGDLAILGLSGGRRT	2642
QUERY:	2602	LESGVNVTVSQPTLLVNGRTRRFTNIEFQYSTLLLSIRYGLTPDTLDEEKARVLDQARQR	2661
		||+||||||||  +++|||||+|+|+ ||  | |+ |||    |+|||| |||+ ||||
SBJCT:	2643	LENGVNVTVSQINTNLSGRTRRYTDIQLQYRALCLNTRYG---TTVDEEKVRVLELARQR	2699
QUERY:	2662	ALGTAWAKEQQRARDGREGSRLWTEGEKQQLLSTGRVQGYEOYYVLPVEQYPELADSSSN	2721
		+  |||+|||+ |+| || | ||+|||||+|+|||||||+|++|  |||||||+||++|
SBJCT:	2700	AVRQAWAREQQRLREGEEGLRAWTDGEKQQVLNTGRVQGYDGFFVTSVEQYPELSDSANN	2759
QUERY:	2722	IQFLRQNEMGKR 2733
		| |+||+|||+|
SBJCT:	2760	IHFMRQSEMGRR 2771
SCORE = 161 BITS (407), EXPECT = 2E − 37
IDENTITIES = 93/157 (59%), POSITIVES = 118/157 (74%), GAPS = 4/157 (2%)
QUERY:	1	MDVKDRR-HRSLTRGRCGKECRYTSSSLDSEDCRVPTQKSYSSSETLKAYDEDSRMEYGN	59
		||||+|+ +||||| |   | |||||| |||+ + | |||||||||||||| |+|+ ||+
SBJCT:	1	MDVKERKPYRSLTRRR-DAERRYTSSSADSEEGKGP-QKSYSSSETLKAYDQDARLAYGS	58
QUERY:	60	RVTDLIHRESDEFPRQGTNFTLELGICEPS-PHRSGYCSDNGILHQGYSLSTGSDADSD	118
		|| |++ +|++|| | |||||| |||+ | + || +| +|+|+|+ | |||+   |||| +
SBJCT:	59	RVKDMVPQEAEEFCRTGTNFTLRELGLGEMTPPHGTLYRTDIGLPHCGYSNGASSDADLE	118
QUERY:	119	TEGGMSPEHAIRLWGRGIKSRRSSGLSSRENSALTLT 155
		+  +|||| +|||||  +| ||| |||| || ||||
SBJCT:	119	ADTVLSPEHPVRLWGRSTRSGRSSCLSSRANSNLTLT 155
SCORE = 72.1 BITS (176), EXPECT = 8E − 11
IDENTITIES = 59/152 (38%), POSITIVES = 68/152 (43%), GAPS = 42/152 (27%)
QUERY:	285	PAPAPND--LATTP------ESVQLQDSWVLNSNVPLETR--------------------	316
		|+||| |  |+  |      |    ||+|+||||+|||||
SBJCT:	211	PSPAPTDESLSGEPPAGSAQEPTEAQDNWLLNSNIPLEVENLGEQPFLGTLQDNLIEMDI	270
QUERY:	317	-------------HFLFKXXXXXXXXXXXXXXXYPLTSGTVYTPPPRLLPRNTFSRKAFK	363
		|||||               ||||| |||+|||| |||+|||| ||
SBJCT:	271	LSASRHDGAYSDGHFLFKPGGTSPLFCTTSPGYPLTSSTVYSPPPRPLPRSTFSRPAFN	329
QUERY:	364	LKKPSKYCYCSWKCXXXXXXXXXXXXXXXXXYFI 395
		||||||||+|||                 ||+
SBJCT:	330	LKKPSKYCNWKCAALSAILISATLVILLAYFV 361
*FCTR3F DOES NOT CONTAIN THESE AMINO ACIDS

[0109] The 997-2733 amino acid fragment of the FCTR3bcde and f protein was also found to have 1695 of 1737 amino acid residues (97%) identical to, and 1695 of 1737 residues (97%) positive with the amino a 1737 amino acid residue protein KIAA1 127 protein [Homo sapiens] (GenBank Acc:(AB032953) (SEQ ID NO:71), (Table 3S).

TABLE 3S
BLASTP of FCTR3b, c, d, e, and f against Homo sapiens KIAA1127 protein
(SEQ ID NO:71)
>GI|6329763|DBJ|BAA86441.1| (AB032953) K1AA1127 PROTEIN [HOMO SAPIENS]
LENGTH = 1737
SCORE = 3295 BITS (8545), EXPECT = 0.0
IDENTITIES = 1695/1737 (97%), POSITIVES = 1695/1737 (97%)
QUERY:	997	TFFSAAPGQNPIVPETQVLHEEIELPGSNVKLRYLSSRTAGYKSLLKITMTQSTVPLNLI	1056
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1	TFFSAAPGQNPIVPETQVLHEEIELPGSNVRLRYLSSRTAGYKSLLKITMTQSTVPLNLI	60
QUERY:	1057	RVHLMVAVEGHLFQKSFQASPNLASTFIWDKTDAYGQRVYGLSDAVVSVGFEYETCPSLI	1116
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	61	RVHLMVAVEGHLFQKSFQASPNLAYTFIWDKTDAYGQRVYGLSDAVVSVGFEYETCPSLI	120
QUERY:	1117	LWEKRTALLQGFELDPSNLGGWSLDKHHILNVKSGILHKGTGENQFLTQQPAIITSIMGN	1176
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	121	LWEKRTALLQGFELDPSNLGGWSLDKHHILNVKSGILEKGTGENQFLTQQPAIITSIMGN	180
QUERY:	1177	GRRRSISCPSCNGLAEGNKLLAPVALAVGIDGSLYVGDFNYIRRIFPSRNVTSILELRNK	1236
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	181	GRRRSISCPSCNGLAEGNKLLAPVALAVGIDGSLYVGDFYIRRIFPSRNVTSILELRNK	240
QUERY:	1237	EFKHSNNPAHKYYLAVDPVSGSLYVSDTNSRRIYRVKSLSGTKDLAGNSEVVAGTGEQCL	1296
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	241	EFKHSNNPAHKYYLAVDPVSGSLYVSDTNSRRIYRVKSLSGTKDLAGNSEVVAGTGEQCL	300
QUERY:	1297	PFDEARCGDGGKAIDATLMSPRGIAVDKNCLMYFVDATMIRKVDQNGIISTLLGSNDLTA	1356
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	301	PFDEARCGDGGICAIDATLMSPRGIAVDKNGLMYFVDATMIRKVDQNGIISTLLGSNDLTA	360
QUERY:	1357	VRPLSCDSSMDVAQVRLEWPTDLAVNPMDNSLYVLENNVILRITENHQVSIIAGRPMHCQ	1416
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	361	VRPLSCDSSMDVAQVRLEWPTDLAVNPMDNSLYVLENNVILRITENHQVSIIAGRPMHCQ	420
QUERY:	1417	VPGIDYSLSKXXXXXXXXXXXXXXXXXTGVLYITETDEKKINRLRQVTTNGEICLLAGAA	1476
		||||||||||                 |||||||||||||||||||||||||||||||||
SBJCT:	421	VPGIDYSLSKLAIHSALESASAIAISHTGVLYITETDEKKINRLRQVTTNGEICLLAGAA	480
QUERY:	1477	SXXXXXXXXXXXXYSGDDAYATDAILNSPSSLAVAPDGTIYIADLGNIRIRAVSKNKPVL	1536
		|            |||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	481	SDCDCKNDVNCNCYSGDDAYATDAILNSPSSLAVAPDGTIYIADLGNIRIRAVSKNKPVL	540
QUERY:	1537	NAFNQYEAASPGEQELYVFNADGIRQYTVSLVTGEYLYNFTYSTDNDVTELIDNNGNSLK	1596
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	541	NAFNQYEAASPGEQELYVFNADGIHQYTVSLVTGEYLYNFTYSTDNDVTELIDNNGNSLK	600
QUERY:	1597	IRRDSSGMPRELLMPDNQIITLTVGTNGGLKVVSTQNLELGLMTYDGNTGLLATKSDETG	1656
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	601	IRRDSSGMPRHLLMPDNQIITLTVGTNGGLKVVSTQNLELGLMTYDGNTGLLATKSDETG	660
QUERY:	1657	WTTFYDYDHEGRLTNVTRPTGVVTSLHREMEKSITIDIENSNRDDDVTVITNLSSVEASY	1716
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	661	WTTFYDYDHEGRLTNVTRPTCVVTSLHREMEKSITIDIENSNRDDDVTVITNLSSVEASY	720
QUERY:	1717	TVVQDQVRNSYQLCNNGTLRVMYANGMGISFHSEPHVLAGTITPTIGRCNISLPMENGLN	1776
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	721	TVVQDQVRNSYQLCNNGTLRVMYANGMGISFHSEPRVLAGTITPTIGRCNISLPNENGLN	780
QUERY:	1777	SIEWRLRKEQIKGKVTIFGRKLRVHGRNLLSIDYDRNIRTEKIYDDHRKFTLRIIYDQVG	1836
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	781	SIEWRLRKEQIKGKVTIFGRKLRVHGRNLLSIDYDRNIRTEKIYDDHRKFTLRIIYDQVG	840
QUERY:	1837	RPFLWLFSSGLAAVNVSYFFNGRLAGLQRGAIASERTDIDKQGRIVSRMFADGKVWSYSYL	1896
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	841	RPFLWLPSSGLAAVNVSYFFNGRLAGLQRGAMSERTDIDKQGRIVSRMFADGKVWSYSYL	900
QUERY:	1897	DKSMVLLLQSQRQYIFEYDSSDRLLAVTMPSVARHSMSTHTSIGYIRNIYNPPESNASVI	1956
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	901	DKSMVLLLQSQRQYIFEYDSSDRLLAVTMPSVARHSMSTHTSIGYIRNIYNPPESNASVI	960
QUERY:	1957	FDYSDDGRILKTSFLGTGRQVFYKYGKLSKLSEIVYDSTAVTFGYDETTGVLKMVNLQSG	2016
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	961	FDYSDDGRILKTSFLGTGRQVFYKYGKLSKLSEIVYDSTAVTFGYDETTGVLKMVNLQSG	1020
QUERY:	2017	GFSCTIRYRKIGPLVDKQIYRFSEEGMVNARFDYTYHDNSFRIASIKPVISETPLPVDLY	2076
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1021	GFSCTIRYRKIGPLVDKQIYRFSEEGMVNARFDYTYRDNSFRIASIKPVISETPLPVDLY	1080
QUERY:	2077	RYDEISGKVEHFGKFGVIYYDINQIITTAVMTLSKHFDTHGRIKEVQYEMFRSLMYWNTV	2136
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1081	RYDEISGKVEHFGKFGVIYYDINQIITTAVMTLSKHFDTRGRIKEVQYEMFRSLMYWMTV	1140
QUERY:	2137	QYDSNGRVIKRELKLGPYANTTKYTYDYDGDGQLQSVAVNDRPTWRYSYDXXXXXXXXXX	2196
		||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1141	QYDSNGRVIKRELKLGPYANTTKYTYDYDGDGQLQSVAVNDRPTWRYSYDLNGNLHLLNP	1200
QUERY:	2197	XXSVRLMPLRYDLRDRITRLGDVQYKIDDDGYLCQRGSDIFEYNSKGLLTRAYNKASGWS	2256
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1201	GNSVRLMPLRYDLRDRITRLGDVQYKIDDDGYLCQRGSDIFEYNSKGLLTRAYNKASGWS	1260
QUERY:	2257	VQYRYDGVGRRASYKTNLGRHLQYFYSDLHNPTRITRVYNHSNSEITSLYYDLQGRLFAM	2316
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1261	VQYRYDGVGRRASYKTNLGHRLQYFYSDLHNPTRITHVYNHSNSEITSLYYDLQGHLFAM	1320
QUERY:	2317	ESSSGEEYYVASDNTGTPLAVFSINGLMIRQLQYTAYGEIYYDSNPDFQMVIGFHGGLYD	2376
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1321	ESSSGEEYYVASDNGTPLAVFSINGLMIKQLQYTAYGEIYYDSNPDFQMVIGFHGGLYD	1380
QUERY:	2377	PLTKLVRFTQRDYDVLAGRWTSPDYTMWKNVGKEPAPFNLYMFKSNNPLSSELDLKNYVT	2436
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1381	PLTKLVHFTQRDYDVLAGRWTSPDYTMWKNVGKEPAPFNLYMFKSNNPLSSELDLKNYVT	1440
QUERY:	2437	DVKSWLVMFGFQLSNIIPGFPRAKMYFVPPPYELSESQASENGQLITGVQQTTERHNQAF	2496
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1441	DVXSWLVMFGFQLSNIIPGFPRAKMYFVPPPYELSESQASENGQLITGVQQTTERHNQAF	1500
QUERY:	2497	MALEGQVITKKLHASIREKAGHWFATTTPIIGRGIMFAIKEGRVTTGVSSIASEDSRKVA	2556
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1501	NALEGQVITKKLHASIREKAGRWFATTTPIIGKGIMFAIKEGRVTTGVSSIASEDSRKVA	1560
QUERY:	2557	SVLNNAYYLDKMHYSIEGKDTHYFVKIGSADGDLVTLGTTIGRKVLESGVNVTVSQPTLL	2616
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1561	SVLNNAYYLDKMHYSIEGKDTHYFVKIGSADGDLVTLGTTIGRKVLESGVNVTVSQFTLL	1620
QUERY:	2617	VNGRTRRFTNIEFQYSTLLLSIRYGLTPDTLDEEKARVLDQARQRALGTAWAKEQQKARD	2676
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1621	VNGRTRRFTNIEFQYSTLLLSIRYGLTPDTLDEEKARVLDQARQRALGTAWAKEQQKARD	1680
QUERY:	2677	GREGSRLWTEGEKQQLLSTGRVQGYEGYYVLPVEQYPELADSSSNIQFLRQNEMGKR	2733
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1681	GREGSRLWTEGEKQQLLSTGRVQGYEGYYVLPVEQYPELADSSSNIQFLRQNEMGKR	1737

[0110] The amino acid sequences of the FCTR3bcde and f proteins were also found to have 2528 of 2774 amino acid residues (91%) identical to, and 2557 of 2774 residues (92%) positive with, the 2765 amino acid residue protein neurestin alpha [Rattus norvegicus] (GenBank Acc:AF086607) (SEQ ID NO:72), shown in Table 3T.

TABLE 3T
BLASTP of FCTR3bcd and f against Rattus norvegicus Neurestin alpha
(SEQ ID NO:72)
>GI|9910320|REF|NP 064473.1| NEUXESTIN ALPHA [RATTUS NORVEGICUS]
GI|5712201|GB|AAD47383.1|AF086607 1 (AF086607) NEURESTIN ALPHA [RATTUS NORVEGICUS]
LENGTH = 2765
SCORE = 4988 BITS (12938), EXPECT = 0.0
IDENTITIES = 2528/2774 (91%), POSITIVES = 2557/2774 (92%), GAPS = 50/2774 (1%)
QUERY:	1	NDVKDRRHRSLTRGRCGKECRYTSSSLDSEDCRVPTQKSYSSSETLKAYDHDSPNHYGNR	60
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1	MDVKDRRHRSLTRGRCGKECRYTSSSLDSHDCRVPTQKSYSSSETLKAYDHDSRMHYGNR	60
QUERY:	61	VTDLIHRESDEFPRQGTNFTLAELGICEPSPHRSGYCSDMGILEQGYSLSTGSDADSDTE	120
		||||+||||||| ||| |||||||||||||||||||||||||||||||||||||||||||
SBJCT:	61	VTDLVHRESDEFSRQGANFTLAELGICEPSPHRSGYCSDMGILHQGYSLSTGSDADSDTE	120
QUERY:	121	GGMSPEHAIRLWGRGIKSRRSSGLSSRENSALTLTXXXXXXXXXXXXGRYXXXXXXXXXXX	180
		|||||||||||||||||||||||||||||||||||            ||
SBJCT:	121	GGMSPEHAIRLWGRGIKSRRSSGLSSRENSALTLTDSDNENKSDDDNGRPIPPTSSSSLL	180
QUERY:	181	XXXXXXXXHNPPPVSCQMPLLDSNTSHQIMDTNPDEEFSPNSYLLRACXXXXXXXXXXXX	240
		||||||||||||||||||||||||||||||||||||||||
SBJCT:	181	PSAQLPSSHNPPPVSCQMPLLDSNTSHQIMDTNPDEEFSPNSYLLRACSGPQQASSSGPP	240
QUERY:	241	NHHSQXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXQIHAPAPAPNDLATTPESVQ	300
		|||||                                   ||||||||||||||||||||
SBJCT:	241	NHHSQSTLRPPLPPPHNHTLSHHHSSANSLNPNSLTNRRSQIHAPAPAPNDLATTPESVQ	300
QUERY:	301	LQDSWVLNSNVPLETREFLFKXXXXXXXXXXXXXXXYPLTSGTVYTPPPRLLPRNTFSRK	360
		|||||||||||||||||||||               ||||||||||||||||||||||||
SBJCT:	301	LQDSWVLNSNVPLETRHRLFKTSSGSTPLFSSSSPGYPLTSGTVYTPPPRLLPRNTESRK	360
QUERY:	361	AFKLKKPSKYCSWKCXXXXXXXXXXXXXXXXXYFI-------------------------	395
		|||||||||||||||                 |||
SBJCT:	361	AFKLKKPSKYCSWXCAALSAIAAALLLAILLAYFIAMHLLGLNWQLQPDGHTFNNGVRT	420
QUERY:	396	----------------VPWSLKNSSIDSGEAEVGRRVTQEVPPGVFWRSQIHISQPQFLK	439
		||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	421	GLPGNDDVATVPSGGKVPWSLKNSSIDSGEAEVGRRVTQEVPPGVFWRSQIHISQPQFLK	480
QUERY:	440	FNISLGKDALFGVYIRRGLPPSHAQYDFMERLDGKEKWSVVESPRERRSIQTLVQNEAVF	499
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	481	FNISLGKDALFGVYIRRGLPPSHAQYDFMERLDGKEKWSVVESPRERRSIQTLVQNEAVF	540
QUERY:	500	VQYLDVGLWHLAFYNDGKDKEMVSFNTVVLDSVQDCPRNCHGNGECVSGVCHCFPGFLGA	559
		|||||||||||||||||||||||||||||||||||||||||||||||||+||||||||||
SBJCT:	541	VQYLDVGLWHLAFYNDGKDKEMVSFNTVVLDSVQDCPRNCHGNGECVSGLCHCFPGFLGA	600
QUERY:	560	DCAKAACPVLCSGNGQYSKGTCQCYSGWKGAECDVPMNQCIDPSCGGHGSCIDGNCVCSA	619
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||+|
SBJCT:	601	DCAKAACPVLCSGNGQYSKGTCQCYSGWKGAECDVPMNQCIDPSCGGHGSCIDGNCVCAA	660
QUERY:	620	GYKGEHCEEVDCLDPTCSSHGVCVNGECLCSPGWGGLNCELARVQCPDQCSGHGTYLPDT	679
		|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||+
SBJCT:	661	GYKGEHCEEVDCLDPTCSSHGVCVNGECLCSPGWGGLNCELARVQCPDQCSGHGTYLPDS	720
QUERY:	680	GLCSCDPNWMGPDCSVEVCSVDCGTHGVCIGGACRCEEGWTGAACDQRVCHPRCIEHGTC	739
		|||+||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	721	GLCNCDPNWMGPDCSVEVCSVDCGTHGVCIGGACRCEEGWTGAACDQRVCHPRCIERGTC	780
		*********
QUERY:	740	KDGKCECREGWNGEHCTIGRQTAGTETDGCPDLCNGNGRCTLGQNSWQCVCQTGWRGPGC	799
		||||||||||||||||||         |||||||||||||||||||||||||||||||||
SBJCT:	781	KDGKCECREGWNGEHCTI---------DGCPDLCNGNGRCTLGQNSWQCVCQTGWRGPGC	831
QUERY:	800	NVAMETSCADNKDNEGDGLVDCLDPDCCLQSACQNSLLCRGSRDPLDIIQQGQTDWPAVK	859
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	832	NVAMETSCADNKDNEGDGLVDCLDPDCCLQSACQNSLLCRGSRDPLDIIQQGQTDWPAVK	891
QUERY:	860	SFYDRIKLLAGKDSTHIIPGENPFNSSLVSLIRGQVVTTDGTPLVGVNVSFVKYPRYGYT	919
		||||||||||||||||||||+|||||||||||||||||||||||||||||||||||||||
SBJCT:	892	SFYDRIKLLAGICDSTHIIPGDNPFNSSLVSLIRGQVVTTDGTPLVGVNVSFVKYPKYGYT	951
QUERY:	920	ITRQDGTFDLIANGGASLTLHFERAPFMSQERTVWLPPWNSFYAMDTLVMKTEENSIPSCD	979
		|||||||||||||||++||||||||||||+||||| ||||||||||||||||||||||||
SBJCT:	952	ITRQDGTFDLIANGGSALTLHFERAPFMSRERTVWPPWNSFYAMDTLVMKTEENSIPSCD	1011
QUERY:	980	LSGFVRPDPIIISSFLSTFFSAAPGQNPIVPETQVLHEEIELPGSNVKLRYLSSRTAGYK	1039
		||||||||||||||||||||||+|  ||||||||||||||||||+|||||||||||||||
SBJCT:	1012	LSGFVRPDPIIISSPLSTFFSASPAANPIVPETQVLHEEIELPGTNVKLRYLSSRTAGYK	1071
QUERY:	1040	SLLKITMTQSTVPLNLIRVHLMVAVEGHLFQKSFQASPNLASTFIWDKTDAYGQRVYGLS	1099
		||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||
SBJCT:	1072	SLLKITMTQSTVPLNLIRVHLMVAVEGHLFQKSFQASPNLAYTFIWDKTDAYGQRVYGLS	1131
QUERY:	1100	DAVVSVGFEYETCPSLILWEKRTALLQGFELDPSNLGGWSLDKHHILNVKSGILHKGTGE	1159
		||||||||||||||||||||||||||||||||||||||||||||| |||||||| |||||
SBJCT:	1132	DAVVSVGFEYETCPSLILWEKRTALLQGFELDPSNLGGWSLDKHHTLNVKSGILLKGTGE	1191
QUERY:	1160	NQFLTQQPAIITSIMGNGRRRSISCPSCNGLAEGNKLLAPVALAVGIDGSLYVGDFNYIR	1219
		|||||||||||||||||||||||||||||||||||||||||||||||||||+||||||||
SBJCT:	1192	NQFLTQQPAIITSIMGNGRRRSISCPSCNGLAEGNKLLAPVALAVGIDGSLFVGDFNYIR	1251
QUERY:	1220	RIFPSRNVTSILELRNKEFRHSNNPAHKYYLAVDPVSGSLYVSDTNSRRIYRVKSLSGTK	1279
		|||||||||||||||||||||||+| ||||||||||+||||||||||||||||||||| |
SBJCT:	1252	RIFPSRNVTSILELRNKEFKHSNSPGHKYYLAVDPVTGSLYVSDTNSRRIYRVKSLSGAK	1311
QUERY:	1280	DLAGNSEVVAGTGEQCLPFDEARCGDGGKAIDATLMSPRGIAVDKNGLMYFVDATMIRKV	1339
		||||||||||||||||||||||||||||||+|||||||||||||||||||||||||||||
SBJCT:	1312	DLAGNSEVVAGTGEQCLPFDEARCGDGGKAVDATLMSPRGIAVDKNGLMYFVDATMIRKV	1371
QUERY:	1340	DQNGIISTLLGSNDLTAVRPLSCDSSMDVAQVRLEWPTDLAVNPMDNSLYVLENNVILRI	1399
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1372	DQNGIISTLLGSNDLTAVRPLSCDSSMDVAQVRLEWPTDLAVNPMDNSLYVLENNVILRI	1431
QUERY:	1400	TENHQVSIIAGRPMHCQVPGIDYSLSKXXXXXXXXXXXXXXXXXTGVLYITETDEKKINR	1459
		|||||||||||||||||||||||||||                 ||||||||||||||||
SBJCT:	1432	TRNRQVSIIAGRPMHCQVPGIDYSLSKLAIHSALESASAIAISHTGVLYITETDEKKINR	1491
QUERY:	1460	LRQVTTNGEICLLAGAASXXXXXXXXXXXXYSGDDAYATDAILNSPSSLAVAPDGTIYIA	1519
		||||||||||||||||||            |||||||||||||||||||||||||||||||
SBJCT:	1492	LRQVTTNGEICLLAGAASDCDCKNDVNCICYSGDDAYATDAILNSPSSLAVAPDGTIYIA	1551
QUERY:	1520	DLGNIRIRAVSKNKPVLNAFNQYEAASPGEQELYVFNADGIHQYTVSLVTGEYLYNFTYS	1579
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1552	DLGNIRIRAVSKNKPVLNAFNQYEAASPGEQELYVFNADGIHQYTVSLVTGEYLYNFTYS	1611
QUERY:	1580	TDNDVTELIDNNGNSLKIRRDSSGMPRHLLMPDNQIITLTVGTNGGLKVVSTQNLELGLM	1639
		||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||
SBJCT:	1612	ADNDVTELIDNNGNSLKIRRDSSGMPRRLLMPDNQIITLTVGTNGGLKAVSTQNLELGLM	1671
QUERY:	1640	TYDGNTGLLATKSDETGWTTFYDYDHEGRLTNVTRPTGVVTSLHREMEKSITIDIENSNR	1699
		||||||||||||||||||||||||||||||||||||||||||||||||||||+|||||||
SBJCT:	1672	TYDGNTGLLATKSDETGWTTFYDYDEEGRLTNVTRPTGVVTSLHREMEKSITVDIENSNR	1731
QUERY:	1700	DDDVTVITNLSSVEASYTVVQDQVRNSYQLCNNGTLRVMYANGMGISFHSEPHVLAGTIT	1759
		|+|||||||||||||||||||||||||||||+|||||||||||||+||||||||||||+|
SBJCT:	1732	DNDVTVITNLSSVEASYTVVQDQVRNSYQLCSNGTLRVMYANGMGVSFHSEPHVLAGTLT	1791
QUERY:	1760	PTIGRCNISLPMENGLNSIEWRLRKEQIKGKVTIFGRKLRVHGRNLLSIDYDRNIRTEKI	1819
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1792	PTIGRCNISLPMENGLNSIEWRLRKEQIKGKVTIFGRKLRVHGRNLLSIDYDRNIRTEKI	1851
QUERY:	1820	YDDHRKFTLRIIYDQVGRPFLWLPSSGLAAVNVSYFFNGRLAGLQRGAMSERTDIDKQGR	1879
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1852	YDDHRKFTLRIIYDQVGRPFLWLPSSGLAAVNVSYFFNGRLAGLQRGAMSERTDIDKQGR	1911
QUERY:	1880	IVSRMFADGKVWSYSYLDKSMVLLLQSQRQYIFEYDSSDRLLAVTMPSVARHSMSTHTSI	1939
		||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||
SBJCT:	1912	IVSRMFADGKVWSYSYLDKSMVLLLQSQRQYIFEYDSSDRLHAVTMPSVARHSMSTHTSI	1971
QUERY:	1940	GYIRNIYNPPESNASVIFDYSDDGRILKTSFLGTGRQVFYKYGKLSKLSEIVYDSTAVTF	1999
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1972	GYIRNIYNPPESNASVIFDYSDDCRILKTSFLGTGRQVFYKYGKLSKLSEIVYDSTAVTF	2031
QUERY:	2000	GYDETTGVLKMVNLQSGGFSCTIRYRKIGPLVDKQIYRFSEEGMVNARFDYTYHDNSFRI	2059
		|||||||||||||||||||||||||||+||||||||||||||||+|||||||||||||||
SBJCT:	2032	GYDETTGVLKMVNLQSGGFSCTIRYRKVGPLVDKQIYRFSEEGMINARFDYTYRDNSFRI	2091
QUERY:	2060	ASIKFVISETPLPVDLYRYDEISGKVEHFGKFGVIYYDINQIITTAVMTLSKHFDTHGRI	2119
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2092	ASIKPVISETPLPVDLYRYDEISGKVEHFGKFGVIYYDINQIITTAVNTLSKHFDTHGRI	2151
QUERY:	2120	KEVQYEMFRSLMYWMTVQYDSMGRVIKRELKLGPYANTTKYTYDYDGDGQLQSVAVNDRP	2179
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2152	KEVQYEMFRSLMYWMTVQYDSMGRVIKRELKLGPYANTThYTYDYDGDGQLQSVAVNDRP	2211
QUERY:	2180	TWRYSYDXXXXXXXXXXXXSVRLMPLRYDLRDRITRLGDVQYKIDDDGYLCQRGSDIFEY	2239
		|||||||            | |||||||||||||||||||||||||||||||||||||||
SBJCT:	2212	TWRYSYDLNGNLHLLNPGNSARLMPLRYDLRDRITRLGDVQYKIDDDGYLCQRGSDIFEY	2271
QUERY:	2240	NSKGLLTRAYNKASGWSVQYRYDGVGRRASYKTNLGHHLQYFYSDLHNPTRITHVYNHSN	2299
		||||||||||||||||||||||||| |||||||||||||||||||||+||||||||||||
SBJCT:	2272	NSKGLLTRAYNKASGWSVQYRYDGVSRRASYKTNLGHRLQYFYSDLHHPTRITHVYNHSN	2331
QUERY:	2300	SEITSLYYDLQGRLFAMESSSGEEYYVASDNTGTPLAVFSINGLMIKQLQYTAYGEIYYD	2359
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2332	SEITSLYYDLQGHLPAMESSSGEEYYVASDNTGTPLAVFSINGLMIKQLQYTAYGEIYYD	2391
QUERY:	2360	SNPDFQMVIGFHGGLYDPLTKLVHFTQRDYDVLAGRWTSPDYTNWKNVGKEPAPFNLYMF	2419
		|||||||||||||||||||||||||||||||||||||||||||||+||||||||||||||
SBJCT:	2392	SNPDFQMVIGFHGGLYDPLTKLVHFTQRDYDVLAGRWTSPDYTMWRNVGKEPAPFNLYMF	2451
QUERY:	2420	KSNNPLSSELDLKNYVTDVKSWLVMFGFQLSNIIPGFPRAKMYFVPPPYELSESQASENG	2479
		|+|||||+||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2452	KNNNPLSNELDLKNYVTDVKSWLVMFGFQLSNIIPGFPRAKMYFVPPPYELSESQASENG	2511
QUERY:	2480	QLITGVQQTTERHNQAFMALEGQVITKKLHASIREKAGHWFATTTPIIGKGIMFAIKEGR	2539
		|||||||||||||||||+|||||||+||||| ||||||||||||||||||||||||||||
SBJCT:	2512	QLITGVQQTTERHNQAFLALEGQVISKKLHAGIREKAGHWFATTTPIIGKGIMFAIKEGR	2571
QUERY:	2540	VTTGVSSIASEDSRKVASVLNNAYYLDKNRYSIEGKDTHYFVKIGSADGDLVTLGTTIGR	2599
		|||||||||||||||||||||||||||||||||||||||||||||+||||||||||||||
SBJCT:	2572	VTTGVSSIASEDSRKVASVLNNAYYLDKMHYSIEGKDTHYFVKIGAADGDLVTLGTTIGR	2631
QUERY:	2600	KVLESGVNVTVSQPTLLVNGRTRRFTNIEFQYSTLLLSIRYGLTPDTLDEEKARVLDQAR	2659
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2632	KVLESGVNVTVSQPTLLVNGRTRRFTNIEFQYSTLLLSIRYGLTPDTLDEEKARVLDQAR	2691
QUERY:	2660	QRALGTAWAKEQQKARDGREGSRLWTEGEKQQLLSTGRVQGYEGYYVLPVEQYPELADSS	2719
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2692	QRALGTAWAKEQQKARDGREGSRLWTEOERQQLLSTGRVQGYEGYYVLPVEQYPELADSS	2751
QUERY:	2720	SNIQFLRQNEMGKR 2733
		||||||||||||||
SBJCT:	2752	SNIQFLRQNEMGKR 2765
* = FCTR3F DOES NOT CONTAIN THESE AMINO ACIDS

[0111] The amino acid sequences of the FCTR3bcde and f proteins were also found to have 2536 of 2774 amino acid residues (91%) identical to, and 2558 of 2774 residues (91%) positive with, the 2764 amino acid residue protein Odd Oz/ten-m homolog 2 (Drosophila) (GenBank Acc:NP035986.2) (SEQ ID NO:65), shown in Table 3U.

TABLE 3U
BLASTP of FCTR3bcde and f against Odd Oz/ten-m homolog 2
(SEQ ID NO:65)
>GI|7657415|REF|NP 035986.2| ODD OZ/TEN-M HOMOLOG 2 (DROSOPHILA); ODD OZ/TEN-M
HOMOLOG 3
(DROSOPHILA) [MUS MUSCULUS]
GI|4760778|DBJ|BAA77397.1| (AB025411) TEN-M2 [MUS MUSCULUS]
LENGTH = 2764
SCORE = 4996 BITS (12961), EXPECT = 0.0
IDENTITIES = 2536/2774 (91%), POSITIVES = 2558/2774 (91%), GAPS = 51/2774 (1%)
QUERY:	1	MDVKDRRHRSLTRGRCGKECRYTSSSLDSEDCRVPTQKSYSSSETLKAYDHDSRNHYGNR	60
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1	MDVKDRRHRSLTRGRCGKECRYTSSSLDSEDCRVPTQKSYSSSETLKAYDHDSRMEYGNR	60
QUERY:	61	VTDLIHRESDEFPRQGTNFTLAELGICEPSPHRSGYCSDMGILHQGYSLSTGSDADSDTE	120
		||||+||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	61	VTDLVHRESDEFSRQGTNFTLAELGICEPSPERSGYCSDMGILHQGYSLSTGSDADSDTE	120
QUERY:	121	GGMSPEHAIRLWGRGIKSRRSSGLSSRENSALTLTXXXXXXXXXXXXGRXXXXXXXXXXX	180
		|||||||||||||||||||||||||||||||||||            ||
SBJCT:	121	GGMSPEHAIRLWGRGIKSRRSSGLSSRENSALTLTDSDNENKSDDDNGRPIPPTSSSSLL	180
QUERY:	181	XXXXXXXXHNPPPVSCQMPLLDSNTSHQIMDTNPDEEFSPNSYLLRACXXXXXXXXXXXX	240
		||||||||||||||||||||||||||||||||||||||||
SBJCT:	181	PSAQLPSSHNPPPVSCQMPLLDSNTSHQIMDTNPDEEFSPNSYLLRACSGPQQASSSGPP	240
QUERY:	241	NRHSQXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXQIHAPAPAPNDLATTPESVQ	300
		|||||                                   ||||||||||||||||||||
SBJCT:	241	NHHSQSTLRPPLPPPHNHTLSHHHSSANSLNRNSLTNRRSQIHAPAPAPNDLATTPESVQ	300
QUERY:	301	LQDSWVLNSNVPLETRHFLFEXXXXXXXXXXXXXXXYPLTSGTVYTPPPRLLPRNTFSRK	360
		|||||||||||||||||||||               ||||||||||||||||||||||||
SBJCT:	301	LQDSWVLNSNVPLETRHFLFKTSSGSTPLFSSSSPGYPLTSGTVYTPPPRLLPRNTFSRK	360
QUERY:	361	AFKLKKPSKYCSWRCXXXXXXXXXXXXXXXXXYFI-------------------------	395
		|||||||||||||||                 |||
SBJCT:	361	AFKLKKPSKYCSWKCAALSAIAAALLLAILLAYFIAMHLLGLNWQLQPADGHTFNNGVRT	420
QUERY:	396	----------------VPWSLKNSSIDSGEAEVGRRVTQEVPPGVFWRSQIHISQPQFLK	439
		||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	421	GLPGNDDVATVPSGGKVPWSLKNSSIDSGEAEVGRRVTQEVPPGVFWRSQIHISQPQFLK	480
QUERY:	440	FNISLGKDALFGVYIRRGLPPSHAQYDFMERLDGEEKWSVVESPRERRSIQTLVQNEAVF	499
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	481	FNISLGKDALFGVYIRRGLPPSHAQYDFMERLDGKEKWSVVESPRERRSIQTLVQNEAVF	540
QUERY:	500	VQYLDVGLWHLAFYNDGKDKEMVSFNTVVLDSVQDCPRNCHGNGECVSGVCHCFPGFLGA	559
		|||||||||||||||||||||||||||||||||||||||||||||||||+||||||||||
SBJCT:	541	VQYLDVGLWHLAFYNDGEDKEMVSFNTVVLDSVQDCPRNCHGNGECVSGLCHCFPGFLGA	600
QUERY:	560	DCAKAACPVLCSGNGQYSKGTCQCYSGWKGAECDVPNNQCIDPSCGGHGSCIDGNCVCSA	619
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||+|
SBJCT:	601	DCAKAACPVLCSGNGQYSKGTCQCYSGWKGAECDVPMNQCIDPSCGGHGSCIDGNCVCAA	660
QUERY:	620	GYKGEHCEEVDCLDPTCSSHGVCVNGECLCSPGWGGLNCELARVQCPDQCSGHGTYLPDT	679
		|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||+
SBJCT:	661	GYKGEHCEEVDCLDPTCSSHGVCVNGECLCSPGWGGLNCELARVQCPDQCSGHGTYLPDS	720
QUERY:	680	GLCSCDPNWNGPDCSVEVCSVDCGTEGVCIGGACRCEEGWTGAACDQRVCHPRCIEHGTC	739
		|||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||
SBJCT:	721	GLCSCDPNNMGPDCSV-VCSVDCGTHGVCIGGACRCEEGWTGAACDQRVCHPRCIEHGTC	779
		*********
QUERY:	740	KDGKCECREGWNGEHCTIGRQTAGTETDGCPDLCNGNGRCTLGQNSWQCVCQTGWRGPGC	799
		||||||||||||||||||         |||||||||||||||||||||||||||||||||
SBJCT:	780	KDGKCECREGWNGEHCTI---------DGCPDLCNGNGRCTLGQNSWQCVCQTGWRGPGC	830
QUERY:	800	NVAMETSCADNKDNEGDGLVDCLDPDCCLQSACQNSLLCRGSRDPLDIIQQGQTDWPAVK	859
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	831	NVANETSCADNKDNEGDGLVDCLDPDCCLQSACQNSLLCRGSRDPLDIIQQGQTDWPAVK	890
QUERY:	860	SFYDRIKLLAGKDSTHIIPGENPFNSSLVSLIRGQVVTTDGTPLVGVNVSFVKYPKYGYT	919
		||||||||||||||||||||+||||||||||||||||| ||||||||||||||||||||||
SBJCT:	891	SFYDRIKLLAGKDSTHIIPGDNPFNSSLVSLIRGQVVTMDGTPLVGVNVSFVKYPKYGYT	950
QUERY:	920	ITRQDGTFDLIANGGASLTLHFERAPFMSQERTVWLPWNSFYAMDTLVMKTEENSIPSCD	979
		|||||||||||||||++|||||||||||||||||||||||||||||||||||||||||||
SBJCT:	951	ITRQDGTFDLIANGGSALTLHFERAPFMSQERTVWLPWNSFYAMDTLVMKTEENSIPSCD	1010
QUERY:	980	LSGFVRPDPIIISSPLSTFFSAAPGQNPIVPETQVLHEEIELPGSNVKLRYLSSRTAGYK	1039
		||||||||||||||||||||||+|  ||||||||||||||||||+|||||||||||||||
SBJCT:	1011	LSGFVRPDPIIISSPLSTFFSASPASNPIVPETQVLHEEIELPGTNVKLRYLSSRTAGYK	1070
QUERY:	1040	SLLKITMTQSTVPLNLIRVHLMVAVEGHLFQKSFQASPNLASTFIWDKTDAYGQRVYGLS	1099
		||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||
SBJCT:	1071	SLLKITMTQSTVPLNLIRVHLMVAVEGHLFQKSFQASPNLAYTFIWDKTDAYGQRVYGLS	1130
QUERY:	1100	DAVVSVGFEYETCPSLILWEKRTALLQGFELDPSNLGGWSLDKHHILNVKSGILHKGTGE	1159
		||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||
SBJCT:	1131	DAVVSVGFEYETCPSLILWEKRTALLQGFELDPSNLGGWSLDKHHTLNVKSGILHKGTGE	1190
QUERY:	1160	NQFLTQQPAIITSIMGNGRRRSISCPSCNGLAEGNKLLAPVALAVGIDGSLYVGDFNYIR	1219
		|||||||||||||||||||||||||||||||||||||||||||||||||||+||||||||
SBJCT:	1191	NQFLTQQPAIITSIMGNGRRRSISCPSCNGLAEGNKLLAPVALAVGIDGSLFVGDFNYIR	1250
QUERY:	1220	RIFPSRNVTSILELRNXEFKHSNNPAHKYYLAVDPVSGSLYVSDTNSRRIYRVKSLSGTK	1279
		|||||||||||||||||||||||+| ||||||||||+||||||||||||||||||||| |
SBJCT:	1251	RIFPSRNVTSILELRNKEFKHSNSPGHKYYLAVDPVTGSLYVSDTNSRRIYRVKSLSGAK	1310
QUERY:	1280	DLAGNSEVVAGTGEQCLPFDEARCGDGGKAIDATLMSPRGIAVDKNGLMYFVDATMIRKV	1339
		||||||||||||||||||||||||||||||+|||||||||||||||||||||||||||||
SBJCT:	1311	DLAGNSEVVAGTGEQCLPFDEARCGDGGKAVDATLMSPRGIAVDKNGLMYFVDATMIRKV	1370
QUERY:	1340	DQNGIISTLLGSNDLTAVRPLSCDSSMDVAQVRLEWPTDLAVNPMDNSLYVLENNVILRI	1399
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1371	DQNGIISTLLGSNDLTAVRPLSCDSSMDVAQVRLEWPTDLAVNPMDNSLYVLENNVILRI	1430
QUERY:	1400	TENHQVSIIAGRPNHCQVPGIDYSLSKXXXXXXXXXXXXXXXXXTGVLYITETDEKRINR	1459
		|||||||||||||||||||||||||||                 ||||||||||||||||
SBJCT:	1431	TENHQVSIIAGRPMHCQVPGIDYSLSRLAIHSALESASAIAISHTGVLYITETDEKKINR	1490
QUERY:	1460	LRQVTTNGEICLLAGAASXXXXXXXXXXXXYSGDDAYATDAILNSPSSLAVAPDGTIYIA	1519
		||||||||||||||||||            ||||||||||||||||||||||||||||||
SBJCT:	1491	LRQVTTNGEICLLAGAASDCDCKNDVNCICYSGDDAYATDAILNSPSSLAVAPDGTIYIA	1550
QUERY:	1520	DLGNIRIRAVSKNKPVLNAFNQYEAASPGEQELYVFNADGIHQYTVSLVTGEYLYNFTYS	1579
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1551	DLGNIRIRAVSKNKPVLNAFNQYEAASPGEQELYVFNADGIHQYTVSLVTGEYLYNFTYS	1610
QUERY:	1580	TDNDVTELIDNNGNSLKIRRDSSGMPRHLLMPDNQIITLTVGTNGGLKVVSTQNLELGLM	1639
		||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||
SBJCT:	1611	ADNDVTELIDNNGNSLKIRRDSSGMPRHLLMPDNQIITLTVGTNGGLKAVSTQNLELGLM	1670
QUERY:	1640	TYDGNTGLLATKSDETGWTTFYDYDHEGRLTNVTRPTGVVTSLHREMEKSITIDIENSNR	1699
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1671	TYDGNTGLLATKSDETGWTTFYDYDHEGRLTNVTRPTGVVTSLHREMERSITIDIENSNR	1730
QUERY:	1700	DDDVTVITNLSSVEASYTVVQDQVRNSYQLCNNGTLRVMYANGMGISFHSEPHVLAGTIT	1759
		|||||||||||||||||||||||||||||||||||||||||||| +||||||||||||||
SBJCT:	1731	DDDVTVITNLSSVEASYTVVQDQVRNSYQLCNNGTLRVMYANGMAVSFHSEPHVLAGTIT	1790
QUERY:	1760	PTIGRCNISLPMENGLNSIEWRLRKEQIKGKVTIFGRKLRVHGRNLLSIDYDRNIRTEKI	1819
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1791	PTIGRCNISLPMENGLNSIEWRLRKRQIKGKVTIFGRKLRVHGRNLLSIDYDRNIRTEKI	1850
QUERY:	1820	YDDHRKFTLRIIYDQVGRPFLWLPSSGLAAVNVSYFFNGRLAGLQRGAMSERTDIDKQGR	1879
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1851	YDDHRRFTLRIIYDQVGRPFLWLPSSGLAAVNVSYFFNGRLAGLQRGAMSERTDIDRQGR	1910
QUERY:	1880	IVSRMFADGKVWSYSYLDKSMVLLLQSQRQYIFEYDSSDRLLAVTMPSVAPESMSTHTSI	1939
		||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||
SBJCT:	1911	IVSRMFADGKVWSYSYLDRSMVLLLQSQRQYIFEYDSSDRLHAVTMPSVARHSMSTHTSI	1970
QUERY:	1940	GYIRNIYNPPESNASVIFDYSDDGRILRTSFLGTGRQVFYKYGKLSRLSEIVYDSTAVTF	1999
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	1971	GYIRNIYNPPESNASVIFDYSDDGRILKTSFLGTGRQVFYKYGRLSRLSEIVYDSTAVTF	2030
QUERY:	2000	GYDETTGVLKMVNLQSGGFSCTIRYRKIGPLVDKQIYRFSEEGMVNARFDYTYHDNSFRI	2059
		|||||||||||||||||||||||||||+||||||||||||||||+|||||||||||||||
SBJCT:	2031	GYDETTGVLKMVNLQSGGFSCTIRYRXVGPLVDKQIYRFSEEGMINARFDYTYHDNSFRI	2090
QUERY:	2060	ASIKPVISETPLPVDLYRYDEISGKVEHFGKFGVIYYDINQIITTAVNTLSKHFDTHGRI	2119
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2091	ASIKPVISETPLPVDLYRYDEISGKVEHFGKFGVIYYDINQIITTAVMTLSKHFDTHGRI	2150
QUERY:	2120	KEVQYEMFRSLMYWMTVQYDSMQRVIKRELKLGPYANTTRYTYDYDCDGQLQSVAVNDRP	2179
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2151	KEVQYEMFRSLMYWMTVQYDSMGRVIKRELKLGPYANTTKYTYDYDGDGQLQSVAVNDRP	2210
QUERY:	2180	TWRYSYDXXXXXXXXXXXXSVRLMPLRYDLRDRITRLGDVQYKIDDDGYLCQRGSDIFEY	2239
		|||||||            | |||||||||||||||||||||||||||||||||||||||
SBJCT:	2211	TWRYSYDLNGNLHLLNPGNSARLMPLRYDLRDRITRLGDVQYKIDDDGYLCQRGSDIFEY	2270
QUERY:	2240	NSKGLLTRAYNKASGWSVQYRYDGVGRRASYKTNLGHHLQYFYSDLHNPTRITHVYNHSN	2299
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2271	NSKGLLTRAYNKASGWSVQYRYDGVGRRASYKTNLGHHLQYFYSDLHNPTRITHVYNHSN	2330
QUERY:	2300	SEITSLYYDLQGHLFANESSSGEEYYVASDNTGTPLAVFSINGLMIKQLQYTAYGEIYYD	2359
		||||||||||||||||||||||||||||||||||||||+|||||||||||||||||||||
SBJCT:	2331	SEITSLYYDLQGHLFAMESSSGEEYYVASDNTGTPLVYSINGLMIKQLQYTAYGEIYYD	2390
QUERY:	2360	SNPDFQMVIGFHGGLYDPLTKLVHFTQRDYDVLAGRWTSPDYTMWKNVGKEPAPFNLYMF	2419
		|||||||||||||||||||||||||||||||||||||||||||||+||||||||||||||
SBJCT:	2391	SNPDFQMVIGFHGGLYDPLTKLVRFTQRDYDVLAGRWTSPDYTMWRNVGKEPAPFNLYMF	2450
QUERY:	2420	KSNNPLSSELDLKNYVTDVKSWLVMFGFQLSNIIPGFPRAKMYFVPPPYELSESQASENG	2479
		|+|||||+||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2451	KNNNPLSNELDLKNYVTDVKSWLVMFGBQLSNIIPGFPRAKMYFVPPPYELSESQASENG	2510
QUERY:	2480	QLITGVQQTTERHMQAFMALEGQVITKKLHASIREKAGHWFATTTPIIGKGIMFAIKEGR	2539
		|||||||||||||||||+||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2511	QLITGVQQTTERHNQAFLALEGQVITKKLHASIREKAGHWFATTTPIIGKGIMFAIKEGR	2570
QUERY:	2540	VTTGVSSIASEDSRKVASVLNNAYYLDKMHYSIEGRDTHYFVKIGSADGDLVTLGTTIGR	2599
		|||||||||||||||||||||||||||||||||||||||||||||+||||||||||||||
SBJCT:	2571	VTTGVSSIASEDSRKVASVLNNAYYLDKMHYSIEGKDTHYFVKIGAADGDLVTLGTTIGR	2630
QUERY:	2600	KVLESGVNVTVSQPTLLVNQRTRRFTNIEFQYSTLLLSIRYGLTPDTLDEEKARVLDQAR	2659
		|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2631	KVLESGVNVTVSQPTLLVNGRTRRFTNIEFQYSTLLLSIRYGLTPDTLDEEKARVLDQAG	2690
QUERY:	2660	QRALGTAWAKEQQKARDGREGSRLWTEGEKQQLLSTGRVQGYRGYYVLPVEQYPELADSS	2719
		||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT:	2691	QRALGTAWAKEQQKARDGREGSRLWTEGEKQQLLSTGRVQGYEGYYVLPVEQYPELADSS	2750
QUERY:	2720	SNIQFLRQNEMGKR 2733
		||||||||||||||
SBJCT:	2751	SNIQFLRQNEMGKR 2764
* = FCTR3F DOES NOT CONTAIN THESE AMINO ACIDS

[0112] FCTR3 is related to rat neurestin, a gene implicated in neuronal development (Otaki J M, Firestein S Dev Biol 1999 Aug. 1;212(1):165-81) Neurestin shows homology to human gamma-heregulin, a Drosophila receptor-type pair-rule gene product, Odd Oz (Odz)/Ten(m), and Ten(a). Neurestin has putative roles in synapse formation and brain morphogenesis. A mouse neurestin homolog, DOC4, has independently been isolated from the NIH-3T3 fibroblasts. DOC4 is also known as tenascin M (TNM), a Drosophila pair-rule gene homolog containing extracellular EGF-like repeats. The significant homology to these molecules and in particular, γ-heregulin, have important implications regarding the potential contribution of FCTR3 to disease progression. Heregulin is the ligand for HER-2/ErbB2/NEU, a proto-oncogene receptor tyrosine kinase implicated in breast and prostate cancer progression that was originally identified in rat neuro/glioblastoma cell lines. Extopic expression of HER-2/ErbB2/NEU in MDA-MB-435 breast adenocarcinoma cells confers chemoresistance to Taxol-induced apoptosis relative to vector transfected control cells (Yu et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by up-regulation of p21Cipi, which inhibits p34Cdc2 kinase. Molec. Cell 2: 581-591, 1998).

[0113] FCTR3 related tenascins and cancer biology

[0114] As mentioned, FCTR3 also has significant homology to DOC4, (AKA tenascin M), a Drosophila pair-rule gene homolog containing extracellular EGF-like repeats. The tenascins are a growing family of extracellular matrix proteins that play prominent roles in tissue interactions critical to embryogenesis. Overexpression of tenascins has been described in multiple human solid malignancies.

[0115] The role of the tenascin family of related proteins is to regulate epithelial-stromal interactions, participate in fibronectin-dependent cell attachment and interaction. Indeed, tenascin-C (TN) is overexpressed in the stroma of malignant ovarian tumours particularly at the interface between epithelia and stroma leading to suggestions that it may be involved in the process of invasion (Wilson et al (1996) Br J Cancer 74: 999-1004). Tenascin-C is considered a therapeutic target for certain malignant brain tumors (Gladson CL: J Neuropathol Exp Neurol 1999 October;58(10):1029-40). Stromal or moderate to strong periductal Tenascin-C expression in DCIS (ductal carcinoma in situ) correlates with tumor cell invasion. (Jahkola et al. Eur J Cancer 1998 October;34(11):1687-92. Tenascin-C expression at the invasion border of early breast cancer is a useful predictor of local and distant recurrence. Jahkola T, et al. Br J Cancer. 1998 December;78(11):1507-13). Tenascin (TN) is an extracellular matrix protein found in areas of cell migration during development and expressed at high levels in migratory glioma cells. Treasurywala S, Berens M E Glia 1998 October;24(2):236-43 Migration arrest in glioma cells is dependent on the alphaV integrin subunit. Phillips G R, Krushel L A, Crossin K L J Cell Sci 1998 April; 111 (Pt 8): 1095-104 Domains of tenascin involved in glioma migration. Finally, tenascin expression in hormone-dependent tissues of breast and endometrium indicate that Tenascin expression reflects malignant progression and is down-regulated by antiprogestins during terminal differentiation of rat mammary tumors (Vollmer et al. Cancer Res 1992 Sep. 1;52(17):4642-8)

[0116] Potential role of FCTR3 in oncologic disease progression:

[0117] Based on the bioactivity described in the medical literature for related molecules, FCTR3 may play a role in one or more aspects of tumor cell biology that alter the interactions of tumor epithelial cells with stromal components. In consideration, FCTR3 may play a role in the following malignant properties:

[0118] Autocrine/paracrine stimulation of tumor cell proliferation

[0119] Autocrine/paracrine stimulation of tumor cell survival and tumor cell resistance to cytotoxic therapy

[0120] Local tissue remodeling, paranechmal and basement membrane invasion and motility of tumor cells thereby contributing to metastasis.

[0121] Tumor-mediated immunosuppression of T-cell mediated immune effector cells and pathways resulting in tumor escape from immune surveilance.

[0122] Therapeutic intervention targeting FCTR3 in oncologic and central nervous system indications:

[0123] Predicted disease indications from expression profiling in 41 normal human tissues and 55 human cancer cell lines (see Example 2) include a subset of human gliomas, astrocytomas, mixed glioma/astrocytomas, renal cells carcinoma, breast adenocarcinoma, ovarian cancer, melanomas. Targeting of FCTR3 by human or humanized monoclonal antibodies designed to disrupt predicted interactions of FCTR3 with its cognate ligand may result in significant anti-tumor/anti-metastatic activity and the amelioration of associated symptomatology. Identification of small molecules that specifically/selectively interfere with downstream signaling components engaged by FCTR3/ligandinteractions would also be expected to result in significant anti-tumor/anti-metastatic activity and the amelioration of associated symptomatology. Likewise, modified antisense ribonucleotides or antisense gene expression constructs (plasmids, adenovirus, adeno-associated viruses, “naked” DNA approaches) designed to diminish the expression of FCTR3 transcripts/messenger RNA (mRNA) would be anticipated based on predicted properties of FCTR3 to have anti-tumor impact.

[0124] Based on the relatedness to neurestin and heregulins, as well as its high level expression in brain tissue, FCTR3 may also be used for remyelination in order to promote regeneration/repair/remyleination of injured central nervous system cells resulting from ischemia, brain trauma and various neurodegenerative diseases.. This postulate is based on reports indicating that neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis (Cannella et al. . Proc. Nat. Acad. Sci. 95: 10100-10105, 1998). The expression of the related molecule neurestin can be induced in external tufted cells during regeneration of olfactory sensory neurons.

[0125] FCTR4

[0126] FCTR4 is a plasma membrane protein related to NF-Kappa-B P65delta3 protein. The clone is expressed in fetal liver tissues.

[0127] The novel FCTR4 nucleic acid of 609 nucleotides (also referred to as 29692275.0.1) is shown in Table 4A. An ORF begins with an ATG initiation codon at nucleotides 99-101 and ends with a TAA codon at nucleotides 522-524. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 4A, and the start and stop codons are in bold letters.

TABLE 4A
FCTR4 Nucleotide Sequence
CTGACATACTATATTAGTTGTTTGTTCACTGTCTCC (SEQ ID NO:14)
ACTCCAGCTAGAATATAAGTTCCATACGGCAGAGTT
TTTGTTCACTGCTATATTTTATAAGCATGAATGAAT
GCATGAACGAATGGACTGATAACCCACAAGCCAAAG
ACCTCCATGACCTGCCACTGCCCTCCTTTCATTTTA
TTCTCACCTCTACCAATACTAAATCACCTAGTTATG
TAAATACGATATGCACTTTCATGGCCCCTTGCTTTG
TCATATGCTGTTCCCTTTGCCTGGAATATAAACTCT
CAAAATACCATCCACATTTTAAAATCTTCTCCAGAA
AGCTTCCTCTGTCCACCCCCACCCTCCCACCCCCAT
ATAGAGTAAGTCAGTCTTTCCTTTGTGCTACATTTG
TACCTGTATCTACAGTGGCTCTAATCAAACTGCACT
GTGTCTCTCACTTCCTAGATTGTGAACTCTTTGAGG
CTGAAGACTACTTATTCATCTCTTTACCTCCAATGC
CTAGGACAGGACCTTCATAAAGCAACTACTCTATAA
ATGTTGAAACATATGCATGACTATTCTGTAACAGGA
ATGAAAATATGGCATTTCAAGAAGTCACTACTC

[0128] The FCTR4 protein encoded by SEQ ID NO:14 has 141 amino acid residues and is presented using the one-letter code in Table 4B. The Psort profile for FCTR4 predicts that this sequence has no N-terminal signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. The most likely cleavage site for a peptide is between amino acids 39 and 40, i.e., at the dash in the amino acid sequence ACT-CCA, based on the SignalP result. The predicted molecular weight of this protein is 16051.5 Daltons.

TABLE 4B
Encoded FCTR4 protein sequence
MNECMNEWTDNPQAKDLHDLPLPSFHFILTSTNTKS (SEQ ID NO:15)
PSYVNTICTFMAPCFVICCSLCLEYKLSKYHPHFKI
FSRKLPLSTPTLPPPYRVSQSFLCATFVPVSTVALI
KLHCVSHFLDCELFEAEDYLFISLPPMPRTGPS.

[0129] The predicted amino acid sequence was searched in the publicly available GenBank database FCTR4 protein showed 30 % identities (22 over 72 amino acids) and 43% homologies (31 over 72 amino acids) with hypothetical 10 kD protein of Trypanosoma cruzi (86 aa; ACC:Q99233) shown in Table 4C. The best homologies with a human protein were 54% identities (114 over 343 amino acids) with NF-Kappa-B P65delta3 protein (71 aa fragment; ACC:Q13313) (SEQ ID NO:77).

TABLE 4C
BLASTP of FCTR4 against protein sequences
BLAST X search results are shown below:
ptnr:SPTREMBL-ACC:Q99233 HYPOTHETICAL 10 KD PROTEIN +3, 68, 0.60, 1, (SEQ ID NO:73)
ptnr:SPTREMBL-ACC:Q16896 GABA RECEPTOR SUBUNIT - AEDES +3, 66, 0.81, 4 (SEQ ID NO:74)
ptnr:SPTREMBL-ACC:O76473 GABA RECEPTOR SUBUNIT - LEPTI . . . +3, 66, 0.99, 2 (SEQ ID NO:75)
ptnr:TREMBLNEW-ACC:AAD28317 F13J11.13 PROTEIN - Arabid . . . +3, 62, 0.99, 1 (SEQ ID NO:76)

[0130] Based upon homology, FCTR4 proteins and each homologous protein or peptide may share at least some activity.

[0131] FCTR5

[0132] FCTR5 is a protein bearing sequence homology to human complement CIR component precursor. The clone is expressed in breast, heart, lung, fetal lung, salivary gland, adrenal gland, spleen, kidney, and fetal kidney.

[0133] The novel FCTR5 nucleic acid of 1667 nucleotides (also referred to as 32125243.0.21) is shown in Table 5A. An ORF begins with an ATG initiation codon at nucleotides 34-36 and ends with a TGA codon at nucleotides 1495-1497. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 5A, and the start and stop codons are in bold letters.

TABLE 5A
FCTR5a Nucleotide Sequence (SEQ ID NO:16)
GTTCTCTCGCAGGTCCCAGATGTCCAGTTCCAGATGCCTGGACCCAGAGTGTGGGGGAAATATCTCTGGAGAAGCCCTCA
CTCCAAAGGCTGTCCAGGCGCAATGTGGTGGCTGCTTCTCTGGGGAGTCCTCCAGGCTTGCCCAACCCGGGGCTCCGTCC
TCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACG
GACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGG
GGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCC
CTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACT
GCCCACCTCCACAAGGGCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAG
GGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCG
CGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATG
CCTGTCTGCGGACGACCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTT
CCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCC
ACACCATCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGAT
GAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTT
TAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATA
ATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTG
AAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTC
TGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCCTCTATGTGGTAT
GGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTAC
ACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATTGACCCTGGGGGCTTGAACAGGGACT
GACCAGCACAGTGGAGGCCCCAGGCAACAGAGGGCCTGGAGTGAGGACTGAACACTGGGGTAGGGGGTGGGGGTTTCTCT
TGCAGTGGCTTGGTGCAACAGTGATGTGAATAGGATTTCCCTTTTTTTTTTTTTTTTTAAAAAAAAA

[0134] The FCTR5 protein encoded by SEQ ID NO: 16 has 487 amino acid residues, and is presented using the one-letter code in Table 5B. FCTR5 was searched against other databases using SignalPep and PSort search protocols. The FCTR5 protein is most likely microbody (peroxisome) (Certainty=0.6406) and seems to have no N-terminal signal sequence. The predicted molecular weight of FCTR5 protein is 53511.9 daltons.

TABLE 5B
Encoded FCTR5a protein sequence (SEQ ID NO:17).
MPGPRVWGKYLWRSPHSKGCPGAMWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVF
QDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVN
YSQPISEASRGSEAINAPGDNPAKVQNBCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSS
RAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNE
SHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVF
SDNMFCVGDETQRHSVCQGDSGSLYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKN

[0135] An alternative embodiment, FCTR5b, is a 1691 base sequence shown in Table 5C.

TABLE 5C
FCTR5b Nucleotide Sequence (SEQ ID NO:18)
TTTTTTTTTAAAAAAAAAAAAAAAAAGGGAAATCCTATTCACATCACTGTTGCACCAAGCCACTGCAAGAGAAACCCCCACCC
CCTACCCCAGTGTTCAGTCCTCACTCCAGGCCCTCTGTTGCCTGGGGCCTCCACTGTGCTGGTCAGTCCCTGTTCAAGCCCCC
AGGGTCAATTCTTGCCATTCATCACTCCCTTGATCCAGTCCACATAGCTGAGCACCTTGGTGTAGAAGTCATACCCTTCGCCA
CACCCTATGCCCCAGGACACAATGCCCGTGGCCACCCAGTGATGGGCATGATTGTCCCATACCACATAGAGGCTGCCACTGTC
CCCCTGGCAGACACTGTGCCTTTGCGTCTCATCCCCAACACAGAACATATTGTCAGAAAACACCTCGGGTCTCTGTCTCTTTT
GGAGCCAGGCGTTGCAGGCCTCCCTGGGAGCTACAGGCAGCCTCGAGTACTTCAGCTCAGTAGTTAGCCAGCCCATCTCCATG
CCAAACCCACTGACGTAGCCCAACAAGCCGCTGCGGTAGAGGGTCTCATTATCGGGCAGACAGACCGGGAGGACGTTGGGGCC
CAGGGGGATGCTGTGCTGCAGCTCCAGGAGGGCGATGTCCCCGCTAAAGTTATGGGACTCATTCTGACGGTAGTCGGGGTGCA
CAACGACACGGTGGACAGGGTGGTTCCCCAGTTTCAGCATCTCATCTATGGCTGTGTGGCCCAAGAACACATTCACACTCTGG
TTCTTCCTGAGAGAAACACTGTCCTTGGGGTAGATGGTGTGGGCAGCAGTGAGGATCCATCTGTCCCCCAGCAGGGCCCCGCC
CCCACGGCCGTGGATACTGGTGAAGGCTTGCCAGGGGAAGTTGCCCAGCTTGGCTCTGGAAGAACCGAGGGTCGTCTGATTCT
GGGCAATGGGGGTGACTGGCCGTCCGCAGACAGGCATACACTGAAGAACCTCCTCCCCATCCTGTCTGTCTTTCCAGGTCCCT
GGGGTTGCACAGGTGAGTGCCCCTGCTGCCGCGGCCTGATAATAGGGCTCCTGGCAGTGGTTCTGGACCTTGGCAGGGTTGTC
TCCAGGTGCGTTGATGGCCTCAGAGCCCCTGCTGGCCTCGCTGATGGGCTGACTATAGTTCACAGCCACGGTTTGGTAGAGGG
CCAGGAAGCCCTTGTGGAGGTGGGCAGTCTTGTTCTCCGAGGAAGGCTGTGTGCGGAAGGTCAGCCGCAAACTCCTCCCTGAG
GATACAAACTCCCTCTGACCAGGGGGCCTGCCCAGAGGGGAGCCTTGCTGACCACAGAACTGGCTTGGATCCGAACCGACGAA
TGAGATTGTGACAGAGTCCCCTGCACAGTCCTGGGACGGCTCCAGGTCGAAGTCCTGGAAGACGAGCCTCACAGCAAAGCCCT
CTGGAGCCTTGATGTCCGTGCTGCTCTCTTGGCCTTTGCCATACGGCTCTGGGTACCCGGGGGATGTCAGCTGCTGGGGTAGC
TCTTGGGCCAAGAGGACGGAGCCCCGGGTTGGGCAAGCCTGGAGGACTCCCCAGAGAAGCAGCCACCACATTGCGCCTGGACA
GCCTTTGGAGTGAGGGCTTCTCCAGAGATATTTCCCCCACACTCTGGGTCCAGGCATCTGGAACTGGACATCTGGGACCTGCG
AGAGAACTGGCCCAGGATAGGGAACAAAAGG

[0136] The FCTR5b protein encoded by SEQ ID NO: 18 has 487 amino acid residues, and is presented using the one-letter code in Table 5D. FCTR5 was searched against other databases using SignalPep and PSort search protocols. The FCTR5b protein is most likely microbody (peroxisome) (Certainty=0.6406) and seems to have no N-terminal signal sequence. The predicted molecular weight of FCTR5 protein is 53511.9 daltons.

TABLE 5D
Encoded FCTR5b protein sequence (SEQ ID NO:19).
MPGPRVWGKYLWRSPHSKGCPGAMWWLLLWGVLQACPTRGSVLLAQQLPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVF
QDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVN
YSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSS
RAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNE
SHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVF
SDNMFCVGDETQRHSVCQGDSGSLYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKN

[0137] The predicted amino acid sequence was searched in the publicly available GenBank database FCTR5a protein showed 58 % identities (177 over 302 amino acids) and 74% homologies (226 over 302 amino acids) with human complement CIR component precursor (EC 3.4.21.41) (705 aa.; ACC:P00736). Based upon homology, FCTR5 proteins and each homologous protein or peptide may share at least some activity.

[0138] In a search of sequence databases, it was found, for example, that the nucleic acid sequence the nucleotides 17-1594 of FCTR5a have 1575 of 1578 bases (99 %) identical to Homo sapiens complement C1r-like proteinase precursor (GENBANK-ID: XM—007061.1) (SEQ ID NO:78) (Table 5E).

TABLE 5E
BLASTN of FCTR5a against Homo sapiens complement C1r-like
proteinase precursor (SEQ ID NO:78)
>GI|11436767|REF|XM_007061 .1| HOMO SAPIENS
COMPLEMENT C1R-LIKE PROTEINASE PRECURSOR, (LOC51279), MRNA
LENGTH = 3318
SCORE = 3104 BITS (1566), EXPECT = 0.0
IDENTITIES = 1575/1578 (99%)
STRAND = PLUS/PLUS
QUERY: 17	CAGATGTCCAGTTCCAGATGCCTGGACCCAGAGTGTGGGGGAAATATCTCTGGAGAAGCC	76
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1	CAGATGTCCAGTTCCAGATGCCTGGACCCAGAGTGTGGGGGAAATATCTCTGGAGAAGCC	60
QUERY: 77	CTCACTCCAAAGGCTGTCCAGGCGCAATGTGGTGGCTGCTTCTCTGGGGAGTCCTCCAGG	136
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 61	CTCACTCCAAAGGCTGTCCAGGCGCAATGTGGTGGCTGCTTCTCTGGGGAGTCCTCCAGG	120
QUERY: 137	CTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCC	196
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 121	CTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCC	180
QUERY: 197	CCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAG	256
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 181	CCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAG	240
QUERY: 257	AGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTG	316
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 241	AGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTG	300
QUERY: 317	CAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGC	376
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 301	CAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGC	360
QUERY: 377	AAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGQGAGGAGTT	436
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 361	AAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTT	420
QUERY: 437	TGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTCCACAAGG	496
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 421	TGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTCCACAAGG	480
QUERY: 497	GCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCA	556
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 481	GCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCA	540
QUERY: 557	GCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACT	616
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 541	GCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACT	600
QUERY: 617	GCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGA	676
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 601	GCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGA	660
QUERY: 677	CCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTCCGGACGGC	736
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 661	CCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGC	720
QUERY: 737	CAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCA	796
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 721	CAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCA	780
QUERY: 797	ACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGOCGGGGCCCTGCTGGGGG	856
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 781	ACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGG	840
QUERY: 857	ACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGGACAGTGTTTCTCTCAGGA	916
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 841	ACAGATGGATCCTCACTGCTGCCCACACCGTCTACCCCAAGGACAGTGTTTCTCTCAGGA	900
QUERY: 917	AGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGG	976
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 901	AGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGG	960
QUERY: 977	GGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATA	1036
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 961	GGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATA	1020
QUERY: 1037	ACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACG	1096
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1021	ACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACG	1080
QUERY: 1097	TCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACG	1156
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1081	TCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACG	1140
QUERY: 1157	TCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGC	1216
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1141	TCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGC	1200
QUERY: 1217	CTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGT	1276
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1201	CTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGT	1260
QUERY: 1277	TTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGG	1336
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1261	TTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGG	1320
QUERY: 1337	ACAGTGGCAGCCTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCA	1396
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1321	ACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCA	1380
QUERY: 1397	TTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCT	1456
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1381	TTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCT	1440
QUERY: 1457	ATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATTGACCCTGGGGGCTTGAACAGG	1516
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1441	ATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATTGACCCTGGGGGCTTGAACAGG	1500
QUERY: 1517	GACTGACCAGCACAGTGGACGCCCCAGGCAACAGAGGGCCTGGAGTGAGGACTGAACACT	1576
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1501	GACTGACCAGCACAGTGGAGGCCCCAGGCAACAGAGGGCCTGGAGTGAGGACTGAACACT	1550
QUERY: 1577	GGGGTAGGGGGTGGGGGT	1594
	||||||||||||||||||
SBJCT: 1551	GGGGTAGGGGTTGGGGGT	1578

[0139] In this search it was also found that the FCTR5a nucleic acid had homology to three fragments of Homo sapiens complement component 1, r subcomponent. It has 102 of 117 bases (87%) identical to 1458-1574, 82 of 94 bases (87%) identical to 2052-2145, and 54 of 63 bases (85%) identical to 1678-1740 all fragments of Homo sapiens complement component 1, r subcomponent (GenBank Acc: NM—001733.1) (Table 5F).

TABLE 5F
BLASTN of FCTR5a against Homo sapiens complement
component 1, r subcomponent (SEQ ID NO:79)
>GI|4502492|REF|NM_001733.1| HOMO SAPIENS
COMPLEMENT COMPONENT 1, R SUBCOMPONENT (C1R), MRNA
LENGTH = 2386
SCORE = 113 BITS (57), EXPECT = 3E-22
IDENTITIES = 102/117 (87%)
STRAND = PLUS/PLUS
QUERY: 783	AGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGG	842
	||||||| ||||||||||||||||||| |  |||||||  |||||||| || ||||||||
SBJCT: 1458	AGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTCACCAACATCCACGGGCGCGGGGGCGG	1517
QUERY: 843	GGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGGA	899
	|||||||||||| ||| | ||||||||||| |||||||||||| | || ||||||||
SBJCT: 1518	GGCCCTGCTGGGCGACCGCTGGATCCTCACAGCTGCCCACACCCTGTATCCCAAGGA	1574
SCORE = 91.7 BITS (46), EXPECT = 1E-15
IDENTITIES = 82/94 (87%)
STRAND = PLUS/PLUS
QUERY: 1380	CTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTA	1439
	|||||||||||||||||| |||||||||||||| |||||  ||   || |||| ||||||
SBJCT: 2052	CTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGCAGCAGGGGCTATGGCTTCTA	2111
QUERY: 1440	CACCAAGGTGCTCAGCTATGTGGACTGGATCAAG	1473
	|||||| ||||||| ||| |||||||||||||||
SBJCT: 2112	CACCAAAGTGCTCAACTACGTGGACTGGATCAAG	2145
SCORE = 54.0 BITS (27), EXPECT = 2E-04
IDENTITIES = 54/63 (85%)
STRAND = PLUS/PLUS
QUERY: 1006	CACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAG	1065
	||||| |||||||||||| |||||||| | || |||   |||||||||||||| ||||||
SBJCT: 1678	CACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTGCTGGAG	1737
QUERY: 1066	CTG	1068
	|||
SBJCT: 1738	CTG	1740

[0140] The amino acid sequence of the protein of FCTR5a 485 of 487 amino acid residues (99%) identical to, and 487 of 487 residues (100%) positive with, the 487 amino acid complement C1r-like proteinase precursor from Homo sapiens (GenBank-ACC: AAF44349.1) (SEQ ID NO:80) (Table 5G).

TABLE 5G
BLASTP of FCTR5a and b against Complement C1R-like
proteinase precursor (SEQ ID NO:80)
>GI|7706083|REF|NP_057630.1| COMPLEMENT
C1R-LIKE PROTEINASE PRECURSOR, [HOMO SAPIENS]
GI|11436768|REF|XP_007061.1| COMPLEMENT
C1R-LIKE PROTEINASE PRECURSOR, [HOMO SAPIENS]
GI|7271475|GB|AAF44349.1|AF178985_1 (AF178985) COMPLEMENT
C1R-LIKE PROTEINASE PRECURSOR [HOMO SAPIENS]
LENGTH = 487
SCORE = 972 BITS (2513), EXPECT = 0.0
IDENTITIES = 485/487 (99%), POSITIVES = 487/487 (100%)
R
QUERY: 1	MPGPRVWGKYLWRSPHSKGCPGAMWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGYPEP	60
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1	MPGPRVWGKYLWRSPHSKGCPGAMWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGYPEP	60
QUERY: 61	YGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLG	120
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 61	YGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLG	120
QUERY: 121	RPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEA	180
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 121	RPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEA	180
QUERY: 181	INAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIA	240
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 181	INAPGDNPAKVQNECQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIA	240
QUERY: 241	QNQTTLGSSRAXLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVN	300
	||||||||||||||||||||||||||||||||||||||||||||+|||||||||||||||
SBJCT: 241	QNQTTLGSSRAKLGNFPWQAFTSIEGRGGGALLGDRWILTAAHTVYPKDSVSLRKNQSVN	300
QUERY: 301	VFLGHTAIDEMLKLGNRPVERVVVHPDYRQNESENFSGDIALLELOHSIPLGPNVLPVCL	360
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 301	VFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCL	360
QUERY: 361	PDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMF	420
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 361	PDNETLYRSGLLGYVSGFGMEMGNLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMF	420
QUERY: 421	CV0DETQRHSVCQGDSGSLYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIK	480
	||||||||||||||||||+|||||||||||||||||||||||||||||||||||||||||
SBJCT: 421	CVGDETQRBSVCQGDSGSVYVVWDNHAHRHVATGIVSWGIGCGEGYDFYTKVLSYVDWIE	480
QUERY: 481	GVMNGKN	487
	|||||||
SBJCT: 481	GVMNGKN	487
R = AT RESIDUE 46, FCTR5B DIFFERS FROM FCTRSA IN THAT Q46R. THE REST OF THE HOMOLOGY IS THE SAME.

[0141] The full amino acid sequence of the protein of FCTR5a has 175 of 303 amino acid residues (58%) identical to, and 226 of 303 residues (74%) positive with the 400-701 amino acid segment, 72 of 157 residues (45%) identical and 94 of 157 residues (59%/0) positive with amino acids 1-155, and 36 of 139 residues (25%) identical and 58 of 139 residues (40%) positive with amino acids 188-312 of the 705 amino acid Complement C1R Component Precursor from Homo sapiens (GenBank-ACC: AAAS1851.1) (SEQ ID NO:43) (Table 5H).

TABLE 5H
BLASTP of FCTR5a and b against Complement C1R
Component Precursor (SEQ ID NO:81)
>GI|115204|SP|P00736|C1R_HUMAN COMPLEMENT
C1R COMPONENT PRECURSOR
GI|67614|PIR|C1HURB COMPLEMENT SUBCOMPONENT
C1R (EC 3.4.21.41) PRECURSOR - HUMAN
GI|179644|GB|AAA51851.1| (M14058) HUMAN COMPLEMENT
C1R [HOMO SAPIENS]
LENGTH = 705
SCORE = 361 BITS (928), EXPECT = 8E-99
IDENTITIES = 175/303 (58%), POSITIVES = 226/303 (74%), GAPS = 9/303 (2%)
QUERY: 189	AXVQNHCQEPYYQ--------AAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIA	240
	|++| +| ||||+            |  ||   | ||+ | ||++ +|+||||+|| |+
SBJCT: 400	ARIQYYCEEPYYKMQTRAGSRESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVE	459
QUERY: 241	QNQTTLGSSRAKLGNFPWQAFTSIEGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVN	300
	| |  +|  +||+|||||| ||+|||||||||||||||||||||+|||+  + + | |++
SBJCT: 460	QRQRIIGGQKAKMGNFPWQVFTNIEGRGGGALLGDRWILTAAETLYPKEEEA-QSNASLD	518
QUERY: 301	VFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQESIPLGPNVLPVCL	360
	|||||| ++|++||||||+ || |||||||+||+|| ||||||||++|+ ||||+||+||
SBJCT: 519	VFLGHTNVEELMKLGNHPIRRVSVEPDYRQDESYNFEGDIALLELENSVTLGPNLLPICL	578
QUERY: 361	PDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMF	420
	|||+| |  ||+|||||||+    +  +|++ |||||  +||  ||+ + | +||| |||
SBJCT: 579	PDNDTFYDLGLMGYVSGRGVMEEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMB	638
QUERY: 421	CVGDETQRHSVCQGDSGSLYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIK	480
	| |  + +   |||||| ++ | | +   |||||||||||||  || ||||||+||||||
SBJCT: 639	CAGHPSLKQDACQGDSGGVFAVRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIK	698
QUERY: 481	GVM	483
	|
SBJCT: 699	REM	701
SCORE = 122 BITS (306), EXPECT = 1E-26
IDENTITIES = 72/157 (45%), POSITIVES = 94/157 (59%), GAPS = 3/157 (1%)
R
QUERY: 24	MWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVF	83
	|| | |      |   ||+ + |+|  ++||| +|+||    |++| |  | |+ |+|||
SBJCT: 1	MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF	60
QUERY: 84	QDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQP	143
	| ||||||+ |  | | ||       +|||| ||||| |||++||+| |  + ||| |
SBJCT: 61	QQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFETDF	120
QUERY: 144	SS-ENKTAHLEKGFLALYQTVAVNYSQPISEASRGSE	179
	|+ || |   +||||| ||  ||+  +  | +  | |
SBJCT: 121	SNEENGTIMFYKGFLAYYQ--AVDLDECASRSKSGEE	155
SCORE = 36.3 BITS (83), EXPECT = 0.93
IDENTITIES = 36/139 (25%), POSITIVES = 58/139 (40%), GAPS = 17/139 (12%)
R
QUERY: 35	ACPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVF-QDFDLEPSQD	93
	+|    |  |  |    ++|  ||  |      +  |+   |  + | | + ||++  |
SBJCT: 188	SCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPFDIDDHQQ	247
QUERY: 94	--CAGDSVTISFVGSDpSQFCGOQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAH	151
	|  | + |   | +  +|||+|     |||   +  +|  ++ | | |  | ++
SBJCT: 248	VECPYDQLQIYANGKNIGEFCGKQ-----RPP---DLDTSSNAVDLLFFTDESGDS----	295
QUERY: 152	LHKGFLALYQTVAVNYSQP	170
	+|+   | |  +   ||
SBJCT: 29G	--RGWKLRYTTEIIKCPQP	312
R = AT RESIDUE 46, FCTR5B DIFFERS FROM FCTR5A IN THAT Q46R. THE REST OF THE HOMOLOGY IS THE SAME.

[0142] Based upon homology, FCTR5 proteins and each homologous protein or peptide may share at least some activity.

[0143] FCTR6

[0144] The novel nucleic acid of 1078 nucleotides FCTR6a (also designated 27455183.0.19) encoding a novel human blood coagulation factor XI-like protein is shown in Table 6A. An ORF was identified beginning with an ATG initiation codon at nucleotides 243-245 and ending with a TAA codon at nucleotides 1044-1046. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 6A, and the start and stop codons are in bold letters.

TABLE 6A
FCTR6a Nucleotide Sequence (SEQ ID NO:20)
TTGATCCGTGCCAAGTGGCTTTTTGTGGGCTCTGTAGAGTGCTCTAAACCCAGCTCGGCCTTTGCTGTATTAGACAGAAGCAC
CTCATTCATATCCCTGGGGCCCCTGATGGTGCAGTGGTCTGGCTGTGGTCTGCACACCAGCTATTCTGTTTTGTTTTGTTTTG
TTTTTTTCCTACCTTTTTCCAATCCTCACACCTTCTGATCAACAGCCCCAGTAGGGTTTAAAGGTCCTAGAGCTACATGGGAT
TTAGGTTTCTGGGCACAGCCAATTCTGCCACTTTTGAGACTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACC
AGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCAT
TCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACC
TGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGCGTGGCAGGTTGGGGCCAGACCAAT
GCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGTGCCAATGGTCATCATGGACTGCGAGGAGTGTTCAAAGATGTT
TCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTC
TGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGATAAGAACACC
CCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGGAGGCAGGCCCTTCAATGCAGA
GAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGC
TCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACTGATAATAAAATAGAGGCTATTCTTTCAACCGAAA

[0145] The FCTR6a protein encoded by SEQ ID NO:20 has 267 amino acid residues and is presented using the one-letter code in Table 6B. FCTR6a was searched against other databases using SignalPep and PSort search protocols. The PCTR6a protein is most likely mitochondrial matrix space (Certainty=0.4372) and seems to have no N-terminal signal sequence. The predicted molecular weight of FCTR6a protein is 29412.8 daltons.

TABLE 6B!Encoded FCTR6a protein sequence (SEQ ID NO:21).
MGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKL
DDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSG
GPLVCTPEPGEKWYQVGIISWGKSCGDKNTPGIYTSLVNYNLWIEKVTQLGGRPENAEKRRTSVKQKPMGSPVSGVPEPGSPR
SWLLLCPLSHVLFRAILY

[0146] In an alternative embodiment, FCTR6b (alternatively referred to as 27455183.0.145) has the 1334 residue sequence shown in Table 6C. An ORP was identified beginning with an ATG initiation codon at nucleotides 499-501 and ending with a TAA codon at nucleotides 1300-1302. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 6C, and the start and stop codons are in bold letters.

TABLE 6C
FCTR6b Nucleotide Sequence (SEQ ID NO:22)
GATTTTAGAAGGTTAATCAAAAACCCGGGGACAGTTTCTTCATGGCATAACCACAGACCTTTGTGGCACCCGCTGT
CGTGGGATATCAAATATCCTCTGGGGTTCGGAATGTGGGCTTATTACTGAAGATCCTGTCTGCTTGGTCAGTGGCAGGTC
TAGACTAACTTCTGGTCCTGAGTTTCTAAAGTGCTGGTAGACCAGTTGATACAAAACAGATATAATAATGAATGCCTTAT
CTATCTGAAGGTCAGTTTGATCCGTGCCAAGTGGCTTTTTGTGGGCTGTGTAGAGTGCTCTAAACCCAGCTCGGCCTTTG
CTGTATTAGACAGAAGCACCTCATTCATATCCCTGGCGCCCCTGATGGTGCAGTGGTCTGGCTGTGGTCTGCACACCAGC
TATTCTGTTTTGTTTTGTTTTGTTTTGTTTTTTCCTACCTTTTTCCAATCCTCACACCTTCTGATCAACAGCCCCAGTAG
GGTTTAAAGGTCCTAGAGCTACATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCACTTTTGAGACTTCCCTTCCCC
TTCCACTTGCCCCTCTCTCGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGC
CCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGC
CTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCA
CATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAA
GTGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATA
CAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGT
ACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTAC
AACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAA
ACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATG
TGTTGTTCAGAGCTATTTTGTACTGATAATAAAATAGAGGCTATTCTTTCAACCGAAA

[0147] The FCTR6b protein encoded by SEQ ID NO:22 has 267 amino acid residues and is presented using the one-letter code in Table 6B. The Psort profile for FCTR4 predicts that this sequence has no N-terminal signal peptide and is likely to be localized at the mitochondrial matrix space (Certainty=0.4372). The predicted molecular weight of this protein is 29498.9 Daltons.

TABLE 6D
Encoded FCTR6b protein sequence (SEQ ID NO:23).
MGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKL
DDLKVPICLPTQPGPATWRECWVAGWGQTNAADNSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSG
GPLVCTPEPGEKWYQVGIISWGKSCGEKTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPR
SWLLLCPLSHVLFRAILY

[0148] In a search of sequence databases, it was found, for example, that the FCTR6a nucleic acid sequence has 853 of 897 bases (95 %) identical to bases 551-1447, and 346 of 388 bases (89%) identical to bases 127-513 of Macaca fascicularis brain cDNA, clone QccE-17034 (GENBANK-ID: AB046651) (Table 6E).

TABLE 6E
BLASTN of FCTR6a against Macaca fascicularis brain cDNA,
clone QccE-17034 (SEQ ID NO:82)
>GI|9651112|DBJ|AB046651.1|AB046651 MACACA FASCICULARIS BRAIN CDNA,
CLONE QCCE-17034
LENGTH = 1746
SCORE = 1429 BITS (721), EXPECT = 0.0
IDENTITIES = 853/897 (95%)
STRAND = PLUS/PLUS
QUERY: 434	CCTTTTTCCAATCCTCACACCTTCTGATCAACAGCCCCAGTAGGGTTTAAAGGTCCTAGA	493
	||||||||||||||||||||||||||| | |||||||||||||||| |||| ||||||||
SBJCT: 551	CCTTTTTCCAATCCTCACACCTTCTGAGCTACAGCCCCAGTAGGGTCTAAATGTCCTAGA	610
QUERY: 494	GCTACATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCACTTTTGAGACTTCCCTTC	553
	|||| ||| |||||||||||||| |||||||||||||| ||||||||||| |||||||||
SBJCT: 611	GCTATATGAGATTTAGGTTTCTGAGCACAGCCAATTCTCCCACTTTTGAGCCTTCCCTTC	670
QUERY: 554	CCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGC	613
	||||| |||| |||||||||||||||||||||||||||||||||||||||| ||||||||
SBJCT: 671	CCCTTTCACTCGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAATGTCGTGC	730
QUERY: 614	TGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTC	673
	||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||
SBJCT: 731	TGGGGACCAACGACTTAACTAGCTCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTC	790
QUERY: 674	TTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTT	733
	||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| |
SBJCT: 791	TTCACAAGGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCCT	850
QUERY: 734	CGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTG	793
	||||||||| ||||||||||||||||||||||||||||||||| ||||||| |||||| |
SBJCT: 851	CGCCCATCACACTCGATGACCTGAAGGTGCCCATCTGCCTCCCTACGCAGCACGGCCCCG	910
QUERY: 794	CCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACT	853
	||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 911	CCACATGGCACGAATGCTGGGTGCCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACT	970
QUERY: 854	CTGTGAAAACGGATCTGATGAAAGTGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAA	913
	|||||||||||||||||||||||| ||| |||||||||||||||||||||||||||||||
SBJCT: 971	CTGTGAAAACGGATCTGATGAAAGCGCCGATCGTCATCATGGACTGGGAGGAGTGTTCAA	1030
QUERY: 914	AGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATG	973
	||  |||||||||||| |||||||||||||||||||| |||||||| |||||||||||||
SBJCT: 1031	AGGCGTTTCCAAAACTCACCAAAAATATGCTGTGTGCTGGATACAATAATGAGAGCTATG	1090
QUERY: 974	ATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGT	1033
	| |||||| |||||||||| ||||| ||||||||||||||||||||||||||||||||||
SBJCT: 1091	ACGCCTGCCAGGGTGACAGCGGGGGACCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGT	1150
QUERY: 1034	GGTACCAGGTCGGCATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGA	1093
	||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1151	GGTACCAGGTGGGTATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGA	1210
QUERY: 1094	TATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCA	1153
	|||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||
SBJCT: 1211	TATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAGGTGACCCAGCTAGAGGGCA	1270
QUERY: 1154	GGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAG	1213
	||||||||| ||| ||||||| |||||| |||||||||||||||||||||||||||| ||
SBJCT: 1271	GGCCCTTCAGTGCGGAGAAAATGAGGACCTCTGTCAAACAGAAACCTATGGGCTCCCGAG	1330
QUERY: 1214	TCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCC	1273
	||||||| ||||||||||||||| ||| ||||||||||||||||||||||||||||||||
SBJCT: 1331	TCTCGGGGGTCCCAGAGCCAGGCGGCCTCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCC	1390
QUERY: 1274	ATGTGTTGTTCAGAGCTATTTTGTACTGATAATAAAATAGAGGCTATTCTTTCAACC	1330
	|||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 1391	ATGTGTTGTTCAGAGCTATTTTGTACTGATAATAAAATAGACGCTATTTTTTTAACC	1447
SCORE = 428 BITS (216), EXPECT = E-117
IDENTITIES = 346/388 (89%), GAPS = 1/388 (0%)
STRAND = PLUS/PLUS
QUERY: 1	GATTTTAGAAGGTTAATCAAAAACCCGGGGACAGTTTCTTCATGGCATAACCACAGACCT	60
	||||||||||||||||||||||||||  |||||||||| ||||| |||||||| |||||
SBJCT: 127	GATTTTAGAAGGTTAATCAAAAACCCAAGGACAGTTTCATCATGTCATAACCAAAGACCC	186
QUERY: 61	TTGTGGCACCCGCTGTCGTGGGATATCAAATATCCTCTGGGGTTCGGAATGTGGGCTTAT	120
	|||||||||| |||||| ||||||| |||||||| | |||||||| |||||||| |||||
SBJCT: 187	TTGTGGCACCTGCTGTCATGGGATAACAAATATCTTGTGGGGTTCTGAATGTGGACTTAT	246
QUERY: 121	TACTGAAGATCCTGTCTGCTTGGTCAGTGGCAGGTCTAGACTAACTTCTGGTCCTGAGTT	180
	|||||||| ||||||||||||||||||||| ||||||||||||||||||||||||||| |
SBJCT: 247	TACTGAAGCTCCTGTCTGCTTGG-TCAGTGGTGGTCTAGACTAACTTCTGGTCCTGAGAT	305
QUERY: 181	TCTAAAGTGCTGGTAGACCAGTTGATACAAAACAGATATAATAATGAATGCCTTATCTAT	240
	|||||||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 306	TCTAAAGTGTTCGTAGACCGGTTGAGATAAAAGATATATAATAATGAATGCCTTACCTAT	365
QUERY: 241	CTGAAGGTCAGTTTGATCCGTGCCAAGTGGCTTTTTGTGGGCTGTGTAGAGTGCTCTAAA	300
	|||||   |||||||||||||||||||||||||||||||||||||||||||||||||
SBJCT: 366	CTGAAAACCAGTTTGATCCGTGCCAAGGGGCTTTTTGTGGGCTCTGTAGAGTGCCCTAAA	425
QUERY: 301	CCCAGCTCGGCCTTTGCTGTATTAGACAGAAGCACCTCATTCATATCCCTGGGGCCCCTG	360
	|||||||||||||||||||||||||||||||||  |||||||||||||||||||
SBJCT: 426	CCCAGCTCTGCCTTTGCTGTGTTAGACAGAAGCACGCCATTCACATCTCTGGGGCCCCCA	485
QUERY: 361	ATGGTGCAGTGGTCTGGCTGTGGTCTGC	388
	|||||||  |||||||||||||||||
SBJCT: 486	ATGGTGCCATGGTGTGGTTGTGGTCTGC	513

[0149] In a search of sequence databases, it was found, for example, that the FCTR6a nucleic acid sequence has 295 of 378 bases (78 %/O) identical to bases 410-779 of Mus musculus adult male testis cDNA, RIKEN full-length enriched (GENBANK-ID:AK09660) (Table 6F).

TABLE 6F
BLASTN of FCTR6a against Mus musculus adult male testis cDNA, RIKEN
full-length enriched (SEQ ID NO:83)
>GI|12855429|DBJ|AK016601.1|AK016601MUS MUSCULUS ADULT MALE
TESTIS CDNA, RIKEN FULL-LENGTH ENRICHED
LIBRARY, CLONE:4933401F05, FULL INSERT SEQUENCE
LENGTH = 1047
SCORE = 97.6 BITS (49), EXPECT = 2E-17
IDENTITIES = 295/378 (78%), GAPS = 8/378 (2%)
STRAND = PLUS/PLUS
QUERY: 697	AACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTG	756
	||||||||||| |||||||||||| ||||||| ||   |||| | | | || |||| |||
SBJCT: 410	AACATGGACAACGACATTGCCTTGTTGCTGCTAGCCAAGCCCTTGACGTTCARTGAGCTG	469
QUERY: 757	AAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTG	816
	| ||||||||||||||| ||      ||||| |||| |||  |||| |||||||||||||
SBJCT: 470	ACGGTGCCCATCTGCCTTCCTCTCTGGCCCGCCCCTCCCAGCTGGCACGAATGCTGGGTG	529
QUERY: 817	GCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAA	876
	||||| ||||||   |||||  |  |||||||  | ||| ||  |||||||||||||||
SBJCT: 530	GCAGGATGGGGCGTAACCAACTCAACTGACAAGGAATCTATGTCAACGGATCTGATGAAG	589
QUERY: 877	GTGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAA	936
	||||| |||   ||||| || |||||||| || | | |||||||||| |  || |||| |
SBJCT: 590	GTGCCCATGCGTATCATAGAGTGGGAGGAATGCTTACAGATGTTTCCCAGCCTCACCACA	649
QUERY: 937	AATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGG	996
	|| ||||||||||||  |||    ||||||||||| ||||| |||        |||||||
SBJCT: 650	AACATGCTGTGTGCCTCATATGGTAATGAGAGCTACGATGCTTGC--------CAGTGGG	701
QUERY: 997	GGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGC	1056
	|| || || ||||||||| |||| |||||    | |||||||||||||||||||||||||
SBJCT: 702	GGACCGCTTGTCTGCACCACAGATCCTGGCAGTAGGTGGTACCAGGTGGGCATCATCAGC	761
QUERY: 1057	TGGGGAAAGAGCTGTGGA	1074
	||||| ||||||||||||
SBJCT: 762	TGGGGCAAGAGCTGTGGA	779

[0150] The FCTR6a amino acid has 247 of 267 amino acid residues (92%) identical to, and 251 of 307 residues (94%) positive with, the 267 amino acid hypothetical protein [Macaca fascicularis] (GenBank: AB046651) (SEQ ID NO:84) (Table 6G).

TABLE 6G
BLASTP of FCTR6a and b against hypothetical protein [Macaca fascicularis]
(SEQ ID NO:84)
>GI|9651113|DBJ| BAB03569.1| (AB046651) HYPOTHETICAL PROTEIN
[MACACA FASCICULARIS]
LENGTH = 267
SCORE = 467 BITS (1202), EXPECT = E-131
IDENTITIES = 247/267 (92%), POSITIVES = 251/267 (94%)
QUERY: 1	MGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILH	60
	| |||| |||| ||| |||| ||||||||||||||+|||||||||| |||||||||||||
SBJCT: 1	MRFRFLSTANSPTFEASLPLSLAPLWFSATSPEELNVVLGTNDLTSSSMEIKEVASIILH	60
QUERY: 61	KDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSV	120
	||||||||||||||||||||| ||||||||||||| ||||| ||||||||||||||||||
SBJCT: 61	KDFKRANMDNDIALLLLASPITLDDLKVPICLPTQEGPATWHECWVAGWGQTNAADKNSV	120
QUERY: 121	KTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWY	180
	|||||| |||||||||||| ||||||||||||| |||||||+||||||||||||||||||
SBJCT: 121	KTDLMKAPMVIMDWEECSKAFPKLTKNNLCAGYNNESYDACQGDSGGPLVCTPEPGEKWY	180
	K                       E
QUERY: 181	QVGIISWGKSCGDKNTPGIYTSLVNYNLWIEKVTQLGGRPFNAEKRRTSVKQKPMGSPVS	240
	||||||||||||+||||||||||||||||||||||| ||||+||| ||||||||||| ||
SBJCT: 181	QVGIISWGKSCGEENTPGIYTSLVNYNLWIEKVTQLEGRPFSAEKMRTSVKQKPMGSRVS	240
QUERY: 241	GVPEPGSPRSWLLLCPLSEVLFRAILY	267
	||||||| |||||||||||||||||||
SBJCT: 241	GVPEPGGLRSWLLLCPLSEVLFRAILY	267
K AND E ARE RESIDUES THAT DIFFER BETWEEN FCTR6A AND B. D193K, AND G217E.

[0151] The FCTR6a amino acid has 80 of 201 amino acid residues (39%) identical to, and 119 of 201 residues (58%) positive with, the 638 amino acid plasma kallikrein B1 precursor (GENBANK-ID:NP—000883.1) (SEQ ID NO:85) (Table 6H).

TABLE 6H
BLASTP of FCTR6a and b against plasma kallikrein B1 precursor
(SEQ ID NO:85)
>GI|4504877|REF|NP_000883.1| PLASMA KALLIKREIN B1 PRECURSOR;
KALLIKREIN, PLASMA; KALLIRREIN B
PLASMA; KALLIRREIN 3, PLASMA; FLETCHER FACTOR [HOMO SAPIENS]
GI|125184|SP|P03952|KAL HUMAN PLASMA KALLIEREIN PRECURSOR
(PLASMA PREKALLIRREIN) (KININOGENIN)
(FLETCHER FACTOR)
GI|67591|PIR||KQHUP PLASMA KALLIKREIN (EC 3.4.21.34) PRECURSOR - HUMAN
GI|190263|GB|AAA60153.1| (M13143) PLASMA PREKALLIEREIN [HOMO SAPIENS
GI|8809781|GB|AAF79940.1| (AF232742) PLASMA KALLIKREIN PRECURSOR
[HOMO SAPIENS]
LENGTH 638
SCORE = 133 BITS (334), EXPECT = 3E-30
IDENTITIES = 80/201 (39%), POSITIVES = 119/201 (58%), GAPS = 18/201 (8%)
QUERY: 20	LPLAPLWFSATSPEELSVVLGTNDLT--SPSMEIREVASIILHKDFKRANMDNDIALLLL	77
	|||  +|         | +|  +|+|  +|  +|||   ||+|+++| +  ++||||+ |
SBJCT: 439	LPLQDVW------RIYSGILNLSDITKDTPFSQIKE---IIIEQNYKVSEGNHDIALIKL	489
QUERY: 78	ASPIKLDDLKVPICLPTQPGPAT-WRECWVAGWGQTNAADKNSVKTDLMKVPMVIMDWEE	136
	+|+   + + |||||++   +| +  ||| ||| +   +|  ++  | || + ++  ||
SBJCT: 490	QAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSK--EKGEIQNILQKVNIPLVTNRE	547
QUERY: 137	CSKMFP--KLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGDK	194
	| | +   |+|+ |+|||||    |||||||||||||  +    |  ||| |||+ |  +
SBJCT: 548	CQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVC--KHNGMWRLVGITSWGEGCARR	605
QUERY: 195	NTPGIYTSLVNYNLWIEKVTQ	215
	||+|| +  |  || + ||
SBJCT: 606	EQPGVYTKVAEYMDWILEKTQ	626
K IS A RESIDUE THAT DIFFERS BETWEEN FCTR6A AND B. D193K.

[0152] The FCTR6a amino acid has 73 of 183 amino acid residues (39%) identical to, and 110 of 183 residues (59%) positive with, the 643 amino acid kallikrein [Sus scrofa] (GENBANK-ID:BAA37147.1) (SEQ ID NO:86) (Table 61).

TABLE 61
BLASTP of FCTR6a and b against kallikrein [Sus scrofa]
(SEQ ID NO:86)
>GI|4165315|DBJ|BAA371471.1| (AB022425) KALLIRREIN [SUS SCROFA]
LENGTH = 643
SCORE = 128 BITS (322), EXPECT = 9E-29
IDENTITIES = 73/183 (39%), POSITIVES = 110/183 (59%), GAPS = 12/183 (6%)
QUERY: 38	VLGTNDLT--SPSMEIKEVASIILEKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQ	95
	+|  +++|  +|  ++||   ||+|+++|     +||||| |+|+   | + |||||++
SBJCT: 459	ILNISEITKETPFSQVKE---IIIHQNYKILESGHDIALLKLETPLNYTDFQKPICLPSR
QUERY: 96	PGP-ATWRECWVAGWGQTNAADKNSVKTDLMKVPMVIMDWEECSKMFP--KLTKNMLCAG	152
	+  ||| ||| |   +|  ++  | || + ++  ||| | +   |++| |+|||
SBJCT: 516	DDTNVVYTNCWVTGWGFTE--EKGEIQNILQKVNIPLVSNEECQKSYPLEKISKQMICAG	573
QUERY: 153	YKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGDKNTPGIYTSLVNYNLWIEK	212
||    |||||+|||||||  +    |+ ||  |||+ |  +  ||+|| ++ |  || +
SBJCT: 574	YKEGGKDACKGESGGPLVC--KYNGIWHLVGTTSWGEGCARREQPGVYTKVIEYMDWILE	631
QUERY: 213	VTQ	215
	||
SBJCT: 632	KTQ	634
K IS A RESIDUE THAT DIFFERS BETWEEN FCTRGA AND B. D193K.

[0153] The FCTR6a amino acid has 81 of 205 amino acid residues (39%) identical to, and 112 of 205 residues (54%) positive with, the 625 amino acid Coagulation factor XI [Homo sapiens] (embCAA64368.1) (SEQ ID NO:87) (Table 6J).

TABLE 6J
BLASTP of FCTR6a and b against Coagulation factor XI [Homo sapiens]
(SEQ ID NO:87)
>GI|180352|GB|AAA51985.1| (M20218) COAGULATION FACTOR XI
[HOMO SAPIENS]
LENGTH = 625
SCORE = 127 BITS (320), EXPECT = 1E-28
IDENTITIES = 81/205 (39%), POSITIVES = 112/205 (54%),
GAPS = 17/205
QUERY: 20	LPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKE------VASIILHKDFKRANMDNDIA	73
	|  |  ++   ||+ | |  |  + +    ||||      |  ||+|  +| |    |||
SBJCT: 427	LTAAHCFYGVESPKILRVYSGILNQS----EIKEDTSFFGVQEIIIEDQYKMAESGYDIA	482
QUERY: 74	LLLLASPIKLDDLKVPICLPTQPG-PATWRECWVAGWGQTNAADKNSVKTDLMKVPMVIM	132
	|| | + +   | + |||||++      + +||| |||     ||  ++  | |  + ++
SBJCT: 483	LLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDK--IQNTLQKAKIPLV	540
QUERY: 133	DWEECSKMFP--KLTKNMLCAGYKNBSYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKS	190
	||| | +   |+|  |+||||+    ||||||||||| |  +  | |+ ||| |||+
SBJCT: 541	TNEECQKRYRGEKITHKMICAGYREGGKDACKGDSGGPLSC--KHNEVWHLVGITSWGEG	598
QUERY: 191	CGDKNTPGIYTSLVNYNLWIEKVTQ	215
	|  +  ||+||++| |  || + ||
SBJCT: 599	CAQRERPGVYTNVVEYVDWILEKTQ	623
K IS A RESIDUE THAT DIFFERS BETWEEN FCTR6A AND B. D193K.

[0154] The number of new cases of renal cell carcinoma in the United States in 1996 was projected to be 30,600 with an estimated 12,000 deaths. Tumors with a proposed histogenesis from the proximal tubule (clear-cell and chromophilic tumors) amount to 85% of renal cancers, whereas tumors with a proposed histogenesis from the connecting tubule/collecting duct (chromophobic-, oncocytic-, and duct Bellini-type tumors) amount to only 11%.

[0155] Adenocarcinomas may be separated into clear cell and granular cell carcinomas, although the 2 cell types may occur together in some tumors. The distinction between well-differentiated renal carcinomas and renal adenomas can be difficult. The diagnosis is usually made arbitrarily on the basis of size of the mass, but size alone should not influence the treatment approach, since metastases can occur with lesions as small as 0.5 centimeters.

[0156] While radical nephrectomy with regional lymphadenectomy, is the accepted, often curative therapy for stage I (localized disease) renal cell cancer, very little therapy is available for advance disease that represent about 70% of the patients. Radiotherapy as a postoperative adjuvant has not been effective, and when used preoperatively, may decrease local recurrence but does not appear to improve 5-yr survival. A chemotherapeutic agent capable of significantly altering the course of metastastic renal cell carcinoma has not been identified. (Renal Cell Cancer (PDQ®) Treatment—Health Professionals, Cancemet, NCI) There is therefore a need to identify genes that are differentially modulated in renal-cell carcinomas. In addition there is a need for methods to assay candidate therapeutic substances for modulating expression of these genes. These substances might be recombinant protein expressed by the identified genes or antibodies that bind to the identified proteins. There is yet additionally a need for an effective method of identifying target molecules or related components. These and related needs and defects are addressed in the present invention.

[0157] Novel kallikrein-like/coagulation factor XI-like Proteins and Nucleic Acids Encoding Same

[0158] FCTR6 is surprisingly found to be differentially expressed in clear cell Renal cell carcinoma tissues vs the normal adjacent kidney tissues. The present invention discloses a novel protein encoded by a cDNA and/or by genomic DNA and proteins similar to it, namely, new proteins bearing sequence similarity to kallikrein-like, nucleic acids that encode these proteins or fragments thereof, and antibodies that bind immunospecifically to a protein of the invention. It may have use as a therapeutic agent in the treatment of renal cancer and liver cirrhosis.

[0159] The utility of kallikrein family members in protein therapy of Renal cancer

[0160] The treatment of renal cell carcinoma with recombinant kallikrein could improve disease outcome through several potential mechanisms. The literature suggests that members of this protein family are inhibitory to the process of angiogenesis, a process of vital importance to tumor progression. Renal cell carcinoma is known to be a highly angiogenic cancer. Thus, treatment of renal cell carcinoma with kallikrein may effectively shutdown the active recruitment of a blood supply to a tumor. Members of this protein family are known to play a role in vascular coagulation. Similar to anti-angiogenic therapy, a factor produced by cancer cells that is pro-coagulatory may also act to inhibit cancer growth by effectively “clogging” the tumor vascular supply. In addition, through its proteolytic activity, kallikrein may degrade ECM proteins or growth factors necessary for the progressive growth of cancer cells. Following is a relevant reference underlining the importance of Kallikrein in cancer therapy.

[0161] The New Human Kallikrein Gene Family: Implications in Carcinogenesis.

[0162] Diamandis E P; Yousef G M; Luo I; Magklara I; Obiezu C V

[0163] Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.

[0164] Trends Endocrinol Metab 2000 Mar; 11(2):54-60.

[0165] ABSTRACT: The traditional human kallikrein gene family consists of three genes, namely KLK1 [encoding human kallikrein 1 (hK1) or pancreatic/renal kallikrein], KLK2 (encoding hK2, previously known as human glandular kallikrein 1) and KLK3 [encoding hK3 or prostate-specific antigen (PSA)]. KLK2 and KLK3 have important applications in prostate cancer diagnostics and, more recently, in breast cancer diagnostics. During the past two to three years, new putative members of the human kallikrein gene family have been identified, including the PRSSL1 gene [encoding normal epithelial cell-specific 1 gene (NES1)], the gene encoding zyme/protease M/neurosin, the gene encoding prostase/KLK-L1, and the genes encoding neuropsin, stratum corneum chymotryptic enzyme and trypsin-like serine protease. Another five putative kallikrein genes, provisionally named KLK-L2, KLK-L3, KLK-L4, KLK-L5 and KLK-L6, have also been identified. Many of the newly identified kallikrein-like genes are regulated by steroid hormones, and a few kallikreins (NES1, protease M, PSA) are known to be downregulated in breast and possibly other cancers. NES1 appears to be a novel breast cancer tumor suppressor protein and PSA a potent inhibitor of angiogenesis. This brief review summarizes recent developments and possible applications of the newly defined and expanded human kallikrein gene locus.

[0166] The utility of kallikrein-like/coagulation factor XI-like family members in protein therapy of liver cirrosis

[0167] Results related to inflammation shown below in Example A, Table CC3, panel 4, indicate over-expression of 27455183.0.19 in the liver cirrhosis sample, as compared to panel 1 data (Table CC1), where there is little or no expression in normal adult liver. Panel 4 was generated from various human cell lines that were untreated or resting as well as the same cells that were treated with a wide variety of immune modulatory molecules. There are several disease tissues represented as well as organ controls.

[0168] Potential Role(s) of FCTR6 in Inflammation:

[0169] Liver cirrhosis occurs in patients with hepatitis C and also in alcoholics. This protein is 41% related to coagulation factor XI and its potential role in liver cirrhosis may be related to cleavage of kininogen. A reference for this follows:

[0170] Thromb Haemost 2000 May;83(5):709-14 High molecular weight kininogen is cleaved by FXIa at three sites: Arg409-Arg4 10, Lys502-Thr503 and Lys325-Lys326. Mauron T, Lammle B, Wuillemin W A Central Hematology Laboratory, University of Bern, Inselspital, Switzerland.

[0171] Abstract:

[0172] We investigated the cleavage of high molecular weight kininogen (HK) by activated coagulation factor XI (FXIa) in vitro. Incubation of HK with FXIa resulted in the generation of cleavage products which were subjected to SDS-Page and analyzed by silver-staining, ligand-blotting and immunoblotting, respectively. Upon incubation with FXIa, bands were generated at 111, 100, 88 kDa on nonreduced and at 76, 62 and 51 kDa on reduced gels. Amino acid sequence analysis of the reaction mixtures revealed three cleavage sites at Arg409-Arg410, at Lys502-Thr5O3 and at Lys325-Lys326. Analysis of HK-samples incubated with FXIa for 3 min, 10 min and 120 min indicated HK to be cleaved first at Arg409-Arg410, followed by cleavage at Lys502-Thr503 and then at Lys325-Lys326. In conclusion, HK is cleaved by FXIa at three sites. Cleavage of HK by FXIa results in the loss of the surface binding site of HK, which may constitute a mechanism of inactivation of HK and of control of contact system activation.

[0173] Impact of Therapeutic Targeting of FCTR6 in Inflammation:

[0174] Therapeutic targeting of FCTR6 with a monoclonal antibody is anticipated to limit or block the extent of breakdown of kininogen and thereby reduce the degradation of liver that occurs in liver cirrhosis. A pertinent reference is:

[0175] Thromb Haemost 1999 November;82(5):1428-32 Parallel reduction of plasma levels of high and low molecular weight kininogen in patients with cirrhosis.

[0176] Cugno M, Scott C F, Salerno F, Lorenzano E, Muller-Esterl W, Agostoni A, Colman R W Department of Internal Medicine, IRCCS Maggiore Hospital, University of Milan, Italy. massimo.cugno@unimi.it

[0177] Abstract:

[0178] Little is known about the regulation of high-molecular-weight-kininogen (HK) and low-molecular-weight-kininogen (LK) or the relationship of each to the degree of liver function impairment in patients with cirrhosis. In this study, we evaluated HK and LK quantitatively by a recently described particle concentration fluorescence immunoassay (PCFIA) and qualitatively by SDS PAGE and immunoblotting analyses in plasma from 33 patients with cirrhosis presenting various degrees of impairment of liver function. Thirty-three healthy subjects served as normal controls. Patients with cirrhosis had significantly lower plasma levels of HK (median 49 microg/ml [range 22-99 microg/ml]) and LK (58 microg/ml [15-100 microg/ml]) than normal subjects (HK 83 microg/ml [65-115 microg/ml]; LK 80 microg/ml [45-120 microg/ml]) (p<0.0001). The plasma concentrations of HK and LK were directly related to plasma levels of cholinesterase (P<0.0001) and albumin (P<0.0001 and P<0.001) and inversely to the Child-Pugh score (P<0.0001) and to prothrombin time ratio (P<0.0001) (reflecting the clinical and laboratory abnormalities in liver disease). Similar to normal individuals, in patients with cirrhosis, plasma HK and LK levels paralleled one another, suggesting that a coordinate regulation of those proteins persists in liver disease. SDS PAGE and immunoblotting analyses of kininogens in cirrhotic plasma showed a pattern similar to that observed in normal controls for LK (a single band at 66 kDa) with some lower molecular weight forms noted in cirrhotic plasma. A slight increase of cleavage of HK (a major band at 130 kDa and a faint but increased band at 107 kDa) was evident. The increased cleavage of HK was confirmed by the lower cleaved kininogen index (CKI), as compared to normal controls. These data suggest a defect in hepatic synthesis as well as increased destructive cleavage of both kininogens in plasma from patients with cirrhosis. The decrease of important regulatory proteins like kininogens may contribute to the imbalance in coagulation and fibrinolytic systems, which frequently occurs in cirrhotic patients.

[0179] In summary, the differential expression of FCTR6 (Kallikrein family) in renal cell carcinoma is an important finding that could have immense potential in renal carcinogenesis. In addition, overexpression of the above gene in liver cirrhosis demonstrates its anticipated use as an immunotherapeutic target.

[0180] FCTR7

[0181] The novel nucleic acid of 1498 nucleotides FCTR7 (also designated. 32592466.0.64) encoding a novel trypsin inhibitor-like protein is shown in Table 7A. An ORF begins with an ATG initiation codon at nucleotides 470-472 and ends with a TAA codon at nucleotides 1369-1371. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon.

TABLE 7A
FCTR7 Nucleotide Sequence (SEQ ID NO:24)
AGGCGCCTGGTTCTGCGCGTACTGGCTGTACGGAGCAGGAGCAAGAGGTCGCCGCCAGCCTCCGCCGCCGAGCCTCGTTCGTG
TCCCCGCCCCTCGCTCCTGCAGCTACTGCTCAGAAACGCTGGGGCGCCCACCCTGGCAGACTAACGAAGCAGCTCCCTTCCCA
CCCCAACTGCAGGTCTAATTTTGGACGCTTTGCCTGCCATTTCTTCCAGGTTGAGGGAGCCGCAGAGGCGGAGGCTCGCGTAT
TCCTGCAGTCAGCACCCACGTCGCCCCCGGACGCTCGGTGCTCAGGCCCTTCGCGAGCGGGGCTCTCCGTCTGCGGTCCCTTG
TGAAGGCTCTGGGCGGCTGCAGAGGCCGGCCGTCCGGTTTGGCTCACCTCTCCCAGGAAACTTCACACTGGAGAGCCAAAAGG
AGTGGAAGAGCCTGTCTTGGAGATTTTCCTGGGGAAATCCTGAGGTCATTCATTATGAAGTGTACCGCGCGGGAGTGGCTCAG
AGTAACCACAGTGCTGTTCATGGCTAGAGCAATTCCAGCCATGGTGGTTCCCAATGCCACTTTATTGGAGAAACTTTTGGAAA
AATACATGGATGAGGATGGTGAGTGGTGGATAGCCAAACAACGAGGGAAAAGGGCCATCACAGACAATGACATGCAGAGTATT
TTGGACCTTCATATAATTAAACGAAGTCAGGTGTATCCAACAGCCTCTAATATGGAGTATATGACATGGGATGTAGAGCTGGA
AAGATCTGCAGAATCCAGGGCTGAAATTGCTTCTGGGAACATGGACCTGCAACCTTGCTTCCATCAATTGGACAGAATTTGGG
AGCACACTGGGGAAGATATAGGCCCCCGACGTTTCATGTACAATCGTGGTATAATGAAGTGAAAGACTTTAGCTACCCATATG
AACATGAATGCAACCCATATTGTCCATTCAGGTGTTCTGGCCCTGTATGTACACATTATACACAGGTCGTGTGGCCAACTAGT
AACAGAATCGGTTGTGCCATTAATTTGTGTCATAACATGAACATCTGGGGGCAGATATGGCCCAAAGCTGTCTACCTGGTGTG
CAATTACTCCCCAAAGGGAAACTGGTGGGGCCATGCCCCTTACAAACATGGGCGGCCCTGTTCTGCTTGCCCACCTAGTTTTG
GAGGGGGCTGTAGAGAAAATCTGTGCTACAAAGAAGGGTCAGACAGGTATTATCCCCCTCGAGAAGAGGAAACAAATGAAATA
GAACCGCAGCAGTCACAAGTCCATGACACCCATGTCCGGACAAGATCAGATGATAGTAGCAGAAATGAAGTCATTAGCTTTGG
GAAAAGTAATGAAAATATAATGGTTTTAGAAATCCTGTGTTAAATATTGCTATATTTTCTTAGCAGTTATTTCTACAGTTAAT
TACATAGTCATGATTGTTCTACGTTTCATATATTATATGGTCCTTTGTATATGCCCCTAATAAAATGAATCTAAACATTGAAA
AAAA

[0182] The FCTR7 protein encoded by SEQ ID NO:24 has 300 amino acid residues and is presented using the one-letter code in Table 7B. The FCTR7 gene was found to be expressed in: brain; germ cell tumors. FCTR7 gene maps to Unigene cluster Hs.182364 which is expressed in the following tissues: brain, breast, ear, germ cell, heart, liver, lung, whole embryo, ovary, pancreas, pooled, prostate, stomach, testis, uterus, vascular. Therefore the FCTR7 protein described in this invention is also expressed in the above tissues.

[0183] The SignalP, Psort and/or Hydropathy profile for FCTR7 predict that this sequence has a signal peptide and is likely to be localized outside of the cell with a certainty of 0.4228. The SignalP shows a cleavage site between amino acids 20 and 21, i.e., at the dash in the sequence amino acid ARA-IP. The predicted molecular weight of FCTR7 is 34739.9 Daltons. Hydropathy profile shows an amino terminal hydrophobic region. This region could function as a signal peptide and target the invention to be secreted or plasma membrane localized.

TABLE 7B
Encoded FCTR7 protein sequence (SEQ ID NO:25).
NECTAREWLRVTTVLFMARAIPAMVVPNATLLEKLLEKYMDEDGEWWIAKQRGKRAITDNDMQSILDLHNKLRSQVYPTASNN
EYMTWDVELERSAESRAESCLWEHGPASLLPSIGQNLGAHWGRYRPPTFHVQSWYDEVKDFSYPYEHECNPYCPFRCSGPVCT
HYTQVVWATSNRIGCAINLCHNMNIWGQIWPKAVYLVCNYSPKGNWWGHAPYKHGRPCSACPPSFGGGCRENLCYKEGSDRYY
PFREEETNEIERQQSQVEDTHVRTRSDDSSRNEVISFGKSNENIMVLEILC

[0184] This gene maps to Unigene cluster Hs. 182364 which has been assigned the following mapping information shown in table 7C. Therefore the chromosomal assignment for this gene is the same as that for Unigene cluster 182364.

TABLE 7C
Mapping Information.
Chromosome:    8
Gene Map 98:   Marker SHGC-32056, Interval D8S279-D8S526
Gene Map 98:   Marker SGC32056, Interval D8S526-D8S275
Gene Map 98:   Marker sts-G20223, Interval D8S526-D8S275
Gene Map 98:   Marker stSG30385, Interval D8S526-D8S275
Whitehead map: EST67946, Chr.8
dbSTS entries: G25853, G29349, G20223

[0185] The predicted amino acid sequence was searched in the publicly available GenBank database

[0186] FCTR7 protein showed Score=743 (261.5 bits), Expect=1.4e-73, P=1.4e-73, 54% identities (129 over 237 amino acids) and 43% homologies (167 over 237 amino acids) with human 25 kD trypsin inhibitor protein (258 aa; ACC:043692) (Table 7D).

TABLE 7D
BLAST X search results are shown below:
ptnr:SPTREMBL-ACC:O43692 25 KDA TRYPSIN INHIBITOR - HO. . . +2 743 8.4e-73 1 (SEQ ID NO:88)
ptnr:SPTREMBL-ACC:O44228 HRTT-1 - HALOCYNTHIA RORETZI . . . +2 325 2.9e-28 1 (SEQ ID NO:89)
ptnr:SWISSPROT-ACC:P48060 GLIOMA PATHOGENESIS-RELATED . . . +2 314 5.3e-27 1 (SEQ ID NO:90)
ptnr:PIR-ID:JC4131 glioma pathogenesis-related protein. . . +2 309 2.0e-26 1 (SEQ ID NO:91)
ptnr:SWISSNEW-ACC:O19010 CYSTEINE-RICH SECRETORY PROTE. . . +2 258 9.4e-21 1 (SEQ ID NO:92)

[0187] The nucleotide sequence of FCTR7 has 954 of 957 residues (99 %) identical to the 1-957 base segment, and 174 of 175 residues (99%) identical to bases 1317-1953 of the 2664 nucleotide Homo sapiens putative secretory protein precursor, mRNA (GenBank-ACC: AF142573) (SEQ ID NO:93) (Table 7E).

TABLE 7E
BLASTN of FCTR7 against Putative secretory protein precursor
(SEQ ID NO:93)
>gi|12002310|gb|AF142573.1|AF142573Homo sapiens putative
secretory protein precursor, mRNA, complete cds
Length = 2664
Score = 1865 bits (941), Expect = 0.0
Identities = 954/957 (99%), Gaps = 1/957 (0%)
Strand = Plus/Plus
Query: 364	gtccggtttggctcacctctcccaggaaacttcacactggagagccaaaaggagtggaag	423
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 1	gtccggtttggctcacctctcccaggaaacttcacactggagagccaaaaggagtggaag	60
Query: 424	agcctgtcttggagattttcctggggaaatcctgaggtcattcattatgaagtgtaccgc	483
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 61	agcctgtcttggagattttcctggggaaatcctgaggtcattcattatgaagtgtaccgc	120
Query: 484	gcgggagtggctcagagtaaccacagtgctgttcatggctagagcaattccagccatggt	543
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 121	gcgggagtggctcagagtaaccacagtgctgttcatggctagagcaattccagccatggt	180
Query: 544	ggttcccaatgccactttattggagaaacttttggaaaaatacatggatgaggatggtga	603
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 181	ggttcccaatgccactttattggagaaacttttggaaaaatacatggatgaggatggtga	240
Query: 604	gtggtggatagccaaacaacgagggaaaagggccatcacagacaatgacatgcagagtat	663
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 241	gtggtggatagccaaacaacgagggaaaagggccatcacagacaatgacatgcagagtat	300
Query: 664	tttggaccttcataataaattacgaagtcaggtgtatccaaaagcctctaatatggagta	723
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 301	tttggaacttcataataaattacgaagtcaggtgtatccaacagcctctaatatggagta	360
Query: 724	tatgacatgggatgtagagctggaaagatatgaagaatccagggctgaaa-ttgcttgtg	782
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 361	tatgacatgggatgtagagctggaaagatctgcagaatcctgggctgaaagttgcttgtg	420
Query: 783	ggaacatggaactgcaagcttgcttacatcaattggacagaatttgggagcacactgggg	842
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 421	ggaacatggacctgcaagattgcttccatcaattggacagaatttgggagcacactgggg	480
Query: 843	aagatataggcccccgacgtttcatgtacaatcgtggtatgatgaagtgaaagactttag	902
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 481	aagatataggccccCgacgtttcatgtacaatcgtggtatgatgaagtgaaagactttag	540
Query: 903	ctacccatatgaacatgaatgcaacccatattgtccattcaggtgttatggccctgtatg	962
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 541	ctacccatatgaacatgaatgcaacccatattgtccattcaggtgttctggccctgtatg	600
Query: 963	tacacattataaacaggtagtgtgggcaaatagtaacagaatcggttgtgccattaattt	1022
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 601	tacaaattataaacaggtcgtgtgggcaactagtaacagaatcggttgtgcaattaattt	660
Query: 1023	gtgtcataacatgaaaatctgggggcagatatggcccaaagctgtatacctggtgtgcaa	1082
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 661	gtgtaataaaatgaacatctgggggcagatatggccaaaagatgtataactggtgtgaaa	720
Query: 1083	ttactccacaaagggaaaatggtggggccatgccacttacaaaaatgggaggccctgtta	1142
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 721	ttactccccaaagggaaactggtggggccatgccccttacaaacatgggcggccctgttc	780
Query: 1143	tgcttgcccacctagttttggagggggctgtagagaaaatctgtgctacaaagaagggtc	1202
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 781	tgcttgcccacctagttttggagggggctgtagagaaaatctgtgctacaaagaagggtc	840
Query: 1203	agacaggtattatccccctcgagaagaggaaacaaatgaaatagaacggcagcagtcaca	1262
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 841	agacaggtattatccccctcgagaagaggaaacaaatgaaatagaacgacagcagtcaca	900
Query: 1263	agtccatgacacccatgtccggacaagatcagatgatagtagcagaaatgaagtcat	1319
	|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 901	agtccatgacacccatgtccggacaagatcagatgatagtagcagaaatgaagtcat	957
Score = 339 bits (171), Expect = 3e-90
Identities = 174/175 (99%)
Strand = Plus/Plus
Query: 1317	cattagctttgggaaaagtaatgaaaatataatggttttagaaatcctgtgttaaatatt	1376
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 1779	cattagctttgggaaaagtaatgaaaatataatggttttagaaatcctgtgttaaatatt	1838
Query: 1377	gctatattttcttagcagttatttctacagttaattacatagtcatgattgttctacgtt	1436
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 1839	gctatattttcttagcagttatttctacagttaattacatagtcatgattgttctacgtt	1898
Query: 1437	tcatatattatatggtgctttgtatatgcccctaataaaatgaatctaaacattg	1491
	|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 1899	tcatatattatatggtgctttgtatatgccactaataaaatgaatctaaacattg	1953

[0188] The FCTR7 amino acid has 284 of 285 amino acid residues (99%) identical to, and 284 of 285 amino acid residues (99%) similar to, the 500 amino acid Putative secretory protein precursor [Homo sapiens] (GenBank-Acc No.: AF142573) (SEQ ID NO:94) (Table 7F).

TABLE 7F
BLASTP alignments of FCTR7 against Putative secretory
protein precursor, (SEQ ID NO:94)
>gi|12002311|gb|AAG43287.1|AF142573 1 (AF142573)
putative secretory protein precursor [Homo sapiens]
Length = 500
Score = 581 bits (1499), Expect = e-165
Identities = 284/285 (99%), Positives = 2 84/285 (99%)
Query: 1	MKCTAREWLRVTTVLFMARAIPAMVVPNATLLEKLLEKYMDEDGEWWIAKQRGKRAITDN	60
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 1	MKCTAREWLRVTTVLFMARAIPAMVVPNATLLEKLLEKYMDEDGEWWIAKQRGKRAITDN	60
Query: 61	DMQSILDLUNKLRSQVYPTASNMEYMTWDVELERSAESRAESCLWEHGPASLLPSIGQNL	120
	|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 61	DMQSILDLHNKLRSQVYPTASNMEYMTWDVELERSAESWAESCLWEHGPASLLPSIGQNL	120
Query: 121	GAHWGRYRPPTFHVQSWYDEVKDFSYPYEHECNPYCPFRCSGPVCTHYTQVVWATSNRIG	180
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 121	GAHWGRYRPPTFNVQSWYDEVKDFSYPYEHECNPYCPFRCSGPVCTNYTQVVWATSNRIG	180
Query: 181	CAINLCHNMNIWGQIWPKAVYLVCNYSPKGNWWGHAPYKHGRPCSACPPSFCGGCRENLC	240
	||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 181	CAINLCHNMNIWGQIWPKAVYLVCNYSPKGNWWGHAPYKHGRPCSACPPSFGGGCRENLC	240
Query: 241	YKEGSDRYYPPREEETNEIERQQSQVHDTHVRTRSDDSSRNEVIS	285
	|||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 241	YKEGSDRYYPPREEETNEIERQQSQVHDTHVRTRSDDSSRNEVIS	285

[0189] The FCTR7 amino acid has 137 of 176 amino acid residues (78%) identical to, and 151 of 176 amino acid residues (86%) similar to, the 188 amino acid Late gestation lung protein 1 [Rattus norvegicus] (GenBank-Acc No.: AF109674) (SEQ ID NO:95) (Table 7G).

TABLE 7G
BLASTP alignments of FCTR7 against Late gestation
lung protein 1, (SEQ ID NO:95)
>gi|4324682|gb|AAD16986.1| (AF109674) late gestation
lung protein 1 [Rattus norvegicus]
Length = 188
Score = 277 bits (709), Expect = 1e-73
Identities = 137/176 (78%), Positives = 151/176 (86%)
Query: 68	LHNKLRSQVYPTASNMEYMTWDVELERSAESRAESCLWEHGPASLLPSIGQNLGAHWGRY	127
	|||||| |||| |||||||||| ||||||   |  ||||||||||| ||||||  |||||
Sbjct: 2	LHNKLRGQVYPPASNMEYMTWDEELERSAAAWAQRCLWEHGPASLLVSIGQNLAVHWGRY	61
Query: 128	RPPTFHVQSWYDEVKDFSYPYEHECNPYCPFRCSGPVCTHYTQVVWATSNRIGCAINLCH	187
	| | ||||||||||||++||| |||||+|| |||| +||||||+||||+|+||||++ |
Sbjct: 62	RSPGFRVQSWYDEVKDYTYPYPHECNPWCPERCSGAMCTHYTQMVWATTNKIGCAVHTCR	121
Query: 188	NMNIWGQIWPKAVYLVCNYSPKGNWWGHAPYKHGRPCSACPPSFGGGCRENLCYKE	243
	+|++|| ++  |||||||||||||| | |||||||||| || |+||||| ||||+|
Sbjct: 122	SMSVWGDIWENAVYLVCNYSPKGNWIGEAPYKHGRPCSECPSSYGGGCRNNLCYRE	177

[0190] The FCTR7 amino acid has 130 of 237 amino acid residues (55%) identical to, and 165 of 237 amino acid residues (70%) similar to, the 258 amino acid R3H domain-containing preproprotein; 25 kDa trypsin inhibitor [Homo sapiens] (GenBank-Acc No.: D45027) (SEQ ID NO:96) (Table 7H).

TABLE 7H
BLASTP alignments of FCTR7 against R3H domain-containing
preproprotein, 25 kDa trypsin inhibitor (SEQ ID NO:96)
>gi|7705676|ref|NP 056970.1| R3H domain-containing
preproprotein; 25 kDa trypsin inhibitor; R3H
domain (binds single-stranded nucleic acids) containing
[Homo sapiens]
gi|2943716|dbj|BAA25066.1| (D45027) 25 kDa trypsin inhibitor
[Homo sapiens]
Length = 258
Score = 265 bits (678), Expect = 4e-70
Identities = 130/237 (55%), Positives = 165/237 (70%), Gaps = 3/237 (1%)
Query: 12	TTVLFMARAIPAMVVPNATLLEKLLEKYMDEDGEWWIAKQRGKRAITDNDMQSILDLHNK	71
	+||+ +     +    | | +|  |+  +|      | | | || |+ ||| +||| ||+
Sbjct: 20	STVVLLNSTDSSPPTNNFTDIEAALKAQLDSAD---IPKARRKRYISQNDMIAILDYHNQ	76
Query: 72	LRSQVYPTASNMEYMTWDVELERSAESRAESCLWEHGPASLLPSIGQNLGAHWGRYRPPT	131
	+| +|+| |+||||| ||  |  |||  |  |+|+|||+ ||  +||||    ||||
Sbjct: 77	VRGKVFPPAANMEYMVWDENLAKSAEAWAATCIWDHGPSYLLRFLGQNLSVRTGRYRSIL	136
Query: 132	FHVQSWYDEVKDFSYPYEHECNPYCPFRCSGPVCTHYTQVVWATSNRIGCAINLCHNNNI	191
	|+ |||||||+++||  +||| || || ||+||||||+||||||||||||+ | |||+
Sbjct: 137	QLVKPWYDEVKDYAFPYPQDCNPRCPMRCFGPMCTHYTQMVWATSNRIGCAIHTCQNMNV	196
Query: 192	WGQIWPKAVYLVCNYSPKGNWWGHAPYKHGRPCSACPPSFGGGCRENLCYKEGSDRY	248
	|| +| +||||||||+||||| | |||| | |||+||||+|| | +|||+   +  |
Sbjct: 197	WGSVWRRAVYLVCNYAPKGNWIGEAPYKVGVPCSSCPPSYGGSCTDNLCFPGVTSNY	253

[0191] The FCTR7 amino acid has 109 of 233 amino acid residues (47%) identical to, and 146 of 233 amino acid residues (63%) similar to, the 253 amino acid Novel protein similar to a trypsin inhibitor [Homo sapiens] 25 kDa trypsin inhibitor (ENBLAcc No.: AL117382) (SEQ ID NO:97) (Table 7I).

TABLE 71
BLASTP alignments of FCTR7 against Novel protein similar to a
trypsin inhibitor, (SEQ ID NO:97)
>gi|9885193|emb|CAC04190.1| (AL117382) dJ881L22.3
(novel protein similar to a trypsin inhibitor) [Homo sapiens]
Length = 253
Score = 225 bits (575), Expect = 4e-58
Identities = 109/233 (47%), Positives = 146/233 (63%), Gaps = 8/233 (3%)
Query: 10	RVTTVLFMARAIPAMVVPNATLLEKLLEKYMDEDGEWWIAKQRGKRAITDNDMQSILDLH	69
	+    | |  | ||   | +|+  |            + + | ++ |+  || ++|| |
Sbjct: 19	QAVNALIMPNATPAPAQPESTAMRLL--------SGLEVPRYRRKRHISVRDMNALLDYH	70
Query: 70	NKLRSQVYPTASNMEYMTWDVELERSAESRAESCLWEHGPASLLPSIGQNLGAHWGRYRP	129
	| +|+ ||| |+||||| ||  | | ||  |  |+| |||+ |+  +||||  | |+||
Sbjct: 71	NHIRASVYPPAANMEYMVWDKRLARAAEAWATQCIWAHGPSQLMRYVGQNLSIHSGQYRS	130
Query: 130	PTFHVQSWYDEVKDFSYPYEHECNPYCPFRCSGPVCTHYTQVVWATSNRIGCAINLCHNM	189
	++|| +|   + +|   +|||+||+|| || |+||||+|||+|||+||||+ | ++
Sbjct: 131	VVDLMKSWSEEKWHYLFPAPRDCNPHCPWRCDGPTCSHYTQMVWASSNRLGCAIHTCSSI	190
Query: 190	NIWGQIWPKAVYLVCNYSPKGNWWGHAPYKHGRPCSACPPSFGGGCRENLCYK	242
	++||  | +| ||||||+ |||| | +||| |+|||+||||+ | |  |+|+|
Sbjct: 191	SVWGNTWHRAAYLVCNYAIKGNWIGESPYKMGKPCSSCPPSYQGSCNSNMCFK	243

[0192] The FCTR7 amino acid has 129 of 237 amino acid residues (54%) identical to, and 167 of 237 amino acid residues (70%) similar to, the 258 amino acid 25 kDa Trypsin Inhibitor from Homo sapiens (EMBLAcc No.: 043692) (SEQ ID NO:88) (Table 7J).

TABLE 7J
BLASTP alignments of FCTR7 against 25 kDa
Trypsin Inhibitor, (SEQ ID NO:88)
ptnr:SPTREMBL-ACC:O43692 25 KDA TRYPSIN INHIBITOR - Homo sapiens
(Human), 258 aa.
Score = 743 (261.5 bits), Expect = 1.6e-73, P = 1.6e-73
Identities = 129/237 (54%), Positives = 167/237 (70%)

[0193] The FCTR7 amino acid has 79 of 193 amino acid residues (40%) identical to, and 110 of 193 amino acid residues (56%) similar to, the 266 amino acid Glioma Pathogenesis-Related Protein (RTVP-1 Protein)—Homo sapiens (SWISSPROT Acc No.: P48060) (SEQ ID NO:90) (Table 7K).

TABLE 7K
BLASTP alignments of FCTR7 against Glioma Pathogenesis-
Related Protein, (SEQ ID NO:90)
ptnr:SWISSPROT-ACC:P48060 OLIOMA PATHOORNESIS-RELATED PROTEIN
(RTVP-1 PROTEIN) - Homo sapiens (Human), 266 aa
Score = 314 (110.5 bits), Expect = 4.7e-28, P = 4.7e-28
Identities = 79/193 (40%), Positives = 110/193 (56%)

[0194] The FCTR7 amino acid has 66 of 186 amino acid residues (35%) identical to, and 91 of 186 amino acid residues (48%) similar to, the 186 amino acid Neutrophil granules matrix glycoprotein SGP28 precursor from Homo sapiens (SWISSPROT Acc No.: S68691) (SEQ ID NO:98) (Table 7L).

TABLE 7L
BLASTP alignments of FCTR7 against Neutrophil granules
matrix glycoprotein, (SEQ ID NO:98)
ptnr:PIR-ID:S68691 neutrophil granules matrix glycoprotein
SGP28 precursor - Human
Score = 254 (89.4 bits), Expect = 1.1e-21, P = 1.1e-21
Identities = 66/186 (35%), Positives = 91/186 (48%)

[0195] A novel developmentally regulated gene with homology to a tumor derived trypsin inhibitor is expressed in lung mesenchyme, as described in Am. J. Physiol. 0:0-0(1999). cDNA cloning of a novel trypsin inhibitor with similarity to pathogenesis-related proteins, and its frequent expression in human brain cancer cells is disclosed in Biochim. Biophys. Acta 1395:202-208(1998). RTVP-1, a novel human gene with sequence similarity to genes of diverse species, is expressed in tumor cell lines of glial but not neuronal origin, as published in Gene 180:125-130(1996). The human glioma pathogenesis-related protein is structurally related to plan pathogenesis-related proteins and its gene is expressed specifically in brain tumors (Gene 159:131-135(1995)). Structure comparison of human glioma pathogenesis-related protein GliPR and the plant pathogenesis-related protein P14a indicates a functional link between the human immune system and a plant defense system (Proc. Natl. Acad. Sci. U.S.A. 95:2262-2266(1998)). GliPR is highly expressed in the human brain tumor, glioblastoma multiform/astrocytome, but neither in normal fetal or adult brain tissue, nor in other nervous system tumors. GliPR belongs to a family that groups mammalian SCP/TPX1; insects AG3/AG5; FUNGI SC7/SC14 and plants PR-1. SGP28, a novel matrix glycoprotein in specific granules of human neutrophils with similarity to a human testis-specific gene product and to a rodent sperm-coating glycoprotein (FEBS Lett. 380, 246-250, 1996). The primary structure and properties of helothermine, a peptide toxin that blocks ryanodine receptors is described in Biophys. J. 68:2280-2288(1995). As GliPR, Helothermine belongs to a family that groups mammalian SCP/TPX 1; insects AG3/AG5; FUNGI SC7/SC14 and plants PR-1.

[0196] Based upon homology, FCTR7 protein and each homologous protein or peptide may share at least some activity.

[0197] Therapeutic uses:

[0198] FCTR7 protein has homology to trypsin inhibitors, Q91055 helothermine, tumor derived tyrpsin inhibitors, glioma pathogenesis-related protein, Q9ZOU6 LATE GESTATION LUNG PROTEIN 1, and to the Prosite family which groups mammalian SCP/TPX1;INSECTS AG3/AG5; FUNGI SC7/SC14 AND PLANTS PR-1 proteins. Therefore the FCTR7 protein disclosed in this invention could function like the proteins which it has homology to. These functions include tissue development in vitro and in vivo, and cancer pathogenesis.

[0199] Based the tissue expression pattern, the gene is implicated in diseases of tissues in which it is expressed. These diseases include but are not limited to:

[0200] Glioma,

[0201] cancer,

[0202] lung diseases,

[0203] gestation,

[0204] male and female reproductive diseases,

[0205] deafness,

[0206] neurological disorders,

[0207] gastric disorders, and

[0208] pancreatic diseases like diabetes.

[0209] These materials are further useful in the generation of antibodies that bind immunospecifically to the novel FCTR7 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the “Anti-FCTRX Antibodies” section below. In one embodiment, a contemplated FCTR7 epitope is from aa 40 to 120. In another embodiment, a FCTR7 epitope is from aa 130 to 170. In additional embodiments, FCTR7 epitopes are from aa 210 to 230, and from aa 240 to 280.

TABLE 8A
Summary Of Nucleic Acids And Proteins Of The Invention
			Nucleic Acid	Amino Acid
Name	Tables	Clone; Description of Homolog	SEQ ID NO	SEQ ID NO
FCTR1	1A, 1B,	58092213.0.36 follistatin-like protein	1	2
FCTR2	2A, 2B	AC012614_1.0.123; KIAA1061-like protein	3	4
FCTR3	3A, 3B	10129612.0.118; neurestin-like protein	5	6
	3C, 3D	10129612.0.405; neurestin-like protein	7	8
	3E	10129612.0.154; neurestin-like protein	9
	3F	10129612.0.67; neurestin-like protein	10
	3G	10129612.0.258; neurestin-like protein	11
	3H, 3I	10129612.0.352; neurestin-like protein	12	13
FCTR4	4A, 4B	29692275.0.1; NF-Kappa-B P65delta3-like	14	15
		protein
FCTR5	5A, 5B	32125243.0.21; human complement C1R	16	17
		component precursor-like protein
	5C, 5D		18	19
FCTR6	6A, 6B	27455183.0.19; novel human blood	20	21
		coagulation factor XI-like protein
	6C, 6D	27455183.0.145; novel human blood	22	23
		coagulation factor XI-like protein
FCTR7	7A, 7B	32592466.0.64; trypsin inhibitor-like	24	25
		protein
FCTR1	Example 2	Ag809 Forward	26
FCTR1	Example 2	Ag809 Probe	27
FCTR1	Example 2	Ag809 Reverse	28
FCTR4	Example 2	Ag2773 Forward	29
FCTR4	Example 2	Ag2773 Probe	30
FCTR4	Example 2	Ag2773 Reverse	31
FCTR5	Example 2	Ag427 Forward	32
FCTR5	Example 2	Ag427 Probe	33
FCTR5	Example 2	Ag427 Reverse	34
FCTR6	Example 2	Ag1541 Forward	35
FCTR6	Example 2	Ag1541 Probe	36
FCTR6	Example 2	Ag1541 Reverse	37

[0210]

TABLE 8B
Summary of Query Sequences Disclosed
Table	Database	Acc. No.	Sequence Name	Species	SEQ ID NO.
1C, 1K	remtrEmbl	BAA21725	IGFBP-like protein	mouse	38
1D	sptrEmbl	Q61581	Follistatin-like protein-2	Mouse	39
1E	SptrEmbl	Q07822	Mac25 protein	Human	40
1F, 1K	SptrEmbl	O88812	Mac25 protein	Mouse	41
1G, 1K	SptrEmbl	Q16270	Prostacyclin-stimulating factor	Human	42
1H, 1K	PIR	B40098	Colorectal cancer suppressor	Rat	43
1I	TrEmblne	AAD9360	PTP sigma (brain) precursor	Human	44
	w
1J	SptrEmbl	Q13332	PTP sigma precursor	Human	45
2C	GenBank	AB028984	KIAA1061 cDNA	Human	46
2D	TrEmblne	BAA85677	KIAA1263	Human	47
	w
2E	TrEmblne	BAA83013	KIAA1061 protein fragment	Human	48
	w
2F	Embl	CAB70877.1	Hypothetical protein DKFzp566D234.1	Human	49
2G	GenBank	Q62632	Follistatin-related protein-1 precursor	Rat	50
2H	GenBank	Q62536	Follistatin-related protein-1 precursor	Mouse	51
2I	GenBank	JG0187	Follistatin related protein	African	52
				clawed
				frog
2J	GenBank	Q12841	Follistatin related protein-1 precursor	Human	53
2K	Embl	CAB42968.1	Flik protein	Chicken	54
2L	GenBank	T13822	Frazzled gene protein	Fruit fly	55
2M	GenBank	AAC38849.1	Roundabout 1	Fruit fly	56
2N	GenBank	O60469	Down Syndrome Cell Adhesion Molecule	Human	57
			Precursor
2O	SwissProt	Q13449	Limbic system-associated membrane	Human	58
			protein precursor
2P	SptrEmbl	O70246	Putative neuronal cell adhesion molecule,	Mouse	59
			short form
2Q	SptrEmbl	O02869	CHLAMP, G11-isoform precursor	Chicken	60
2R	SwissProt	Q62813	Limbic system-associated membrane	Rat	61
			protein precursor
3J	GenBank	NM_011856.2	Odd Oz/ten-m homology 2	Fruit fly	62
3K	Embl	AJ245711.1	Teneurin-2 cDNA, short splice variant	Chicken	63
3L	GenBank	AB032953	KIAA 1127 cDNA	Human	64
3M, 3U	GenBank	AB025411	Ten-m2 cDNA	Mouse	65
3N	GenBank	NM_020088.1	Neurestin alpha cDNA	Rat	66
3O	Embl	GGA278031	Teneurin-2	Chicken	67
3P	GenBank	NP_035986.2	Odd Oz/ten-m homology 2	Fruit fly	68
3Q	Embl	CAC09416.1	Teneurin-2	Chicken	69
3R	GenBank	BAA77399.1	Ten-m4	Mouse	70
3S	GenBank	AB032953	KIAA1127 protein	Human	71
3T	GenBank	AF086607	Neurestin alpha	Rat	72
4C	SptrEmbl	Q99233	Hypothetical 10 kD protein	Trypanosome	73
4C	SptrEmbl	Q16896	GABA receptor subunit		74
4C	SptrEmbl	O76473	GABA receptor subunit		75
4C	TrEmblne	AAD28317	FI3J11.13 protein		76
	w
Text p. 90	SptrEmbl	Q13313	NF-kappa B P65 delta 3 protein	Human	77
5E	GenBank	XM_007061.1	Complement C1R-like proteinase	Human	78
			precursor
5F	GenBank	NM_001733.1	Complement component 1, R	Human	79
			subcomponent cDNA
5G	GenBank	AAF44349.1	Complement C1R-like proteinase	Human	80
			precursor
5H	GenBank	AAA5185.1	Complement C1R component precursor	Human	81
6E	GenBank	AB046651	Brain cDNA clone Qcc-17034	Macaque	82
6F	GenBank	AK09660	Adult testis cDNA, RIKEN full length	Mouse	83
			enriched
6G	GenBank	AB046651	Hypothetical protein	Macaque	84
6H	GenBank	NP_000838.1	Plasma kallikrein B1 precursor	Human	85
6I	GenBank	BAA37147.1	Kallikrein	Pig	86
6J	Embl	CAA64368.1	Coagulation factor XI	Human	87
7D, 7J	SptrEmbl	O43692	25 kDa trypsin inhibitor	Human	88
7D	SptrEmbl	O44228	HRTT-1		89
7D, 7K	SptrEmbl	P418060	Glioma pathogenesis-related protein	Human	90
7D	PIR-ID	JC4131	Glioma pathogenesis-related protein	Human	91
7D	SwissProt	O19010	Cysteine-rcih secretory protein		92
7E	GenBank	AF142573	Putatitive secretory protein precursor	Human	93
			cDNA
7F	GenBank	AF142573	Putative secretory protein precursor	Human	94
7G	GenBank	AF109674	Late gestation lung protein 1	Rat	95
7H	GenBank	D45027	R3H domain containing preprotein, 25	Human	96
			kDa trypsin inhibitor
7I	Embl	AL117382	Novel protein similar to a trypsin	Human	97
			inhibitor
7L	PIR-ID	S68691	Neutrophil granules matrix glycoprotein	Human	98
			SGP28 precursor

[0211] FCTRX Nucleic Acids and Polypeptides

[0212] One aspect of the invention pertains to isolated nucleic acid molecules that encode FCTRX polypeptides or biologically-active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify FCTRX-encoding nucleic acids (e.g., FCTRX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of FCTRX nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

[0213] An FCTRX nucleic acid can encode a mature FCTRX polypeptide. As used herein, a “mature” form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product “mature” form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a “mature” form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a “mature” form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

[0214] The term “probes”, as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, e.g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

[0215] The term “isolated” nucleic acid molecule, as utilized herein, is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′- and 3′-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated FCTRX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e.g., brain, heart, liver, spleen, etc.). Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

[0216] A nucleic acid molecule of the invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24 as a hybridization probe, FCTRX molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, et al., (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; and Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993.)

[0217] A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to FCTRX nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

[0218] As used herein, the term “oligonucleotide” refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.

[0219] In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, or a portion of this nucleotide sequence (e.g., a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of an FCTRX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, is one that is sufficiently complementary to the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, thereby forming a stable duplex.

[0220] As used herein, the term “complementary” refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term “binding” means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

[0221] Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

[0222] Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. See e.g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993, and below.

[0223] A “homologous nucleic acid sequence” or “homologous amino acid sequence,” or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of FCTRX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for an FCTRX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human FCTRX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, as well as a polypeptide possessing FCTRX biological activity. Various biological activities of the FCTRX proteins are described below.

[0224] An FCTRX polypeptide is encoded by the open reading frame (“ORF”) of an FCTRX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG “start” codon and terminates with one of the three “stop” codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bonafide cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.

[0225] The nucleotide sequences determined from the cloning of the human FCTRX genes allows for the generation of probes and primers designed for use in identifying and/or cloning FCTRX homologues in other cell types, e.g. from other tissues, as well as FCTRX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24; or an anti-sense strand nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24; or of a naturally occurring mutant of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24.

[0226] Probes based on the human FCTRX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express an FCTRX protein, such as by measuring a level of an FCTRX-encoding nucleic acid in a sample of cells from a subject e.g., detecting FCTRX mRNA levels or determining whether a genomic FCTRX gene has been mutated or deleted.

[0227] “A polypeptide having a biologically-active portion of an FCTRX polypeptide” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a “biologically-active portion of FCTRX” can be prepared by isolating a portion of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, that encodes a polypeptide having an FCTRX biological activity (the biological activities of the FCTRX proteins are described below), expressing the encoded portion of FCTRX protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of FCTRX.

[0228] FCTRX Nucleic Acid and Polypeptide Variants

[0229] The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, due to degeneracy of the genetic code and thus encode the same FCTRX proteins as that encoded by the nucleotide sequences shown in SEQ ID NO NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25.

[0230] In addition to the human FCTRX nucleotide sequences shown in SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the FCTRX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the FCTRX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame (ORF) encoding an FCTRX protein, preferably a vertebrate FCTRX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the FCTRX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the FCTRX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the FCTRX polypeptides, are intended to be within the scope of the invention.

[0231] Moreover, nucleic acid molecules encoding FCTRX proteins from other species, and thus that have a nucleotide sequence that differs from the human sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the FCTRX cDNAs of the invention can be isolated based on their homology to the human FCTRX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

[0232] Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

[0233] Homologs (i.e., nucleic acids encoding FCTRX proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

[0234] As used herein, the phrase “stringent hybridization conditions” refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60° C. for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

[0235] Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6× SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65° C., followed by one or more washes in 0.2× SSC, 0.01% BSA at 50° C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

[0236] In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6× SSC, 5× Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55° C., followed by one or more washes in 1× SSC, 0.1% SDS at 37° C. Other conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

[0237] In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5× SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40° C., followed by one or more washes in 2× SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50° C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. Proc Natl Acad Sci USA 78: 6789-6792.

[0238] Conservative Mutations

[0239] In addition to naturally-occurring allelic variants of FCTRX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, thereby leading to changes in the amino acid sequences of the encoded FCTRX proteins, without altering the functional ability of said FCTRX proteins. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made in the sequence of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequences of the FCTRX proteins without altering their biological activity, whereas an “essential” amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the FCTRX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

[0240] Another aspect of the invention pertains to nucleic acid molecules encoding FCTRX proteins that contain changes in amino acid residues that are not essential for activity. Such FCTRX proteins differ in amino acid sequence from SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25; more preferably at least about 70% homologous to SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25; still more preferably at least about 80% homologous to SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25; even more preferably at least about 90% homologous to SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25; and most preferably at least about 95% homologous to SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25.

[0241] An isolated nucleic acid molecule encoding an FCTRX protein homologous to the protein of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

[0242] Mutations can be introduced into SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the FCTRX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an FCTRX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for FCTRX biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

[0243] The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved “strong” residues or fully conserved “weak” residues. The “strong” group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the “weak” group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, VLIM, HFY, wherein the letters within each group represent the single letter amino acid code.

[0244] In one embodiment, a mutant FCTRX protein can be assayed for (i) the ability to form protein:protein interactions with other FCTRX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant FCTRX protein and an FCTRX ligand; or (iii) the ability of a mutant FCTRX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).

[0245] In yet another embodiment, a mutant FCTRX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).

[0246] Antisense Nucleic Acids

[0247] Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, or fragments, analogs or derivatives thereof. An “antisense” nucleic acid comprises a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire FCTRX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of an FCTRX protein of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25; or antisense nucleic acids complementary to an FCTRX nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, are additionally provided.

[0248] In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence encoding an FCTRX protein. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence encoding the FCTRX protein. The term “noncoding region” refers to 5′ and 3′ sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions).

[0249] Given the coding strand sequences encoding the FCTRX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of FCTRX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of FCTRX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of FCTRX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used).

[0250] Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0251] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an FCTRX protein to thereby inhibit expression of the protein (e.g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

[0252] In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other. See, e.g., Gaultier, et al., 1987. Nucl. Acids Res. 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (see, e.g., Inoue, et al. 1987. Nucl. Acids Res. 15: 6131-6148) or a chimeric RNA-DNA analogue (see, e.g., Inoue, et al., 1987. FEBS Lett. 215: 327-330.

[0253] Ribozymes and PNA Moieties

[0254] Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

[0255] In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. Nature 334: 585-591) can be used to catalytically cleave FCTRX mRNA transcripts to thereby inhibit translation of FCTRX mRNA. A ribozyme having specificity for an FCTRX-encoding nucleic acid can be designed based upon the nucleotide sequence of an FCTRX cDNA disclosed herein (i.e., SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an FCTRX-encoding mRNA. See, e.g., U.S. Pat. No. 4,987,071 to Cech, et al. and U.S. Pat. No. 5,116,742 to Cech, et al. FCTRX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993) Science 261:1411-1418.

[0256] Alternatively, FCTRX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the FCTRX nucleic acid (e.g., the FCTRX promoter and/or enhancers) to form triple helical structures that prevent transcription of the FCTRX gene in target cells. See, e.g., Helene, 1991. Anticancer Drug Des. 6: 569-84; Helene, et al. 1992. Ann. N.Y. Acad. Sci. 660: 27-36; Maher, 1992. Bioassays 14: 807-15.

[0257] In various embodiments, the FCTRX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996. Bioorg Med Chem 4: 5-23. As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. supra; Perry-O'Keefe, et al., 1996. Proc. Natl. Acad. Sci. USA 93: 14670-14675.

[0258] PNAs of FCTRX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of FCTRX can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., SI nucleases (see, Hyrup, et al., 1996.supra); or as probes or primers for DNA sequence and hybridization (see, Hyrup, et al., 1996, supra; Perry-O'Keefe, et al., 1996. supra).

[0259] In another embodiment, PNAs of FCTRX can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of FCTRX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. supra and Finn, et al., 1996. Nucl Acids Res 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5′-(4-methoxytrityl)amino-5′-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5′ end of DNA. See, e.g., Mag, et al., 1989. Nucl Acid Res 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment. See, e.g., Finn, et al., 1996. supra. Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment. See, e.g., Petersen, et al., 1975. Bioorg. Med. Chem. Lett. 5: 1119-11124.

[0260] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al., 1989. Proc. Natl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaitre, et al., 1987. Proc. Natl. Acad. Sci. 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (see, e.g., Krol, et al., 1988. BioTechniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988. Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

[0261] FCTRX Polypeptides

[0262] A polypeptide according to the invention includes a polypeptide including the amino acid sequence of FCTRX polypeptides whose sequences are provided in SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, while still encoding a protein that maintains its FCTRX activities and physiological functions, or a functional fragment thereof.

[0263] In general, an FCTRX variant that preserves FCTRX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

[0264] One aspect of the invention pertains to isolated FCTRX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-FCTRX antibodies. In one embodiment, native FCTRX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, FCTRX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, an FCTRX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

[0265] An “isolated” or “purified” polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the FCTRX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of FCTRX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language “substantially free of cellular material” includes preparations of FCTRX proteins having less than about 30% (by dry weight) of non-FCTRX proteins (also referred to herein as a “contaminating protein”), more preferably less than about 20% of non-FCTRX proteins, still more preferably less than about 10% of non-FCTRX proteins, and most preferably less than about 5% of non-FCTRX proteins. When the FCTRX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the FCTRX protein preparation.

[0266] The language “substantially free of chemical precursors or other chemicals” includes preparations of FCTRX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of FCTRX proteins having less than about 30% (by dry weight) of chemical precursors or non-FCTRX chemicals, more preferably less than about 20% chemical precursors or non-FCTRX chemicals, still more preferably less than about 10% chemical precursors or non-FCTRX chemicals, and most preferably less than about 5% chemical precursors or non-FCTRX chemicals.

[0267] Biologically-active portions of FCTRX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the FCTRX proteins (e.g., the amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25) that include fewer amino acids than the full-length FCTRX proteins, and exhibit at least one activity of an FCTRX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the FCTRX protein. A biologically-active portion of an FCTRX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

[0268] Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native FCTRX protein.

[0269] In an embodiment, the FCTRX protein has an amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25. In other embodiments, the FCTRX protein is substantially homologous to SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, and retains the functional activity of the protein of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the FCTRX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, and retains the functional activity of the FCTRX proteins of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25.

[0270] Determining Homology Between Two or More Sequences

[0271] To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid “homology” is equivalent to amino acid or nucleic acid “identity”).

[0272] The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970. J Mol Biol 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24.

[0273] The term “sequence identity” refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term “substantial identity” as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

[0274] Chimeric and Fusion Proteins

[0275] The invention also provides FCTRX chimeric or fusion proteins. As used herein, an FCTRX “chimeric protein” or “fusion protein” comprises an FCTRX polypeptide operatively-linked to a non-FCTRX polypeptide. An “FCTRX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to an FCTRX protein (SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25), whereas a “non-FCTRX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the FCTRX protein, e.g., a protein that is different from the FCTRX protein and that is derived from the same or a different organism. Within an FCTRX fusion protein the FCTRX polypeptide can correspond to all or a portion of an FCTRX protein. In one embodiment, an FCTRX fusion protein comprises at least one biologically-active portion of an FCTRX protein. In another embodiment, an FCTRX fusion protein comprises at least two biologically-active portions of an FCTRX protein. In yet another embodiment, an FCTRX fusion protein comprises at least three biologically-active portions of an FCTRX protein. Within the fusion protein, the term “operatively-linked” is intended to indicate that the FCTRX polypeptide and the non-FCTRX polypeptide are fused in-frame with one another. The non-FCTRX polypeptide can be fused to the N-terminus or C-terminus of the FCTRX polypeptide.

[0276] In one embodiment, the fusion protein is a GST-FCTRX fusion protein in which the FCTRX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant FCTRX polypeptides.

[0277] In another embodiment, the fusion protein is an FCTRX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of FCTRX can be increased through use of a heterologous signal sequence.

[0278] In yet another embodiment, the fusion protein is an FCTRX-immunoglobulin fusion protein in which the FCTRX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The FCTRX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between an FCTRX ligand and an FCTRX protein on the surface of a cell, to thereby suppress FCTRX-mediated signal transduction in vivo. The FCTRX-immunoglobulin fusion proteins can be used to affect the bioavailability of an FCTRX cognate ligand. Inhibition of the FCTRX ligand/FCTRX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the FCTRX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-FCTRX antibodies in a subject, to purify FCTRX ligands, and in screening assays to identify molecules that inhibit the interaction of FCTRX with an FCTRX ligand.

[0279] An FCTRX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An FCTRX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the FCTRX protein.

[0280] FCTRX Agonists and Antagonists

[0281] The invention also pertains to variants of the FCTRX proteins that function as either FCTRX agonists (i.e., mimetics) or as FCTRX antagonists. Variants of the FCTRX protein can be generated by mutagenesis (e.g., discrete point mutation or truncation of the FCTRX protein). An agonist of the FCTRX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the FCTRX protein. An antagonist of the FCTRX protein can inhibit one or more of the activities of the naturally occurring form of the FCTRX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the FCTRX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the FCTRX proteins.

[0282] Variants of the FCTRX proteins that function as either FCTRX agonists (i.e., mimetics) or as FCTRX antagonists can be identified by screening combinatorial libraries of mutants (e.g., truncation mutants) of the FCTRX proteins for FCTRX protein agonist or antagonist activity. In one embodiment, a variegated library of FCTRX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of FCTRX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential FCTRX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of FCTRX sequences therein. There are a variety of methods which can be used to produce libraries of potential FCTRX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential FCTRX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. See, e.g., Narang, 1983. Tetrahedron 39: 3; Itakura, et al., 1984. Annu. Rev. Biochem. 53: 323; Itakura, et al., 1984. Science 198: 1056; Ike, et al., 1983. Nucl. Acids Res. 11: 477.

[0283] Polypeptide Libraries

[0284] In addition, libraries of fragments of the FCTRX protein coding sequences can be used to generate a variegated population of FCTRX fragments for screening and subsequent selection of variants of an FCTRX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an FCTRX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with SI nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the FCTRX proteins.

[0285] Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of FCTRX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify FCTRX variants. See, e.g., Arkin and Yourvan, 1992. Proc. Natl. Acad. Sci. USA 89: 7811-7815; Delgrave, et al., 1993. Protein Engineering 6:327-331.

[0286] Anti-FCTRX Antibodies

[0287] The invention encompasses antibodies and antibody fragments, such as Fab or (Fab)2, that bind immunospecifically to any of the FCTRX polypeptides of said invention.

[0288] An isolated FCTRX protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind to FCTRX polypeptides using standard techniques for polyclonal and monoclonal antibody preparation. The full-length FCTRX proteins can be used or, alternatively, the invention provides antigenic peptide fragments of FCTRX proteins for use as immunogens. The antigenic FCTRX peptides comprises at least 4 amino acid residues of the amino acid sequence shown in SEQ ID NO NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, and encompasses an epitope of FCTRX such that an antibody raised against the peptide forms a specific immune complex with FCTRX. Preferably, the antigenic peptide comprises at least 6, 8, 10, 15, 20, or 30 amino acid residues. Longer antigenic peptides are sometimes preferable over shorter antigenic peptides, depending on use and according to methods well known to someone skilled in the art.

[0289] In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of FCTRX that is located on the surface of the protein (e.g., a hydrophilic region). As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation (see, e.g., Hopp and Woods, 1981. Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle, 1982. J. Mol. Biol. 157: 105-142, each incorporated herein by reference in their entirety).

[0290] As disclosed herein, FCTRX protein sequences of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, or derivatives, fragments, analogs or homologs thereof, may be utilized as immunogens in the generation of antibodies that immunospecifically-bind these protein components. The term “antibody” as used herein refers to immunoglobulin molecules and immunologically-active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that specifically-binds (immunoreacts with) an antigen, such as FCTRX. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab and F(ab′)2 fragments, and an Fab expression library. In a specific embodiment, antibodies to human FCTRX proteins are disclosed. Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies to an FCTRX protein sequence of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, or a derivative, fragment, analog or homolog thereof. Some of these proteins are discussed below.

[0291] For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by injection with the native protein, or a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, recombinantly-expressed FCTRX protein or a chemically-synthesized FCTRX polypeptide. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), human adjuvants such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. If desired, the antibody molecules directed against FCTRX can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction.

[0292] The term “monoclonal antibody” or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of FCTRX. A monoclonal antibody composition thus typically displays a single binding affinity for a particular FCTRX protein with which it immunoreacts. For preparation of monoclonal antibodies directed towards a particular FCTRX protein, or derivatives, fragments, analogs or homologs thereof, any technique that provides for the production of antibody molecules by continuous cell line culture may be utilized. Such techniques include, but are not limited to, the hybridoma technique (see, e.g., Kohler & Milstein, 1975. Nature 256: 495-497); the trioma technique; the human B-cell hybridoma technique (see, e.g., Kozbor, et al., 1983. Immunol. Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see, e.g., Cole, et al., 1985. In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the invention and may be produced by using human hybridomas (see, e.g., Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see, e.g., Cole, et al., 1985. In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Each of the above citations is incorporated herein by reference in their entirety.

[0293] According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an FCTRX protein (see, e.g., U.S. Pat. No. 4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (see, e.g., Huse, et al., 1989. Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for an FCTRX protein or derivatives, fragments, analogs or homologs thereof. Non-human antibodies can be “humanized” by techniques well known in the art. See, e.g., U.S. Pat. No. 5,225,539. Antibody fragments that contain the idiotypes to an FCTRX protein may be produced by techniques known in the art including, but not limited to: (i) an F(ab′)2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an F(ab′)2 fragment; (iii) an Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent; and (iv) Fv fragments.

[0294] Additionally, recombinant anti-FCTRX antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in International Application No. PCT/US86/02269; European Patent Application No. 184,187; European Patent Application No. 171,496; European Patent Application No. 173,494; PCT International Publication No. WO 86/01533; U.S. Pat. No. 4,816,567; U.S. Pat. No. 5,225,539; European Patent Application No. 125,023; Better, et al., 1988. Science 240: 1041-1043; Liu, et al., 1987. Proc. Natl. Acad. Sci. USA 84: 3439-3443; Liu, et al., 1987. J. Immunol. 139: 3521-3526; Sun, et al., 1987. Proc. Natl. Acad. Sci. USA 84: 214-218; Nishimura, et al., 1987. Cancer Res. 47: 999-1005; Wood, et al., 1985. Nature 314 :446-449; Shaw, et al., 1988. J. Natl. Cancer Inst. 80: 1553-1559); Morrison(1985) Science 229:1202-1207; Oi, et al. (1986) BioTechniques 4:214; Jones, et al., 1986. Nature 321: 552-525; Verhoeyan, et al., 1988. Science 239: 1534; and Beidler, et al., 1988. J. Immunol. 141: 4053-4060. Each of the above citations are incorporated herein by reference in their entirety.

[0295] In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an FCTRX protein is facilitated by generation of hybridomas that bind to the fragment of an FCTRX protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an FCTRX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

[0296] Anti-FCTRX antibodies may be used in methods known within the art relating to the localization and/or quantitation of an FCTRX protein (e.g., for use in measuring levels of the FCTRX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies for FCTRX proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antibody derived binding domain, are utilized as pharmacologically-active compounds (hereinafter “Therapeutics”).

[0297] An anti-FCTRX antibody (e.g., monoclonal antibody) can be used to isolate an FCTRX polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-FCTRX antibody can facilitate the purification of natural FCTRX polypeptide from cells and of recombinantly-produced FCTRX polypeptide expressed in host cells. Moreover, an anti-FCTRX antibody can be used to detect FCTRX protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the FCTRX protein. Anti-FCTRX antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I, 131I, 35S or 3H.

[0298] FCTRX Recombinant Expression Vectors and Host Cells

[0299] Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an FCTRX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors”. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0300] The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably-linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

[0301] The term “regulatory sequence” is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., FCTRX proteins, mutant forms of FCTRX proteins, fusion proteins, etc.).

[0302] The recombinant expression vectors of the invention can be designed for expression of FCTRX proteins in prokaryotic or eukaryotic cells. For example, FCTRX proteins can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

[0303] Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 3140), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

[0304] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

[0305] One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (see, e.g., Wada, et al., 1992. Nucl. Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

[0306] In another embodiment, the FCTRX expression vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerivisae include pYepSec1 (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

[0307] Alternatively, FCTRX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

[0308] In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

[0309] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Banerji, et al., 1983. Cell 33: 729-740; Queen and Baltimore, 1983. Cell 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. Science 249: 374-379) and the (x-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3: 537-546).

[0310] The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to FCTRX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al., “Antisense RNA as a molecular tool for genetic analysis,” Reviews—Trends in Genetics, Vol. 1(1) 1986.

[0311] Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

[0312] A host cell can be any prokaryotic or eukaryotic cell. For example, FCTRX protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

[0313] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

[0314] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding FCTRX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

[0315] A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) FCTRX protein. Accordingly, the invention further provides methods for producing FCTRX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding FCTRX protein has been introduced) in a suitable medium such that FCTRX protein is produced. In another embodiment, the method further comprises isolating FCTRX protein from the medium or the host cell.

[0316] Transgenic FCTRX Animals

[0317] The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which FCTRX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous FCTRX sequences have been introduced into their genome or homologous recombinant animals in which endogenous FCTRX sequences have been altered. Such animals are useful for studying the function and/or activity of FCTRX protein and for identifying and/or evaluating modulators of FCTRX protein activity. As used herein, a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous FCTRX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

[0318] A transgenic animal of the invention can be created by introducing FCTRX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human FCTRX cDNA sequences of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human FCTRX gene, such as a mouse FCTRX gene, can be isolated based on hybridization to the human FCTRX cDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the FCTRX transgene to direct expression of FCTRX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the FCTRX transgene in its genome and/or expression of FCTRX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding FCTRX protein can further be bred to other transgenic animals carrying other transgenes.

[0319] To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an FCTRX gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the FCTRX gene. The FCTRX gene can be a human gene (e.g., the cDNA of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24), but more preferably, is a non-human homologue of a human FCTRX gene. For example, a mouse homologue of human FCTRX gene of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, can be used to construct a homologous recombination vector suitable for altering an endogenous FCTRX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous FCTRX gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector).

[0320] Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous FCTRX gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous FCTRX protein). In the homologous recombination vector, the altered portion of the FCTRX gene is flanked at its 5′- and 3′-termini by additional nucleic acid of the FCTRX gene to allow for homologous recombination to occur between the exogenous FCTRX gene carried by the vector and an endogenous FCTRX gene in an embryonic stem cell. The additional flanking FCTRX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5′- and 3′-termini) are included in the vector. See, e.g., Thomas, et al., 1987. Cell 51: 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced FCTRX gene has homologously-recombined with the endogenous FCTRX gene are selected. See, e.g., Li, et al., 1992. Cell 69: 915.

[0321] The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. Curr. Opin. Biotechnol. 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

[0322] In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, See, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae. See, O'Gorman, et al., 1991. Science 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

[0323] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al., 1997. Nature 385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G0 phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.

[0324] Pharmaceutical Compositions

[0325] The FCTRX nucleic acid molecules, FCTRX proteins, and anti-FCTRX antibodies (also referred to herein as “active compounds”) of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0326] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0327] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0328] Sterile injectable solutions can be prepared by incorporating the active compound (e.g., an FCTRX protein or anti-FCTRX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0329] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0330] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0331] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

[0332] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0333] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No.4,522,811.

[0334] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

[0335] The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Pat. No.5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

[0336] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0337] Screening and Detection Methods

[0338] The isolated nucleic acid molecules of the invention can be used to express FCTRX protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect FCTRX mRNA (e.g., in a biological sample) or a genetic lesion in an FCTRX gene, and to modulate FCTRX activity, as described further, below. In addition, the FCTRX proteins can be used to screen drugs or compounds that modulate the FCTRX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of FCTRX protein or production of FCTRX protein forms that have decreased or aberrant activity compared to FCTRX wild-type protein (e.g.; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease(possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-FCTRX antibodies of the invention can be used to detect and isolate FCTRX proteins and modulate FCTRX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

[0339] The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra.

[0340] Screening Assays

[0341] The invention provides a method (also referred to herein as a “screening assay”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that bind to FCTRX proteins or have a stimulatory or inhibitory effect on, e.g., FCTRX protein expression or FCTRX protein activity. The invention also includes compounds identified in the screening assays described herein.

[0342] In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of an FCTRX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. Anticancer Drug Design 12: 145.

[0343] A “small molecule” as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

[0344] Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993. Proc. Natl. Acad. Sci. U.S.A. 90: 6909; Erb, et al., 1994. Proc. Natl. Acad. Sci. U.S.A. 91: 11422; Zuckermann, et al., 1994. J. Med. Chem. 37: 2678; Cho, et al., 1993. Science 261: 1303; Carrell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2059; Carell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2061; and Gallop, et al., 1994. J. Med. Chem. 37:1233.

[0345] Libraries of compounds may be presented in solution (e.g., Houghten, 1992. Biotechniques 13: 412-421), or on beads (Lam, 1991. Nature 354: 82-84), on chips (Fodor, 1993. Nature 364: 555-556), bacteria (Ladner, U.S. Pat. No. 5,223,409), spores (Ladner, U.S. Pat. No. 5,233,409), plasmids (Cull, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 1865-1869) or on phage (Scott and Smith, 1990. Science 249: 386-390; Devlin, 1990. Science 249: 404-406; Cwirla, et al., 1990. Proc. Natl. Acad. Sci. U.S.A. 87: 6378-6382; Felici, 1991. J. Mol. Biol. 222: 301-310; Ladner, U.S. Pat. No. 5,233,409.).

[0346] In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of FCTRX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to an FCTRX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the FCTRX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the FCTRX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with 125I, 35S, 14C, or 3H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of FCTRX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds FCTRX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an FCTRX protein, wherein determining the ability of the test compound to interact with an FCTRX protein comprises determining the ability of the test compound to preferentially bind to FCTRX protein or a biologically-active portion thereof as compared to the known compound.

[0347] In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of FCTRX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the FCTRX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of FCTRX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the FCTRX protein to bind to or interact with an FCTRX target molecule. As used herein, a “target molecule” is a molecule with which an FCTRX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses an FCTRX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. An FCTRX target molecule can be a non-FCTRX molecule or an FCTRX protein or polypeptide of the invention. In one embodiment, an FCTRX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g. a signal generated by binding of a compound to a membrane-bound FCTRX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with FCTRX.

[0348] Determining the ability of the FCTRX protein to bind to or interact with an FCTRX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the FCTRX protein to bind to or interact with an FCTRX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e. intracellular Ca2+, diacylglycerol, IP3, etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising an FCTRX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

[0349] In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting an FCTRX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the FCTRX protein or biologically-active portion thereof. Binding of the test compound to the FCTRX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the FCTRX protein or biologically-active portion thereof with a known compound which binds FCTRX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an FCTRX protein, wherein determining the ability of the test compound to interact with an FCTRX protein comprises determining the ability of the test compound to preferentially bind to FCTRX or biologically-active portion thereof as compared to the known compound.

[0350] In still another embodiment, an assay is a cell-free assay comprising contacting FCTRX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the FCTRX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of FCTRX can be accomplished, for example, by determining the ability of the FCTRX protein to bind to an FCTRX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of FCTRX protein can be accomplished by determining the ability of the FCTRX protein further modulate an FCTRX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, supra.

[0351] In yet another embodiment, the cell-free assay comprises contacting the FCTRX protein or biologically-active portion thereof with a known compound which binds FCTRX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an FCTRX protein, wherein determining the ability of the test compound to interact with an FCTRX protein comprises determining the ability of the FCTRX protein to preferentially bind to or modulate the activity of an FCTRX target molecule.

[0352] The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of FCTRX protein. In the case of cell-free assays comprising the membrane-bound form of FCTRX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of FCTRX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)n, N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

[0353] In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either FCTRX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to FCTRX protein, or interaction of FCTRX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-FCTRX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or FCTRX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of FCTRX protein binding or activity determined using standard techniques.

[0354] Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the FCTRX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated FCTRX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with FCTRX protein or target molecules, but which do not interfere with binding of the FCTRX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or FCTRX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the FCTRX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the FCTRX protein or target molecule.

[0355] In another embodiment, modulators of FCTRX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of FCTRX mRNA or protein in the cell is determined. The level of expression of FCTRX mRNA or protein in the presence of the candidate compound is compared to the level of expression of FCTRX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of FCTRX mRNA or protein expression based upon this comparison. For example, when expression of FCTRX mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of FCTRX mRNA or protein expression. Alternatively, when expression of FCTRX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of FCTRX mRNA or protein expression. The level of FCTRX mRNA or protein expression in the cells can be determined by methods described herein for detecting FCTRX mRNA or protein.

[0356] In yet another aspect of the invention, the FCTRX proteins can be used as “bait proteins” in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos, et al., 1993. Cell 72: 223-232; Madura, et al., 1993. J. Biol. Chem. 268: 12046-12054; Bartel, et al., 1993. Biotechniques 14: 920-924; Iwabuchi, et al., 1993. Oncogene 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with FCTRX (“FCTRX-binding proteins” or “FCTRX-bp”) and modulate FCTRX activity. Such FCTRX-binding proteins are also likely to be involved in the propagation of signals by the FCTRX proteins as, for example, upstream or downstream elements of the FCTRX pathway.

[0357] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for FCTRX is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming an FCTRX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with FCTRX.

[0358] The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

[0359] Detection Assays

[0360] Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

[0361] Chromosome Mapping

[0362] Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the FCTRX sequences, SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, or fragments or derivatives thereof, can be used to map the location of the FCTRX genes, respectively, on a chromosome. The mapping of the FCTRX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

[0363] Briefly, FCTRX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the FCTRX sequences. Computer analysis of the FCTRX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the FCTRX sequences will yield an amplified fragment.

[0364] Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, et al., 1983. Science 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

[0365] PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the FCTRX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

[0366] Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al., HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

[0367] Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

[0368] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, e.g., in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland, et al., 1987. Nature, 325: 783-787.

[0369] Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the FCTRX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

[0370] Tissue Typing

[0371] The FCTRX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP (“restriction fragment length polymorphisms,” described in U.S. Pat. No. 5,272,057).

[0372] Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the FCTRX sequences described herein can be used to prepare two PCR primers from the 5′- and 3′-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

[0373] Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The FCTRX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

[0374] Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

[0375] Predictive Medicine

[0376] The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining FCTRX protein and/or nucleic acid expression as well as FCTRX activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is .afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant FCTRX expression or activity. The disorders include Also within the scope of the invention is the use of a Therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Colorectal cancer, adenomatous polyposis coli, myelogenous leukemia, congenital ceonatal alloimmune thrombocytopenia, multiple human solid malignancies, malignant ovarian tumours particularly at the interface between epithelia and stroma, malignant brain tumors, mammary tumors, human gliomas, astrocytomas, mixed glioma/astrocytomas, renal cells carcinoma, breast adenocarcinoma, ovarian cancer, melanomas, renal cell carcinoma, clear cell and granular cell carcinomas, autocrine/paracrine stimulation of tumor cell proliferation, autocrine/paracrine stimulation of tumor cell survival and tumor cell resistance to cytotoxic therapy, paranechmal and basement membrane invasion and motility of tumor cells thereby contributing to metastasis, tumor-mediated immunosuppression of T-cell mediated immune effector cells and pathways resulting in tumor escape from immune surveilance, neurological disorders, neurodegenerative disorders, nerve trauma, familial myelodysplastic syndrome, Charcot-Marie-Tooth neuropathy, demyelinating Gardner syndrome, familial myelodysplastic syndrome; mental health conditions, immunological disorders, allergy and infection, asthma, bronchial asthma, Avellino type eosinophilia, lung diseases, reproductive disorders, male infertility, female reproductive system disorders, male and female reproductive diseases, hemangioma, deafness, glycoprotein Ia deficiency, desmoid disease, turcot syndrome, liver cirrhosis, hepatitis C, gastric disorders, pancreatic diseases like diabetes, Schistosoma mansoni infection, Spinocerebellar ataxia, Plasmodium falciparum parasitemia, Corneal dystrophy—Groenouw type 1, Corneal dystrophy—lattice type I, and Reis-Bucklers corneal dystrophy. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with FCTRX protein, nucleic acid expression or activity. For example, mutations in an FCTRX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with FCTRX protein, nucleic acid expression, or biological activity.

[0377] Another aspect of the invention provides methods for determining FCTRX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as “pharmacogenomics”). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

[0378] Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of FCTRX in clinical trials.

[0379] These and other agents are described in further detail in the following sections.

[0380] Diagnostic Assays

[0381] An exemplary method for detecting the presence or absence of FCTRX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting FCTRX protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes FCTRX protein such that the presence of FCTRX is detected in the biological sample. An agent for detecting FCTRX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to FCTRX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length FCTRX nucleic acid, such as the nucleic acid of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to FCTRX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

[0382] An agent for detecting FCTRX protein is an antibody capable of binding to FCTRX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′)2) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect FCTRX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of FCTRX mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of FCTRX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of FCTRX genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of FCTRX protein include introducing into a subject a labeled anti-FCTRX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

[0383] In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

[0384] In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting FCTRX protein, mRNA, or genomic DNA, such that the presence of FCTRX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of FCTRX protein, mRNA or genomic DNA in the control sample with the presence of FCTRX protein, mRNA or genomic DNA in the test sample.

[0385] The invention also encompasses kits for detecting the presence of FCTRX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting FCTRX protein or mRNA in a biological sample; means for determining the amount of FCTRX in the sample; and means for comparing the amount of FCTRX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect FCTRX protein or nucleic acid.

[0386] Prognostic Assays

[0387] The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant FCTRX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with FCTRX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant FCTRX expression or activity in which a test sample is obtained from a subject and FCTRX protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of FCTRX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant FCTRX expression or activity. As used herein, a “test sample” refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

[0388] Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant FCTRX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant FCTRX expression or activity in which a test sample is obtained and FCTRX protein or nucleic acid is detected (e.g., wherein the presence of FCTRX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant FCTRX expression or activity).

[0389] The methods of the invention can also be used to detect genetic lesions in an FCTRX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding an FCTRX-protein, or the misexpression of the FCTRX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from an FCTRX gene; (ii) an addition of one or more nucleotides to an FCTRX gene; (iii) a substitution of one or more nucleotides of an FCTRX gene, (iv) a chromosomal rearrangement of an FCTRX gene; (v) an alteration in the level of a messenger RNA transcript of an FCTRX gene, (vi) aberrant modification of an FCTRX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of an FCTRX gene, (viii) a non-wild-type level of an FCTRX protein, (ix) allelic loss of an FCTRX gene, and (x) inappropriate post-translational modification of an FCTRX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in an FCTRX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

[0390] In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, et al., 1988. Science 241: 1077-1080; and Nakazawa, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the FCTRX-gene (see, Abravaya, et al., 1995. Nucl. Acids Res. 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to an FCTRX gene under conditions such that hybridization and amplification of the FCTRX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

[0391] Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990. Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (see, Kwoh, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 1173-1177); Qβ Replicase (see, Lizardi, et al, 1988. BioTechnology 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

[0392] In an alternative embodiment, mutations in an FCTRX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Pat. No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

[0393] In other embodiments, genetic mutations in FCTRX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al., 1996. Human Mutation 7: 244-255; Kozal, et al., 1996. Nat. Med. 2: 753-759. For example, genetic mutations in FCTRX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

[0394] In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the FCTRX gene and detect mutations by comparing the sequence of the sample FCTRX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. Proc. Natl. Acad. Sci. USA 74: 560 or Sanger, 1977. Proc. Natl. Acad. Sci. USA 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995. Biotechniques 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, et al., 1996. Adv. Chromatography 36: 127-162; and Griffin, et al., 1993. Appl. Biochem. Biotechnol. 38: 147-159).

[0395] Other methods for detecting mutations in the FCTRX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985. Science 230: 1242. In general, the art technique of “mismatch cleavage” starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type FCTRX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988. Proc. Natl. Acad. Sci. USA 85: 4397; Saleeba, et al., 1992. Methods Enzymol. 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

[0396] In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called “DNA mismatch repair” enzymes) in defined systems for detecting and mapping point mutations in FCTRX cDNAs obtained from samples of cells. For example, the mutY enzyme of E. coli cleaves A at GIA mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994. Carcinogenesis 15: 1657-1662. According to an exemplary embodiment, a probe based on an FCTRX sequence, e.g., a wild-type FCTRX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Pat. No. 5,459,039.

[0397] In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in FCTRX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989. Proc. Natl. Acad. Sci. USA: 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal. Tech. Appl. 9: 73-79. Single-stranded DNA fragments of sample and control FCTRX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991. Trends Genet. 7: 5.

[0398] In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985. Nature 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.

[0399] Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

[0400] Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448) or at the extreme 3′-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. Tibtech. 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992. Mol. Cell Probes 6: 1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991. Proc. Natl. Acad. Sci. USA 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3′-terminus of the 5′ sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

[0401] The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an FCTRX gene.

[0402] Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which FCTRX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

[0403] Pharmacogenomics

[0404] Agents, or modulators that have a stimulatory or inhibitory effect on FCTRX activity (e.g., FCTRX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, Also within the scope of the invention is the use of a Therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Colorectal cancer, adenomatous polyposis coli, myelogenous leukemia, congenital ceonatal alloimmune thrombocytopenia, multiple human solid malignancies, malignant ovarian tumours particularly at the interface between epithelia and stroma, malignant brain tumors, mammary tumors, human gliomas, astrocytomas, mixed glioma/astrocytomas, renal cells carcinoma, breast adenocarcinoma, ovarian cancer, melanomas, renal cell carcinoma, clear cell and granular cell carcinomas, autocrine/paracrine stimulation of tumor cell proliferation, autocrine/paracrine stimulation of tumor cell survival and tumor cell resistance to cytotoxic therapy, paranechmal and basement membrane invasion and motility of tumor cells thereby contributing to metastasis, tumor-mediated immunosuppression of T-cell mediated immune effector cells and pathways resulting in tumor escape from immune surveilance, neurological disorders, neurodegenerative disorders, nerve trauma, familial myelodysplastic syndrome, Charcot-Marie-Tooth neuropathy, demyelinating Gardner syndrome, familial myelodysplastic syndrome; mental health conditions, immunological disorders, allergy and infection, asthma, bronchial asthma, Avellino type eosinophilia, lung diseases, reproductive disorders, male infertility, female reproductive system disorders, male and female reproductive diseases, hemangioma, deafness, glycoprotein Ia deficiency, desmoid disease, turcot syndrome, liver cirrhosis, hepatitis C, gastric disorders, pancreatic diseases like diabetes, Schistosoma mansoni infection, Spinocerebellar ataxia, Plasmodium falciparum parasitemia, Corneal dystrophy—Groenouw type I, Corneal dystrophy—lattice type I, and Reis-Bucklers corneal dystrophy) In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of FCTRX protein, expression of FCTRX nucleic acid, or mutation content of FCTRX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

[0405] Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996. Clin. Exp. Pharmacol. Physiol., 23: 983-985; Linder, 1997. Clin. Chem., 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

[0406] As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

[0407] Thus, the activity of FCTRX protein, expression of FCTRX nucleic acid, or mutation content of FCTRX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an FCTRX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

[0408] Monitoring of Effects During Clinical Trials

[0409] Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of FCTRX (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase FCTRX gene expression, protein levels, or upregulate FCTRX activity, can be monitored in clinical trails of subjects exhibiting decreased FCTRX gene expression, protein levels, or downregulated FCTRX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease FCTRX gene expression, protein levels, or downregulate FCTRX activity, can be monitored in clinical trails of subjects exhibiting increased FCTRX gene expression, protein levels, or upregulated FCTRX activity. In such clinical trials, the expression or activity of FCTRX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a “read out” or markers of the immune responsiveness of a particular cell.

[0410] By way of example, and not of limnitation, genes, including FCTRX, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates FCTRX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of FCTRX and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of FCTRX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

[0411] In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an FCTRX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the FCTRX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the FCTRX protein, mRNA, or genomic DNA in the pre-administration sample with the FCTRX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of FCTRX to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of FCTRX to lower levels than detected, i.e., to decrease the effectiveness of the agent.

[0412] Methods of Treatment

[0413] The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant FCTRX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Ostoeodystrophy, and other diseases, disorders and conditions of the like.

[0414] These methods of treatment will be discussed more fully, below.

[0415] Disease and Disorders

[0416] Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are “dysfunctional” (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to “knockout” endoggenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989. Science 244: 1288-1292); or (v) modulators (i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

[0417] Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof, or an agonist that increases bioavailability.

[0418] Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like).

[0419] Prophylactic Methods

[0420] In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant FCTRX expression or activity, by administering to the subject an agent that modulates FCTRX expression or at least one FCTRX activity. Subjects at risk for a disease that is caused or contributed to by aberrant FCTRX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the FCTRX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of FCTRX aberrancy, for example, an FCTRX agonist or FCTRX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

[0421] Therapeutic Methods

[0422] Another aspect of the invention pertains to methods of modulating FCTRX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of FCTRX protein activity associated with the cell. An agent that modulates FCTRX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of an FCTRX protein, a peptide, an FCTRX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more FCTRX protein activity. Examples of such stimulatory agents include active FCTRX protein and a nucleic acid molecule encoding FCTRX that has been introduced into the cell. In another embodiment, the agent inhibits one or more FCTRX protein activity. Examples of such inhibitory agents include antisense FCTRX nucleic acid molecules and anti-FCTRX antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of an FCTRX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) FCTRX expression or activity. In another embodiment, the method involves administering an FCTRX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant FCTRX expression or activity.

[0423] Stimulation of FCTRX activity is desirable in situations in which FCTRX is abnormally downregulated and/or in which increased FCTRX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).

[0424] Determination of the Biological Effect of the Therapeutic

[0425] In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

[0426] In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.

[0427] Prophylactic and Therapeutic Uses of the Compositions of the Invention

[0428] The FCTRX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: Also within the scope of the invention is the use of a Therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Colorectal cancer, adenomatous polyposis coli, myelogenous leukemia, congenital ceonatal alloimmune thrombocytopenia, multiple human solid malignancies, malignant ovarian tumours particularly at the interface between epithelia and stroma, malignant brain tumors, mammary tumors, human gliomas, astrocytomas, mixed glioma/astrocytomas, renal cells carcinoma, breast adenocarcinoma, ovarian cancer, melanomas, renal cell carcinoma, clear cell and granular cell carcinomas, autocrine/paracrine stimulation of tumor cell proliferation, autocrine/paracrine stimulation of tumor cell survival and tumor cell resistance to cytotoxic therapy, paranechmal and basement membrane invasion and motility of tumor cells thereby contributing to metastasis, tumor-mediated immunosuppression of T-cell mediated immune effector cells and pathways resulting in tumor escape from immune surveilance, neurological disorders, neurodegenerative disorders, nerve trauma, familial myelodysplastic syndrome, Charcot-Marie-Tooth neuropathy, demyelinating Gardner syndrome, familial myelodysplastic syndrome; mental health conditions, immunological disorders, allergy and infection, asthma, bronchial asthma, Avellino type eosinophilia, lung diseases, reproductive disorders, male infertility, female reproductive system disorders, male and female reproductive diseases, hemangioma, deafness, glycoprotein Ia deficiency, desmoid disease, turcot syndrome, liver cirrhosis, hepatitis C, gastric disorders, pancreatic diseases like diabetes, Schistosoma mansoni infection, Spinocerebellar ataxia, Plasmodium falciparum parasitemia, Corneal dystrophy—Groenouw type I, Corneal dystrophy—lattice type I, and Reis-Bucklers corneal dystrophy.

[0429] As an example, a cDNA encoding the FCTRX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: Also within the scope of the invention is the use of a Therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Colorectal cancer, adenomatous polyposis coli, myelogenous leukemia, congenital ceonatal alloimmune thrombocytopenia, multiple human solid malignancies, malignant ovarian tumours particularly at the interface between epithelia and stroma, malignant brain tumors, mammary tumors, human gliomas, astrocytomas, mixed glioma/astrocytomas, renal cells carcinoma, breast adenocarcinoma, ovarian cancer, melanomas, renal cell carcinoma, clear cell and granular cell carcinomas, autocrine/paracrine stimulation of tumor cell proliferation, autocrine/paracrine stimulation of tumor cell survival and tumor cell resistance to cytotoxic therapy, paranechmal and basement membrane invasion and motility of tumor cells thereby contributing to metastasis, tumor-mediated immunosuppression of T-cell mediated immune effector cells and pathways resulting in tumor escape from immune surveilance, neurological disorders, neurodegenerative disorders, nerve trauma, familial myelodysplastic syndrome, Charcot-Marie-Tooth neuropathy, demyelinating Gardner syndrome, familial myelodysplastic syndrome; mental health conditions, immunological disorders, allergy and infection, asthma, bronchial asthma, Avellino type eosinophilia, lung diseases, reproductive disorders, male infertility, female reproductive system disorders, male and female reproductive diseases, hemangioma, deafness, glycoprotein Ia deficiency, desmoid disease, turcot syndrome, liver cirrhosis, hepatitis C, gastric disorders, pancreatic diseases like diabetes, Schistosoma mansoni infection, Spinocerebellar ataxia, Plasmodium falciparum parasitemia, Corneal dystrophy—Groenouw type I, Corneal dystrophy—lattice type I, and Reis-Bucklers corneal dystrophy.

[0430] Both the novel nucleic acid encoding the FCTRX protein, and the FCTRX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (i.e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

EXAMPLES

[0431] The following examples illustrate by way of non-limiting example various aspects of the invention.

[0432] The following examples illustrate by way of non-limiting example various aspects of the invention.

Example 1

Method of Identifying the Nucleic Acids

[0433] The novel nucleic acids of the invention were identified by TblastN using a proprietary sequence file, run against the Genomic Daily Files made available by GenBank. The nucleic acids were further predicted by the proprietary software program GenScan™, including selection of exons. These were further modified by means of similarities using BLAST searches. The sequences were then manually corrected for apparent inconsistencies, thereby obtaining the sequences encoding the full-length proteins.

Example 2

Quantitative Expression Analysis of FCTR2 in Various Cells and Tissues

[0434] The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR; TAQMAN®). RTQ PCR was performed on a Perkin-Elmer Biosystems ABI PRISM® 7700 Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing cells and cell lines from normal and cancer sources), Panel 2 (containing samples derived from tissues, in particular from surgical samples, from normal and cancer sources), Panel 3 (containing samples derived from a wide variety of cancer sources) and Panel 4 (containing cells and cell lines from normal cells and cells related to inflammatory conditions).

[0435] First, the RNA samples were normalized to constitutively expressed genes such as β-actin and GAPDH. RNA (˜50 ng total or ˜1 ng polyA+) was converted to cDNA using the TAQMAN® Reverse Transcription Reagents Kit (PE Biosystems, Foster City, Calif.; Catalog No. N808-0234) and random hexamers according to the manufacturer's protocol. Reactions were performed in 20 ul and incubated for 30 min. at 48° C. cDNA (5 ul) was then transferred to a separate plate for the TAQMAN® reaction using β-actin and GAPDH TAQMAN® Assay Reagents (PE Biosystems; Catalog Nos. 4310881E and 4310884E, respectively) and TAQMAN® universal PCR Master Mix (PE Biosystems; Catalog No. 4304447) according to the manufacturer's protocol. Reactions were performed in 25 ul using the following parameters: 2 min. at 50° C.; 10 min. at 95° C.; 15 sec. at 95° C./1 min. at 60° C. (40 cycles). Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100. The average CT values obtained for β-actin and GAPDH were used to normalize RNA samples. The RNA sample generating the highest CT value required no further diluting, while all other samples were diluted relative to this sample according to their β-actin /GAPDH average CT values.

[0436] Normalized RNA (5 ul) was converted to cDNA and analyzed via TAQMAN® using One Step RT-PCR Master Mix Reagents (PE Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions. Probes and primers were designed for each assay according to Perkin Elmer Biosystem's Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration=250 nM, primer melting temperature (Tm) range=58°-60° C., primer optimal Tm=59° C., maximum primer difference=2° C., probe does not have 5′ G, probe Tm must be 10° C. greater than primer Tm, amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, Tex., USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5′ and 3′ ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200nM.

[0437] PCR conditions: Normalized RNA from each tissue and each cell line was spotted in each well of a 96 well PCR plate (Perkin Elmer Biosystems). PCR cocktails including two probes (a probe specific for the target clone and another gene-specific probe multiplexed with the target probe) were set up using 1× TaqMan™ PCR Master Mix for the PE Biosystems 7700, with 5 mM MgCl2, dNTPs (dA, G, C, U at 1:1:1:2 ratios), 0.25 U/ml AmpliTaq Gold™ (PE Biosystems), and 0.4 U/μl RNase inhibitor, and 0.25 U/el reverse transcriptase. Reverse transcription was performed at 48° C. for 30 minutes followed by amplification/PCR cycles as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute.

[0438] In the results for Panel 1, the following abbreviations are used:

[0439] ca.=carcinoma,

[0440] *=established from metastasis,

[0441] met=metastasis,

[0442] s cell var=small cell variant,

[0443] non-s=non-sm=non-small,

[0444] squam=squamous,

[0445] pl. eff=pl effusion=pleural effusion,

[0446] glio=glioma,

[0447] astro=astrocytoma, and

[0448] neuro=neuroblastoma.

[0449] Panel 2

[0450] The plates for Panel 2 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have “matched margins” obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted “NAT” in the results below. The tumor tissue and the “matched margins” are evaluated by two independent pathologists (the surgical pathologists and again by a pathologists at NDRI or CHTN). This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissue were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, Calif.), Research Genetics, and Invitrogen.

[0451] RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s: 18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

[0452] Panel 4

[0453] Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4r) or cDNA (Panel 4d) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, Calif.) and thymus and kidney (Clontech) were employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, Calif.). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, Pa.).

[0454] Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, Md.) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

[0455] Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco/Life Technologies, Rockville, Md.), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 μg/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μg/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2×106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10−5 M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1-7 days for RNA preparation.

[0456] Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, Utah), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μg/ml for 6 and 12-14 hours.

[0457] CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and +ve selection. Then CD45RO beads were used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco) and plated at 106 cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 μg/ml anti-CD28 (Pharmingen) and 3 ug/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

[0458] To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resupended at 106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 μg/ml or anti-CD40 (Pharmingen) at approximately 10 μg/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.

[0459] To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μg/ml anti-CD28 (Pharmingen) and 2 μg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, Md.) were cultured at 105-106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1 μg/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μg/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were restimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 ,ug/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

[0460] The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×105 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×105 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 μg/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5 M (Gibco), and 10 mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

[0461] For these cell lines and blood cells, RNA was prepared by lysing approximately 107 cells/ml using Trizol (Gibco BRL). Briefly, {fraction (1/10)} volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at −20 degrees C. overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μl of RNAse-free water and 35 μl buffer (Promega) 5 μl DTT, 7 μl RNAsin and 8 μl DNAse were added. The tube was incubated at 37 degrees C. for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with {fraction (1/10)} volume of 3 M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNAse free water. RNA was stored at −80 degrees C.

[0462] The above detailed procedures were carried out to obtain the taqman profiles of the clones in question.

[0463] Given below are the Primers and the Taqman results for the following clones:

[0464] 58092213.0.36—Probe Name: Ag809 (Table 9 and Table 10)

[0465] 29692275.0.1—Probe Name: Ag2773 (Table 11 and Table 12)

[0466] 32125243.0.21—Probe Name: Ag427 (Table 13 and Table 14)

[0467] 27455183.0.19—Probe Name: Ag1541 (Table 15 and Table 16, 17, 18)

TABLE 8
Primer Design for Probe Ag809 (FCTR1)
				Start	SEQID
Primer	Sequences	TM	Length	Pos	NO
Forward	5′-ATGTGATCTTTGGCTGTGAAGT-3′	58.7	22	337	24
Probe	FAM-5′-CTACCCCATGGCCTCCATCGAGT-3′-TAMRA	69.4	23	365	25
Reverse	5′-GGATGTCCAAGCCATCCTT-3′	59.9	19	393	26

[0468]

TABLE 9
TAQMAN RESULTS FOR FCTR1
	Panel		Panel		Panel
Tissue_Name	1	Tissue_Name	2D	Tissue_Name	4D
Liver	79.6	Normal Colon	6.8	93768_Secondary Th1_anti-	2.0
adenocarcinoma		GENPAK		CD28/anti-CD3
		061003
Heart (fetal)	43.8	83219 CC Well	6.1	93769_Secondary Th2_anti-	1.5
		to Mod Diff		CD28/anti-CD3
		(ODO3866)
Pancreas	2.1	83220 CC NAT	2.5	93770_Secondary Th1_anti-	2.5
		(ODO3866)		CD28/anti-CD3
Pancreatic ca.	4.7	83221 CC Gr.2	0.9	93573_Secondary Th1_resting	1.0
CAPAN 2		rectosigmoid		day 4-6 in IL-2
		(ODO3868)
Adrenal gland	2.3	83222 CC NAT	1.2	93572_Secondary Th2_resting	3.0
		(ODO3868)		day 4-6 in IL-2
Thyroid	6.5	83235 CC Mod	3.8	93571_Secondary Tr1_resting	1.7
		Diff (ODO3920)		day 4-6 in IL-2
Salivary gland	12.3	83236 CC NAT	1.3	93568_primary Th1_anti-	0.4
		(ODO3920)		CD28/anti-CD3
Pituitary gland	8.7	83237 CC Gr.2	6.9	93569_primary Th2_anti-	1.5
		ascend colon		CD28/anti-CD3
		(ODO3921)
Brain (fetal)	0.0	83238 CC NAT	4.0	93570_primary Tr1_anti-	2.0
		(ODO3921)		CD28/anti-CD3
Brain (whole)	3.0	83241 CC from	1.2	93565_primary Th1_resting dy 4-	5.4
		Partial		6 in IL-2
		Hepatectomy
		(ODO4309)
Brain (amygdala)	2.4	83242 Liver NAT	0.6	93566_primary Th2_resting dy 4-	3.1
		(ODO4309)		6 in IL-2
Brain	0.0	87472 Colon	4.4	93567_primary Tr1_resting dy 4-6	0.0
(cerebellum)		mets to lung		in IL-2
		(OD04451-01)
Brain	13.0	87473 Lung NAT	1.2	93351_CD45RA CD4	11.2
(hippocampus)		(OD04451-02)		lymphocyte_anti-CD28/anti-CD3
Brain (thalamus)	3.0	Normal Prostate	10.2	93352_CD45RO CD4	1.2
		Clontech A+		lymphocyte_anti-CD28/anti-CD3
		6546-1
Cerebral Cortex	2.3	84140 Prostate	41.8	93251_CD8 Lymphocytes_anti-	0.9
		Cancer		CD28/anti-CD3
		(OD04410)
Spinal cord	2.6	84141 Prostate	25.7	93353_chronic CD8 Lymphocytes	0.0
		NAT (OD04410)		2ry_resting dy 4-6 in IL-2
CNS ca.	12.1	87073 Prostate	11.0	93574_chronic CD8 Lymphocytes	0.6
(glio/astro) U87-		Cancer		2ry_activated CD3/CD28
MG		(OD04720-01)
CNS ca.	100.0	87074 Prostate	10.0	93354_CD4_none	1.1
(glio/astro) U-		NAT (OD04720-
118-MG		02)
CNS ca. (astro)	6.5	Normal Lung	7.9	93252_Secondary	0.0
SW1783		GENPAK		Th1/Th2/Tr1_anti-CD95 CH11
		061010
CNS ca.* (neuro;	52.1	83239 Lung Met	6.5	93103_LAK cells_resting	0.5
met) SK-N-AS		to Muscle
		(ODO4286)
CNS ca. (astro)	12.6	83240 Muscle	2.6	93788_LAK cells_IL-2	0.0
SF-539		NAT (ODO4286)
CNS ca. (astro)	11.9	84136 Lung	14.8	93787_LAK cells_IL-2 + IL-12	0.7
SNB-75		Malignant
		Cancer
		(OD03126)
CNS ca.	0.0	84137 Lung NAT	3.2	93789_LAK cells_IL-2 + IFN	1.1
(glio)SNB-19		(OD03126)		gamma
CNS ca.	0.9	84871 Lung	2.1	93790_LAK cells_IL-2 + IL-18	0.3
(glio)U251		Cancer
		(OD04404)
CNS ca. (glio)	12.6	84872 Lung NAT	1.9	93104_LAK cells_PMA/ionomycin	0.0
SF-295		(OD04404)		and IL-18
Heart	13.9	84875 Lung	0.3	93578_NK Cells IL-2_resting	1.3
		Cancer
		(OD04565)
Skeletal muscle	3.2	85950 Lung	1.3	93109_Mixed Lymphocyte	0.5
		Cancer		Reaction_Two Way MLR
		(OD04237-01)
Bone marrow	3.6	85970 Lung NAT	2.6	93110_Mixed Lymphocyte	0.5
		(OD04237-02)		Reaction_Two Way MLR
Thymus	4.2	83255 Ocular	0.1	93111_Mixed Lymphocyte	2.7
		Mel Met to Liver		Reaction_Two Way MLR
		(ODO4310)
Spleen	61.6	83256 Liver NAT	0.6	93112_Mononuclear Cells	0.0
		(ODO4310)		(PBMCs)_resting
Lymph node	3.3	84139	2.5	93113_Mononuclear Cells	1.3
		Melanoma Mets		(PBMCs)_PWM
		to Lung
		(OD04321)
Colorectal	11.9	84138 Lung	2.6	93114_Mononuclear Cells	1.0
		NAT (OD04321)		(PBMCs)_PHA-L
Stomach	28.3	Normal Kidney	5.6	93249_Ramos (B cell)_none	1.2
		GENPAK
		061008
Small intestine	4.5	83786 Kidney	0.6	93250_Ramos (B cell)_ionomycin	2.3
		Ca, Nuclear
		grade 2
		(OD04338)
Colon ca. SW480	46.7	83787 Kidney	3.7	93349_B lymphocytes_PWM	4.3
		NAT (OD04338)
Colon ca.*	19.0	83788 Kidney Ca	0.8	93350_B lymphoytes_CD40L and	1.4
(SW480		Nuclear grade		IL-4
met)SW620		1/2 (OD04339)
Colon ca. HT29	5.3	83789 Kidney	3.1	92665_EOL-1	7.2
		NAT (OD04339)		(Eosinophil)_dbcAMP
				differentiated
Colon ca. HCT-	5.0	83790 Kidney	1.5	93248_EOL-1	3.0
116		Ca, Clear cell		(Eosinophil)_dbcAMP/PMAiono-
		type (OD04340)		mycin
Colon ca. CaCo-2	49.3	83791 Kidney	5.1	93356_Dendritic Cells_none	1.5
		NAT (OD04340)
83219 CC Well to	3.0	83792 Kidney	14.5	93355_Dendritic Cells_LPS 100	0.7
Mod Diff		Ca, Nuclear		ng/ml
(ODO3866)		grade 3
		(OD04348)
Colon ca. HCC-	27.7	83793 Kidney	2.5	93775_Dendritic Cells_anti-CD40	0.5
2998		NAT OD04348)
Gastric ca.* (liver	10.5	87474 Kidney	1.7	93774_Monocytes_resting	0.5
met) NCI-N87		Cancer
		(OD04622-01)
Bladder	3.7	87475 Kidney	2.0	93776_Monocytes_LPS 50 ng/ml	0.0
		NAT (OD04622-
		03)
Trachea	23.5	85973 Kidney	0.3	93581_Macrophages_resting	1.3
		Cancer
		(OD04450-01)
Kidney	1.8	85974 Kidney	2.0	93582_Macrophages_LPS 100	1.8
		NAT		ng/ml
		(OD04450-03)
Kidney (fetal)	1.9	Kidney Cancer	7.0	93098_HUVEC	2.3
		Clontech		(Endothelial)_none
		8120607
Renal ca. 786-0	7.0	Kidney NAT	1.5	93099_HUVEC	9.0
		Clontech		(Endothelial)_starved
		8120608
Renal ca. A498	6.8	Kidney Cancer	2.0	93100_HUVEC (Endothelial)_IL-	1.2
		Clontech		1b
		8120613
Renal ca.RXF	4.7	Kidney NAT	4.1	93779_HUVEC (Endothelial)_IFN	1.4
393		Clontech		gamma
		8120614
Renal ca.ACHN	9.8	Kidney Cancer	2.2	93102_HUVEC	0.8
		Clontech		(Endothelial)_TNF alpha + IFN
		9010320		gamma
Renal ca.UO-31	1.3	Kidney NAT	3.5	93101_HUVEC	1.1
		Clontech		(Endothelial)_TNF alpha + IL4
		9010321
Renal ca.TK-10	0.6	Normal Uterus	3.1	93781_HUVEC (Endothelial)_IL-	3.0
		GENPAK		11
		061018
Liver	0.8	Uterus Cancer	17.6	93583_Lung Microvascular	0.8
		GENPAK		Endothelial Cells_none
		064011
Liver (fetal)	1.1	Normal Thyroid	3.7	93584_Lung Microvascular	0.5
		Clontech A+		Endothelial Cells_TNFa (4 ng/ml)
		6570-1		and IL1b (1 ng/ml)
Liver ca.	54.0	Thyroid Cancer	1.2	92662_Microvascular Dermal	1.1
(hepatoblast)		GENPAK		endothelium_none
HepG2		064010
Lung	3.9	Thyroid Cancer	0.6	92663_Microsvasular Dermal	1.0
		INVITROGEN		endothelium_TNFa (4 ng/ml) and
		A302152		IL1b (1 ng/ml)
Lung (fetal)	9.0	Thyroid NAT	2.6	93773_Bronchial	0.0
		INVITROGEN		epithelium_TNFa (4 ng/ml) and
		A302153		IL1b (1 ng/ml)**
Lung ca. (small	34.4	Normal Breast	3.4	93347_Small Airway	0.4
cell) LX-1		GENPAK		Epithelium_none
		061019
Lung ca. (small	3.0	84877 Breast	0.9	93348_Small Airway	0.5
cell) NCI-H69		Cancer		Epithelium_TNFa (4 ng/ml) and
		(OD04566)		IL1b (1 ng/ml)
Lung ca. (s.cell	13.0	85975 Breast	67.8	92668_Coronery Artery	5.8
var.) SHP-77		Cancer		SMC_resting
		(OD04590-01)
Lung ca. (large	6.8	85976 Breast	51.1	92669_Coronery Artery	2.3
cell)NCI-H460		Cancer Mets		SMC_TNFa (4 ng/ml) and IL1b (1
		(OD04590-03)		ng/ml)
Lung ca. (non-	3.4	87070 Breast	12.7	93107_astrocytes_resting	2.7
sm. cell) A549		Cancer
		Metastasis
		(OD04655-05)
Lung ca. (non-	34.4	GENPAK Breast	8.9	93108_astrocytes_TNFa (4	0.0
s.cell) NCI-H23		Cancer 064006		ng/ml) and IL1b (1 ng/ml)
Lung ca (non-	10.5	Breast Cancer	6.2	92666_KU-812 (Basophil)_resting	6.8
s.cell) HOP-62		Clontech
		9100266
Lung ca. (non-	47.6	Breast NAT	3.3	92667_KU-812	8.4
s.cl) NCI-H522		Clontech		(Basophil)_PMA/ionoycin
		9100265
Lung Ca.	4.7	Breast Cancer	3.4	93579_CCD1106	1.6
(squam.) SW		INVITROGEN		(Keratinocytes)_none
900		A209073
Lung Ca.	0.7	Breast NAT	8.7	93580_CCD1106	1.4
(squam.) NCI-		INVITROGEN		(Keratinocytes)_TNFa and IFNg**
H596		A2090734
Mammary gland	9.9	Normal Liver	1.1	93791_Liver Cirrhosis	4.2
		GENPAK
		061009
Breast ca.* (pl.	5.6	Liver Cancer	0.6	93792_Lupus Kidney	1.9
effusion) MCF-7		GENPAK
		064003
Breast ca.* (pl.ef)	21.3	Liver Cancer	0.6	93577_NCI-H292	39.5
MDA-MB-231		Research
		Genetics RNA
		1025
Breast ca.* (pl.	66.0	Liver Cancer	1.4	93358_NCI-H292_IL-4	39.0
effusion) T47D		Research
		Genetics RNA
		1026
Breast ca. BT-	7.6	Paired Liver	1.3	93360_NCI-H292_IL-9	65.5
549		Cancer Tissue
		Research
		Genetics RNA
		6004-T
Breast ca.MDA-N	18.7	Paired Liver	1.3	93359_NCI-H292_IL-13	37.1
		Tissue Research
		Genetics RNA
		6004-N
Ovary	12.1	Paired Liver	1.1	93357_NCI-H292_IFN gamma	31.9
		Cancer Tissue
		Research
		Genetics RNA
		6005-T
Ovarian	3.5	Paired Liver	0.3	93777_HPAEC_-	0.5
ca.OVCAR-3		Tissue Research
		Genetics RNA
		6005-N
Ovarian	4.0	Normal Bladder	5.9	93778_HPAEC_IL-1 beta/TNA	1.2
ca.OVCAR-4		GENPAK		alpha
		061001
Ovarian ca.	9.1	Bladder Cancer	1.7	93254_Normal Human Lung	42.3
OVCAR-5		Research		Fibroblast_none
		Genetics RNA
		1023
Ovarian ca.	12.7	Bladder Cancer	1.9	93253_Normal Human Lung	17.8
OVCAR-8		INVITROGEN		Fibroblast_TNFa (4 ng/ml) and IL-
		A302173		1b (1 ng/ml)
Ovarian	9.8	87071 Bladder	2.0	93257_Normal Human Lung	100.0
ca.IGROV-1		Cancer		Fibroblast_IL-4
		(OD04718-01)
Ovarian ca.*	0.4	87072 Bladder	3.3	93256_Normal Human Lung	72.7
(ascites) SK-OV-		Normal Adjacent		Fibroblast_IL-9
3		(OD04718-03)
Uterus	6.9	Normal Ovary	2.2	93255_Normal Human Lung	60.7
		Res. Gen.		Fibroblast_IL-13
Plancenta	4.6	Ovarian Cancer	29.1	93258_Normal Human Lung	81.8
		GENPAK		Fibroblast_IFN gamma
		064008
Prostate	15.7	87492 Ovary	100.0	93106_Dermal Fibroblasts	76.8
		Cancer		CCD1070_resting
		(OD04768-07)
Prostate ca.*	35.9	87493 Ovary	2.2	93361_Dermal Fibroblasts	30.2
(bone met) PC-3		NAT (OD04768-		CCD1070_TNF alpha 4 ng/ml
		08)
Testis	14.6	Normal Stomach	13.1	93105_Dermal Fibroblasts	38.2
		GENPAK		CCD1070_IL-1 beta 1 ng/ml
		061017
Melanoma	13.5	NAT Stomach	8.8	93772_dermal fibroblast_IFN	34.2
Hs688(A).T		Clontech		gamma
		9060359
Melanoma* (met)	71.2	Gastric Cancer	2.5	93771_dermal fibroblast_IL-4	80.7
Hs688(B).T		Clontech
		9060395
Melanoma	1.7	NAT Stomach	9.7	93259_IBD Colitis 1**	0.0
UACC-62		Clontech
		9060394
Melanoma M14	9.5	Gastric Cancer	15.9	93260_IBD Colitis 2	0.3
		Clontech
		9060397
Melanoma LOX	2.4	NAT Stomach	12.9	93261_IBD Crohns	1.4
IMVI		Clontech
		9060396
Melanoma*	3.4	Gastric Cancer	12.1	735010_Colon_normal	35.6
(met)SK-MEL-5		GENPAK
		064005
Adipose	5.9			735019_Lung_none	11.0
				64028-1_Thymus_none	5.8
				64030-1_Kidney_none	9.7

[0469] Taqman results shown in Table 9 demonstrates that cFCTR1 is highly expressed by tumor cell lines and also overexpressed in tumor tissues, specifically breast and ovarian tumor compared to Normal Adjacent Tissues (NAT). There are reports that follistatin can act as a modulator of tumor growth and its expression also correlate with polycystic ovary syndrome, a benign form of ovarian tumor.

TABLE 10
Primer Design for Probe Ag2773 (FCTR4)
				Start	SEQ ID
Primer	Sequences	TM	Length	Pos	NO
Forward	5′-CCTTGCTTTGTCATATGCTGTT-3′	59.3	22	243	29
Probe	FAM-5′-CCCTTTGCCTGGAATATAAACTCTCA-3′-TAMRA	64.6	26	265	30
Reverse	5′-AGAGGAAGCTTTCTGGAGAAGA-3′	58.9	22	313	31

[0470]

TABLE 11
TAQMAN RESULTS FOR CLONE FCTR4
	Panel		Panel		Panel
Tissue_Name	1D	Tissue_Name	2D	Tissue_Name	4D
Liver	18.3	Normal Colon	41.2	93768_Secondary Th1_anti-	12.7
adenocarcinoma		GENPAK 061003		CD28/anti-CD3
Heart (fetal)	4.3	83219 CC Well to	5.2	93769_Secondary Th2_anti-	14.2
		Mod Diff		CD28/anti-CD3
		(ODO3866)
Pancreas	3.1	83220 CC NAT	2.5	93770_Secondary Tr1_anti-	14.7
		(ODO3866)		CD28/anti-CD3
Pancreatic	20.0	83221 CC Gr.2	0.7	93573_Secondary Th1_resting day 4-	4.7
ca.CAPAN 2		rectosigmoid		6 in IL-2
		(ODO3868)
Adrenal gland	7.4	83222 CC NAT	1.4	93572_Secondary Th2_resting day 4-	3.5
		(ODO3868)		6 in IL-2
Thyroid	6.8	83235 CC Mod	14.0	93571_Secondary Tr1_resting day 4-	7.0
		Diff (ODO3920)		6 in IL-2
Salivary gland	2.5	83236 CC NAT	13.9	93568_primary Th1_anti-CD28/anti-	22.4
		(ODO3920)		CD3
Pituitary gland	5.7	83237 CC Gr.2	16.2	93569_primary Th2_anti-CD28/anti-	16.3
		ascend colon		CD3
		(ODO3921)
Brain (fetal)	14.4	83238 CC NAT	5.2	93570_primary Tr1_anti-CD28/anti-	21.8
		(ODO3921)		CD3
Brain (whole)	19.6	83241 CC from	13.9	93565_primary Th1_resting dy 4-6 in	30.2
		Partial		IL-2
		Hepatectomy
		(ODO4309)
Brain	3.7	83242 Liver NAT	12.7	93566_primary Th2_resting dy 4-6 in	14.4
(amygdala)		(ODO4309)		IL-2
Brain	2.1	87472 Colon	3.4	93567_primary Tr1_resting dy 4-6 in	7.4
(cerebellum)		mets to lung		IL-2
		(OD04451-01)
Brain	22.7	87473 Lung NAT	1.5	93351_CD45RA CD4	7.6
(hippocampus)		(OD04451-02)		lymphocyte_anti-CD28/anti-CD3
Brain (thalamus)	7.4	Normal Prostate	1.0	93352_CD45RO CD4	11.1
		Clontech A+		lymphocyte_anti-CD28/anti-CD3
		6546-1
Cerebral Cortex	47.3	84140 Prostate	3.1	93251_CD8 Lymphocytes_anti-	9.6
		Cancer		CD28/anti-CD3
		(OD04410)
Spinal cord	8.3	84141 Prostate	10.6	93353_chronic CD8 Lymphocytes	9.7
		NAT (OD04410)		2ry_resting dy 4-6 in IL-2
CNS Ca.	19.9	87073 Prostate	9.7	93574_chronic CD8 Lymphocytes	6.2
(glio/astro)U87-		Cancer		2ry_activated CD3/CD28
MG		(OD04720-01)
CNS ca.	57.0	87074 Prostate	8.3	93354_CD4_none	6.4
(glio/astro) U-		NAT (OD04720-
118-MG		02)
CNS ca. (astro)	10.0	Normal Lung	36.6	93252_Secondary Th1/Th2/Tr1_anti-	9.3
SW1783		GENPAK 061010		CD95 CH11
CNS ca.*	44.8	83239 Lung Met	11.7	93103_LAK cells_resting	11.0
(neuro; met)SK-		to Muscle
N-AS		(ODO4286)
CNS ca. (astro)	37.4	83240 Muscle	3.4	93788_LAK cells_IL-2	10.4
SF-539		NAT (ODO4286)
CNS ca. (astro)	62.0	84136 Lung	15.1	93787_LAK cells_IL-2 + IL-12	7.4
SNB-75		Malignant Cancer
		(OD03126)
CNS ca. (glio)	24.8	84137 Lung NAT	17.4	93789_LAK cells_IL-2 + IFN gamma	11.6
SNB-19		(OD03126)
CNS ca. (glio)	40.3	84871 Lung	5.0	93790_LAK cells_IL-2 + IL-18	13.3
U251		Cancer
		(OD04404)
CNS ca. (glio)	100.0	84872 Lung NAT	6.3	93104_LAK cells_PMA/ionomycin	4.8
SF-295		(OD04404)		and IL-18
Heart	0.0	84875 Lung	3.2	93578_NK Cells IL-2_resting	6.2
		Cancer
		(OD04565)
Skeletal muscle	0.0	85950 Lung	15.8	93109_Mixed Lymphocyte	12.3
		Cancer		Reaction_Two Way MLR
		(OD04237-01)
Bone marrow	33.7	85970 Lung NAT	10.5	93110_Mixed Lymphocyte	8.7
		(OD04237-02)		Reaction_Two Way MLR
Thymus	12.4	83255 Ocular	5.9	93111_Mixed Lymphocyte	3.5
		Mel Met to Liver		Reaction_Two Way MLR
		(ODO4310)
Spleen	21.3	83256 Liver NAT	3.6	93112_Mononuclear Cells	4.5
		(ODO4310)		(PBMCs)_resting
Lymph node	13.4	84139 Melanoma	10.6	93113_Mononuclear Cells	21.2
		Mets to Lung		(PBMCs)_PWM
		(OD04321)
Colorectal	38.2	84138 Lung NAT	10.6	93114_Mononuclear Cells	8.9
		(OD04321)		(PBMCs)_PHA-L
Stomach	9.9	Normal Kidney	26.2	93249_Ramos (B cell)_none	100.0
		GENPAK 061008
Small intestine	17.9	83786 Kidney	22.2	93250_Ramos (B cell)_ionomycin	28.7
		Ca, Nuclear
		grade 2
		(OD04338)
Colon	27.7	83787 Kidney	11.7	93349_B lymphocytes_PWM	20.0
ca.SW480		NAT (OD04338)
Colon ca.*	30.8	83788 Kidney Ca	45.1	93350_B lymphoytes_CD40L and IL-	7.8
(SW480		Nuclear grade		4
met)SW620		1/2 (OD04339)
Colon ca.HT29	8.1	83789 Kidney	14.8	92665_EOL-1 (Eosinophil)_dbcAMP	8.0
		NAT (OD04339)		differentiated
Colon ca.HCT-	35.4	83790 Kidney	26.6	93248_EOL-1	3.8
116		Ca, Clear cell		(Eosinophil)_dbcAMP/PMAionomycin
		type (ODO4340)
Colon Ca. CaCo-	37.6	83791 Kidney	10.4	93356_Dendritic Cells_none	6.8
2		NAT (OD04340)
83219 CC Well	17.8	83792 Kidney	2.4	93355_Dendritic Cells_LPS 100 ng/ml	3.3
to Mod Diff		Ca, Nuclear
(ODO3866)		grade 3
		(OD04348)
Colon ca.HCC-	19.9	83793 Kidney	18.8	93775_Dendritic Cells_anti-CD40	6.3
2998		NAT (OD04348)
Gastric ca.*	73.2	87474 Kidney	5.6	93774_Monocytes_resting	10.6
(liver met) NCI-		Cancer
N87		(OD04622-01)
Bladder	43.2	87475 Kidney	0.5	93776_Monocytes_LPS 50 ng/ml	3.5
		NAT (OD04622-
		03)
Trachea	10.3	85973 Kidney	21.2	93581_Macrophages_resting	7.6
		Cancer
		(OD04450-01)
Kidney	9.2	85974 Kidney	9.3	93582_Macrophages_LPS 100 ng/ml	3.9
		NAT (OD04450-
		03)
Kidney (fetal)	0.0	Kidney Cancer	0.0	93098_HUVEC (Endothelial)_none	8.5
		Clontech
		8120607
Renal ca.786-0	53.6	Kidney NAT	0.9	93099_HUVEC (Endothelial)_starved	17.9
		Clontech
		8120608
Renal ca.A498	36.1	Kidney Cancer	0.0	93100_HUVEC (Endothelial)_IL-1b	6.0
		Clontech
		8120613
Renal ca.RXF	31.6	Kidney NAT	0.9	93779_HUVEC (Endothelial)_IFN	7.8
393		Clontech		gamma
		8120614
Renal ca.ACHN	21.6	Kidney Cancer	2.7	93102_HUVEC (Endothelial)_TNF	5.7
		Clontech		alpha + IFN gamma
		9010320
Renal ca.UO-31	28.7	Kidney NAT	5.0	93101_HUVEC (Endothelial)_TNF	5.6
		Clontech		alpha + IL4
		9010321
Renal ca.TK-10	7.0	Normal Uterus	5.3	93781_HUVEC (Endothelial)_IL-11	4.9
		GENPAK 061018
Liver	14.2	Uterus Cancer	9.0	93583_Lung Microvascular	4.9
		GENPAK 064011		Endothelial Cells_none
Liver (fetal)	14.5	Normal Thyroid	3.4	93584_Lung Microvascular	4.9
		Clontech A+		Endothelial Cells_TNFa (4 ng/ml) and
		6570-1		IL1b (1 ng/ml)
Liver ca.	59.9	Thyroid Cancer	1.8	92662_Microvascular Dermal	8.6
(hepatoblast)		GENPAK 064010		endothelium_none
HepG2
Lung	17.8	Thyroid Cancer	3.6	92663_Microsvasular Dermal	6.0
		INVITROGEN		endothelium_TNFa (4 ng/ml) and IL1b
		A302152		(1 ng/ml)
Lung (fetal)	9.6	Thyroid NAT	4.9	93773_Bronchial epithelium_TNFa (4	0.9
		INVITROGEN		ng/ml) and IL1b (1 ng/ml)**
		A302153
Lung ca. (small	70.2	Normal Breast	8.5	93347_Small Airway Epithelium_none	1.3
cell) LX-1		GENPAK 061019
Lung ca. (small	29.9	84877 Breast	1.5	93348_Small Airway	13.2
cell) NCI-H69		Cancer		Epithelium_TNFa (4 ng/ml) and IL1b
		(OD04566)		(1 ng/ml)
Lung ca. (s.cell	3.9	85975 Breast	23.8	92668_Coronery Artery SMC_resting	3.4
var.) SHP-77		Cancer
		(OD04590-01)
Lung ca. (large	2.0	85976 Breast	24.5	92669_Coronery Artery SMC_TNFa	2.0
cell) NCI-H460		Cancer Mets		(4 ng/ml) and IL1b (1 ng/ml)
		(OD04590-03)
Lung ca. (non-	28.5	87070 Breast	12.9	93107_astrocytes_resting	4.7
sm. cell) A549		Cancer
		Metastasis
		(OD04655-05)
Lung ca. (non-	36.1	GENPAK Breast	11.8	93108_astrocytes_TNFa (4 ng/ml)	1.9
s.cell) NCI-H23		Cancer 064006		and IL1b (1 ng/ml)
Lung ca (non-	29.9	Breast Cancer	3.2	92666_KU-812 (Basophil)_resting	5.8
s.cell HOP-62		Clontech
		9100266
Lung ca. (non-	17.2	Breast NAT	1.8	92667_KU-812	12.0
s.cl) NCI-H522		Clontech		(Basophil)_PMA/ionoycin
		9100265
Lung ca.	63.7	Breast Cancer	11.0	93579_CCD1106	4.9
(squam.) SW		INVITROGEN		(Keratinocytes)_none
900		A209073
Lung ca.	10.0	Breast NAT	7.1	93580_CCD1106	0.3
(squam.) NCI-		INVITROGEN		(Keratinocytes)_TNFa and IFNg**
H596		A2090734
Mammary gland	4.6	Normal Liver	8.8	93791_Liver Cirrhosis	1.8
		GENPAK 061009
Breast ca.* (pl.	0.0	Liver Cancer	4.9	93792_Lupus Kidney	1.6
effusion) MCF-		GENPAK 064003
7
Breast ca.*	38.7	Liver Cancer	1.0	93577_NCI-H292	11.1
(pl.ef) MDA-MB-		Research
231		Genetics RNA
		1025
Breast ca.* (pl.	0.0	Liver Cancer	0.8	93358_NCI-H292_IL-4	12.2
effusion) T47D		Research
		Genetics RNA
		1026
Breast ca.BT-	4.6	Paired Liver	3.0	93360_NCI-H292_IL-9	7.6
549		Cancer Tissue
		Research
		Genetics RNA
		6004-T
Breast ca.MDA-	19.0	Paired Liver	7.3	93359_NCI-H292_IL-13	6.1
N		Tissue Research
		Genetics RNA
		6004-N
Ovary	1.7	Paired Liver	0.2	93357_NCI-H292_IFN gamma	5.8
		Cancer Tissue
		Research
		Genetics RNA
		6005-T
Ovarian	4.8	Paired Liver	0.0	93777_HPAEC_-	6.8
ca.OVCAR-3		Tissue Research
		Genetics RNA
		6005-N
Ovarian	0.0	Normal Bladder	19.8	93778_HPAEC_IL-1 beta/TNA alpha	5.4
ca.OVCAR-4		GENPAK 061001
Ovarian	39.0	Bladder Cancer	3.1	93254_Normal Human Lung	2.1
ca.OVCAR-5		Research		Fibroblast_none
		Genetics RNA
		1023
Ovarian	36.6	Bladder Cancer	9.9	93253_Normal Human Lung	1.9
ca.OVCAR-8		INVITROGEN		Fibroblast_TNFa (4 ng/ml) and IL-1b
		A302173		(1 ng/ml)
Ovarian	0.0	87071 Bladder	6.6	93257_Normal Human Lung	3.6
ca.IGROV-1		Cancer		Fibroblast_IL-4
		(OD04718-01)
Ovarian ca.*	65.5	87072 Bladder	4.0	93256_Normal Human Lung	3.3
(ascites) SK-		Normal Adjacent		Fibroblast IL-9
OV-3		(OD04718-03)
Uterus	1.6	Normal Ovary	0.3	93255_Normal Human Lung	2.3
		Res. Gen.		Fibroblast_IL-13
Plancenta	8.9	Ovarian Cancer	6.8	93258_Normal Human Lung	2.9
		GENPAK 064008		Fibroblast_IFN gamma
Prostate	0.0	87492 Ovary	100.0	93106_Dermal Fibroblasts	5.6
		Cancer		CCD1070_resting
		(OD04768-07)
Prostate ca.*	9.2	87493 Ovary	3.6	93361_Dermal Fibroblasts	17.4
(bone met)PC-3		NAT (OD04768-		CCD1070_TNF alpha 4 ng/ml
		08)
Testis	29.5	Normal Stomach	8.6	93105_Dermal Fibroblasts	3.8
		GENPAK 061017		CCD1070_IL-1 beta 1 ng/ml
Melanoma	14.3	NAT Stomach	0.7	93772_dermal fibroblast_IFN gamma	2.6
Hs688(A).T		Clontech
		9060359
Melanoma*	22.9	Gastric Cancer	3.9	93771_dermal fibroblast_IL-4	3.4
(met)		Clontech
Hs688(B).T		9060395
Melanoma	9.7	NAT Stomach	5.3	93259_IBD Colitis 1**	0.2
UACC-62		Clontech
		9060394
Melanoma M14	12.7	Gastric Cancer	13.2	93260_IBD Colitis 2	0.4
		Clontech
		9060397
Melanoma LOX	4.5	NAT Stomach	1.1	93261_IBD Crohns	0.3
IMVI		Clontech
		9060396
Melanoma*	21.8	Gastric Cancer	23.0	735010_Colon_normal	3.3
(met) SK-MEL-5		GENPAK 064005
Adipose	6.7			735019_Lung_none	3.9
				64028-1_Thymus_none	7.7
				64030-1_Kidney_none	21.8

[0471] Table 12 shows the taqman results of clone FCTR4 indicating overexpression in ovarian cancer as compared to Normal Adjacent Tissue AT). In addition, increased expression is demonstrated by ovarian tumor cell line suggesting that antibodies could be used to treat ovarian tumors.

TABLE 13
Primer Design for Probe Ag427 (FCTR5)
			Start	SEQ ID
Primer	Sequences	Length	Pos	NO
Forward	5′-GAGCTACAGGCAGCCTCGAGT-3′	21	443	32
Probe	TET-5′-TGGCCCAGCTGACCCTGCTCA-3′-TAMPA	21		33
Reverse	5′-GGCTACGTCAGTGGGTfTGG-3′	20	449	34

[0472]

TABLE 14
Taqman results for FCTR5
Tissue_Name	Panel 1	Tissue_Name	Panel 4D
Endothelial cells	10.7	93768_Secondary Th1_anti-CD28/anti-CD3	15.9
Endothelial cells (treated)	15.2	93769_Secondary Th2_anti-CD28/anti-CD3	14.7
Pancreas	16.2	93770_Secondary Tr1_anti-CD28/anti-CD3	21.9
Pancreatic ca.CAPAN 2	10.5	93573_Secondary Th1_resting day 4-6 in IL-2	12.3
Adipose	45.1	93572_Secondary Th2_resting day 4-6 in IL-2	16.2
Adrenal gland	61.6	93571_Secondary Tr1_resting day 4-6 in IL-2	16.2
Thyroid	13.1	93568_primary Th1_anti-CD28/anti-CD3	13.9
Salavary gland	33.7	93569_primary Th2_anti-CD28/anti-CD3	14.6
Pituitary gland	15.8	93570_primary Tr1_anti-CD28/anti-CD3	26.2
Brain (fetal)	7.2	93565_primary Th1_resting dy 4-6 in IL-2	56.3
Brain (whole)	6.3	93566_primary Th2_resting dy 4-6 in IL-2	27.7
Brain (amygdala)	8.4	93567_primary Tr1_resting dy 4-6 in IL-2	31.6
Brain (cerebellum)	6.8	93351_CD45RA CD4 lymphocyte_anti-	12.1
		CD28/anti-CD3
Brain (hippocampus)	7.9	93352_CD45RO CD4 lymphocyte_anti-	17.1
		CD28/anti-CD3
Brain substantia nigra	9.5	93251_CD8 Lymphocytes_anti-CD28/anti-CD3	9.1
Brain (thalamus)	7.9	93353_chronic CD8 Lymphocytes	13.4
		2ry_resting dy 4-6 in IL-2
Brain (hypothalamus)	23.0	93574_chronic CD8 Lymphocytes	9.2
		2ry_activated CD3/CD28
Spinal cord	9.5	93354_CD4_none	7.6
CNS ca. (glio/astro)U87-MG	12.6	93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	20.2
CNS ca. (glio/astro)U-	11.6	93103_LAK cells_resting	57.0
118-MG
CNS ca. (astro)SW1783	4.3	93788_LAK cells_IL-2	18.8
CNS ca.* (neuro; met )SK-N-	10.4	93787_LAK cells_IL2 + IL-12	14.2
AS
CNS ca. (astro) SF-539	11.6	93789_LAK cells_IL-2 + IFN gamma	20.9
CNS ca. (astro) SNB-75	4.4	93790_LAK cells_IL-2 + IL-18	14.8
CNS ca. (glio)SNB-19	31.6	93104 LAK_cells_PMA/ionomycin and IL-18	12.9
CNS ca. (glio)U251	17.3	93578_NK Cells IL-2_resting	17.4
CNS ca. (glio)SF-295	20.9	93109_Mixed Lymphocyte Reaction_Two	43.5
		Way MLR
Heart	14.3	93110_Mixed Lymphocyte Reaction_Two	19.3
		WayMLR
Skeletal muscle	11.7	93111_Mixed Lymphocyte Reaction_Two	12.6
		Way MLR
Bone marrow	21.9	93112_Mononuclear Cells (PBMCs)_resting	8.7
Thymus	20.9	93113_Mononuclear Cells (PBMCs)_PWM	28.5
Spleen	23.8	93114_Mononuclear Cells (PBMCs)_PHA-L	26.2
Lymph node	24.2	93249_Ramos (B cell)_none	0.3
Colon (ascending)	17.2	93250_Ramos (B cell)_ionomycin	1.2
Stomach	11.1	93349_B lymphocytes_PWM	25.7
Small intestine	21.5	93350_B lymphoytes_CD40L and IL-4	13.0
Colon ca.SW480	12.2	92665_EOL-1 (Eosinophil)_dbcAMP	26.4
		differentiated
Colon ca.* (SW480	8.6	93248_EOL-1	11.4
met)SW620		(Eosinophil)....dbcAMP/PMAionomycin
Colon ca.HT29	16.2	93356_Dendritic Cells_none	40.3
Colon ca.HCT-116	8.1	93355_Dendritic Cells_LPS 100 ng/ml	33.0
Colon ca.CaCo-2	22.1	93775_Dendritic Cells_anti-CD40	20.5
Colon ca.HCT-15	18.6	93774_Monocytes_resting	23.3
Colon ca.HCC-2998	21.9	93776_Monocytes_LPS 50 ng/ml	6.9
Gastric ca.* (liver met) NCI-	42.9	93581_Macrophages_resting	14.7
N87
Bladder	95.3	93582_Macrophages_LPS 100 ng/ml	64.6
Trachea	18.3	93098_HUVEC (Endothelial)_none	6.8
Kidney	25.7	93099_HUVEC (Endothelial)_starved	13.9
Kidney (fetal)	15.8	93100_HUVEC (Endothelial)_IL-1b	7.5
Renal ca.786-0	16.5	93779_HUVEC (Endothelial)_IFN gamma	27.7
Renal ca.A498	16.5	93102_HUVEC (Endothelial)_TNF alpha +	11.8
		IFN gamma
Renal ca.RXF 393	7.4	93101_HUVEC (Endothelial)_TNF alpha +	6.7
		IL4
Renal ca.ACHN	11.9	93781_HUVEC (Endothelial)_IL-11	10.4
Renal ca.UO-31	15.8	93583_Lung Microvascular Endothelial	8.8
		Cells_none
Renal ca.TK-10	28.7	93584_Lung Microvascular Endothelial	8.6
		Cells_TNFa (4 ng/ml) and IL1b (1
		nglml)
Liver	100.0	92662_Microvascular Dermal	22.1
		endothelium_none
Liver (fetal)	81.8	92663_Microsvasular Dermal
		endothelium_TNFa (4 ng/ml) and IL1b	18.7
		(1 ng/ml)
Liver ca. (hepatoblast) HepG2	28.3	93773_Bronchial epithelium_TNFa (4	35.4
ng/ml) and IL1b (1 ng/ml) **
Lung	10.7	93347_Small Airway Epithelium_none	10.9
Lung (fetal)	10.9	93348_Small Airway Epithelium_TNFa (4	50.0
		ng/ml) and IL1b (1 ng/ml)
Lung Ca. (small cell) LX-1	24.3	92668_Coronery Artery SMC_resting	27.9
Lung ca. (small cell)	41.5	92669_Coronery Artery SMC_TNFa (4	25.4
NCI-H69		ng/ml) and ILIb (1 ng/ml)
Lung ca. (s.cell var.) SHP-77	4.6	93107_astrocytes_resting	7.4
Lung ca. (larg cell)NCI-H460	46.3	93108_astrocytes_TNFa (4 ng/ml) and IL1b	10.7
		(1 ng/ml)
Lung ca. (non-sm. cell) A549	45.4	92666_KU-812 (Basophil)_resting	3.2
Lung ca. (non-s.cell)	54.3	92667_KU-812 (Basophil)_PMA/ionoycin	6.7
NCI-H23
Lung ca (non-s.cell) HOP-62	50.7	93579_CCD1106 (Keratinocytes)_none	12.2
Lund ca. (non-s.cl) NCI-H522	38.4	93580_CCD1106 (Keratinocytes)_TNFa	100.0
		and IFNg **
Lung ca. (squam.) SW 900	30.8	93791_Liver Cirrhosis	27.6
Lung ca. (squam.) NCI-H596	15.5	93792_Lupus Kidney	32.3
Mammary gland	65.5	93577_NCI-H292	77.4
Breast ca.* (pl. effusion)	4.4	93358_NCI-H292_IL-4	70.2
MCF-7
Breast ca.* (pl.ef) MDA-MB-	3.5	93360_NCI-H292_IL-9	54.3
231
Breast ca.* (pl. effusion)T47D	8.7	93359_NCI-H292_IL-13	47.0
Breast ca. BT-549	5.7	93357_NCI-H292_IFN gamma	52.9
Breast ca.MDA-N	16.6	93777_HPAEC_-	23.8
Ovary	20.5	93778_HPAEC_IL-1 beta/TNA alpha	21.5
Ovarian ca.OVCAR-3	21.6	93254_Normal Human Lung Fibroblast_none	49.3
Ovarian ca.OVCAR-4	8.3	93253_Normal Human Lung	40.3
		Fibroblast_TNFa (4 ng/ml) and IL-1b
		(1 ng/ml)
Ovarian ca.OVCAR-5	26.1	93257_Normal Human Lung Fibroblast_IL-4	48.3
Ovarian ca.OVCAR-8	48.0	93256_Normal Human Lung Fibroblast_IL-9	29.3
Ovarian ca.IGROV-1	9.3	93255_Normal Human Lung Fibroblast_IL-13	73.7
Ovarian ca.*(ascites)SK-OV-3	8.8	93258_Normal Human Lung Fibroblast_IFN	66.9
		gamma
Uterus	13.4	93106_Dermal Fibroblasts	20.2
CCD1070_resting
Plancenta	9.4	93361_Dermal Fibroblasts CCD1070_TNF	35.1
		alpha 4 ng/ml
Prostate	21.3	93105_Dermal Fibroblasts CCD1070_IL-1
		beta 1 ng/ml
Prostate ca.* (bone met)PC-3	17.7	93772_dermal fibroblast_IFN gamma	21.8
Testis	11.7	93771_dermal fibroblast_IL-4	21.2
Melanoma Hs688(A).T	9.0	93259_IBD Colitis 1**	8.8
Melanoma* (met) Hs688(B).T	12.9	93260_IBD Colitis 2	3.5
Melanoma UACC-62	12.4	93261_IBD Crohns	1.3
Melanoma M14	9.5	735010_Colon_normal	20.3
Melanoma LOX IMVI	8.1	735019_Lung_none	40.3
Melanoma* (met) SK-MEL-5	8.8	64028-1_Thymus_none	33.5
Melanoma SK-MEL-28	8.0	64030-1_Kidney_none	21.0

[0473] Taqman results in Table 14 show high expression of clone FCTR5 in bladder, liver and adrenal gland suggesting a possible role in the treatment of diseases involving these tissues.

TABLE 15
Primer Design for Probe Ag1541 (FCTR6)
					SEQ ID
Primer	Sequences	TM	Length	tart Pos.	NO
Forward	5′-AGAAGAACACCCCAGGGATATA-3′	58.8	22	1076	35
Probe	FAM-5′-CCTCGTTGGTGAACTACAACCTCTGG-3′-TAMRA	67.9	26	1100	36
Reverse	5′-CCTCTAGCTGGGTCACTTTCTC-3′	59.5	22	1129	37

[0474]

TABLE 16
TAQMAN RESULTS FOR FCTR6 (PANEL ID)
		Panel ID
	Tissue_Name	Run 1	Run 2
	Liver adenocarcinoma	0.0	0.0
	Heart (fetal)	0.0	0.0
	Pancreas	0.0	0.0
	Pancreatic ca.CAPAN 2	0.0	0.0
	Adrenal gland	0.0	0.0
	Thyroid	0.0	0.0
	Salivary gland	0.0	0.0
	Pituitary gland	0.0	0.0
	Brain (fetal)	0.5	0.4
	Brain (whole)	1.1	1.7
	Brain (amygdala)	0.0	1.8
	Brain (cerebellum)	0.6	1.9
	Brain (hippocampus)	3.3	3.4
	Brain (thalamus)	1.0	1.2
	Cerebral Cortex	1.6	2.6
	Spinal cord	2.5	0.4
	CNS ca. (glio/astro)U87-MG	0.0	0.0
	CNS ca. (glio/astro)U-118-MG	0.0	0.0
	CNS ca. (astro)SW1783	0.0	0.0
	CNS ca.* (neuro; met )SK-N-AS	0.0	0.0
	CNS ca. (astro)SF-539	0.0	0.0
	CNS ca. (astro) SNB-75	0.7	0.0
	CNS ca. (glio)SNB-19	0.0	0.0
	CNS ca. (glio)U251	0.0	0.0
	CNS ca. (glio)SF-295	0.0	0.8
	Heart	0.0	0.0
	Skeletal muscle	0.0	0.0
	Bone marrow	0.0	0.0
	Thymus	0.0	0.0
	Spleen	0.0	0.0
	Lymph node	0.0	0.0
	Colorectal	0.0	0.6
	Stomach	1.9	0.0
	Small intestine	0.0	1.0
	Colon ca. SW480	0.0	0.0
	Colon ca.* (SW480 met)SW620	0.0	0.0
	Colon ca. HT29	0.0	0.0
	Colon ca. HCT-116	0.6	0.4
	Colon ca.CaCo-2	1.5	0.0
	83219 CC Well to Mod Duff (ODO3866)	0.0	0.0
	Colon ca.HCC-2998	0.0	0.0
	Gastric ca.* (liver met) NCI-N87	1.2	0.0
	Bladder	0.0	0.0
	Trachea	0.0	0.4
	Kidney	0.8	1.2
	Kidney (fetal)	0.5	0.7
	Renal ca.786-0	0.0	0.0
	Renal ca.A498	0.0	0.0
	Renal ca.RXF 393	0.0	0.0
	Renal ca.ACHN	0.0	0.0
	Renal ca. UO-31	0.0	0.0
	Renal ca.TK-10	0.0	0.0
	Liver	0.0	0.0
	Liver (fetal)	0.2	0.0
	Liver ca. (hepatoblast) HepG2	0.0	0.0
	Lung	0.0	0.0
	Lung (fetal)	0.0	0.0
	Lung ca. (small cell) LX-1	1.7	2.3
	Lung ca. (small cell)NCI-H69	0.0	0.0
	Lung ca. (s.cell var.) SHP-77	1.3	2.5
	Lung ca. (large cell)NCI-H460	0.0	0.0
	Lung ca. (non-sm. cell) A549	0.0	0.0
	Lung ca. (non-s.cell) NCI-H23	1.2	0.4
	Lung ca (non-s.cell) HOP-62	0.0	0.0
	Lung ca. (non-s.cl) NCI-H522	0.0	0.0
	Lung ca. (squam.) SW 900	0.0	0.7
	Lung ca. (squam.) NCI-H596	0.0	1.3
	Mammary gland	0.0	1.5
	Breast ca.* (pl. effusion) MCF-7	0.0	0.0
	Breast ca.* (pl.ef) MDA-MB-231	5.8	0.5
	Breast ca.* (pl. effusion) T47D	1.2	0.3
	Breast ca. BT-549	0.5	0.0
	Breast ca. MDA-N	0.0	0.0
	Ovary	0.0	0.0
	Ovarian ca. OVCAR-3	0.0	0.0
	Ovarian ca.OVCAR-4	0.0	0.0
	Ovarian ca.OVCAR-5	3.6	0.7
	Ovarian ca.OVCAR-8	0.0	0.0
	Ovarian ca.IGROV-1	0.0	0.0
	Ovarian ca.* (ascites) SK-OV-3	0.0	0.0
	Uterus	0.0	0.0
	Plancenta	0.0	0.0
	Prostate	0.0	0.7
	Prostate ca.* (bone met)PC-3	0.0	0.0
	Testis	100.0	100.0
	Melanoma Hs688(A).T	0.0	0.0
	Melanoma* (met) Hs688(B).T	0.0	0.0
	Melanoma UACC-62	0.0	0.0
	Melanoma M14	0.0	0.0
	Melanoma LOX IMVI	0.0	0.0
	Melanoma* (met)SK-MEL-5	0.0	0.0
	Adipose	0.5	0.0

[0475]

TABLE 17
Taqman Results for FCTR6 (Panel 2D)
	Panel 2D
Tissue_Name	Run 1	Run 2
Normal Colon GENPAK 061003	5.4	2.4
83219 CC Well to Mod Duff (ODO3866)	7.3	0.0
83220 CC NAT (ODO3866)	5.8	1.5
83221 CC Gr.2 rectosigmoid (ODO3868)	3.4	0.0
83222 CC NAT (ODO3868)	0.0	0.0
83235 CC Mod Duff (ODO3920)	11.0	1.4
83236 CC NAT (ODO3920)	0.0	0.0
83237 CC Gr.2 ascend colon (ODO3921)	6.2	2.5
83238 CC NAT (ODO3921)	10.2	0.0
83241 CC from Partial Hepatectom (ODO4309)	3.6	0.0
83242 Liver NAT (ODO4309)	0.0	2.4
87472 Colon mets to lung (ODO4451-01) 7.2	4.4
87473 Lung NAT (ODO4451-02)	0.0	0.0
Normal Prostate Clontech A+ 6546-1	4.8	2.9
84140 Prostate Cancer (ODO4410)	3.5	0.0
84141 Prostate NAT (ODO4410)	3.4	0.0
87073 Prostate Cancer (ODO4720-01)	9.0	8.5
87074 Prostate NAT (ODO4720-02)	0.0	0.0
Normal Lung GENPAK 061010	17.7	6.5
83239 Lung Met to Muscle (ODO4286)	0.0	2.3
83240 Muscle NAT (ODO4286)	0.0	0.0
84136 Lung Malignant Cancer (ODO3126) 6.5	5.7
84137 Lung NAT (ODO3126)	0.0	0.0
84871 Lung Cancer (ODO4404)	0.0	0.0
84872 Lung NAT (ODO4404)	0.0	0.0
84875 Lung Cancer (ODO4565)	0.0	0.0
85950 Lung Cancer (ODO4237-01)	0.0	0.0
85970 Lung NAT (ODO4237-02)	0.0	0.0
83255 Ocular Mel Met to Liver (ODO4310)	4.3	0.0
83256 Liver NAT (ODO4310)	0.0	0.0
84139 Melanoma Mets to Lung (ODO4321) 0.0	0.0
84138 Lung NAT (ODO4321)	0.0	0.0
Normal Kidney GENPAK 061008	28.1	39.2
83786 Kidney Ca, Nuclear grade 2 (ODO4338)	0.0	3.0
83787 Kidney NAT (ODO4338)	22.7	31.6
83788 Kidney Ca Nuclear grade ½ (ODO4339) 0.0	3.1
83789 Kidney NAT (ODO4339)	97.3	100.0
83790 Kidney Ca, Clear cell type (ODO4340)	0.0	0.0
83791 Kidney NAT (ODO4340)	100.0 34.4
83792 Kidney Ca, Nuclear grade 3 (ODO4348)	2.0	4.9
83793 Kidney NAT (ODO4348)	30.2	19.9
87474 Kidney Cancer (ODO4622-01)	0.0	2.4
87475 Kidne NAT (ODO4622-03)	8.4	7.2
85973 Kidney Cancer (ODO4450-01)	0.0	0.0
85974 Kidney NAT (ODO4450-03)	47.3	12.9
Kidney Cancer Clontech 8120607	0.0	0.0
Kidney NAT Clontech 8120608	0.0	0.0
Kidney Cancer Clontech 8120613	0.0	0.0
Kidney NAT Clontech 8120614	20.6	22.9
Kidney Cancer Clontech 9010320	0.0	0.0
Kidney NAT Clontech 9010321	3.4	26.4
Normal Uterus GENPAK 061018	0.0	0.0
Uterus Cancer GENPAK 064011	14.9	0.0
Normal Thyroid Clontech A+ 6570-1	0.0	0.0
Thyroid Cancer GENPAK 064010	0.0	0.0
Thyroid Cancer INVITROGEN A3021 52	0.0	0.0
Thyroid NAT INVITROGEN A302153	0.0	0.0
Normal Breast GENPAK 061019	5.2	3.5
84877 Breast Cancer ODO4566)	0.0	0.0
85975 Breast Cancer (ODO4590-01)	0.0	0.0
85976 Breast Cancer Mets (ODO4590-03)	0.0	0.0
87070 Breast Cancer Metastasis (ODO4655-05)	0.0	0.0
GENPAK Breast Cancer 064006	0.0	2.5
Breast Cancer Clontech 9100266	6.2	0.0
Breast NAT Clontech 9100265	0.0	0.0
Breast Cancer INVITROGEN A209073	1.5	2.5
Breast NAT INVITROGEN A2090734	24.3	26.2
Normal Liver GENPAK 061009	10.5	2.7
Liver Cancer GENPAK 064003	5.9	1.7
Liver Cancer Research Genetics RNA 1025	21.6	11.0
Liver Cancer Research Genetics RNA 1026	0.0	0.0
Paired Liver Cancer Tissue Research Genetics	3.3	13.5
RNA 6004-T
Paired Liver Tissue Research Genetics RNA 6004-N	3.2	1.4
Paired Liver Cancer Tissue Research Genetics	0.0	0.0
RNA 6005-T
Paired Liver Tissue Research Genetics RNA 6005-N	0.0	0.0
Normal Bladder GENPAK 061001	0.0	0.0
Bladder Cancer Research Genetics RNA 1023	0.0	0.0
Bladder Cancer INVITROGEN A302173	4.6	2.3
87071 Bladder Cancer (ODO471 8-01)	17.9	11.4
87072 Bladder Normal Adjacent (OD0471 8-03) 0.0	0.0
Normal Ovary Res. Gen.	0.0	0.0
Ovarian Cancer GENPAK 064008	1.7	4.8
87492 Ovary Cancer (ODO4768-07)	0.0	2.1
87493 Ovary NAT (ODO4768-08)	0.0	0.0
Normal Stomach GENPAK 061017	3.3	2.9
NAT Stomach Clontech 9060359	0.0	0.0
Gastric Cancer Clontech 9060395	0.0	0.0
NAT Stomach Clontech 9060394	0.0	0.0
Gastric Cancer Clontech 9060397	0.0	0.0
NAT Stomach Clontech 9060396	0.0	0.0
Gastric Cancer GENPAK 064005	6.3	3.8

[0476]

TABLE 18
Taqman Results for clone 27455183.0.19 (Panel 4D)
	Panel 4D
Tissue_Name	Run 1	Run 2
93768_Secondary Th1_anti-CD28/anti-CD3	0.0	0.0
93769_Secondary Th2_anti-CD28/anti-CD3	0.0	0.0
93770_Secondary Tr1_anti-CD28lanti-CD3	13.5	17.1
93573_Secondary Th1_resting day 4-6 in IL-2	0.0	0.0
93572_Secondary Th2_resting day 4-6 in IL-2	0.0	0.0
93571_Secondary Tr_resting day 4-6 in IL-2	0.0	0.0
93568_primary Th1_anti-CD28/anti-CD3	0.0	0.0
93569_primary Th2_anti-CD28/anti-CD3	0.0	0.0
93570_primary Tr1_anti-CD28/anti-CD3	0.0	0.0
93565_primary Th1_resting dy 4-6 in IL-2	0.0	0.0
93566_primary Th2_resting dy 4-6 in lL-2	0.0	0.0
93567_primary Tr1_resting dy 4-6 in IL-2	0.0	0.0
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	0.0	0.0
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	0.0	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0.0	0.0
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0.0	0.0
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.0	0.0
93354_CD4_none	5.8	0.0
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	10.0	0.0
93103_LAK cells_resting	0.0	0.0
93788_LAK cells_IL-2	0.0	0.0
93787_LAK cells_IL-2 + IL-12	0.0	0.0
93789_LAK cells_IL-2 + IFN gamma	0.0	0.0
93790_LAK cells IL-2 + IL-18	0.0	0.0
93104_LAK cells_PMA/ionomycin and IL-18	0.0	0.0
93578_NK Cells IL-2_resting	0.0	0.0
93109_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0
93110_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0
93111_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0
93112_Mononuclear Cells (PBMCs)_resting	0.0	0.0
93113_Mononuclear Cells (PBMCs)_PWM	0.0	0.0
93114_Mononuclear Cells (PBMCs)_PHA-L	0.0	0.0
93249_Ramos (B cell)_none	0.0	38.2
93250_Ramos (B cell)_ionomycin	0.0	0.0
93349_B lymphocytes_PWM	0.0	68.8
93350_B lymphoytes_CD40L and IL-4	31.0	0.0
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.0	0.0
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionomycin	0.0	0.0
93356_Dendritic Cells_none	0.0	0.0
93355_Dendritic Cells_LPS 100 ng/ml	0.0	0.0
93775_Dendritic Cells_anti-CD40	32.5	0.0
93774_Monocytes_resting	0.0	0.0
93776_Monocytes_LPS 50 ng/ml	0.0	0.0
93581_Macrophages_resting	0.0	0.0
93582_Macrophages_LPS 100 ng/ml	0.0	0.0
93098_HUVEC (Endothelial)_none	0.0	0.0
93099_HUVEC (Endothelial)_starved	11.3	0.0
93100_HUVEC (Endothelial)_IL-1b	0.0	14.6
93779_HUVEC (Endothelial)_IFN gamma	0.0	0.0
93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0	0.0
93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0	0.0
93781_HUVEC (Endothelial)_IL-11	0.0	0.0
93583_Lung Microvascular Endothelial Cells_none	0.0	0.0
93584_Lung Microvascular Endothelial Cells_TNFa	0.0	0.0
(4 ng/ml) and IL1b (1 ng/ml)
92662_Microvascular Dermal endothelium_none	0.0	0.0
92663_Microsvasular Dermal endothelium_TNFa	0.0	0.0
(4 ng/ml) and ILlb (1 ng/ml)
93773_Bronchial epithelium_TNFa	0.0	0.0
(4 ng/ml) and IL1b (1 ng/ml) **
93347_Small Airway Epithelium_none	0.0	0.0
93348_Small Airway Epithelium_TNFa (4 ng/ml) and	0.0	0.0
IL1b (1 ng/ml)
92668_Coronery Artery SMC_resting	0.0	0.0
92669_Coronery Artery SMC_TNFa	0.0	0.0
(4 ng/ml) and IL1b (1 ng/ml)
93107_astrocytes_resting	0.0	0.0
93108_astroces_TNFa 4 ng/ml and IL1b 1 ng/ml	0.0	0.0
92666_KU-812 (Basophil)_resting	0.0	40.3
92667_KU-812 (Basophil)_PMA/ionoycin	0.0	0.0
93579_CCD1106 (Keratinocytes)_none	0.0	0.0
93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	0.0	0.0
93791_Liver Cirrhosis	100.0	99.3
93792_Lupus Kidney	0.0	0.0
93577_NCI-H292	0.0	0.0
93358_NCI-H292_IL-4	0.0	0.0
93360_NCI-H292_IL-9	10.6	0.0
93359_NCI-H292_IL-13	0.0	65.5
93357_NCI-H292_IFN gamma	0.0	24.8
93777_HPAEC_-	0.0	0.0
93778_HPAEC_IL-1 beta/TNA alpha	0.0	0.0
93254_Normal Human Lung Fibroblast_none	0.0	0.0
93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml)	0.0	0.0
and IL-1b (1 ng/ml)
93257_Normal Human Lung Fibroblast_IL-4	0.0	0.0
93256_Normal Human Lung Fibroblast_IL-9	0.0	0.0
93255_Normal Human Lung Fibroblast_IL-13	0.0	0.0
93258_Normal Human Lung Fibroblast_IFN gamma	0.0	0.0
93106_Dermal Fibroblasts CCD1070_resting	0.0	0.0
93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	0.0	43.8
93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0	0.0
93772_dermal fibroblast_IFN gamma	42.0	27.7
93771_dermal fibroblast_IL-4	10.7	90.1
93259_IBD Colitis 1**	0.0	0.0
93260_IBD Colitis 2	13.8	0.0
93261_IBD Crohns	0.0	46.7
735010_Colon_normal	15.6	0.0
735019_Lung_none	112.9	116.8 I
64028-1_Thymus_none	69.3	100.0
64030-1_Kidney_none	0.0	0.0

[0477] Taqman results in Table 18 demonstrate that clone FCTR6 is differentially expressed in clear cell Renal cell carcinoma tissues versus the normal adjacent kidney tissues and thus could have a potential role in the treatment of renal cell carcinoma.

EQUIVALENTS

[0478] Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims.

Claims

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25; (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form; (c) an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25; and (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.

2. The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25.

3. The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24.

4. The polypeptide of claim 1, wherein the amino acid sequence of said variant comprises a conservative amino acid substitution.

5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25; (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form; (c) an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25; (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and (f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).

6. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally-occurring allelic nucleic acid variant.

7. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of a naturally-occurring polypeptide variant.

8. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24.

9. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24; (b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, provided that no more than 20% of the nucleotides differ from said nucleotide sequence; (c) a nucleic acid fragment of (a); and (d) a nucleic acid fragment of (b).

10. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence chosen from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, 12, 14, 16, 18, 20, 22, and 24, or a complement of said nucleotide sequence.

11. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) a first nucleotide sequence comprising a coding sequence differing by one or more nucleotide sequences from a coding sequence encoding said amino acid sequence, provided that no more than 20% of the nucleotides in the coding sequence in said first nucleotide sequence differ from said coding sequence; (b) an isolated second polynucleotide that is a complement of the first polynucleotide; and (c) a nucleic acid fragment of (a) or (b).

12. A vector comprising the nucleic acid molecule of claim 11.

13. The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.

14. A cell comprising the vector of claim 12.

15. An antibody that binds immunospecifically to the polypeptide of claim 1.

16. The antibody of claim 15, wherein said antibody is a monoclonal antibody.

17. The antibody of claim 15, wherein the antibody is a humanized antibody.

18. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising: (a) providing the sample; (b) contacting the sample with an antibody that binds immunospecifically to the polypeptide; and (c) determining the presence or amount of antibody bound to said polypeptide, thereby determining the presence or amount of polypeptide in said sample.

19. A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising: (a) providing the sample; (b) contacting the sample with a probe that binds to said nucleic acid molecule; and (c) determining the presence or amount of the probe bound to said nucleic acid molecule, thereby determining the presence or amount of the nucleic acid molecule in said sample.

20. The method of claim 19 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.

21. The method of claim 20 wherein the cell or tissue type is cancerous.

22. A method of identifying an agent that binds to a polypeptide of claim 1, the method comprising: (a) contacting said polypeptide with said agent; and (b) determining whether said agent binds to said polypeptide.

23. The method of claim 22 wherein the agent is a cellular receptor or a downstream effector.

24. A method for identifying an agent that modulates the expression or activity of the polypeptide of claim 1, the method comprising: (a) providing a cell expressing said polypeptide; (b) contacting the cell with said agent, and (c) determining whether the agent modulates expression or activity of said polypeptide, whereby an alteration in expression or activity of said peptide indicates said agent modulates expression or activity of said polypeptide.

25. A method for modulating the activity of the polypeptide of claim 1, the method comprising contacting a cell sample expressing the polypeptide of said claim with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

26. A method of treating or preventing a FCTRX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the polypeptide of claim 1 in an amount sufficient to treat or prevent said FCTRX-associated disorder in said subject.

27. The method of claim 26 wherein the disorder is a neurodegenerative disorder.

28. The method of claim 26 wherein the disorder is related to cell signal processing and metabolic pathway modulation.

29. The method of claim 26, wherein said subject is a human.

30. A method of treating or preventing a FCTRX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the nucleic acid of claim 5 in an amount sufficient to treat or prevent said FCTRX-associated disorder in said subject.

31. The method of claim 30 wherein the disorder is a neurodegenerative disorder.

32. The method of claim 30 wherein the disorder is related to cell signal processing and metabolic pathway modulation.

33. The method of claim 30, wherein said subject is a human.

34. A method of treating or preventing a FCTRX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the antibody of claim 15 in an amount sufficient to treat or prevent said FCTRX-associated disorder in said subject.

35. The method of claim 34 wherein the disorder is selected from the group consisting of Also within the scope of the invention is the use of a Therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Colorectal cancer, adenomatous polyposis coli, myelogenous leukemia, congenital ceonatal alloimmune thrombocytopenia, multiple human solid malignancies, malignant ovarian tumours particularly at the interface between epithelia and stroma, malignant brain tumors, mammary tumors, human gliomas, astrocytomas, mixed glioma/astrocytomas, renal cells carcinoma, breast adenocarcinoma, ovarian cancer, melanomas, renal cell carcinoma, clear cell and granular cell carcinomas, autocrine/paracrine stimulation of tumor cell proliferation, autocrine/paracrine stimulation of tumor cell survival and tumor cell resistance to cytotoxic therapy, paranechmal and basement membrane invasion and motility of tumor cells thereby contributing to metastasis, tumor-mediated immunosuppression of T-cell mediated immune effector cells and pathways resulting in tumor escape from immune surveilance, neurological disorders, neurodegenerative disorders, nerve trauma, familial myelodysplastic syndrome, Charcot-Marie-Tooth neuropathy, demyelinating Gardner syndrome, familial myelodysplastic syndrome; mental health conditions, immunological disorders, allergy and infection, asthma, bronchial asthma, Avellino type eosinophilia, lung diseases, reproductive disorders, male infertility, female reproductive system disorders, male and female reproductive diseases, hemangioma, deafness, glycoprotein Ia deficiency, desmoid disease, turcot syndrome, liver cirrhosis, hepatitis C, gastric disorders, pancreatic diseases like diabetes, Schistosoma mansoni infection, Spinocerebellar ataxia, Plasmodium falciparum parasitemia, Corneal dystrophy—Groenouw type I, Corneal dystrophy—lattice type I, and Reis-Bucklers corneal dystrophy.

36. The method of claim 34 wherein the disorder is related to cell signal processing and metabolic pathway modulation.

37. The method of claim 34, wherein the subject is a human.

38. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically-acceptable carrier.

39. A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.

40. A pharmaceutical composition comprising the antibody of claim 15 and a pharmaceutically-acceptable carrier.

41. A kit comprising in one or more containers, the pharmaceutical composition of claim 38.

42. A kit comprising in one or more containers, the pharmaceutical composition of claim 39.

43. A kit comprising in one or more containers, the pharmaceutical composition of claim 40.

44. A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 1 in a first mammalian subject, the method comprising: (a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and (b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease; wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.

45. The method of claim 44 wherein the predisposition is to cancers.

46. A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 5 in a first mammalian subject, the method comprising: (a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and (b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

47. The method of claim 46 wherein the predisposition is to cancers.

48. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising an amino acid sequence of at least one of SEQ ID NOS:2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, or a biologically active fragment thereof.

49. A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 15 in an amount sufficient to alleviate the pathological state.